

# REPORT ON CANCER IN NEVADA 1997-2001

September 2004

Written, compiled and edited by:

Andrea Rivers, B.A.
Contracting Clerical/ Management Assistant

Tim Pollard, B.A. Health Resource Analyst

Wei Yang, Ph.D. State Biostatistician and Director

Center for Health Data and Research Bureau of Health Planning and Statistics Emil DeJan, Bureau Chief Nevada State Health Division Department of Human Resources State of Nevada

# **ACKNOWLEDGEMENTS**

#### **Report Prepared by:**

Andrea Rivers, B.A.

Contracting Clerical/ Management Assistant

Center for Health Data and Research

Tim Pollard, B.A.

Health Resource Analyst

Center for Health Data and Research

Wei Yang, Ph.D.

State Biostatistician and Director

Center for Health Data and Research

Karen Power, M.P.H.

Program Manager – Central Cancer Registry

Bureau of Health Planning and Statistics

3811 West Charleston, Suite 208

Las Vegas, Nevada 89102

Phone (702) 486-6260

Fax (702) 486-7602

http://health2k.state.nv.us/cancer/

Joseph Greenway, Director

Center for Health Information Analysis

University of Nevada, Las Vegas

4505 Maryland Parkway, Box 455058

Las Vegas, Nevada 89154-5058

Phone (702) 895-4389

Fax (702) 895-4276

http://www.unlv.edu/Research\_Centers/chia/

Jean Gunter, Program Officer

Office of Vital Statistics

Bureau of Health Planning and Statistics

505 East King Street, Room 102

Carson City, NV 89701

Phone: (775) 684-4162

Fax: (775) 684-4156

http://health2k.state.nv.us/vital/

Judy Calder, Ed.D., Director

Center for Applied Research

College of Human and Community Sciences

University of Nevada, Reno

Reno, Nevada 89557-0017

Phone: (775) 784-6718

Fax: (775) 784-4506

http://sabcar.unr.edu/index.php

## **Data Provided By:**

# ACKNOWLEDGEMENTS (CONTINUED)

#### **Editing Review and Comments:**

Ihsan Azzam, M.P.H. Health Program Specialist Bureau of Community Health

Emil DeJan, M.P.H. Bureau Chief Bureau of Health Planning and Statistics

Bradford Lee, M.D. State Health Officer Nevada State Health Division

Deborah McBride, M.B.A. Health Program Manager Women's Health Connections Bureau of Community Health

Karen Power, M.P.H.
Program Manager – Central Cancer Registry
Bureau of Health Planning and Statistics

Randall Todd, Dr.P.H. State Epidemiologist

**Cover Art Courtesy of:** 

Hardin MD online medical pictures at: <a href="http://www.lib.uiowa.edu/hardin/md/pictures.html">http://www.lib.uiowa.edu/hardin/md/pictures.html</a>.

More health information can be found online at the Center for Health Data and Research's Nevada Interactive Health Databases System at: <a href="http://health2k.state.nv.us/nihds/center.htm">http://health2k.state.nv.us/nihds/center.htm</a>.

Readers of this publication are welcome to offer their suggestions and/or comments concerning this publication by filling out the attached form at the end of this report. Readers are also welcome to submit requests for additional information by submitting them to:

Center for Health Data and Research Bureau of Health Planning and Statistics Nevada State Health Division 505 E. King Street, Room 102 Carson City, NV 89701-4749 Phone: (775) 684-4182

Fax: (775) 684-4156 E-mail: wyang@nvhd.state.nv.us

# **PREFACE**

This report provides a comprehensive overview of the risks and burden of cancer in Nevada from 1997 to 2001. Cancer represents a group of diseases that will affect nearly half of the population at some time during their lifetime. Nationally, cancer-related costs total billions of dollars in treatment annually. Cancer has also consistently been the second leading cause of death for Nevada and the Nation for the last 20 years. This report provides a variety of information on cancer from four different data sources and has been organized to focus on specific aspects of cancer, (e.g. screening, diagnosis, inpatient treatment, mortality, and survival rate) with each section adding to the overall picture of cancer in Nevada.

The first section provides a comparison of the 22 leading types of cancer that comprise 91.8% of all types of cancer in Nevada; including incidence, inpatient hospital discharges, mortality, and survival rate subsections for comparison.

The second section includes various statistics on all cancers, reported among Nevada residents, to provide a complete look at cancer in the state. There are subsections for diagnosis, treatment, mortality and survival rate statistics for the 1997 to 2001 period.

The top ten leading types of cancer diagnosed in Nevada from 1997 to 2001, which accounts for 74.9% of the total number of cancer cases, are then highlighted within their own section to provide a more detailed look at the types of cancer that are most prevalent in Nevada. The reader should note that these types of cancer are presented based on the number of cases reported. Therefore, those cancers whose ranking is within the top ten based on inpatient discharges or mortality are not necessarily highlighted within their own section.

Statistics on those cancers not highlighted in the top ten sections are available in the Overview section and in a general section for All Other Cancers at the end of this report, where the remaining twelve leading cancers are briefly profiled.

Each major section in this report includes regional, gender, racial/ethnic, and age statistics in order to draw attention to potential targets for prevention and treatment efforts. These efforts in prevention and treatment will help to achieve progress toward reducing the risks and burden of Cancer in Nevada.

For note, trend statistics are not included in this edition of the *Report on Cancer in Nevada* since the estimated completeness of earlier cancer reporting was significantly lower than in more recent years, which would significantly affect any trends that would be included in this report. However, trend information will be included in the next edition.

This report is also available online at the Center for Health Data and Research's website: http://health2k.state.nv.us/nihds/publications/index.htm

# TABLE OF CONTENTS

ACKNOWLEDGEMENTS	i
PREFACE	1
TABLE OF CONTENTS	2
LIST OF FIGURES AND TABLES	6
TECHNICAL NOTES	29
OVERVIEW	36
HIGHLIGHTS	37
INCIDENCE	45
HIGHLIGHTS	45
INPATIENT HOSPITAL DISCHARGES	58
HIGHLIGHTS	58
MORTALITY	
HIGHLIGHTS	
SURVIVAL RATE	
HIGHLIGHTS	75
ALL CANCERS	81
HIGHLIGHTS	82
INCIDENCE	85
INPATIENT HOSPITAL DISCHARGES	93
MORTALITY	100
SURVIVAL RATE	107
LUNG AND BRONCHUS CANCER	110
GENERAL PROFILE	111
HIGHLIGHTS	112
INCIDENCE	114
INPATIENT HOSPITAL DISCHARGES	122
MORTALITY	129
SURVIVAL RATE	136
BREAST CANCER	139
GENERAL PROFILE	140
HIGHLIGHTS	141

SCREENING (BRFSS)	143
INCIDENCE	144
INPATIENT HOSPITAL DISCHARGES	152
MORTALITY	159
SURVIVAL RATE	166
PROSTATE CANCER	169
GENERAL PROFILE	170
HIGHLIGHTS	171
SCREENING (BRFSS)	174
INCIDENCE	175
INPATIENT HOSPITAL DISCHARGES	183
MORTALITY	190
SURVIVAL RATE	197
COLORECTAL CANCER	200
GENERAL PROFILE	201
HIGHLIGHTS	202
SCREENING (BRFSS)	205
INCIDENCE	206
INPATIENT HOSPITAL DISCHARGES	214
MORTALITY	221
SURVIVAL RATE	228
URINARY BLADDER CANCER	231
GENERAL PROFILE	232
HIGHLIGHTS	233
INCIDENCE	235
INPATIENT HOSPITAL DISCHARGES	243
MORTALITY	250
SURVIVAL RATE	257
NON-HODGKIN'S LYMPHOMA	260
GENERAL PROFILE	261
HIGHLIGHTS	262
INCIDENCE	264
INPATIENT HOSPITAL DISCHARGES	272

MORTALITY	279
SURVIVAL RATE	286
KIDNEY AND RENAL PELVIS CANCER	289
GENERAL PROFILE	290
HIGHLIGHTS	291
INCIDENCE	294
INPATIENT HOSPITAL DISCHARGES	302
MORTALITY	309
SURVIVAL RATE	316
LEUKEMIA	319
GENERAL PROFILE	320
HIGHLIGHTS	321
INCIDENCE	323
INPATIENT HOSPITAL DISCHARGES	331
MORTALITY	338
SURVIVAL RATE	345
LIP, ORAL CAVITY AND PHARYNX CANCER	348
GENERAL PROFILE	349
HIGHLIGHTS	350
INCIDENCE	352
INPATIENT HOSPITAL DISCHARGES	360
MORTALITY	367
SURVIVAL RATE	374
PANCREATIC CANCER	377
GENERAL PROFILE	378
HIGHLIGHTS	379
INCIDENCE	381
INPATIENT HOSPITAL DISCHARGES	389
MORTALITY	396
SURVIVAL RATE	403
ALL OTHER CANCERS	406
SKIN CANCER	408
UTERINE CANCER	412

FEEDBACK AND SUGGESTIONS	160
REFERENCES	468
APPENDIX B – FORMULAS	465
APPENDIX A – CODES USED FOR GROUPING	460
ALL OTHER SITES	457
HODGKIN'S LYMPHOMA	453
MULTIPLE MYELOMA	449
LARYNX CANCER	445
ESOPHAGEAL CANCER	441
CERVICAL CANCER	436
LIVER AND INTRAHEPATIC BILE DUCTS CANCER	432
STOMACH CANCER	428
BRAIN AND OTHER CENTRAL NERVOUS SYSTEM CANCER	424
THYROID GLAND CANCER	420
OVARIAN CANCER	416

# LIST OF FIGURES AND TABLES

HIGHLIGHTS	
Figure 1. Top Ten Leading Types of Cancer by Percentage of Total Incidence, Discharges and Mortality, Nevada Residents, 1997-2001	38
Figure 2. Highest Incidence to Mortality Age-Adjusted Rate Ratios by Type of Cancer, Nevada Residents, 1997-2001	
Figure 3. Lowest Incidence to Mortality Age-Adjusted Rate Ratios by Type of Cancer, Nevada Residents, 1997-2001	
Table 1. Nevada Incidence, Inpatient Hospital Discharges and Mortality by Type of Cancer, Neva	ada,
Table 1. Nevada Incidence, Inpatient Hospital Discharges and Mortality by Type of Cancer, Neva 1997-2001 (Continued)	ada,
Table 2. Leading Types of Cancer for Nevada Incidence, Inpatient Hospital Discharges and Mortality, Nevada Residents, 1997-2001	42
Table 3. Top Ten Types of Cancer by Gender, Incidence, Hospital Discharges, and Mortality,  Nevada Residents, 1997-2001	43
Table 4. Incidence to Mortality Age-Adjusted Rate Ratios for the Leading Types of Cancer, Neva Residents, 1997-2001	
INCIDENCE	
HIGHLIGHTS	
Figure 4. Top Ten Leading Cancers as a Percentage of Total Cases, Nevada (1997-2001) and SEI 11 (1997-2001)	
Figure 5. Comparison of Age-Adjusted (2001) Incidence Rates of Blacks compared to Whites, Nevada Residents, 1997-2001	46
Figure 6. Comparison of Age-Adjusted (2001) Incidence Rates of Native Americans compared to Whites, Nevada Residents, 1997-2001	
Figure 7. Comparison of Age-Adjusted (2001) Incidence Rates of Asians compared to Whites, Nevada Residents, 1997-2001	47
Figure 8. Comparison of Age-Adjusted (2001) Incidence Rates of Hispanics compared to Whites, Nevada Residents, 1997-2001	
Table 5. Nevada Incidence by Type of Cancer, Nevada (1997-2001) and SEER-11 (1997-2001) Table 5. Nevada Incidence by Type of Cancer, Nevada (1997-2001) and SEER-11 (1997-2001)	49
(Continued)	
Nevada, 1997-2001	
Table 6. Nevada Incidence by Type of Cancer and Gender,	
Nevada, 1997-2001 (Continued)	
Table 7. Nevada Incidence by Type of Cancer and Stage of Cancer,	
Nevada, 1997-2001	
Table 7. Nevada Incidence by Type of Cancer and Stage of Cancer,	54
Nevada, 1997-2001 (Continued)	54
Table 8. Top Ten Types of Cancer Incidence by County/Region of Residence,	
Nevada Residents, 1997-2001	
Table 9. Top Ten Types of Cancer Incidence by Age Group, Nevada Residents, 1997-2001	56

Table 10. Median Age at Time of Diagnosis by Leading Types of Cancer and Race/Ethnicity,  Nevada Residents, 1997-200157
INPATIENT HOSPITAL DISCHARGES
HIGHLIGHTS
Figure 9. Top Ten Leading Cancers in Total Inpatient Discharge Charges, Nevada Residents, 1997-2001
Figure 10. Top Ten Leading Cancers in Average Inpatient Discharge Charges, Nevada Residents, 1997-2001
Figure 11. Top Ten Leading Cancers in Median Inpatient Discharge Charges, Nevada Residents, 1997-2001
Figure 12. Top Ten Leading Cancers in Total Number of Days Stayed for Inpatient Hospital
Discharges, Nevada Residents, 1997-200160
Figure 13. Top Ten Leading Cancers in Average Length of Stay (Days) for Inpatient Hospital
Discharges, Nevada Residents, 1997-200161
Figure 14. Top Ten Leading Cancers in Median Length of Stay (Days) for Inpatient Hospital Discharges, Nevada Residents, 1997-2001
Table 11. Nevada Inpatient Hospital Discharges by Type of Cancer and Gender, Nevada, 1997-200162  Table 11. Nevada Inpatient Hospital Discharges by Type of Cancer and Gender, Nevada, 1997-2001  (Continued)
Table 12. Top Ten Types of Cancer Inpatient Hospital Discharges by County/Region of Residence, Nevada Residents, 1997-2001
Table 13. Top Ten Types of Cancer Hospital Discharges by Age Group, Nevada Residents, 1997-2001
MORTALITY
HIGHLIGHTS
Figure 15. Top Ten Leading Cancers by Percentage of Total Cancer Mortality, Nevada Residents,  1997-2001
Figure 16. Comparison of Age-Adjusted (2001) Mortality Rates of Blacks compared to Whites,
Nevada Residents, 1997-2001
Figure 17. Comparison of Age-Adjusted (2001) Mortality Rates of Native Americans compared to Whites, Nevada Residents, 1997-2001
Figure 18. Comparison of Age-Adjusted (2001) Mortality Rates of Asians compared to Whites, Nevada Residents, 1997-2001
Figure 19. Comparison of Age-Adjusted (2001) Mortality Rates of Hispanics compared to Whites, Nevada Residents, 1997-2001
Table 14. Nevada Mortality by Type of Cancer and Gender,
Nevada, 1997-2001
Table 14. Nevada Mortality by Type of Cancer and Gender,
Nevada, 1997-2001 (Continued)
Table 15. Top Ten Types of Cancer Mortality by County/Region of Residence, Nevada Residents, 1997-2001
Table 16. Top Ten Types of Cancer Mortality by Age Group, Nevada Residents, 1997-200173 Table 17. Median Age at Time of Death by Leading Types of Cancer and Race/Ethnicity, Nevada Residents, 1997-2001

# SURVIVAL RATE

Figure 20. Ten Highest One-Year Survival Rates by Type of Cancer, Nevada Residents, 1997-200 Figure 21. Ten Lowest One-Year Survival Rates by Type of Cancer, Nevada Residents, 1997-200 Figure 22. Ten Highest Five-Year Survival Rates by Type of Cancer, Nevada Residents, 1997-200 Figure 23. Ten Lowest Five-Year Survival Rates by Type of Cancer, Nevada Residents, 1997-200 Table 18. One-Year, Five-Year and Median Survival Rates by Type of Cancer, Nevada Residents 1997-2001	0176 00177 0177 s, 78
Table 19. One- and Five-Year Survival Rates by Type of Cancer and Gender, Nevada Residents,	
1997-2001	
ALL CANCERS	
HIGHLIGHTS	
INCIDENCE	
Figure 24. Age-Adjusted (2001) Incidence Rates for All Cancers, Nevada Residents, 1997-2001 Figure 25. All Cancers Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1997-2001	
Figure 26. All Cancers Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1997, 2001	
Table 21. All Cancers Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)	87
Table 22. All Cancers Cases by Age Group and County/Region of Residence at Diagnosis, Nevac Residents (1997-2001) and SEER-11 (1997-2001)	
Table 23. All Cancers Cases by County of Residence at Diagnosis, Nevada Residents, 1997-2001	
Table 24. All Cancers Cases by Race/Ethnicity and Gender, Nevada Residents, 1997-2001	
Table 25. All Cancers Cases by Age Group and Gender, Nevada Residents,	
Table 26. All Cancers Cases by Age Group and Stage, Nevada Residents,	
1997-2001	
Table 27. Cancer Incidence by Stage and Race/Ethnicity, Nevada Residents,	
1997-2001	
Residents, 1997-2001	
INPATIENT HOSPITAL DISCHARGES	
Figure 27. All Cancers Age-Adjusted (2001) Inpatient Discharge Rates, Nevada Residents, 1997-	
2001	
Figure 28. All Cancers Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1997-2001	94
Figure 29. Median Charges for All Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001	
Figure 30. Average Length of Stay for All Cancer Inpatient Discharges by County/Region of	0.7
Residence, Nevada Residents, 1997-2001	
of Residence, Nevada Residents, 1997-2001	
Table 30. Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada	, 0
Residents, 1997-2001	97

Table 31. All Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1997  Table 32. All Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 2001	1997-
Table 33. All Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1997-2001	a
MORTALITY	
Figure 31. Cancer Age-Adjusted (2001) Mortality Rates, Nevada Residents,	100
1997-2001	
Figure 32. Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada	
Residents, 1997-2001	
Figure 33. Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1997-2 Table 34. All Cancers Mortality by Gender, Race/Ethnicity and County/Region of Residence,	
Nevada Residents, 1997-2001	101
Table 34. All Cancers Mortality by Gender, Race/Ethnicity and County/Region of Residence,	100
Nevada Residents, 1997-2001	
Table 35. All Cancers Mortality by Age Group and County/Region of Residence, Nevada Resi	
Table 36. Cancer Mortality by County of Residence, Nevada Residents,	
1997-2001	
Table 37. Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1997-2001	
Table 38. Cancer Mortality by Age Group and Gender, Nevada Residents,	
1997-2001	
Table 39. Median Age at Death from All Cancers by Race/Ethnicity and Gender, Nevada Resident 1997-2001	
SURVIVAL RATE Figure 34. Survival Rates for All Cancers by Race/Ethnicity, Nevada Residents, 1997-2001 Figure 35. Survival Rates for All Cancers by Stage of Cancer at Diagnosis, Nevada Residents, 2001	1997-
Table 40. Cause-Specific Survival Rates for All Cancers by Race/Ethnicity and Gender, Nevac Residents, 1997-2001	
Table 41. Cause-Specific Survival Rates for All Cancers by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1997-2001	109
LUNG AND BRONCHUS CANCER	
GENERAL PROFILE <sup>4</sup> Figure 36. Anatomy of the Respiratory Tract <sup>5</sup>	111
HIGHLIGHTS	
INCIDENCE	
Figure 37. Lung and Bronchus Cancer Age-Adjusted (2001) Incidence Rates, Nevada Residen 1997-2001	
Figure 38. Lung and Bronchus Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1997-2001	115
Figure 39. Lung and Bronchus Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Neva	.da
Residents, 1997-2001	115
Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)	116

Table 43. Lung and Bronchus Cancer Cases by Age Group and County/Region of Residence at
Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)117
Table 44. Lung and Bronchus Cancer Cases by County of Residence at Diagnosis, Nevada
Residents, 1997-2001118
Table 45. Lung and Bronchus Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1997-2001
Table 46. Lung and Bronchus Cancer Cases by Age Group and Gender, Nevada Residents, 1997-2001
Table 47. Lung and Bronchus Cancer Cases by Age Group and Stage, Nevada Residents, 1997-2001120 Table 48. Lung and Bronchus Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1997-2001
Table 49. Median Age at Diagnosis of Lung and Bronchus Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001
INPATIENT HOSPITAL DISCHARGES
Figure 40. Lung and Bronchus Cancer Age-Adjusted (2001) Inpatient Hospital Discharge Rates, Nevada Residents, 1997-2001
Figure 41. Lung and Bronchus Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1997-2001
Figure 42. Median Charges for Lung and Bronchus Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001
Figure 43. Average Length of Stay for Lung and Bronchus Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001
Table 50. Lung and Bronchus Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001
Table 51. Lung and Bronchus Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1997-2001
Table 52. Lung and Bronchus Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1997-2001
Table 53. Lung and Bronchus Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001
Table 54. Lung and Bronchus Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1997-2001
MORTALITY
Figure 44. Lung and Bronchus Cancer Age-Adjusted (2001) Mortality Rates, Nevada Residents, 1997-2001
Figure 45. Lung and Bronchus Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1997-2001
Figure 46. Lung and Bronchus Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1997-2001
Table 55. Lung and Bronchus Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1997-2001
Table 55. Lung and Bronchus Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1997-2001
Table 56. Lung and Bronchus Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001
Table 57. Lung and Bronchus Cancer Mortality by County of Residence, Nevada Residents, 1997-
2001

Table 58. Lung and Bronchus Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1997-2001
Table 59. Lung and Bronchus Cancer Mortality by Age Group and Gender, Nevada Residents, 1997-2001
Table 60. Median Age at Death from Lung and Bronchus Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001
SURVIVAL RATE Figure 47. Survival Rates for Lung and Bronchus Cancer by Race/Ethnicity, Nevada Residents, 1997-2001
Figure 48. Survival Rates for Lung and Bronchus Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1997-2001
Gender, Nevada Residents, 1997-2001
BREAST CANCER
GENERAL PROFILE <sup>4</sup> Figure 49. Anatomy of the Breast <sup>5</sup>
HIGHLIGHTS
SCREENING (BRFSS) Table 63. Female Breast Cancer Screening by County/Region of Residence, Education, Age Group, and Income, Nevada Residents, 1997-2001
INCIDENCE Figure 50. Female Breast Cancer Age-Adjusted (2001) Incidence Rates, Nevada Residents, 1997- 2001
Figure 51. Female Breast Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1997-2001
Figure 52. Female Breast Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1997-2001
Table 64. Breast Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)140
Table 65. Female Breast Cancer Cases by Age Group and County/Region of Residence at Diagnosis Nevada Residents (1997-2001) and SEER-11 (1997-2001)
Table 66. Female Breast Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1997-2001
Table 67. Breast Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1997-2001145 Table 68. Breast Cancer Cases by Age Group and Gender, Nevada Residents, 1997-2001
Table 70. Breast Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1997-200115 Table 71. Median Age at Diagnosis of Breast Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001
INPATIENT HOSPITAL DISCHARGES Figure 53. Female Breast Cancer Age-Adjusted (2001) Inpatient Discharge Rates, Nevada Residents 1997-2001

Figure 54. Female Breast Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of
Residence, Nevada Residents, 1997-2001153
Figure 55. Median Charges for Breast Cancer Inpatient Discharges by County/Region of Residence,
Nevada Residents, 1997-2001
Figure 56. Average Length of Stay for Breast Cancer Inpatient Discharges by County/Region of
Residence, Nevada Residents, 1997-2001
Table 72. Breast Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and
County/Region of Residence, Nevada Residents, 1997-2001
Table 73. Female Breast Cancer Inpatient Discharges by Age Group and County/Region of
Residence, Nevada Residents, 1997-2001
Table 74. Breast Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1997-
2001
Residents, 1997-2001
Table 76. Breast Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1997-2001
MORTALITY
Figure 57. Female Breast Cancer Age-Adjusted (2001) Mortality Rates, Nevada Residents, 1997-
2001
Figure 58. Female Breast Cancer Age-Adjusted Mortality Rates by County/Region of Residence,
Nevada Residents, 1997-2001
Figure 59. Female Breast Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada
Residents, 1997-2001
Table 77. Breast Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence,
Nevada Residents, 1997-2001
Table 77. Breast Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence,
Nevada Residents, 1997-2001
Table 78. Female Breast Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001
Table 79. Female Breast Cancer Mortality by County of Residence, Nevada Residents, 1997-2001163
Table 80. Breast Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1997-2001.163
Table 81. Breast Cancer Mortality by Age Group and Gender, Nevada Residents, 1997-2001164
Table 82. Median Age at Death from Breast Cancer by Race/Ethnicity and Gender, Nevada
Residents, 1997-2001
SURVIVAL RATE
Figure 60. Survival Rates for Breast Cancer by Race/Ethnicity, Nevada Residents, 1997-2001166
Figure 61. Survival Rates for Breast Cancer by Stage of Cancer at Diagnosis, Nevada Residents,
1997-2001166
Table 83. Cause-Specific Survival Rates for Breast Cancer by Race/Ethnicity and Gender, Nevada
Residents, 1997-2001
Table 84. Cause-Specific Survival Rates for Breast Cancer by Stage of Cancer at Diagnosis and
Gender, Nevada Residents, 1997-2001168
PROSTATE CANCER
GENERAL PROFILE <sup>4</sup>
Figure 62. Anatomy of the Male Urogenital System <sup>5</sup>

# HIGHLIGHTS

SCREENING (BRFSS)
Table 85. Prostate Cancer Screening by County/Region of Residence, Education, Age Group, and Income, Nevada Residents, 1997, 1999 and 2001
INCIDENCE
Figure 63. Prostate Cancer Age-Adjusted (2001) Incidence Rates, Nevada Residents, 1997-2001 .175
Figure 64. Prostate Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1997-2001
Figure 65. Prostate Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents,
Table 86. Prostate Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)
Table 87. Prostate Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)
Table 88. Prostate Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1997-2001
Table 89. Prostate Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1997-2001179
Table 90. Prostate Cancer Cases by Age Group and Gender, Nevada Residents, 1997-2001180
Table 91. Prostate Cancer Cases by Age Group and Stage, Nevada Residents,
1997-2001
Table 92. Prostate Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1997-2001182
Table 93. Median Age at Diagnosis of Prostate Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001
INPATIENT HOSPITAL DISCHARGES
Figure 66. Prostate Cancer Age-Adjusted (2001) Inpatient Discharge Rates, Nevada Residents, 1997-2001
Figure 67. Prostate Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1997-2001
Figure 68. Median Charges for Prostate Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001
Figure 69. Average Length of Stay for Prostate Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001
Table 94. Prostate Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and
County/Region of Residence, Nevada Residents, 1997-2001
Table 95. Prostate Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1997-2001
Table 96. Prostate Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1997-2001
Table 97. Prostate Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001
Table 98. Prostate Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1997-2001
MORTALITY
Figure 70. Prostate Cancer Age-Adjusted (2001) Mortality Rates, Nevada Residents, 1997-2001190
Figure 71. Prostate Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1997-2001

1997-2001191
Table 99. Prostate Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence,
Nevada Residents, 1997-2001
Table 99. Prostate Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1997-2001
Table 100. Prostate Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001
Table 101. Prostate Cancer Mortality by County of Residence, Nevada Residents, 1997-2001194 Table 102. Prostate Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1997-2001194 Table 103. Prostate Cancer Mortality by Age Group and Gender, Nevada Residents, 1997-2001195 Table 104. Median Age at Death from Prostate Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001
SURVIVAL RATE
Figure 73. Survival Rates for Prostate Cancer by Race/Ethnicity, Nevada Residents, 1997-2001197 Figure 74. Survival Rates for Prostate Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1997-2001
Table 105. Cause-Specific Survival Rates for Prostate Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001
Table 106. Cause-Specific Survival Rates for Prostate Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1997-2001
COLORECTAL CANCER
GENERAL PROFILE <sup>4</sup>
Figure 75. Anatomy of the Digestive System <sup>5</sup> 201
HIGHLIGHTS
HIGHLIGHTS  SCREENING (BRFSS)  Table 107. Colorectal Cancer Screening by County/Region of Residence, Gender, Education, Age Group, and Income, Nevada Residents, 1997, 1999 and 2001
HIGHLIGHTS  SCREENING (BRFSS)  Table 107. Colorectal Cancer Screening by County/Region of Residence, Gender, Education, Age Group, and Income, Nevada Residents, 1997, 1999 and 2001
HIGHLIGHTS  SCREENING (BRFSS)  Table 107. Colorectal Cancer Screening by County/Region of Residence, Gender, Education, Age Group, and Income, Nevada Residents, 1997, 1999 and 2001
HIGHLIGHTS  SCREENING (BRFSS)  Table 107. Colorectal Cancer Screening by County/Region of Residence, Gender, Education, Age Group, and Income, Nevada Residents, 1997, 1999 and 2001
HIGHLIGHTS  SCREENING (BRFSS)  Table 107. Colorectal Cancer Screening by County/Region of Residence, Gender, Education, Age Group, and Income, Nevada Residents, 1997, 1999 and 2001
HIGHLIGHTS  SCREENING (BRFSS)  Table 107. Colorectal Cancer Screening by County/Region of Residence, Gender, Education, Age Group, and Income, Nevada Residents, 1997, 1999 and 2001
HIGHLIGHTS  SCREENING (BRFSS)  Table 107. Colorectal Cancer Screening by County/Region of Residence, Gender, Education, Age Group, and Income, Nevada Residents, 1997, 1999 and 2001
HIGHLIGHTS  SCREENING (BRFSS)  Table 107. Colorectal Cancer Screening by County/Region of Residence, Gender, Education, Age Group, and Income, Nevada Residents, 1997, 1999 and 2001
HIGHLIGHTS  SCREENING (BRFSS)  Table 107. Colorectal Cancer Screening by County/Region of Residence, Gender, Education, Age Group, and Income, Nevada Residents, 1997, 1999 and 2001
HIGHLIGHTS  SCREENING (BRFSS)  Table 107. Colorectal Cancer Screening by County/Region of Residence, Gender, Education, Age Group, and Income, Nevada Residents, 1997, 1999 and 2001

Residents, 1997-2001213
INPATIENT HOSPITAL DISCHARGES
Figure 79. Colorectal Cancer Age-Adjusted (2001) Inpatient Discharge Rates, Nevada Residents,
1997-2001214
Figure 80. Colorectal Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of
Residence, Nevada Residents, 1997-2001
Figure 81. Median Charges for Colorectal Cancer Inpatient Discharges by County/Region of
Residence, Nevada Residents, 1997-2001
Figure 82. Average Length of Stay for Colorectal Cancer Inpatient Discharges by County/Region of
Residence, Nevada Residents, 1997-2001
Table 116. Colorectal Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and
County/Region of Residence, Nevada Residents, 1997-2001
Table 117. Colorectal Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1997-2001
Table 118. Colorectal Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1997-2001
Table 119. Colorectal Cancer Inpatient Discharges by County/Region of Residence, Nevada
Residents, 1997-2001
Table 120. Colorectal Cancer Inpatient Discharges by Age Group, Charges and Length of Stay,
Nevada Residents, 1997-2001
MORTALITY
Figure 83. Colorectal Cancer Age-Adjusted (2001) Mortality Rates, Nevada Residents, 1997-2001221
Figure 84. Colorectal Cancer Age-Adjusted Mortality Rates by County/Region of Residence,
Nevada Residents, 1997-2001
Figure 85. Colorectal Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents,
1997-2001
Table 121. Colorectal Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence,
Nevada Residents, 1997-2001
Table 121. Colorectal Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence,
Nevada Residents, 1997-2001
Table 122. Colorectal Cancer Mortality by Age Group and County/Region of Residence, Nevada
Residents, 1997-2001
Table 123. Colorectal Cancer Mortality by County of Residence, Nevada Residents, 1997-2001225
Table 124. Colorectal Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1997-
2001225
Table 125. Colorectal Cancer Mortality by Age Group and Gender, Nevada Residents, 1997-2001226
Table 126. Median Age at Death from Colorectal Cancer by Race/Ethnicity and Gender, Nevada
Residents, 1997-2001
SURVIVAL RATE
Figure 86. Survival Rates for Colorectal Cancer by Race/Ethnicity, Nevada Residents, 1997-2001228
Figure 87. Survival Rates for Colorectal Cancer by Stage of Cancer at Diagnosis, Nevada Residents,
1997-2001
Table 127. Cause-Specific Survival Rates for Colorectal Cancer by Race/Ethnicity and Gender,
Nevada Residents, 1997-2001
Table 128. Cause-Specific Survival Rates for Colorectal Cancer by Stage of Cancer at Diagnosis and
Gender, Nevada Residents, 1997-2001 230

# URINARY BLADDER CANCER

GENERAL PROFILE <sup>4</sup>
Figure 88. Anatomy of the Urinary System <sup>5</sup>
HIGHLIGHTS
INCIDENCE
Figure 89. Urinary Bladder Cancer Age-Adjusted (2001) Incidence Rates, Nevada Residents, 1997-2001
Figure 90. Urinary Bladder Cancer Age-Adjusted Incidence Rates by County/Region of Residence,
Nevada Residents, 1997-2001
Figure 91. Urinary Bladder Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada
Residents, 1997-2001
Table 129. Urinary Bladder Cancer Cases by Gender, Race/Ethnicity and County/Region of
Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)237
Table 130. Urinary Bladder Cancer Cases by Age Group and County/Region of Residence at
Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)238
Table 131. Urinary Bladder Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1997-2001
Table 132. Urinary Bladder Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1997-2001
Table 133. Urinary Bladder Cancer Cases by Age Group and Gender, Nevada Residents, 1997-2001240
Table 134. Urinary Bladder Cancer Cases by Age Group and Stage, Nevada Residents, 1997-2001240
Table 135. Urinary Bladder Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1997-
2001
Table 136. Median Age at Diagnosis of Urinary Bladder Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001
INPATIENT HOSPITAL DISCHARGES
Figure 92. Urinary Bladder Cancer Age-Adjusted (2001) Inpatient Discharge Rates, Nevada
Residents, 1997-2001
Figure 93. Urinary Bladder Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of
Residence, Nevada Residents, 1997-2001
Figure 94. Median Charges for Urinary Bladder Cancer Inpatient Discharges by County/Region of
Residence, Nevada Residents, 1997-2001
Figure 95. Average Length of Stay for Urinary Bladder Cancer Inpatient Discharges by
County/Region of Residence, Nevada Residents, 1997-2001
Table 137. Urinary Bladder Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and
County/Region of Residence, Nevada Residents, 1997-2001
Table 138. Urinary Bladder Cancer Inpatient Discharges by Age Group and County/Region of
Residence, Nevada Residents, 1997-2001
Table 139. Urinary Bladder Cancer Inpatient Discharges by Age Group and Gender, Nevada
Residents, 1997-2001
Residents, 1997-2001
Table 141. Urinary Bladder Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1997-2001
MORTALITY
Figure 96, Urinary Bladder Cancer Age-Adjusted (2001) Mortality Rates, Nevada Residents, 1997-

2001	250
Figure 97. Urinary Bladder Cancer Age-Adjusted Mortality Rates by County/Region of Residence Nevada Residents, 1997-2001	
Figure 98. Urinary Bladder Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada	251
Table 142. Urinary Bladder Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1997-2001	251
Table 142. Urinary Bladder Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1997-2001	252
Table 143. Urinary Bladder Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001	
Table 144. Urinary Bladder Cancer Mortality by County of Residence, Nevada Residents, 1997-2001	
Table 145. Urinary Bladder Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1997-2001	
Table 146. Urinary Bladder Cancer Mortality by Age Group and Gender, Nevada Residents, 199	
Table 147. Median Age at Death from Urinary Bladder Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001	256
SURVIVAL RATE Figure 99. Survival Rates for Urinary Bladder Cancer by Race/Ethnicity, Nevada Residents, 199 2001	
Figure 100. Survival Rates for Urinary Bladder Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1997-2001	l
Table 148. Cause-Specific Survival Rates for Urinary Bladder Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001	258
Table 149. Cause-Specific Survival Rates for Urinary Bladder Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1997-2001	259
NON-HODGKIN'S LYMPHOMA	
GENERAL PROFILE <sup>4</sup> Figure 101. Anatomy of the Lymphatic System	261
HIGHLIGHTS	
INCIDENCE Figure 102. Non-Hodgkin's Lymphoma Age-Adjusted (2001) Incidence Rates, Nevada Resident 1997-2001	ts, 264
Figure 103. Non-Hodgkin's Lymphoma Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1997-2001	265
Figure 104. Non-Hodgkin's Lymphoma Age-Adjusted Incidence Rates by Race/Ethnicity, Nevac Residents, 1997-2001	
Table 150. Non-Hodgkin's Lymphoma Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)	
Table 151. Non-Hodgkin's Lymphoma Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)	
Table 152. Non-Hodgkin's Lymphoma Cases by County of Residence at Diagnosis, Nevada Residents, 1997-2001	268

Table 153. Non-Hodgkin's Lymphoma Cases by Race/Ethnicity and Gender, Nevada Residents,
1997-2001
Table 154. Non-Hodgkin's Lymphoma Cases by Age Group and Gender, Nevada Residents, 1997-2001
Table 155. Non-Hodgkin's Lymphoma Cases by Age Group and Stage, Nevada Residents, 1997-2001
Table 156. Non-Hodgkin's Lymphoma Cases by Stage and Race/Ethnicity, Nevada Residents, 1997-2001
Table 157. Median Age at Diagnosis of Non-Hodgkin's Lymphoma by Race/Ethnicity and Gender, Nevada Residents, 1997-2001
INPATIENT HOSPITAL DISCHARGES
Figure 105. Non-Hodgkin's Lymphoma Age-Adjusted (2001) Inpatient Discharge Rates, Nevada Residents, 1997-2001
Figure 106. Non-Hodgkin's Lymphoma Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1997-2001
Figure 107. Median Charges for Non-Hodgkin's Lymphoma Discharges by County/Region of Residence, Nevada Residents, 1997-2001
Figure 108. Average Length of Stay for Non-Hodgkin's Lymphoma Discharges by County/Region of Residence, Nevada Residents, 1997-2001
Table 158. Non-Hodgkin's Lymphoma Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001
Table 159. Non-Hodgkin's Lymphoma Discharges by Age Group and County/Region of Residence, Nevada Residents, 1997-2001
Table 160. Non-Hodgkin's Lymphoma Discharges by Age Group and Gender, Nevada Residents, 1997-2001
Table 161. Non-Hodgkin's Lymphoma Discharges by County/Region of Residence, Nevada Residents, 1997-2001
Table 162. Non-Hodgkin's Lymphoma Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1997-2001
MORTALITY
Figure 109. Non-Hodgkin's Lymphoma Age-Adjusted (2001) Mortality Rates, Nevada Residents, 1997-2001
Figure 110. Non-Hodgkin's Lymphoma Age-Adjusted Mortality Rates by County/Region of
Residence, Nevada Residents, 1997-2001
Figure 111. Non-Hodgkin's Lymphoma Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada
Residents, 1997-2001
Table 163. Non-Hodgkin's Lymphoma Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1997-2001
Table 163. Non-Hodgkin's Lymphoma Mortality by Gender, Race/Ethnicity and County/Region of
Residence, Nevada Residents, 1997-2001
Table 164. Non-Hodgkin's Lymphoma Mortality by Age Group and County/Region of Residence,
Nevada Residents, 1997-2001
Table 165. Non-Hodgkin's Lymphoma Mortality by County of Residence, Nevada Residents, 1997-
2001
Table 166. Non-Hodgkin's Lymphoma Mortality by Race/Ethnicity and Gender, Nevada Residents,
1997-2001
Table 167. Non-Hodgkin's Lymphoma Mortality by Age Group and Gender, Nevada Residents,

1997-2001	284
Table 168. Median Age at Death from Non-Hodgkin's Lymphoma by Race/Ethnicity and Gender, Nevada Residents, 1997-2001	
SURVIVAL RATE Figure 112. Survival Rates for Non-Hodgkin's Lymphoma by Race/Ethnicity, Nevada Residents, 1997-2001	
Figure 113. Survival Rates for Non-Hodgkin's Lymphoma by Stage of Cancer at Diagnosis, Neva Residents, 1997-2001	ıda
Table 169. Cause-Specific Survival Rates for Non-Hodgkin's Lymphoma by Race/Ethnicity and Gender, Nevada Residents, 1997-2001	
Table 170. Cause-Specific Survival Rates for Non-Hodgkin's Lymphoma by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1997-2001	
KIDNEY AND RENAL PELVIS CANCER	
GENERAL PROFILE <sup>4</sup> Figure 114. Anatomy of the Urinary System <sup>5</sup>	290
HIGHLIGHTS	
INCIDENCE Figure 115. Kidney and Renal Pelvis Cancer Age-Adjusted (2001) Incidence Rates, Nevada Residents, 1997-2001	294
Figure 116. Kidney and Renal Pelvis Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1997-2001	•
Figure 117. Kidney and Renal Pelvis Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1997-2001	295
Table 171. Kidney and Renal Pelvis Cancer Cases by Gender, Race/Ethnicity and County/Region Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)	
Table 172. Kidney and Renal Pelvis Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)	297
Table 173. Kidney and Renal Pelvis Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1997-2001	
Table 174. Kidney and Renal Pelvis Cancer Cases by Race/Ethnicity and Gender, Nevada Resider 1997-2001	
Table 175. Kidney and Renal Pelvis Cancer Cases by Age Group and Gender, Nevada Residents, 1997-2001	299
Table 176. Kidney and Renal Pelvis Cancer Cases by Age Group and Stage, Nevada Residents, 1997-2001	300
Table 177. Kidney and Renal Pelvis Cancer Cases by Stage and Race/Ethnicity, Nevada Residents 1997-2001	
Table 178. Median Age at Diagnosis of Kidney and Renal Pelvis Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001	301
INPATIENT HOSPITAL DISCHARGES	
Figure 118. Kidney and Renal Pelvis Cancer Age-Adjusted (2001) Inpatient Discharge Rates, Nevada Residents, 1997-2001	302
Figure 119. Kidney and Renal Pelvis Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1997-2001	303
Figure 120. Median Charges for Kidney and Renal Pelvis Cancer Inpatient Discharges by	

County/Region of Residence, Nevada Residents, 1997-2001
Figure 121. Average Length of Stay for Kidney and Renal Pelvis Cancer Inpatient Discharges by
County/Region of Residence, Nevada Residents, 1997-2001
Table 179. Kidney and Renal Pelvis Cancer Inpatient Discharges by Gender, Charges, Length of
Stay, and County/Region of Residence, Nevada Residents, 1997-2001305
Table 180. Kidney and Renal Pelvis Cancer Inpatient Discharges by Age Group and County/Region
of Residence, Nevada Residents, 1997-2001306
Table 181. Kidney and Renal Pelvis Cancer Inpatient Discharges by Age Group and Gender, Nevada
Residents, 1997-2001307
Table 182. Kidney and Renal Pelvis Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001
Table 183. Kidney and Renal Pelvis Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1997-2001308
MORTALITY
Figure 122. Kidney and Renal Pelvis Cancer Age-Adjusted (2001) Mortality Rates, Nevada
Residents, 1997-2001
Figure 123. Kidney and Renal Pelvis Cancer Age-Adjusted Mortality Rates by County/Region of
Residence, Nevada Residents, 1997-2001
Figure 124. Kidney and Renal Pelvis Cancer Age-Adjusted Mortality Rates by Race/Ethnicity,
Nevada Residents, 1997-2001
Table 184. Kidney and Renal Pelvis Cancer Mortality by Gender, Race/Ethnicity and County/Region
of Residence, Nevada Residents, 1997-2001310
Table 184. Kidney and Renal Pelvis Cancer Mortality by Gender, Race/Ethnicity and County/Region
of Residence, Nevada Residents, 1997-2001311
Table 185. Kidney and Renal Pelvis Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001
Table 186. Kidney and Renal Pelvis Cancer Mortality by County of Residence, Nevada Residents,
1997-2001
Table 187. Kidney and Renal Pelvis Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1997-2001
Table 188. Kidney and Renal Pelvis Cancer Mortality by Age Group and Gender, Nevada Residents, 1997-2001
Table 189. Median Age at Death from Kidney and Renal Pelvis Cancer by Race/Ethnicity and
Gender, Nevada Residents, 1997-2001
SURVIVAL RATE
Figure 125. Survival Rates for Kidney and Renal Pelvis Cancer by Race/Ethnicity, Nevada
Residents, 1997-2001316
Figure 126. Survival Rates for Kidney and Renal Pelvis Cancer by Stage of Cancer at Diagnosis,
Nevada Residents, 1997-2001
Table 190. Cause-Specific Survival Rates for Kidney and Renal Pelvis Cancer by Race/Ethnicity and
Gender, Nevada Residents, 1997-2001317
Table 191. Cause-Specific Survival Rates for Kidney and Renal Pelvis Cancer by Stage of Cancer at
Diagnosis and Gender, Nevada Residents, 1997-2001
LEUKEMIA
GENERAL PROFILE <sup>4</sup>
Figure 127. Anatomy of Stem Cell Maturation

# HIGHLIGHTS

INCIDENCE
Figure 128. Leukemia Age-Adjusted (2001) Incidence Rates, Nevada Residents, 1997-2001323
Figure 129. Leukemia Age-Adjusted Incidence Rates by County/Region of Residence, Nevada
Residents, 1997-2001324
Figure 130. Leukemia Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1997-
2001324
Table 192. Leukemia Cases by Gender, Race/Ethnicity and County/Region of Residence at
Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)325
Table 193. Leukemia Cases by Age Group and County/Region of Residence at Diagnosis, Nevada
Residents (1997-2001) and SEER-11 (1997-2001)
Table 194. Leukemia Cases by County of Residence at Diagnosis, Nevada Residents, 1997-2001.327
Table 195. Le ukemia Cases by Race/Ethnicity and Gender, Nevada Residents, 1997-2001327
Table 196. Leukemia Cases by Age Group and Gender, Nevada Residents,
1997-2001
Table 197. Leukemia Incidence by Age Group and Stage, Nevada Residents,
1997-2001
Table 198. Leukemia Cases by Stage and Race/Ethnicity,
Nevada Residents, 1997-2001
Table 199. Median Age at Diagnosis of Leukemia by Race/Ethnicity and Gender, Nevada Residents, 1997-2001
INPATIENT HOSPITAL DISCHARGES
Figure 131. Leukemia Age-Adjusted (2001) Inpatient Discharge Rates, Nevada Residents, 1997-
2001
Figure 132. Leukemia Age-Adjusted Inpatient Discharge Rates by County/Region of Residence,
Nevada Residents, 1997-2001
Figure 133. Median Charges for Leukemia Inpatient Discharges by County/Region of Residence,
Nevada Residents, 1997-2001
Figure 134. Average Length of Stay for Leukemia Inpatient Discharges by County/Region of
Residence, Nevada Residents, 1997-2001333
Table 200. Leukemia Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region
of Residence, Nevada Residents, 1997-2001
Table 201. Leukemia Inpatient Discharges by Age Group and County/Region of Residence, Nevada
Residents, 1997-2001
Table 202. Leukemia Inpatient Discharges by Age Group and Gender, Nevada Residents, 1997-200133
Table 203. Leukemia Inpatient Discharges by County/Region of Residence, Nevada Residents,
1997-2001337
Table 204. Leukemia Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada
Residents, 1997-2001
MORTALITY
Figure 135. Leukemia Age-Adjusted (2001) Mortality Rates, Nevada Residents, 1997-2001338
Figure 136. Leukemia Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1997-2001
Figure 137. Leukemia Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1997-
2001
Table 205. Leukemia Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada

Residents, 1997-2001	339
Table 205. Leukemia Mortality by Gender, Race/Ethnicity and County/Region of Residence, N. Residents, 1997-2001	
Table 206. Leukemia Mortality by Age Group and County/Region of Residence, Nevada Residence, 1997-2001	dents,
Table 207. Leukemia Mortality by County of Residence, Nevada Residents,	342
1997-2001	342
Table 208. Leukemia Mortality by Race/Ethnicity and Gender, Nevada Residents, 1997-2001.	342
Table 209. Leukemia Mortality by Age Group and Gender, Nevada Residents, 1997-2001	
Table 210. Median Age at Death from Leukemia by Race/Ethnicity and Gender, Nevada Resid	
SURVIVAL RATE	
Figure 138. Survival Rates for Leukemia by Race/Ethnicity, Nevada Residents, 1997-2001	345
Figure 139. Survival Rates for Leukemia by Stage of Cancer at Diagnosis, Nevada Residents, 2001	1997-
Table 211. Cause-Specific Survival Rates for Leukemia by Race/Ethnicity and Gender, Nevad Residents, 1997-2001	a
Table 212. Cause-Specific Survival Rates for Leukemia by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1997-2001	
LIP, ORAL CAVITY AND PHARYNX CANCER	
GENERAL PROFILE <sup>4</sup> Figure 140. Anatomy of the Oral Cavity <sup>5</sup>	349
HIGHLIGHTS	
INCIDENCE	
Figure 141. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted (2001) Incidence Rates, Neva-Residents, 1997-2001	
Figure 142. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Incidence Rates by County/Re of Residence, Nevada Residents, 1997-2001	
Figure 143. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Incidence Rates by Race/Ethn Nevada Residents, 1997-2001	
Table 213. Lip, Oral Cavity and Pharynx Cancer Cases by Gender, Race/Ethnicity and	
County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1 2001)	
Table 214. Lip, Oral Cavity and Pharynx Cancer Cases by Age Group and County/Region of	
Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)	355
Table 215. Lip, Oral Cavity and Pharynx Cancer Cases by County of Residence at Diagnosis,	
Nevada Residents, 1997-2001	
Table 216. Lip, Oral Cavity and Pharynx Cancer Cases by Race/Ethnicity and Gender, Nevada	t
Residents, 1997-2001	356
Table 217. Lip, Oral Cavity and Pharynx Cancer Cases by Age Group and Gender, Nevada	
Residents, 1997-2001	
Table 218. Lip, Oral Cavity and Pharynx Cancer Cases by Age Group and Stage, Nevada Resident 1997-2001	
Table 219. Lip, Oral Cavity and Pharynx Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1997-2001	359

Gender, Nevada Residents, 1997-2001359
INPATIENT HOSPITAL DISCHARGES
Figure 144. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted (2001) Inpatient Discharge Rates,
Nevada Residents, 1997-2001
Figure 145. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Inpatient Discharge Rates by
County/Region of Residence, Nevada Residents, 1997-2001
Figure 146. Median Charges for Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by
County/Region of Residence, Nevada Residents, 1997-2001
Figure 147. Average Length of Stay for Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges
by County/Region of Residence, Nevada Residents, 1997-2001
Table 221. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Gender, Charges, Length
of Stay, and County/Region of Residence, Nevada Residents, 1997-2001363
Table 222. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Age Group and
County/Region of Residence, Nevada Residents, 1997-2001
Table 223. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Age Group and Gender,
Nevada Residents, 1997-2001
Table 224. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by County/Region of
Residence, Nevada Residents, 1997-2001
Table 225. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Age Group, Charges and
Length of Stay, Nevada Residents, 1997-2001366
MORTALITY
Figure 148. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted (2001) Mortality Rates, Nevada
Residents, 1997-2001
Figure 149. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Mortality Rates by County/Region
of Residence, Nevada Residents, 1997-2001
Figure 150. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Mortality Rates by Race/Ethnicity,
Nevada Residents, 1997-2001
Table 226. Lip, Oral Cavity and Pharynx Cancer Mortality by Gender, Race/Ethnicity and
County/Region of Residence, Nevada Residents, 1997-2001
Table 227. Lip, Oral Cavity and Pharynx Cancer Mortality by Age Group and County/Region of
Residence, Nevada Residents, 1997-2001
Table 228. Lip, Oral Cavity and Pharynx Cancer Mortality by County of Residence, Nevada
Residents, 1997-2001
Table 229. Lip, Oral Cavity and Pharynx Cancer Mortality by Race/Ethnicity and Gender, Nevada
Residents, 1997-2001
Table 230. Lip, Oral Cavity and Pharynx Cancer Mortality by Age Group and Gender, Nevada
Residents, 1997-2001
Table 231. Median Age at Death from Lip, Oral Cavity and Pharynx Cancer by Race/Ethnicity and
Gender, Nevada Residents, 1997-2001
SURVIVAL RATE
Figure 151. Survival Rates for Lip, Oral Cavity and Pharynx Cancer by Race/Ethnicity, Nevada
Residents, 1997-2001
Figure 152. Survival Rates for Lip, Oral Cavity and Pharynx Cancer by Stage of Cancer at
Diagnosis, Nevada Residents, 1997-2001
Lanie 757 Cause-Specific Survival Rates for Lin Ural Cavity and Pharynx Cancer by

Race/Ethnicity and Gender, Nevada Residents, 1997-200137
Table 233. Cause-Specific Survival Rates for Lip, Oral Cavity and Pharynx Cancer by Stage of
Cancer at Diagnosis and Gender, Nevada Residents, 1997-200137
PANCREATIC CANCER
GENERAL PROFILE <sup>4</sup>
Figure 153. Anatomy of the Endocrine System <sup>5</sup>
HIGHLIGHTS
INCIDENCE
Figure 154. Pancreatic Cancer Age-Adjusted (2001) Incidence Rates, Nevada Residents, 1997-2001
Figure 155. Pancreatic Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1997-2001
Figure 156. Pancreatic Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents,
1997-2001
Table 234. Pancreatic Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at
Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)38
Table 235. Pancreatic Cancer Cases by Age Group and County/Region of Residence at Diagnosis,
Nevada Residents (1997-2001) and SEER-11 (1997-2001)
Table 236. Pancreatic Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1997-
200138
Table 237. Pancreatic Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1997-200138
Table 238. Pancreatic Cancer Cases by Age Group and Gender, Nevada Residents, 1997-200138
Table 239. Pancreatic Cancer Cases by Age Group and Stage, Nevada Residents, 1997-200138
Table 240. Pancreatic Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1997-200138
Table 241. Median Age at Diagnosis of Pancreatic Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001
INPATIENT HOSPITAL DISCHARGES
Figure 157. Pancreatic Cancer Age-Adjusted (2001) Inpatient Discharge Rates, Nevada Residents,
1997-2001
Figure 158. Pancreatic Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of
Residence, Nevada Residents, 1997-2001
Figure 159. Median Charges for Pancreatic Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001
Figure 160. Average Length of Stay for Pancreatic Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001
Table 242. Pancreatic Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001
Table 243. Pancreatic Cancer Inpatient Discharges by Age Group and County/Region of Residence,
Nevada Residents, 1997-2001
Table 244. Pancreatic Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1997-200139
Table 245. Pancreatic Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001
Table 246. Pancreatic Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1997-2001
MORTALITY

Figure 161. Pancreatic Cancer Age-Adjusted (2001) Mortality Rates, Nevada Residents, 1997-200139 Figure 162. Pancreatic Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1997-2001
Figure 163. Pancreatic Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1997-2001
Table 247. Pancreatic Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1997-2001
Table 248. Pancreatic Cancer Mortality by Age Group and County/Region of Residence, Nevada
Residents, 1997-2001
2001
Table 252. Median Age at Death from Pancreatic Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001
SURVIVAL RATE
Figure 164. Survival Rates for Pancreatic Cancer by Race/Ethnicity, Nevada Residents, 1997-2001403 Figure 165. Survival Rates for Pancreatic Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1997-2001
Table 253. Cause-Specific Survival Rates for Pancreatic Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001
Table 254. Cause-Specific Survival Rates for Pancreatic Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1997-2001
ALL OTHER CANCERS  Table 255. Cancer Incidence, Inpatient Hospital Discharges and Mortality by Type of Cancer,
Nevada Residents, 1997-2001

Table 262. Ovarian Cancer Cases by Age Group and County/Region of Residence at Diagnosis,	
Nevada Residents (1997-2001) and SEER-11 (1997-2001)	117
Table 263. Ovarian Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and	
County/Region of Residence, Nevada Residents, 1997-2001	118
Table 264. Ovarian Cancer Mortality by Age Group and County/Region of Residence, Nevada	
Residents, 1997-2001	119
THYROID GLAND CANCER	
Figure 169. Anatomical Drawing of the Thyroid Gland <sup>4</sup>	120
Table 265. Thyroid Gland Cancer Cases by Age Group and County/Region of Residence at	F∠U
Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)	121
	F∠ 1
Table 266. Thyroid Gland Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and	122
County/Region of Residence, Nevada Residents, 1997-2001	+22
Table 267. Thyroid Gland Cancer Mortality by Age Group and County/Region of Residence,	122
Nevada Residents, 1997-2001	123
BRAIN AND OTHER CENTRAL NERVOUS SYSTEM CANCER	
Figure 170. Anatomical Drawing of the Brain and Nearby Structures <sup>4</sup>	124
Table 268. Brain and Other Central Nervous System Cancer Cases by Age Group and	
County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997)	7-
2001)	
Table 269. Brain and Other Central Nervous System Cancer Inpatient Discharges by Gender,	
Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-20014	126
Table 270. Brain and Other Central Nervous System Cancer Mortality by Age Group and	
County/Region of Residence, Nevada Residents, 1997-2001	127
STOMACH CANCER	
Figure 171. Anatomical Drawing of the Esophagus and Stomach <sup>5</sup>	
Table 271. Stomach Cancer Mortality by Age Group and County/Region of Residence at Diagnosi	
Nevada Residents, 1997-2001	129
Table 272. Stomach Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and	
County/Region of Residence, Nevada Residents, 1997-2001	130
Table 273. Stomach Cancer Mortality by Age Group and County/Region of Residence, Nevada	
Residents, 1997-2001	131
LIVER AND INTRAHEPATIC BILE DUCTS CANCER	
Figure 172. Anatomical Drawing of the Digestive System <sup>5</sup>	132
	132
Table 274. Liver and Intrahepatic Bile Ducts Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)	122
	133
Table 275. Liver and Intrahepatic Bile Ducts Cancer Inpatient Discharges by Gender, Charges,	124
Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001	
Table 276. Liver and Intrahepatic Bile Ducts Cancer Mortality by Age Group and County/Region (	
Residence, Nevada Residents, 1997-2001	133
CERVICAL CANCER	
Figure 173. Anatomical Drawing of the Female Reproductive System <sup>4</sup>	136
Table 277. Cervical Cancer Screening by County/Region of Residence, Education, Age Group, an	
Income, Nevada Residents, 1997-2001	
Table 278. Cervical Cancer Cases by Age Group and County/Region of Residence at Diagnosis.	

Nevada Residents (1997-2001) and SEER-11 (1997-2001)	438
Table 279. Cervical Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and	420
County/Region of Residence, Nevada Residents, 1997-2001	
Table 280. Cervical Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001	
ESOPHAGEAL CANCER	4.4.1
Figure 174. Anatomical Drawing of the Esophagus and Stomach <sup>5</sup>	
Table 281. Esophageal Cancer Cases by Age Group and County/Region of Residence at Diagr Nevada Residents (1997-2001) and SEER-11 (1997-2001)	
Table 282. Esophageal Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and	
County/Region of Residence, Nevada Residents, 1997-2001	
Table 283. Esophageal Cancer Mortality by Age Group and County/Region of Residence, Nev	
Residents, 1997-2001	444
LARYNX CANCER	
Figure 175. Anatomy of the Oral Cavity <sup>5</sup>	445
Table 284. Larynx Cancer Cases by Age Group and County/Region of Residence at Diagnosis Nevada Residents (1997-2001) and SEER-11 (1997-2001)	
Table 285. Larynx Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001	447
Table 286. Larynx Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001	
MULTIPLE MYELOMA	
Figure 176. Picture of Myeloma Cells <sup>4</sup>	449
Table 287. Multiple Myeloma Cases by Age Group and County/Region of Residence at Diagn	
Nevada Residents (1997-2001) and SEER-11 (1997-2001)	450
Table 288. Multiple Myeloma Inpatient Discharges by Gender, Charges, Length of Stay, and	
County/Region of Residence, Nevada Residents, 1997-2001	
Table 289. Multiple Myeloma Mortality by Age Group and County/Region of Residence, Nev Residents, 1997-2001	
	732
HODGKIN'S LYMPHOMA	450
Figure 177. Anatomy of the Lymphatic System <sup>4</sup>	453
Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)	454
Table 291. Hodgkin's Lymphoma Inpatient Discharges by Gender, Charges, Length of Stay, a	
County/Region of Residence, Nevada Residents, 1997-2001	455
Table 292. Hodgkin's Lymphoma Mortality by Age Group and County/Region of Residence,	
Nevada Residents, 1997-2001	456
ALL OTHER SITES	
Table 293. Cancer Cases for All Other Sites by Age Group and County/Region of Residence a	
Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)	457
Table 294. Inpatient Discharges for All Other Sites by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001	458
Table 295. All Other Sites Cancer Mortality by Age Group and County/Region of Residence,	
Nevada Residents, 1997-2001	459

APPENDIX A – CODES USED FOR GROUPING	
Table 296. ICD-O Codes Used	461
Table 296. ICD-O Codes Used (Continued)	462
Table 297. ICD-9 and ICD-10 Codes Used	463
Table 297. ICD-9 and ICD-10 Codes Used (Continued)	464

# APPENDIX B – FORMULAS

**REFERENCES** 

FEEDBACK AND SUGGESTIONS

# **TECHNICAL NOTES**

This report brings together information from four primary data sources. The Nevada Central Cancer Registry (NCCR) within the Bureau of Health Planning and Statistics provided cancer incidence data. The Center for Health Information Analysis at the University of Nevada, Las Vegas (UNLV) provided inpatient hospital discharge (UB92) data. The Office of Vital Records (OVR), also within the Bureau of Health Planning and Statistics, provided the mortality data for this report. The Center for Applied Research at the University of Nevada, Reno (UNR) provided the Behavioral Risk Factor Surveillance System (BRFSS) data that were used to determine the rates of cancer screening.

General considerations that were made for this report include:

#### Aggregation of Data

This is a statistical report. Every attempt has been made to present the data in a format that does not allow the identification of any individual. While demographic information such as sex, race/ethnicity and age has been included in aggregate form, no attempt should be made to identify any individual detailed in this report.

#### Types of Cancer Classification Systems

The classification of the types of cancer was based upon a different coding system for each data source. The NCCR uses the International Classification of Disease, Oncology coding structure (ICD-O) that includes Topography (Primary Site) as well as Morphology (Tumor Type). This is similar to the ICD-10 system used in the 1999 and 2001 mortality data, to classify types of cancers. The 1997 to 1998 mortality data were coded using the ICD-9 classification system, which was also used by the inpatient hospital discharge data. A more detailed description of the codes used for this report is listed under considerations for each data source below, as well as in Appendix B.

#### Each data source is exclusive

While this report presents cancer data from four different sources, it is important to remember that each dataset is external to the others. Individual records were not linked for this report, so caution should be used when comparing data from each data source.

#### Selection of Residence

Only those events where the person was recorded as a Nevada resident at the time of diagnosis, time of discharge or time of death were included in this report. Those individuals who were listed as an Out of State resident were excluded.

#### County/Region of Residence

This report details regional data as: Clark County, Washoe County and All Other Counties, as regions. This aggregation of the 15 remaining counties within Nevada was implemented to accommodate the significantly smaller population

sizes in these counties. Aggregation of the smaller population minimizes any fluctuations in the disease rates presented in this report that may occur due to the large variance in the number of cancer events for each area due to the small size of the resident population for these remaining counties. The counties included in the All Other Counties region are: Carson City, Churchill, Douglas, Elko, Esmeralda, Eureka, Humboldt, Lander, Lincoln, Lyon, Mineral, Nye, Pershing, Storey, and White Pine.

#### Map Representation

The maps presented in this report are provided to facilitate visual comparisons of rates within the state. However, caution should be used when interpreting these rates due to the small cell size and large variance that are present within many of the smaller counties in Nevada.

#### Gender Specific Cancer Rates

For gender specific cancers, such as Prostate, Female Breast, Cervix Uteri, Corpus Uteri & Uterus Not Otherwise Specified (NOS), and Ovary Cancers the rates listed in this report are per 100,000 gender-specific population, unless otherwise noted.

#### Calculation of Rates and Confidence Intervals

Rates and their respective confidence intervals were not calculated for those categories where the number of events was less than ten.

#### Racial/Ethnic Groups

Race/ethnicity groups used in this report: White, Black, Native American, Asian, and Hispanic were calculated to be mutually exclusive, except for the National rates where a similar population base could not be calculated. So, National rates for racial/ethnic groups are calculated based on either the race or ethnicity listed on the record. These rates may not be directly comparable with others listed in this report.

While every effort was made to develop reliable comparisons between all the data sources, each source had their own unique factors to consider. Below, in detail, are the specific differences between each source and how this report uses each type of information.

#### **CANCER INCIDENCE STATISTICS:**

The cancer incidence statistics used for this report are from the NCCR, which compiles cancer cases that are reported by, or abstracted from, hospitals and pathology labs in Nevada. Both Chapter 457 of the Nevada Revised Statutes and those regulations adopted by the State Board of Health regulate the Nevada Central Cancer Registry. More information on the reporting of information on cancer can be found under Chapter 457 of the Nevada Administrative Code. The NCCR also receives information from other states on Nevada residents who were diagnosed, or are being treated, in other states. The main considerations for this data source include:

#### Cancer Registry Reporting

The NCCR is a population-based registry. The validity of the numbers and rates used in this report depend on the completeness of cancer reporting, as well as the accuracy of the population estimates used. The North American Association of Central Cancer Registries (NAACCR) estimates the most current year of data presented in this report (2001) at 100% complete for case ascertainment and meets all other requirements for gold certification. The estimated average completeness for case ascertainment over the five years of data presented in this report is 93.2%, which exceeds the 90% case ascertainment requirement set by NAACR for gold certification.

## Updated Data

The NCCR is constantly being updated with new information, so the numbers published in this report may not match, or be directly comparable, with previously published data. The data that are presented in this report are from the NCCR as of June 2004.

#### Type of Cancers Reported

The number of cases included in this report are those reported as having an invasive disease, except for Breast and Urinary Bladder Cancer that also include those diagnosed with an in situ cancer. This distinction is not available in the other data sources.

## Type of Cancer Classification System

The type of cancer was classified based on ICD-O2 Topography and Morphology codes. These codes provide levels of detail to the type of cancer that are not included in either the inpatient hospital discharge or mortality data. A detailed list of the actual groupings used for cancer incidence data, using both Topography and Morphology codes, can be found in Appendix B.

#### Survival Rates & Calculation

The survival rates listed in this report may not be directly comparable to National survival statistics. The reader should exercise caution in comparing statistics listed in this report to those nationally reported. Major factors that should be considered are:

- 1. The survival rates do not include those reported as an Autopsy Only or Death Certificate Only (DCO) case.
- 2. Only those individuals who died from cancer and those still alive at last update are included in these calculations. Those dying from other causes of death are not included. However, it should be noted that the cause of death is not necessarily specific to the type of cancer listed at time of diagnosis. This is to include those cases where the cancer may have metastasized to another site.
- 3. The NCCR actively matches registry records to the Nevada Death Registry on a continuous basis. National statistics are usually based on

- data submitted at a certain point in time without future updates and data improvements. While calculations account for this difference, caution should be used when comparing the two areas.
- 4. Those individuals who are recorded as having multiple primaries are included for the first primary only.
- 5. Calculations exclude records with invalid dates and unknown ages.
- 6. National statistics typically exclude those cases not actively followed. This report does not make this exclusion.

#### INPATIENT HOSPITAL DISCHARGE STATISTICS:

Inpatient Hospital Discharge data used for this report were compiled by the Center for Health Information Analysis (CHIA) at the University of Nevada, Las Vegas (UNLV/CHIA) from the universal billing form \*92, (UB92) for inpatient hospital discharges. These data represent patients discharged from January 1, 1997 through December 31, 2002, inclusive. This information was gathered and computerized by UNLV/CHIA as part of a contractual agreement between the Department of Human Resources and the University of Nevada under the authority granted in Section 439B of the Nevada Revised Statutes. The information was then given to the Center for Health Data and Research where it was analyzed for this report.

The main considerations for this data source include:

#### Primary Diagnosis Selection

The number of resident inpatient discharges detailed in this report is based on a primary diagnosis of cancer. However, the database contains up to fourteen additional diagnoses. The difference between the two classifications is that there were 59,688 inpatient discharges that had cancer as any of the fifteen diagnoses. The number drops to 33,235 for those with cancer as the primary diagnosis. So, approximately 58.6% of the inpatient discharges related to cancer are published in this report. This was done to minimize any confusion that might occur from someone being treated for different types of cancer, as well as to focus on those discharges where cancer was the primary reason for being admitted.

#### Occurrence Based Data

These statistics are based on the occurrence of inpatient hospital discharges. An individual could be counted more than once had they been admitted to the hospital for cancer more than once during this period. So, caution should be used when comparing inpatient hospital discharge data to the other data sources in this report.

#### Type of Cancer Classification System

The inpatient hospital discharge statistics were coded with the ICD-9 system. This is the same structure that is used for the 1997 to 1998 mortality data. However, mortality data changed in 1999 to the ICD-10 version. A detailed list of the codes used to produce the groupings provided in this report for inpatient hospital discharge statistics can be found in Appendix B.

#### Racial/Ethnic Groups

Race/ethnicity information is not available in this database.

#### **MORTALITY STATISTICS:**

Mortality statistics used in this report are from the Nevada Death Registry maintained by the Office of Vital Records. The OVR, within the Bureau of Health Planning and Statistics, is the official government entity that collects, processes and maintains the State of Nevada's vital records. Deaths are first recorded at the county level before being forwarded to the State Registrar. Funeral Directors, or persons acting as such, are legally charged with filing death certificates.

These certificates are checked for completeness and accuracy and then entered into a database on the State mainframe computer system. When a certificate is found to be inaccurate or incomplete, staff follow up with the providing entity in accordance with NRS 440.150 to make the necessary corrections and/or additions to make the record satisfactory and complete. It should be noted that the quality of mortality data presented in this report is directly related to the accuracy and completeness of the information contained on the death certificates.

The main considerations for this data source include:

#### Underlying Cause of Death

The mortality data presented in this report are classified by the underlying (primary) cause responsible for death. Only those deaths where the underlying cause of death was cancer are included in this report.

#### Type of Cancer Classification System

The 1997 to 1998 data used for this report were originally coded using the ICD-9 coding structure, while the 1999 and 2002 data were coded using the ICD-10 system. The ICD-9 system is a purely numeric coding system while the ICD-10 is an alphanumeric system. While there are many similarities between the ICD-9 and ICD-10 groupings, there are some differences between the types of cancer within the two versions. While there are comparability ratios available for the conversion between the two systems, the groups used in this report are based upon some customized groupings of which comparability ratios are unavailable. The mortality numbers in this report have not been adjusted for coding differences that may have occurred with the transition from the ICD-9 to ICD-10 system. A detailed list of the actual groupings used for cancer mortality data, with both the ICD-9 and ICD-10 codes, can be found in Appendix B.

#### **CANCER SCREENING STATISTICS:**

The cancer screening data shown in this report come from the Behavioral Risk Factor Surveillance System (BRFSS), which is funded by the Center for Disease Control and Prevention (CDC). The data were compiled by the Center for Applied Research at the University of Nevada, Reno (UNR/CAR), through the nation's largest telephone survey. The survey covers years from 1996 to 2001. This information was gathered and computerized by the Center for Applied Research as part of a contractual agreement between the Department of Human Resources and the University of Nevada. The information was then given to the Center for Health Data and Research where it was analyzed for this report.

The main considerations for this data source include:

#### Age of Respondents

The survey covers only those people 18 years of age and older.

#### • Frequency of questions

The tables presented in this report are not for 1996 to 2001 inclusively. Some of the questions were asked on alternate years, while some have only been asked once. So, caution should be used when comparing these data.

#### Weighted percentages

The percentages listed in this report are weighted on the survey population characteristics and may not match percentages that are directly calculated from the numbers listed in the table.

#### **NATIONAL STATISTICS:**

The only national cancer statistics provided in this report are for cancer incidence. This information is from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) program. This program is the most comprehensive source of population-based cancer incidence information available for the United States. SEER covers approximately 14 percent of the US population through 11 population-based cancer registries and three supplemental registries.

The information presented in this report is based upon the customized use of SEER's public-use data featured within the SEER\*Stat program. The databases used for calculations were the "SEER 11 Registries Public-Use Nov 2001 Sub for Expanded Races (1992-2001)" and "SEER 11 Registries Public-Use Nov 2001 Sub for Hispanics (1992-2001)". These databases are based upon SEER's 11 population-based cancer registries, which are: Atlanta, Connecticut, Detroit, Hawaii, Iowa, Los Angeles, New Mexico, San Francisco-Oakland, San Jose-Monterey, Seattle-Puget Sound, and Utah. These registries have been designed to represent the incidence of cancer within the aggregate population of the United States.

The main considerations for this data source include:

#### Aggregation of Data

National statistics published in this report follow the guidelines in the SEER Public-Use data agreement. Therefore, those categories where the number is less than five are not shown.

#### Cancer Registry Reporting

The national data in this report are based upon data collected from population-based registries. The validity of the numbers and rates used in this report depend upon the completeness of the cancer reporting, as well as the accuracy of the population estimates used.

## Period of Reportable Data

The most recent SEER data available are for the 1995 to 2001 period. So, it should be noted that comparisons in this report are based upon the 1997 to 2002 period for Nevada and the 1996 to 2001 period nationally.

### Type of Cancers Reported

The number of cases listed in this report are those cases reported as having malignant behavior, except for Breast and Urinary Bladder Cancer that include those diagnosed with an in situ behavior, in order to be comparable with Nevada data.

#### Prostate Cancer Stage Revision

Prostate Cancer cases where the stage of cancer at time of diagnosis was originally coded as "Localized/regional (Prostate Cases 1995+)" are shown as localized within this report. Therefore, there will not be any regionally diagnosed cases of Prostate Cancer for the Nation listed in this report.

#### Racial/Ethnic Groups

Race/ethnicity groupings, similar to Nevada, were not available for rates, since the population estimates provided in SEER\*Stat were not organized in a similar format. Rates were available by either race or ethnicity, which means that the national rates presented in this report represent rates of Whites, Blacks, Native Americans and Asians (of any ethnicity) and Hispanics (of any race). Caution should be used when interpreting these rates, which may not be directly comparable with others listed in this report.

#### **POPULATION ESTIMATES:**

The Nevada population data used in this report are based on the database established by the Nevada State Demographer's Office and the Nevada Department of Taxations, as well as 1990 and 2001 Census data from the US Bureau of the Census.


## **OVERVIEW**

## **OVERVIEW**

## **HIGHLIGHTS**

- Lung and Bronchus Cancer was the leading type of cancer for incidence, inpatient hospital discharges and mortality in Nevada from 1997 to 2001. This type of cancer accounted for 18.0% of the total cancer incidence, 14.9% of all cancer inpatient hospital discharges, and 32.0% of cancer mortality during this period.
- Thyroid Gland Cancer had by far the highest comparison ratio of incidence to mortality age-adjusted rates of any type of cancer in Nevada from 1997 to 2001, with a ratio of 20.54. This means that for every 100 deaths from Thyroid Gland Cancer there would be 2,054 cases. The second leading type was Uterine Cancer with a ratio of 5.98.
- Pancreatic Cancer had the lowest comparison ratio of incidence to mortality age-adjusted rates of any type of cancer in Nevada, with a ratio of 1.10 during this period. This means that for every 100 deaths from Pancreatic Cancer there were 110 cases. The second lowest leading type of cancer, Liver and Intrahepatic Bile Ducts, had a ratio of 1.20.

Figure 1. Top Ten Leading Types of Cancer by Percentage of Total Incidence, Discharges and Mortality, Nevada Residents, 1997-2001



Note: "N/A" indicates that this type of Cancer was not in the Top Ten for the respective data source.

Figure 2. Highest Incidence to Mortality Age-Adjusted Rate Ratios by Type of Cancer, Nevada Residents, 1997-2001




Figure 3. Lowest Incidence to Mortality Age-Adjusted Rate Ratios by Type of Cancer, Nevada Residents, 1997-2001




Table 1. Nevada Incidence, Inpatient Hospital Discharges and Mortality by Type of Cancer, Nevada, 1997-2001

Time of Course	Incide	nce	Inpatient Dis	scharges	Morta	lity
Type of Cancer	Number	Rate*	Number	Rate*	Number	Rate*
Total	40,863	453.43	33,235	364.78	17,459	204.62
Lip, Oral Cavity and Pharynx	994	10.62	526	5.55	225	2.53
Lip	49	0.53	8		1	
Base of Tongue	140	1.44	79	0.81	3	
Other & Unspecified Parts of Tongue	154	1.62	97	1.03	60	0.64
Parotid Gland	69	0.77	47	0.50	13	0.15
Other & Unspecified Major Salivary glands	29	0.32	9		3	
Floor of Mouth	85	0.93	59	0.60	4	
Gum	21	0.23	27	0.30	3	
Palate	39	0.41	12	0.13	4	
Other & Unspecified Parts of Mouth	52	0.58	27	0.29	25	0.29
Nasopharynx	50	0.54	23	0.24	24	0.26
Tonsil	125	1.31	46	0.48	15	0.16
Oropharynx	44	0.47	23	0.23	8	
Pyriform Sinus	46	0.49	20	0.21	0	
Hypopharynx	33	0.35	25	0.28	3	
Other & Unspecified Oral (Buccal) Cavity & Pharynx	58	0.65	24	0.26	59	0.68
Digestive System	7,357	84.57	6,591	75.45	4,003	47.36
Esophagus	481	5.30	297	3.23	384	4.23
Stomach	565	6.67	583	6.64	325	3.94
Small Intestine	106	1.17	135	1.48	28	0.32
Colon (excluding Rectum)	3,213	37.79	2,825	33.22	1,603	19.53
Cecum	672	8.05	548	6.66	6	
Appendix Ascending Colon	35	0.39	25 543	0.27	2	
· ·	424	5.09	543	6.44		
Hepatic Flexure	109 245	1.28 2.88	99 250	1.21	0 1	
Transverse Colon Splenic Flexure	245 91	1.03	101	2.95 1.18	0	
Descending Colon	147	1.63	155	1.73	0	
Sigmoid Colon	917	10.35	793	9.14	11	0.12
Large Intestine, NOS	573	7.09	311	3.63	1,580	19.23
Rectum	770	8.62	662	7.52	200	2.31
Rectosigmoid Junction	421	4.68	576	6.41	64	0.77
Anus, Anal Canal and Anorectum	126	1.34	133	1.47	24	0.77
Liver	442	4.87	308	3.28	351	4.03
Intrahepatic Bile Ducts	73	0.85	39	0.45	64	0.74
Gallbladder	61	0.74	38	0.47	43	0.53
Other & Unspecified Biliary Tract	100	1.20	145	1.73	34	0.42
Pancreas	951	10.84	741	8.36	845	9.82
Retroperitoneum	32	0.35	53	0.57	6	
Peritoneum, Omentum and Mesentery	3		52	0.56	7	
Other Digestive Organs	13	0.14	4		25	0.31
Respiratory System	7,758	86.35	5,337	58.35	5,729	65.24
Nasal Cavity and Middle Ear	31	0.36	11	0.12	0	
Accessory Sinuses	23	0.24	17	0.18	11	0.12
Larynx	348	3.78	203	2.18	124	1.41
Lung and Bronchus	7,336	81.77	4,965	54.28	5,582	63.56
Pleura	3		66	0.78	4	
Trachea	4		18	0.19	1	
Mediastinum and Other Respiratory Organs	13	0.13	57	0.62	7	
Bones, Joints and Articular Cartilage	90	0.95	116	1.23	37	0.44
Bones, Joints & Articular Cartilage of Limbs	43	0.46	48	0.51	1	
Bones, Joints & Articular Cartilage of Other & Unspec Sites	47	0.49	68	0.71	36	0.43
Soft Tissue (Including Heart)	215	2.32	125	1.38	121	1.34
Heart	1		2		8	
Peripheral Nerves & Autonomic Nervous System	8		0		3	
Connective, Subcutaneous & Other Soft Tissues	206	2.23	123	1.36	110	1.23

<sup>\*</sup> Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 1. Nevada Incidence, Inpatient Hospital Discharges and Mortality by Type of Cancer, Nevada, 1997-2001 (Continued)

- /-	Incide	nce	Inpatient Dis	scharges	Morta	lity
Type of Cancer	Number	Rate*	Number	Rate*	Number	Rate*
Total	40,863	453.43	33,235	364.78	17,459	204.62
Skin (Excluding Basal And Squamous)	1,189	12.82	240	2.72	345	3.89
Melanomas Of The Skin	1,083	11.59	83	0.91	264	2.92
Other Non-Epithelial Skin	106	1.23	157	1.81	81	0.98
Breast	6,493	70.45	2,608	28.45	1,195	14.02
Female Genital System*	2,250	47.38	2,349	49.24	690	15.03
Cervix Uteri*	497	10.39	646	13.39	140	2.99
Corpus Uteri*	808	16.94	801	16.73	59	1.30
Uterus, NOS*	44	0.96	27	0.58	75	1.70
Ovary*	737	15.54	669	14.04	376	8.16
Vagina*	39	0.83	53	1.13	12	0.25
Vulva*	112	2.45	117	2.63	15	0.35
Placenta*	1		1		1	
Other Female Genital Organs*	12	0.24	35	0.71	12	0.26
Male Genital System*	5,605	131.04	2,605	57.52	943	29.68
Prostate*	5,337	125.66	2,536	56.03	922	29.21
Testis*	237	4.63	51	0.98	17	0.34
Penis*	19	0.48	15	0.45	4	
Other Male Genital Organs*	12	0.40	3		0	
Urinary System	3,218	36.33	1,995	22.37	748	9.06
Urinary Bladder	2,068	23.86	1,022	11.93	401	5.09
Kidney	1,014	10.96	819	8.73	322	3.69
Renal Pelvis	76	0.84	86	0.73	5	3.09
Ureter	38		49		12	
		0.44		0.54		0.14
Other Urinary Organs	22 50	0.23 0.54	19 4	0.20	8 6	
Eye and Orbit						
Brain and Other Central Nervous System	580	6.21	762	8.05	338	3.71
Brain	540	5.78	706	7.47	335	3.68
Meninges	20	0.21	37	0.39	0	
Spinal Cord, Cranial Nerves, & Other Parts of CNS	20	0.22	19	0.19	3	
Endocrine System	757	7.77	1,032	10.56	53	0.61
Thyroid Gland	696	7.12	985	10.06	29	0.35
Adrenal Gland	30	0.33	21	0.22	15	0.17
Other Endocrine (Including Thymus)	31	0.32	26	0.28	9	
Hodgkin's Lymphoma	214	2.20	116	1.19	38	0.40
Non-Hodgkin's Lymphoma	1,316	14.65	988	11.01	599	7.08
Multiple Myeloma	372	4.20	321	3.49	261	3.02
Leukemia	1,059	12.05	1,080	11.77	614	7.39
Lymphocytic	451	5.03	440	4.72	164	2.06
Acute Lymphocytic	141	1.44	286	2.92	32	0.34
Chronic Lymphocytic	278	3.23	150	1.76	120	1.55
Other Lymphocytic	32	0.36	4		12	0.17
Myeloid and Monocytic	478	5.40	573	6.30	249	2.89
Acute Myeloid	330	3.66	458	5.00	180	2.07
Acute Monocytic	17	0.19	9		0	
Chronic Myeloid	108	1.27	103	1.17	53	0.63
Other Myeloid/Monocytic	23	0.28	3		16	0.19
Other	130	1.61	67	0.75	201	2.43
Other Acute	49	0.61	47	0.54	88	1.02
Aleukemic, Subleukemic and NOS	81	1.01	20	0.21	113	1.41
Mesothelioma	91	1.08	0		46	0.56
Kaposi Sarcoma	54	0.58	2		0	
Other, III-Defined and Unspecified Sites	1,201	13.98	6,438	70.48	1,468	17.57

<sup>\*</sup> Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 2. Leading Types of Cancer for Nevada Incidence, Inpatient Hospital Discharges and Mortality, Nevada Residents, 1997-2001

Type of Cancer	Incide	ence	Hos Admis		Mort	Mortality		
,	Number	Percent	Number	Percent	Number	Percent		
Lung and Bronchus	7,336	18.0%	4,965	14.9%	5,582	32.0%		
Breast	6,493	15.9%	4,196	12.6%	1,891	10.8%		
Prostate	5,337	13.1%	2,608	7.8%	1,195	6.8%		
Colorectal	4,530	11.1%	2,536	7.6%	922	5.3%		
Urinary Bladder	2,068	5.1%	1,080	3.2%	845	4.8%		
Non-Hodgkin's Lymphoma	1,316	3.2%	1,022	3.1%	614	3.5%		
Kidney and Renal Pelvis	1,090	2.7%	988	3.0%	599	3.4%		
Skin	1,083	2.7%	985	3.0%	415	2.4%		
Leukemia	1,059	2.6%	905	2.7%	401	2.3%		
Lip, Oral Cavity and Pharynx	994	2.4%	828	2.5%	384	2.2%		
Pancreas	951	2.3%	762	2.3%	376	2.2%		
Corpus Uteri & Uterus NOS	852	2.1%	741	2.2%	338	1.9%		
Ovary	737	1.8%	669	2.0%	327	1.9%		
Thyroid Gland	696	1.7%	646	1.9%	325	1.9%		
Brain and Other Central Nervous System	580	1.4%	583	1.8%	264	1.5%		
Stomach	565	1.4%	526	1.6%	261	1.5%		
Liver and Intrahepatic Bile Ducts	515	1.3%	347	1.0%	225	1.3%		
Cervix Uteri	497	1.2%	321	1.0%	140	0.8%		
Esophagus	481	1.2%	297	0.9%	134	0.8%		
Multiple Myeloma	372	0.9%	203	0.6%	124	0.7%		
Larynx	348	0.9%	116	0.3%	38	0.2%		
Hodgkin's Lymphoma	214	0.5%	83	0.2%	29	0.2%		
All Other Sites	2,749	6.7%	7,828	23.6%	2,030	11.6%		
Total	40,863	100.0%	33,235	100.0%	17,459	100.0%		

Note: Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 3. Top Ten Types of Cancer by Gender, Incidence, Hospital Discharges, and Mortality, Nevada Residents, 1997-2001

				То	otal				
Ranking	Incidenc	е		Hospital Adn	nissions		Mortality		
	Type	Number	Percent	Type	Number	Percent	Type	Number	Percent
1	Lung and Bronchus	7,336	18.0%	Lung and Bronchus	4,965	14.9%	Lung and Bronchus	5,582	32.0%
2	Breast	6,493	15.9%	Colorectal	4,196	12.6%	Colorectal	1,891	10.8%
3	Prostate	5,337	13.1%	Breast	2,608	7.8%	Breast	1,195	6.8%
4	Colorectal	4,530	11.1%	Prostate	2,536	7.6%	Prostate	922	5.3%
5	Urinary Bladder	2,068	5.1%	Leukemia	1,080	3.2%	Pancreas	845	4.8%
6	Non-Hodgkin's Lymphoma	1,316	3.2%	Urinary Bladder	1,022	3.1%	Leukemia	614	3.5%
7	Kidney and Renal Pelvis	1,090	2.7%	Non-Hodgkin's Lymphoma	988	3.0%	Non-Hodgkin's Lymphoma	599	3.4%
8	Skin	1,083	2.7%	Thyroid Gland	985	3.0%	Liver and Intrahepatic Bile Ducts	415	2.4%
9	Leukemia	1,059	2.6%	Kidney and Renal Pelvis	905	2.7%	Urinary Bladder	401	2.3%
10	Lip, Oral Cavity and Pharynx	994	2.4%	Corpus Uteri & Uterus NOS	828	2.5%	Esophagus	384	2.2%
	Total of Top 10	31,306		Total of Top 10	20,113	60.5%	Total of Top 10	12,848	73.6%
-	Total	40,863	100.0%	Total	33,235	100.0%	Total	17,459	100.0%

					Male				
Ranking	Incidenc	е		Hospital A	dmissions		Mortality		
	Туре	Number	Percent	Type	Number	Percent	Type	Number	Percent
1	Prostate	5,337	25.4%	Lung and Bronchus	2,601	16.1%	Lung and Bronchus	3,125	33.0%
2	Lung and Bronchus	3,970	18.9%	Prostate	2,536	15.7%	Colorectal	1,055	11.1%
3	Colorectal	2,419	11.5%	Colorectal	2,169	13.5%	Prostate	922	9.7%
4	Urinary Bladder	1,567	7.4%	Urinary Bladde r	762	4.7%	Pancreas	419	4.4%
5	Non-Hodgkin's Lymphoma	737	3.5%	Leukemia	628	3.9%	Leukemia	368	3.9%
6	Kidney and Renal Pelvis	706	3.4%	Kidney and Renal Pelvis	586	3.6%	Non-Hodgkin's Lymphoma	356	3.8%
7	Lip, Oral Cavity and Pharynx	695	3.3%	Non-Hodgkin's Lymphoma	550	3.4%	Esophagus	294	3.1%
8	Skin	634	3.0%	Brain and Other Central Nerv	ous System449	2.8%	Urinary Bladder	288	3.0%
9	Leukemia	629	3.0%	Stomach	398	2.5%	Liver and Intrahepatic Bile Ducts	272	2.9%
10	Pancreas	502	2.4%	Pancreas	390	2.4%	Kidney and Renal Pelvis	226	2.4%
							-		
	Total of Top 10	17,196	81.7%	Total of Top 10	11,069	68.6%	Total of Top 10	7,325	77.3%
-	Total	21,042	100.0%	Total	16,125	100.0%	Total	9,476	100.0%

				Fema	ale				
Ranking	Incidend	e		Hospital Admi	ssions		Mortality		
	Туре	Number	Percent	Type	Number	Percent	Type	Number	Percent
1	Breast	6,420	32.4%	Breast	2,589	15.1%	Lung and Bronchus	2,457	30.8%
2	Lung and Bronchus	3,366	17.0%	Lung and Bronchus	2,364	13.8%	Breast	1,182	14.8%
3	Colorectal	2,111	10.7%	Colorectal	2,027	11.8%	Colorectal	836	10.5%
4	Corpus Uteri & Uterus NOS	852	4.3%	Corpus Uteri & Uterus NOS	828	4.8%	Pancreas	426	5.3%
5	Ovary	737	3.7%	Thyroid Gland	769	4.5%	Ovary	376	4.7%
6	Non-Hodgkin's Lymphoma	579	2.9%	Ovary	669	3.9%	Leukemia	246	3.1%
7	Thyroid Gland	539	2.7%	Cervix Uteri	646	3.8%	Non-Hodgkin's Lymphoma	243	3.0%
8	Urinary Bladder	501	2.5%	Leukemia	452	2.6%	Liver and Intrahepatic Bile Ducts	143	1.8%
9	Cervix Uteri	497	2.5%	Non-Hodgkin's Lymphoma	438	2.6%	Cervix Uteri	140	1.8%
10	Pancreas	449	2.3%	Pancreas	351	2.1%	Corpus Uteri & Uterus NOS	134	1.7%
	Total of Top 10	16,051	81.0%	Total of Top 10	11,133	65.1%	Total of Top 10	6,183	77.5%
-	Total	19,821	100.0%	Total	17,110	100.0%	Total	7,983	100.0%

Note: Those of other/unknown gender are not listed separately, but are included in the total.

Table 4. Incidence to Mortality Age-Adjusted Rate Ratios for the Leading Types of Cancer, Nevada Residents, 1997-2001

Turns of Operator		Incidence	e		Mortality				
Type of Cancer	Number	Rate*	95% C.I.	Number	Rate*	95% C.I.	Ratio		
Lung and Bronchus	7,336	81.8	(79.9-83.7)	5,582	63.6	(61.9-65.3)	1.29		
Breast*	6,420	135.2	(131.9-138.6)	1,182	25.9	(24.4-27.4)	5.22		
Prostate*	5,337	125.7	(122.1-129.4)	922	29.2	(27.2-31.4)	4.30		
Colorectal	4,530	52.4	(50.9-54.0)	1,891	22.9	(21.8-24.0)	2.29		
Urinary Bladder	2,068	23.9	(22.8-24.9)	401	5.1	(4.6-5.6)	4.69		
Non-Hodgkin's Lymphoma	1,316	14.7	(13.9-15.5)	599	7.1	(6.5-7.7)	2.07		
Kidney and Renal Pelvis	1,090	11.8	(11.1-12.5)	327	3.7	(3.3-4.2)	3.15		
Leukemia	1,059	12.0	(11.3-12.8)	614	7.4	(6.8-8.0)	1.63		
Lip, Oral Cavity and Pharynx	994	10.6	(10.0-11.3)	225	2.5	(2.2-2.9)	4.21		
Pancreas	951	10.8	(10.1-11.6)	845	9.8	(9.1-10.5)	1.10		
Skin	1,083	11.6	(10.9-12.3)	264	2.9	(2.6-3.3)	3.98		
Corpus Uteri & Uterus NOS*	852	17.9	(16.7-19.2)	134	3.0	(2.5-3.6)	5.98		
Ovary*	737	15.5	(14.4-16.7)	376	8.2	(7.3-9.0)	1.90		
Thyroid Gland	696	7.1	(6.6-7.7)	29	0.3	(0.2-0.5)	20.54		
Brain and Other Central Nervous System	580	6.2	(5.7-6.8)	338	3.7	(3.3-4.2)	1.67		
Stomach	565	6.7	(6.1-7.3)	325	3.9	(3.5-4.4)	1.69		
Liver and Intrahepatic Bile Ducts	515	5.7	(5.2-6.2)	415	4.8	(4.3-5.3)	1.20		
Cervix Uteri*	497	10.4	(9.5-11.4)	140	3.0	(2.5-3.5)	3.48		
Esophagus	481	5.3	(4.8-5.8)	384	4.2	(3.8-4.7)	1.25		
Larynx	348	3.8	(3.4-4.2)	124	1.4	(1.2-1.7)	2.68		
Multiple Myeloma	372	4.2	(3.8-4.7)	261	3.0	(2.7-3.4)	1.39		
Hodgkin's Lymphoma	214	2.2	(1.9-2.5)	38	0.4	(0.3-0.6)	5.44		
All Other Sites	2,749	31.0	(29.8-32.2)	2,030	24.1	(23.1-25.2)	1.29		
Total	40,863	453.4	(448.9-457.9)	17,459	204.6	(201.5-207.8)	2.22		


 $<sup>\</sup>ast$  Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

## **INCIDENCE**

## **HIGHLIGHTS**

- Lung and Bronchus Cancer was the leading type of cancer in Nevada from 1997 to 2001. This type of cancer accounted for 18.0% of all resident cancer cases during this period. The second leading type, Breast Cancer, accounted for 15.9% of all cancer incidence.
- ➤ When compared to National (1997-2001) incidence, Nevada had a much higher incidence of Lung and Bronchus Cancer, 18.0% vs 12.9%, and a considerably lower incidence of Breast Cancer: 15.9% vs 18.2% during the 1997-2001 period.
- ➤ While Blacks had the highest ratio of the remaining racial/ethnic groups when compared to the age-adjusted cancer incidence rates for Whites, their ratio was just 0.94. This means that for every 100 White cancer cases Blacks would be expected to have 94 cases. Asians, Hispanics and Native Americans had comparison ratios of 0.49, 0.46 and 0.40, respectively, for Nevada from 1997 to 2001.
- ➤ Liver and Inrahepatic Bile Ducts had the highest age-adjusted incidence comparison ratio for Blacks when compared to Whites in Nevada from 1997 to 2001 with a comparison ratio of 1.68. Meaning for every 100 White Liver and Inrahepatic Bile Ducts cases Blacks would be expected to have 168 cases. This cancer type also had the highest comparison ratio for Asians with a 2.03 ratio. Stomach cancer had the highest comparison incidence ratio for Hispanics with 0.93. Multiple Myeloma had the highest comparison ratio for Native Americans when compared to Whites with a ratio of 1.90.
- ➤ Hodgkin's Lymphoma had the lowest median age at time of diagnosis for Nevada residents from 1997 to 2001 at 39 years. The median age for females diagnosed with Hodgkin's Lymphoma was 37 years, while for males it was 43 years.
- ➤ Stomach and Urinary Bladder Cancers had the highest median age at time of diagnosis for Nevada residents during the 1997 to 2001 period at 71 years. The median age for females diagnosed with Stomach Cancer was 72 years, while for males it was 70 years, which was equivalent to the median age at diagnosis of Urinary Bladder Cancer for males during this period.

Figure 4. Top Ten Leading Cancers as a Percentage of Total Cases, Nevada (1997-2001) and SEER-11 (1997-2001)



Note: "N/A" indicates that this type of Cancer was not in the Top Ten for the SEER region.

Figure 5. Comparison of Age-Adjusted (2001) Incidence Rates of Blacks compared to Whites, Nevada Residents, 1997-2001





Figure 6. Comparison of Age-Adjusted (2001) Incidence Rates of Native Americans compared to Whites, Nevada Residents, 1997-2001



Note: "N/A" indicates that a comparison ratio could not be calculated.

Figure 7. Comparison of Age-Adjusted (2001) Incidence Rates of Asians compared to Whites, Nevada Residents, 1997-2001




Figure 8. Comparison of Age-Adjusted (2001) Incidence Rates of Hispanics compared to Whites, Nevada Residents, 1997-2001




Table 5. Nevada Incidence by Type of Cancer, Nevada (1997-2001) and SEER-11 (1997-2001)

	Incid	dence (1997	-2001)	SE	ER-11 (1997-2	·2001)		
Type of Cancer	Number	Rate*	95% C.I.	Number	Rate*	95% C.I.		
Total	40,863	453.43	(448.9-457.9)	815,121	483.42	(482.4-484.5)		
Lip, Oral Cavity and Pharynx	994	10.62	(10.0-11.3)	18,648	11.04	(10.9-11.2)		
Lip	49	0.53	(0.4-0.7)	1,789	1.06	(1.0-1.1)		
Base of Tongue	140	1.44	(1.2-1.7)	1,855	1.11	(1.1-1.2)		
Other & Unspecified Parts of Tongue	154	1.62	(1.4-1.9)	2,400	1.42	(1.4-1.5)		
Parotid Gland	69	0.77	(0.6-1.0)	1,594	0.93	(0.9-1.0)		
Other & Unspecified Major Salivary glands	29	0.32	(0.2-0.5)	441	0.26	(0.2-0.3)		
Floor of Mouth	85	0.93	(0.7-1.2)	1,513	0.91	(0.9-1.0)		
Gum	21	0.23	(0.1-0.4)	736	0.44	(0.4-0.5)		
Palate	39	0.41	(0.3-0.6)	1,127	0.66	(0.6-0.7)		
Other & Unspecified Parts of Mouth	52	0.58	(0.4-0.8)	1,207	0.72	(0.7-0.8)		
Nasopharynx	50	0.54	(0.4-0.7)	1,331	0.77	(0.7-0.8)		
Tonsil	125	1.31	(1.1-1.6)	2,064	1.23	(1.2-1.3)		
Oropharynx	44	0.47	(0.3-0.6)	529	0.32	(0.3-0.3)		
Pyriform Sinus	46	0.49	(0.4-0.7)	978	0.59	(0.5-0.6)		
Hypopharynx	33	0.35	(0.2-0.5)	552	0.33	(0.3-0.4)		
Other & Unspecified Oral (Buccal) Cavity & Pharynx	58 7.057	0.65	(0.5-0.9)	532	0.32	(0.3-0.3)		
Digestive System	7,357	84.57	(82.6-86.6)	151,274	90.82	(90.4-91.3)		
Esophagus	481	5.30	(4.8-5.8)	7,483	4.49	(4.4-4.6)		
Stomach	565	6.67	(6.1-7.3)	15,187	9.10	(9.0-9.2)		
Small Intestine	106	1.17	(1.0-1.4)	2,753	1.64	(1.6-1.7)		
Colon (excluding Rectum)	3,213	37.79	(36.5-39.2)	64,345	38.75	(38.5-39.1)		
Cecum Appendix	672 35	8.05 0.39	(7.4-8.7)	14,990 714	9.05 0.42	(8.9-9.2)		
			(0.3-0.6)			(0.4-0.4)		
Ascending Colon	424 109	5.09 1.28	(4.6-5.6)	9,862 3,655	5.95 2.21	(5.8-6.1)		
Hepatic Flexure		2.88	(1.0-1.6)		3.60	(2.1-2.3)		
Transverse Colon Splenic Flexure	245 91	1.03	(2.5-3.3) (0.8-1.3)	5,972 2,483	1.49	(3.5-3.7) (1.4-1.6)		
Descending Colon	147	1.63	(1.4-1.9)	2,403 3,907	2.34	(2.3-2.4)		
Sigmoid Colon	917	10.35	(9.7-11.1)	19,474	11.70	(11.5-11.9)		
Large Intestine, NOS	573	7.09	(6.5-7.7)	3,288	1.99	(1.9-2.1)		
Rectum	770	8.62	(8.0-9.3)	16,598	9.93	(9.8-10.1)		
Rectosigmoid Junction	421	4.68	(4.2-5.2)	8,180	4.91	(4.8-5.0)		
Anus, Anal Canal and Anorectum	126	1.34	(1.1-1.6)	2,189	1.29	(1.2-1.3)		
Liver	442	4.87	(4.4-5.4)	8,044	4.79	(4.7-4.9)		
Intrahepatic Bile Ducts	73	0.85	(0.7-1.1)	1,460	0.88	(0.8-0.9)		
Gallbladder	61	0.74	(0.6-1.0)	2,064	1.24	(1.2-1.3)		
Other & Unspecified Biliary Tract	100	1.20	(1.0-1.5)	2,372	1.43	(1.4-1.5)		
Pancreas	951	10.84	(10.1-11.6)	18,152	10.93	(10.8-11.1)		
Retroperitoneum	32	0.35	(0.2-0.5)	737	0.43	(0.4-0.5)		
Peritoneum, Omentum and Mesentery	3			1,033	0.61	(0.6-0.7)		
Other Digestive Organs	13	0.14	(0.1-0.3)	677	0.41	(0.4-0.4)		
Respiratory System	7,758	86.35	(84.4-88.3)	114,569	68.69	(68.3-69.1)		
Nasal Cavity and Middle Ear	31	0.36	(0.2-0.5)	563	0.33	(0.3-0.4)		
Accessory Sinuses	23	0.24	(0.2-0.4)	621	0.37	(0.3-0.4)		
Larynx	348	3.78	(3.4-4.2)	6,718	4.02	(3.9-4.1)		
Lung and Bronchus	7,336	81.77	(79.9-83.7)	104,761	62.85	(62.5-63.2)		
Pleura	3			1,529	0.92	(0.9-1.0)		
Trachea	4			117	0.07	(0.1-0.1)		
Mediastinum and Other Respiratory Organs	13	0.13	(0.1-0.2)	260	0.14	(0.1-0.2)		
Bones, Joints and Articular Cartilage	90	0.95	(0.8-1.2)	1,618	0.90	(0.9-0.9)		
Bones, Joints & Articular Cartilage of Limbs	43	0.46	(0.3-0.6)	866	0.48	(0.4-0.5)		
Bones, Joints & Articular Cartilage of Other & Unspec Sites	47	0.49	(0.4-0.7)	752	0.42	(0.4-0.5)		
Soft Tissue (Including Heart)	215	2.32	(2.0-2.7)	4,924	2.81	(2.7-2.9)		
Heart	1		\	48	0.03	(0.0-0.0)		
Peripheral Nerves & Autonomic Nervous System	8			281	0.15	(0.1-0.2)		
Connective, Subcutaneous & Other Soft Tissues	206	2.23	(1.9-2.6)	4,595	2.63	(2.6-2.7)		
						· · · · · · · · · · · · · · · · · · ·		

<sup>\*</sup> Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Table 5. Nevada Incidence by Type of Cancer, Nevada (1997-2001) and SEER-11 (1997-2001) (Continued)

Name	T		Incidence		SEI	ER-11 (1995-	1999)
Skin (Excluding Basal And Squamous)	Type of Cancer	Number	Rate*	95% C.I.	Number	Rate*	95% C.I.
Melanomas OTThe Skin   1,083   11,093   11,093   12,093   12,093   16,131   (16.11-6.5)   Cherk OTHer Dithelial Skin   106   1.23   (10.11-5.5)   5,785   3.22   (2.13-3.3)   Breast*   2,260   47,38   (46.4-48.4)   5,000   55,03   (54.5-55.5)   6,262   (54.5-6.2)   Female Genital System*   2,260   47,38   (46.4-48.4)   8,000   55,03   (54.5-55.5)   6,000	Total	40,863	453.4	(448.9-457.9)	815,121	483.42	(482.4-484.5)
Melanomas OT The Skin   1,083   11,083   11,093   11,093   12,093   12,093   16,31   (16,1-16,5)   Cherk OTher Deliberial Skin   106   1,22   (13,1-9,136,5)   13,095   (13,1-9,136,5)   13,095   (13,1-9,136,5)   14,7688   16,28   (13,1-9,136,5)   14,7688   14,7688   16,28   (14,1-6,16,5)   14,7688   14,7689   14,7688   14,7	Chin (Evoluting Boool And Squamous)	1 100	10.00	(12.1.12.6)	24.077	10.52	(10.2.10.7)
Deba				,			,
Breast*         6,420         185.20         (131)-188.60         147,688         161,28         (165,545)         (56,555)         (54,555)         (54,555)         (54,555)         (56,555)         (54,555)         (56,555)         (54,555)         (56,555)         (54,555)         (56,555)         (56,555)         (56,555)         (56,555)         (56,555)         (56,555)         (56,555)         (56,670)         (56,700) <th< td=""><td></td><td></td><td></td><td>,</td><td></td><td></td><td>,</td></th<>				,			,
Female Cenital System*         2,250         47.38         (45.44.94)         50.00         55.03         (54.55.5)           Corpus Uten*         480         16.94         (15.81.82)         22.211         24.26         (23.924.6)           Uterus, NOS*         44         0.96         (0.71.3)         16.81         (14.16.7)         15.611         16.84         (16.61.71)           Valga*         39         0.83         (0.61.1)         15.611         16.84         (16.61.71)           Valga*         39         0.83         (0.61.1)         15.611         16.67         0.0         (0.61.31)           Placenta*         11         2.45         (20.30)         2.117         2.22         (21.23)           Placenta*         1         0.24         (0.10.4)         594         (0.64         (0.60.77)           Male Genital System*         5,05         13.104         (127.41.814)         115.22         (21.23)         (0.10.8)         (0.54)         (0.64         (0.66.77)           Male Genital System*         5,337         125.66         (127.12.94         119.272         165.54         (164.61.65.5)         (0.74.8)         (0.74.1)         (0.70.8)         (0.77.9)         (0.77.8)         (0.77.8)	• • • • • • • • • • • • • • • • • • •			, ,			
Cernix Uterir				,			
Corpus Uner*         488         (16,94)         (15,18-18.2)         22,211         24,26         (23,9-46)           Ubreus, NOS*         44         40,96         (0,7-13)         15,54         (14,4-16.7)         15,611         16,84         (16,6-17.1)           Valgna*         39         0,83         (0,6-11)         15,611         16,67         0,70         (0,6-0.2)           Valya*         112         2,45         (2,0-3.0)         2,117         2,22         (2,1-2.3)           Placanta*         1         -         -         66         0,00         (0,1-0.4)         0,00         (0,1-0.4)         0,00         (0,1-0.4)         0,00         (0,1-0.4)         0,00         (0,1-0.1)         0,00         (0,1-0.2)         0,00         (0,1-0.2)         0,00         (0,1-0.2)         0,00         (0,1-0.2)         0,00         (0,1-0.2)         0,00         (0,1-0.2)         0,00         (0,1-0.2)         0,00         (0,1-0.2)         0,00         (0,1-0.2)         0,00         (0,1-0.2)         0,00         (0,1-0.2)         0,00         (0,1-0.2)         0,00         (0,1-0.2)         0,00         (0,1-0.2)         0,00         (0,1-0.2)         0,00         (0,1-0.2)         0,00         (0,1-0.2)         0,	· · · · · · · · · · · · · · · · · · ·			,			
Uterius, NOS*   44   0,96   (0,7-13)   423   0,44   (0,4-0.5)     Ovary*   737   15.54   (14.4-16.1)   15.611   16.84   (16.6-17.1)     Vagina*   39   0.83   0.06-1.1   0.675   0.70   (0,6-0.8)     Vulva*   112   2.45   (203)   0.2117   0.22   (21.23)     Placenta*   1       0.86   0.09   (0,1-0.1)     Placenta*   5.605   131.04   (17.4-134.8)   15.594   0.06-0.7     Male Genital Organs*   5.605   131.04   (17.4-134.8)   119.272   (170.8-172.7)     Pascista*   5.605   131.04   (17.4-134.8)   119.272   (170.8-172.7)     Pascista*   237   4.63   (12.1-134.8)   119.272   (170.8-172.7)     Pascista*   129   0.48   (0.3-0.3)   4.95   0.50   (4.9-52.2)     Penis*   19   0.48   (0.3-0.8)   5.29   0.74   (0.7-0.8)     Other Male Genital Organs*   12   0.27   (0.1-0.6)   5.26   0.35   (0.3-0.4)     Urinary System   3,218   6.33   (35.1-37.7)   0.0         Urinary System   3,218   6.33   (35.1-37.7)   0.0         Urinary Bladder   2,068   23.86   (22.8-24.9)   32.84   20.01   (19.8-02.2)     Urinary Bladder   2,068   23.86   (22.8-24.9)   32.84   20.01   (19.8-02.2)     Urinary Drigans   22   0.23   (0.1-0.4)   15.55   (0.3-0.4)     Ureter   38   0.44   (0.3-0.6)   877   0.53   (0.5-0.6)     Other Urinary Organs   22   0.23   (0.1-0.4)   578   0.55   (0.3-0.4)     Eya and Orbit   5.50   5.51   (0.5-0.6)   (0.3-0.4)     Brain and Other Central Nervous System   550   6.21   (0.7-0.8)   (0.1-0.3)   (0.7-0.8)     Erain and Other Central Nervous System   576   7.77   (7.8-4)   (1.9-0.2)   (0.7-0.8)     Endocrine System   757   7.77   7.8-4   (1.9-0.2)   (0.3-0.4)   (0.3-0.4)   (0.3-0.4)     Endocrine System   757   7.77   7.8-4   (1.9-0.2)   (0.3-0.4)   (0.3-0							
Ovary's Valina's Valina'	·			,			,
Vagina*         39         0.83         0.06.1.1         657         0.70         (0.60-0.8)           Vulva*         112         2.45         50.20.3         2.117         2.22         (2.1-2.3)           Placenta*         1           68         0.09         (0.1-0.1)           Maie Genital System*         5.605         131.04         (17.4-134.8)         125.029         171.72         (164.6-165.5)           Penis*         5.33         71.566         (122.1-128.4)         19.272         (164.6-165.5)				, ,			
Vulvar         1112         2.45         (20-30)         2.117         2.22         (21-23)           Placental         1         1         0.0         (0.10-4)         564         0.06         (0.6-0.7)           Male Genital Organs*         12         0.24         (0.10-4)         1554         (170-8-172-7)           Prostate*         5,337         125.86         (122-1-120-4)         119,272         165.54         (164-6-165)           Tesits*         237         4.63         (121-120-4)         119,272         165.54         (164-6-165)         (167-60-100-100-100-100-100-100-100-100-100-	•			,			
Dither Female Genital Organs*   12   0.24   (0.10.4)   554   (0.60.7)   Male Genital System*   5.655   13.04   (171.41.48)   125.020   171.72   (170.8-172.71)   Prostate*   5.337   126.66   (122.1-120.4)   119.272   185.54   (164.6-166.5)   Tesiis*   7.538   1.00.60   1.00.70   1.00.				,			, ,
Other Female Genital Organs*         12         0.24         (0.10.4)         554         0.06.07           Male Genital System*         5.655         5.134         127.14.148         125.02         171.72         (170.8-172.72)           Prostate*         5.337         126.66         (122.1-12.94)         119.272         165.54         (164.6-16.5)           Testis*         237         4.63         (14.1.3)         4.96         5.03         (16.6-6.5)           Penis*         19         0.48         (0.3-0.8)         5.29         0.74         (0.7-0.8)           Other Male Genital Organs*         19         0.48         (0.3-0.8)         5.29         0.74         (0.7-0.8)           Urinary System         2.08         23.86         (22.8-24.9)         33.24         20.01         (19.8-20.2)           Kidney         76         0.84         (0.7-1.1)         1.65.22         9.55         (9.7-10.0)           Penal Delvis         76         0.84         (0.7-1.1)         1.558         0.94         (0.9-10.0)           Urieter         360         6.21         (5.7-6.8)         11.214         6.41         (6.9-6.7)           Eye and Orbit         400         400         7.7	Placenta*	1		, ,		0.09	,
Prostate*   5,337   125.66   (122.1-129.4   119.272   166.54   (164.6-166.5)   Testis*   19   0.48   (0.3-0.8)   5.29   0.74   (0.7-0.8)   Other Male Genital Organs*   12   0.27   (0.1-0.6)   5.29   0.74   (0.7-0.8)   Other Male Genital Organs*   3,218   36.33   (35.1-37.7)   0   0.3-0.4   Other Male Genital Organs*   2,068   23.86   (22.8-24.9)   33.284   20.01   (19.8-0.22)   Kidney   1,014   10.96   (10.3-11.7)   15.59   0.95   (0.3-0.4)   Renal Pelvis   76   0.84   (0.7-1.1)   1.558   0.94   (0.9-1.0)   Other Urinary Organs   22   0.23   (0.1-0.4)   578   0.35   (0.3-0.4)   Eye and Orbit   50   0.54   (0.7-1.1)   1.558   0.94   (0.9-1.0)   Frain and Other Central Nervous System   550   6.21   (5.7-6.8)   11.214   6.41   (6.3-6.5)   Brain and Other Central Nervous System   550   6.21   (0.1-0.3)   190   0.11   (0.1-0.1)   Spinal Cord, Cranial Nerves, & Other Parts of CNS   20   0.22   (0.1-0.3)   190   0.11   (0.1-0.1)   Spinal Cord, Cranial Nerves, & Other Parts of CNS   20   0.22   (0.1-0.3)   190   0.11   (0.1-0.1)   Throid Gland   696   7.12   (6.6-7.7)   11.85   6.6   (6.5-7.6.8)   Adrenal Gland   30   0.33   (0.2-0.5)   6.13   0.28   (0.3-0.3)   Other Endocrine (Including Thymus)   31   0.32   (0.2-0.5)   6.13   0.28   (0.3-0.3)   Other Endocrine (Including Thymus)   31   4.62   0.38-4.7   9.106   5.47   (5.4-6.8)   Hodgkin's Lymphoma   72   4.62   0.38-4.7   9.106   5.47   (5.4-6.8)   Hodgkin's Lymphoma   72   4.62   0.38-4.7   9.106   5.47   (5.4-6.8)   Hodgkin's Lymphocytic   451   0.34   0.38   0.2-0.5   0.36   0.3-0.3   0.3-0.3   Other Endocrine (Including Thymus)   31   0.32   0.3-0.3   0.3-	Other Female Genital Organs*	12	0.24	(0.1-0.4)	594	0.64	, ,
Testis*	Male Genital System*	5,605	131.04	(127.4-134.8)	125,029	171.72	(170.8-172.7)
Penis* Other Male Genital Organs*	Prostate*	5,337	125.66	(122.1-129.4)	119,272	165.54	(164.6-166.5)
Other Male Genital Organs*         12         0.27         (0.1-0.6)         261         0.35         (0.3-0.4)           Urinary System         3,218         36,33         (35,1-37,7)         0             Urinary Bladder         2,068         23,86         (22,8-24,9)         33,264         20,01         (19,8-20,2)           Kidney         1,014         1,036         (10,3-11,7)         16,592         9,85         (9,7-10.0)           Ureter         38         0,44         (0,3-0.6)         877         0,53         (0,5-0.6)           Other Urinary Organs         22         0,23         (0,1-0.4)         578         0,35         (0,7-0.8)           Brain and Other Central Nervous System         550         0,5-1         (0,1-0.4)         1578         0,79         (0,7-0.8)           Brain and Other Cantial Nerves, & Other Parts of CNS         20         0,21         (0,1-0.3)         190         0,11         (0,1-0.1)           Brain Aginal Cord, Canial Nerves, & Other Parts of CNS         20         0,22         (0,1-0.4)         483         0,27         (0,1-0.3)         10         0,11         (0,1-0.1)         1,1         0,1         0,1         0,1         0,1         0,1         0,1	Testis*	237	4.63	(4.1-5.3)	4,967	5.08	(4.9-5.2)
Urinary System	Penis*	19	0.48	(0.3-0.8)	529	0.74	(0.7-0.8)
Virinary Bladder	Other Male Genital Organs*	12	0.27	(0.1-0.6)	261	0.35	(0.3-0.4)
Kidney   1,014   10,96   (10,3-11.7)   16,592   9,85   (9,7-10.0)     Renal Pelvis   76   0.84   (0,7-1.1)   1,558   0.94   (0,9-1.0)     Ureter   38   0.44   (0,3-0.6)   877   0,53   (0,5-0.6)     Other Urinary Organs   22   0,23   (0,1-0.4)   578   0,35   (0,3-0.4)     Eye and Orbit   50   0,54   (0,4-0.7)   1,376   0,79   (0,7-0.8)     Brain and Other Central Nervous System   580   6,21   (5,7-6.8)   11,214   6,41   (6,3-6.5)     Brain   540   5,78   (5,3-6.3)   10,541   (6,0)   (0,1-0.1)     Spinal Cord, Cranial Nerves, & Other Parts of CNS   20   0,22   (0,1-0.3)   190   0,11   (0,1-0.1)     Spinal Cord, Cranial Nerves, & Other Parts of CNS   20   0,22   (0,1-0.4)   483   0,27   (0,2-0.3)     Endocrine System   757   7,77   (7,2-8.4)   13,034   7,22   (7,1-7.3)     Thyroid Gland   606   7,12   (6,6-7.7)   11,885   6,58   (6,5-6.7)     Adrenal Gland   30   0,33   (0,2-0.5)   533   0,28   (0,3-0.4)     Hodgkin's Lymphoma   214   2,20   (1,9-2.5)   5,019   0,271   (2,6-2.8)     Non-Hodgkin's Lymphoma   1,316   14,65   (1,3-9-1.5)   3,257   19,13   (18,9-1.9)     Multiple Myeloma   372   4,20   (1,3-1.2)   20,646   12,06   (1,9-1.2)     Acute Lymphocytic   451   5,03   (4,6-5.5)   8,924   5,18   (1,9-1.6)     Acute Lymphocytic   278   3,23   (2,3-3.7)   5,78   3,49   (3,4-5.6)     Chronic Lymphocytic   32   0,36   (0,2-0.5)   2,96   0,18   (1,9-1.2)     Granulocytic (Myeloid)   30   3,66   (3,3-4.1)   6,141   3,9   (3,5-3.7)     Chronic Myeloid   108   1,27   (1,0-1.6)   2,871   1,88   (1,6-1.7)     Other Monocytic   40   40   40   40   40   40   40   4	Urinary System			(35.1-37.7)	0		
Renal Pelvis         76         0.84         0.7-1.1)         1,558         0.94         (0.9-1.0)           Ureter         38         0.44         (0.3-0.6)         877         0.53         (0.5-0.6)           Other Urinary Organs         22         0.23         (0.1-0.4)         578         0.35         (0.5-0.4)           Eye and Orbit         50         0.54         (0.4-0.7)         1,376         0.79         (0.7-0.8)           Brain and Other Central Nervous System         580         6.21         (5.7-8.8)         11,214         6.41         (6.3-6.5)           Brain Brain All Other Central Nervous System         540         5.78         (5.3-6.3)         110,541         6.03         (5.9-6.1)           Meninges         20         0.21         (0.1-0.3)         190         0.11         (0.1-0.1)           Brain All Meninges         20         0.21         (0.1-0.3)         190         0.11         (0.1-0.1)           Brain All Meninges         20         0.21         (0.1-0.3)         190         0.11         (0.1-0.1)           All Meninges         20         0.21         (0.1-0.3)         190         0.11         (0.2-0.3)           All Meninges         20         0.02	Urinary Bladder		23.86	(22.8-24.9)		20.01	(19.8-20.2)
Ureter         38         0.44         (0.3-0.6)         877         0.53         (0.5-0.6)           Other Urinary Organs         22         0.23         (0.1-0.4)         578         0.35         (0.3-0.4)           Eye and Orbit         50         0.54         (0.4-0.7)         1.376         0.79         (0.7-0.8)           Brain and Other Central Nervous System         580         6.21         (5.7-6.8)         11,214         6.41         (6.3-6.5)           Brain and Other Central Nerves, System         580         6.21         (5.7-6.8)         11,214         6.41         (6.3-6.5)           Meninges         20         0.21         (0.1-0.3)         190         0.11         (0.1-0.1)           Spinal Cord, Cranial Nerves, & Other Parts of CNS         20         0.22         (0.1-0.4)         483         0.27         (0.2-0.3)           Endocrine System         757         7.77         (7.2-8.4)         13.03         0.2-0         11,885         6.58         (6.5-6.7)         11,885         6.58         (6.5-6.7)         11,885         6.58         (6.5-6.7)         11,885         6.58         (6.5-6.7)         11,885         6.58         (6.5-6.7)         11,812         (0.2-0.5)         636         0.36	Kidney	1,014	10.96	(10.3-11.7)	16,592	9.85	(9.7-10.0)
Other Urinary Organs         22         0.23         (0.1-0.4)         578         0.35         (0.3-0.4)           Eye and Orbit         50         0.54         (0.4-0.7)         1,376         0.79         (0.7-0.8)           Brain and Other Central Nervous System         580         6.21         (5.7-6.8)         11,214         6.41         6.03         (5.9-6.1)           Brain Meninges         20         0.21         (0.1-0.3)         190         0.11         (0.1-0.1)           Spinal Cord, Cranial Nerves, & Other Parts of CNS         20         0.22         (0.1-0.4)         483         0.27         (0.2-0.3)           Endocrine System         757         7.77         (7.2-8.4)         13,034         7.22         (7.1-7.3)           Thyroid Gland         696         7.12         (6.6-7.7)         11,885         6.58         (6.5-6.8)         6.65         (6.5-6.7)         11,815         6.58         (6.5-6.7)         11,815         6.58         (6.5-6.7)         11,815         6.58         (6.5-6.7)         11,815         6.58         (6.5-6.7)         11,815         6.58         (6.5-6.7)         11,815         6.58         (6.5-6.7)         11,815         6.58         6.58         (6.5-6.7)         11,815         (6.5-				(0.7-1.1)			
Eye and Orbit         50         0.54         (0.4-0.7)         1,376         0.79         (0.7-0.8)           Brain and Other Central Nervous System         580         6.21         (5.7-6.8)         11,214         6.41         (6.3-6.5)           Brain Brain         540         5.78         (5.3-6.3)         11,214         6.41         (6.3-6.5)           Meninges         20         0.21         (0.1-0.3)         190         0.11         (0.1-0.1)           Spinal Cord, Cranial Nerves, & Other Parts of CNS         20         0.22         (0.1-0.4)         483         0.27         (0.2-0.3)           Endocrine System         757         7.77         (7.2-8.4)         13,034         7.22         (7.1-7.3)           Thyroid Gland         696         7.12         (6.6-7.7)         11,885         6.58         (6.5-6.7)           Adrenal Gland         30         0.33         (0.2-0.5)         636         0.36         (0.3-0.3)           Other Endocrine (Including Thymus)         31         0.32         (0.2-0.5)         636         0.36         (0.3-0.3)           Molty Eymphoma         131         4.20         (1.9-2.5)         5.019         2.71         (2.6-2.8)           Non-Hodgkin's Lymphoma			0.44	(0.3-0.6)		0.53	(0.5-0.6)
Brain and Other Central Nervous System         580         6.21         (5.7-6.8)         11,214         6.41         (6.3-6.5)           Brain Meninges         540         5.78         (5.3-6.3)         10,541         6.03         (5.9-6.1)           Spinal Cord, Cranial Nerves, & Other Parts of CNS         20         0.22         (0.1-0.4)         483         0.27         (0.2-0.3)           Endocrine System         757         7.77         (7.2-8.4)         13,034         7.22         (7.1-7.3)           Thyroid Gland         696         7.12         (6.6-7.7)         11,885         6.58         (6.5-6.7)           Adrenal Gland         30         0.33         (0.2-0.5)         513         0.28         (0.3-0.3)           Hodgkin's Lymphoma         214         2.20         (1.9-2.5)         5.019         2.71         (2.6-2.8)           Non-Hodgkin's Lymphoma         1,316         14.65         (13.9-15.5)         32.597         19.13         (18.9-19.3)           Multiple Myeloma         372         4.20         (1.9-2.5)         5.019         2.71         (2.6-2.8)           Non-Hodgkin's Lymphomy         1,316         14.65         (1.3-12.8)         2.9.646         12.0         (1.9-13.9) <t< td=""><td>Other Urinary Organs</td><td></td><td></td><td>(0.1-0.4)</td><td></td><td></td><td></td></t<>	Other Urinary Organs			(0.1-0.4)			
Brain Meninges         540         5.78         (5.3-6.3)         10,541         6.03         (5.9-6.1)           Spinal Cord, Cranial Nerves, & Other Parts of CNS         20         0.21         (0.1-0.3)         190         0.11         (0.1-0.3)           Endocrine System         757         7.77         (7.2-8.4)         13,034         7.22         (7.1-7.3)           Thyroid Gland         696         7.12         (6.6-7.7)         11,885         6.58         (6.5-6.7)           Adrenal Gland         30         0.33         (0.2-0.5)         513         0.28         (0.3-0.3)           Other Endocrine (Including Thymus)         31         0.32         (0.2-0.5)         513         0.28         (0.3-0.3)           Modgkin's Lymphoma         214         2.20         (1.9-2.5)         5,019         2.71         (2.6-2.8)           Multiple Myeloma         37         4.20         (1.9-2.5)         32,597         19.13         (18.9-19.3)           Leukemia         1,059         12.05         (11.3-12.8)         20,646         12.06         (11.9-12.2)           Lymphocytic         451         5.03         (4.6-5.5)         8,924         5.18         (5.1-5.3)           Acute Lymphocytic	·			(0.4-0.7)			
Meninges Spinal Cord, Cranial Nerves, & Other Parts of CNS         20         0.21         (0.1-0.3)         190         0.11         (0.1-0.1)           Endocrine System         757         7.77         7.72-84         13,034         7.22         (0.1-0.3)           Thyroid Gland         696         7.12         (6.6-7.7)         11,885         6.58         (6.5-6.7)           Adrenal Gland         30         0.33         (0.2-0.5)         513         0.28         (0.3-0.3)           Other Endocrine (Including Thymus)         31         0.32         (0.2-0.5)         636         0.36         (0.3-0.4)           Hodgkin's Lymphoma         1,316         14.65         (13.9-15.5)         32,597         19.13         (18.9-19.3)           Multiple Myeloma         372         4.20         (1.9-2.5)         5,019         2.71         (2.6-2.8)           Leukemia         1,059         12.05         (11.3-12.8)         20.646         12.06         (11.9-12.2)           Leukemia         1,059         12.05         (11.3-12.8)         20.646         12.06         (11.9-12.2)           Leukemia         1,059         12.05         (11.3-12.8)         20.646         12.06         (11.9-12.2)           Leukemia	•			, ,			, ,
Spinal Cord, Cranial Nerves, & Other Parts of CNS         20         0.22         (0.1-0.4)         483         0.27         (0.2-0.3)           Endocrine System         757         7.77         (7.2-8.4)         13,034         7.22         (7.1-7.3)           Thyroid Gland         696         7.12         (6.6-7)         11,885         6.58         (0.3-0.3)           Adrenal Gland         30         0.33         (0.2-0.5)         636         0.36         (0.3-0.4)           Hodgkin's Lymphoma         214         2.20         (1.9-1.5)         5.09         2.71         (2.6-2.8)           Non-Hodgkin's Lymphoma         1,316         14.65         (13.9-15.5)         32,597         19.13         (18.9-19.3)           Multiple Myeloma         372         4.20         (13.8-4.7)         9,106         5.47         (5.4-5.6)           Leukemia         1,059         12.05         (11.3-11.2)         2.046         12.06         (11.9-12.2)           Acute Lymphocytic         451         5.03         (4.6-5.5)         8,924         5.18         (5.1-5.3)           Acute Lymphocytic         278         3.23         (2.8-3.7)         5,798         3.49         (3.4-3.6)           Other Lymphocytic <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>							
Endocrine System         757         7.77         (7.2-8.4)         13,034         7.22         (7.1-7.3)           Thyroid Gland         696         7.12         (6.6-7.7)         11,885         6.58         (6.5-6.7)           Adrenal Gland         30         0.33         (0.2-0.5)         513         0.28         (0.3-0.4)           Hodgkin's Lymphoma         214         2.20         (1.9-2.5)         5.019         2.71         (2.6-2.8)           Non-Hodgkin's Lymphoma         1,316         (16.5)         (13.9-15.5)         32.597         19.13         (18.9-19.3)           Multiple Myeloma         372         4.20         (3.8-4.7)         9,106         5.47         (5.4-5.6)           Leukemia         1,059         12.05         (11.3-12.8)         20.646         12.06         (11.9-12.2)           Lymphocytic         451         5.03         (4.6-5.5)         8,924         5.18         (5.1-5.3)           Acute Lymphocytic         278         3.23         (2.8-3.7)         5,798         3.49         (3.4-3.6)           Other Lymphocytic         32         0.36         (0.2-0.5)         296         0.18         (0.2-0.3)           Granulocytic (Myeloid)         #N/A         #N/A<	· ·						, ,
Thyroid Gland         696         7.12         (6.6-7.7)         11,885         6.58         (6.5-6.7)           Adrenal Gland         30         0.33         (0.2-0.5)         513         0.28         (0.3-0.3)           Other Endocrine (Including Thymus)         31         0.32         (0.2-0.5)         636         0.36         (0.3-0.4)           Hodgkin's Lymphoma         214         2.20         (1.9-2.5)         5,019         2.71         (2.6-2.8)           Non-Hodgkin's Lymphoma         1,316         14.65         (13.9-15.5)         32,597         19.13         (18.9-19.3)           Multiple Myeloma         372         4.20         (3.8-4.7)         9,106         5.47         (5.4-5.6)           Leukemia         1,059         12.05         (11.3-12.8)         20,646         12.06         (11.9-12.2)           Lymphocytic         451         5.03         (4.6-5.5)         8,924         5.18         (5.1-5.3)           Acute Lymphocytic         278         3.23         (2.8-3.7)         5,798         3.49         (3.4-3.6)           Other Lymphocytic         32         0.36         (0.2-0.5)         296         0.18         (0.2-0.2)           Granulocytic (Myeloid)         #N/A	·			, ,			
Adrenal Gland Other Endocrine (Including Thymus)         30         0.33         (0.2-0.5)         513         0.28         (0.3-0.3)           Other Endocrine (Including Thymus)         31         0.32         (0.2-0.5)         506         0.36         (0.3-0.4)           Hodgkin's Lymphoma         214         2.20         (1.9-2.5)         5019         2.71         (2.6-2.8)           Non-Hodgkin's Lymphoma         1,316         14.65         (13.9-15.5)         32,597         19.13         (18.9-19.3)           Multiple Myeloma         372         4.20         (3.8-4.7)         9,106         5.47         (5.4-5.6)           Leukemia         1,059         12.05         (11.3-12.8)         20,646         12.06         (11.9-12.2)           Lymphocytic         451         5.03         (4.6-5.5)         8,924         5.18         (5.1-5.6)           Acute Lymphocytic         278         3.23         (2.8-3.7)         5,798         3.49         (3.4-3.6)           Other Lymphocytic         32         0.36         (0.2-0.5)         296         0.18         (0.2-0.2)           Granulocytic (Myeloid)         330         3.66         (3.3-4.1)         6,141         3.59         (3.5-3.7)           Chronic Myel	•						
Other Endocrine (Including Thymus)         31         0.32         (0.2-0.5)         636         0.36         (0.3-0.4)           Hodgkin's Lymphoma         214         2.20         (1.9-2.5)         5,019         2.71         (2.6-2.8)           Non-Hodgkin's Lymphoma         1,316         14.65         (13.9-15.5)         32,597         19.13         (18.9-19.3)           Multiple Myeloma         372         4.20         (3.8-4.7)         9,106         5.47         (5.4-5.6)           Leukemia         1,059         12.05         (11.3-12.8)         20,646         12.06         (11.9-12.2)           Lymphocytic         451         5.03         (4.6-5.5)         8,924         5.18         (5.1-5.3)           Acute Lymphocytic         278         3.23         (2.8-3.7)         5,798         3.49         (3.4-3.6)           Other Lymphocytic         32         0.36         (0.2-0.5)         296         0.18         (0.2-0.2)           Granulocytic (Myeloid)         #N/A         #N/A         #N/A         9,175         5.36         (5.3-5.5)           Acute Myeloid         330         3.66         (3.3-4.1)         6,14         3.59         (3.5-3.7)           Other Myeloid         #N/A				, ,			
Hodgkin's Lymphoma         214         2.20         (1.9-2.5)         5,019         2.71         (2.6-2.8)           Non-Hodgkin's Lymphoma         1,316         14.65         (13.9-15.5)         32,597         19.13         (18.9-19.3)           Multiple Myeloma         372         4.20         (3.8-4.7)         9,106         5.47         (5.4-5.6)           Leukemia         1,059         12.05         (11.3-12.8)         20,646         12.06         (11.9-12.2)           Lymphocytic         451         5.03         (4.6-5.5)         8,924         5.18         (5.1-5.3)           Acute Lymphocytic         278         3.23         (2.8-3.7)         5,798         3.49         (3.4-3.6)           Other Lymphocytic         32         0.36         (0.2-0.5)         296         0.18         (0.2-0.2)           Granulocytic (Myeloid)         #N/A         #N/A         #N/A         9,175         5.36         (5.3-5.5)           Acute Myeloid         330         3.66         (3.3-4.1)         6,141         3.59         (3.5-3.7)           Chronic Myeloid         #N/A         #N/A         #N/A         #N/A         48/A         48/A         0.10         0.10-1.1           Monocytic <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>, ,</td></t<>							, ,
Non-Hodgkin's Lymphoma         1,316         14.65         (13.9-15.5)         32,597         19.13         (18.9-19.3)           Multiple Myeloma         372         4.20         (3.8-4.7)         9,106         5.47         (5.4-5.6)           Leukemia         1,059         12.05         (11.3-12.8)         20,646         12.06         (11.9-12.2)           Lymphocytic         451         5.03         (4.6-5.5)         8,924         5.18         (5.1-5.3)           Acute Lymphocytic         141         1.44         (1.2-1.7)         2,830         1.51         (1.5-1.6)           Chronic Lymphocytic         278         3.23         (2.8-3.7)         5,798         3.49         (3.4-3.6)           Other Lymphocytic         32         0.36         (0.2-0.5)         296         0.18         (0.2-0.2)           Granulocytic (Myeloid)         #N/A         #N/A         #N/A         9,175         5.36         (5.3-5.5)           Acute Myeloid         330         3.66         (3.3-4.1)         6,141         3.59         (3.5-3.7)           Chronic Myeloid         #N/A         #N/A         #N/A         4N/A         4N/A         40.4         16.8         (1.6-1.7)           Acute Myeloid	, <b>,</b> ,			, ,			, ,
Multiple Myeloma         372         4.20         (3.8-4.7)         9,106         5.47         (5.4-5.6)           Leukemia         1,059         12.05         (11.3-12.8)         20,646         12.06         (11.9-12.2)           Lymphocytic         451         5.03         (4.6-5.5)         8,924         5.18         (5.1-5.3)           Acute Lymphocytic         278         3.23         (2.8-3.7)         5,798         3.49         (3.4-3.6)           Other Lymphocytic         32         0.36         (0.2-0.5)         296         0.18         (0.2-0.2)           Granulocytic (Myeloid)         #N/A         #N/A         #N/A         9,175         5.36         (5.3-5.5)           Acute Myeloid         330         3.66         (3.3-4.1)         6,141         3.59         (3.5-3.7)           Chronic Myeloid         108         1.27         (1.0-1.6)         2,871         1.68         (1.6-1.7)           Other Myeloid         #N/A         #N/A         #N/A         48/A         48/A         163         0.10         (0.1-0.1)           Monocytic         #N/A         #N/A         #N/A         48/A         48/A         48/A         18         0.01         (0.2-0.3)	• • • • • • • • • • • • • • • • • • • •						
Leukemia         1,059         12.05         (11.3-12.8)         20,646         12.06         (11.9-12.2)           Lymphocytic         451         5.03         (4.6-5.5)         8,924         5.18         (5.1-5.3)           Acute Lymphocytic         141         1.44         (1.2-1.7)         2,830         1.51         (1.5-1.6)           Chronic Lymphocytic         278         3.23         (2.8-3.7)         5,798         3.49         (3.4-3.6)           Other Lymphocytic (Myeloid)         32         0.36         (0.2-0.5)         296         0.18         (0.2-0.2)           Granulocytic (Myeloid)         #N/A         #N/A         #N/A         9,175         5.36         (5.3-5.5)           Acute Myeloid         330         3.66         (3.3-4.1)         6,141         3.59         (3.5-3.7)           Chronic Myeloid         108         1.27         (1.0-1.6)         2,871         1.68         (1.6-1.7)           Other Myeloid         #N/A         #N/A         #N/A         48N/A         439         0.26         (0.2-0.3)           Acute Myeloid         #N/A         #N/A         #N/A         48N/A         463         0.10         (0.1-0.1)           Monocytic         #N/A	· · · · · · · · · · · · · · · · · · ·						, ,
Lymphocytic         451         5.03         (4.6-5.5)         8,924         5.18         (5.1-5.3)           Acute Lymphocytic         141         1.44         (1.2-1.7)         2,830         1.51         (1.5-1.6)           Chronic Lymphocytic         278         3.23         (2.8-3.7)         5,798         3.49         (3.4-3.6)           Other Lymphocytic (Myeloid)         32         0.36         (0.2-0.5)         296         0.18         (0.2-0.2)           Granulocytic (Myeloid)         #N/A         #N/A         #N/A         9,175         5.36         (5.3-5.5)           Acute Myeloid         330         3.66         (3.3-4.1)         6,141         3.59         (3.5-3.7)           Chronic Myeloid         108         1.27         (1.0-1.6)         2,871         1.68         (1.6-1.7)           Other Myeloid         #N/A         #N/A         #N/A         #N/A         48/A         439         0.26         (0.2-0.3)           Acute Monocytic         #N/A         #N/A         #N/A         #N/A         48/A         439         0.26         (0.2-0.3)           Acute Monocytic         17         0.19         (0.1-0.3)         407         0.24         (0.2-0.3)	• •						
Acute Lymphocytic 141 1.44 (1.2-1.7) 2,830 1.51 (1.5-1.6) Chronic Lymphocytic 278 3.23 (2.8-3.7) 5,798 3.49 (3.4-3.6) Other Lymphocytic 32 0.36 (0.2-0.5) 296 0.18 (0.2-0.2) Granulocytic (Myeloid) #N/A #N/A #N/A 9,175 5.36 (5.3-5.5) Acute Myeloid 330 3.66 (3.3-4.1) 6,141 3.59 (3.5-3.7) Chronic Myeloid 108 1.27 (1.0-1.6) 2,871 1.68 (1.6-1.7) Other Myeloid #N/A #N/A #N/A #N/A 163 0.10 (0.1-0.1) Monocytic #N/A #N/A #N/A #N/A 439 0.26 (0.2-0.3) Acute Monocytic #N/A #N/A #N/A #N/A 439 0.26 (0.2-0.3) Chronic Monocytic #N/A #N/A #N/A #N/A #N/A 18 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A #N/A #N/A 18 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other Acute 49 0.61 (1.3-1.9) 2,108 1.26 (1.2-1.3) Other Acute 49 0.61 (0.4-0.8) 775 0.47 (0.4-0.5) Other Chronic MNOS 81 1.01 (0.8-1.3) 1,283 0.76 (0.7-0.8)							
Chronic Lymphocytic Other Lymphocytic         278         3.23         (2.8-3.7)         5,798         3.49         (3.4-3.6)           Other Lymphocytic         32         0.36         (0.2-0.5)         296         0.18         (0.2-0.2)           Granulocytic (Myeloid)         #N/A         #N/A         #N/A         9,175         5.36         (5.3-5.5)           Acute Myeloid         330         3.66         (3.3-4.1)         6,141         3.59         (3.5-3.7)           Chronic Myeloid         108         1.27         (1.0-1.6)         2,871         1.68         (1.6-1.7)           Other Myeloid         #N/A         #N/A         #N/A         #N/A         163         0.10         (0.1-0.1)           Monocytic         #N/A         #N/A         #N/A         439         0.26         (0.2-0.3)           Acute Monocytic         #N/A         #N/A         #N/A         407         0.24         (0.2-0.3)           Chronic Monocytic         #N/A         #N/A         #N/A         18         0.01         (0.0-0.0)           Other Monocytic         #N/A         #N/A         #N/A         #N/A         14         0.01         (0.0-0.0)           Other Monocytic         #N/A				, ,			, ,
Other Lymphocytic         32         0.36         (0.2-0.5)         296         0.18         (0.2-0.2)           Granulocytic (Myeloid)         #N/A         #N/A         #N/A         9,175         5.36         (5.3-5.5)           Acute Myeloid         330         3.66         (3.3-4.1)         6,141         3.59         (3.5-3.7)           Chronic Myeloid         108         1.27         (1.0-1.6)         2,871         1.68         (1.6-1.7)           Other Myeloid         #N/A         #N/A         #N/A         #N/A         163         0.10         (0.1-0.1)           Monocytic         #N/A         #N/A         #N/A         4N/A         439         0.26         (0.2-0.3)           Chronic Monocytic         17         0.19         (0.1-0.3)         407         0.24         (0.2-0.3)           Other Monocytic         #N/A         #N/A         #N/A         18         0.01         (0.0-0.0)           Other Monocytic         #N/A         #N/A         #N/A         14         0.01         (0.0-0.0)           Other Monocytic         #N/A         #N/A         #N/A         14         0.01         (0.0-0.0)           Other         130         1.61         (1.3-1.9)							,
Granulocytic (Myeloid)         #N/A         #N/A         #N/A         9,175         5.36         (5.3-5.5)           Acute Myeloid         330         3.66         (3.3-4.1)         6,141         3.59         (3.5-3.7)           Chronic Myeloid         108         1.27         (1.0-1.6)         2,871         1.68         (1.6-1.7)           Other Myeloid         #N/A         #N/A         #N/A         163         0.10         (0.1-0.1)           Monocytic         #N/A         #N/A         #N/A         439         0.26         (0.2-0.3)           Acute Monocytic         17         0.19         (0.1-0.3)         407         0.24         (0.2-0.3)           Chronic Monocytic         #N/A         #N/A         #N/A         18         0.01         (0.0-0.0)           Other Monocytic         #N/A         #N/A         #N/A         14         0.01         (0.0-0.0)           Other Monocytic         #N/A         #N/A         #N/A         #N/A         14         0.01         (0.0-0.0)           Other         130         1.61         (1.3-1.9)         2,108         1.26         (1.2-1.3)           Other Chronic         49         0.61         (0.4-0.8)         775							, ,
Acute Myeloid 330 3.66 (3.3-4.1) 6,141 3.59 (3.5-3.7) Chronic Myeloid 108 1.27 (1.0-1.6) 2,871 1.68 (1.6-1.7) Other Myeloid #N/A #N/A #N/A #N/A 163 0.10 (0.1-0.1) Monocytic #N/A #N/A #N/A #N/A 439 0.26 (0.2-0.3) Acute Monocytic 17 0.19 (0.1-0.3) 407 0.24 (0.2-0.3) Chronic Monocytic #N/A #N/A #N/A #N/A 18 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other Acute 49 0.61 (1.3-1.9) 2,108 1.26 (1.2-1.3) Other Acute 49 0.61 (0.4-0.8) 775 0.47 (0.4-0.5) Other Chronic #N/A #N/A #N/A #N/A #N/A 50 0.03 (0.0-0.0) Aleukemic, Subleukemic and NOS 81 1.01 (0.8-1.3) 1,283 0.76 (0.7-0.8)							
Chronic Myeloid         108         1.27         (1.0-1.6)         2,871         1.68         (1.6-1.7)           Other Myeloid         #N/A         #N/A         #N/A         163         0.10         (0.1-0.1)           Monocytic         #N/A         #N/A         #N/A         439         0.26         (0.2-0.3)           Acute Monocytic         17         0.19         (0.1-0.3)         407         0.24         (0.2-0.3)           Chronic Monocytic         #N/A         #N/A         #N/A         18         0.01         (0.0-0.0)           Other Monocytic         #N/A         #N/A         #N/A         14         0.01         (0.0-0.0)           Other Monocytic         #N/A         #N/A         #N/A         14         0.01         (0.0-0.0)           Other Monocytic         #N/A         #N/A         #N/A         14         0.01         (0.0-0.0)           Other Monocytic         #N/A         #N/A         #N/A         #N/A         14         0.01         (0.0-0.0)           Other Monocytic         #N/A         4N/A         #N/A         #N/A         14         0.01         (0.0-0.0)           Other Monocytic         #N/A         49         0.61         (0.4-							, ,
Other Myeloid         #N/A         #N/A         #N/A         #N/A         48/A         439         0.26         (0.1-0.1)           Monocytic         #N/A         #N/A         #N/A         439         0.26         (0.2-0.3)           Acute Monocytic         17         0.19         (0.1-0.3)         407         0.24         (0.2-0.3)           Chronic Monocytic         #N/A         #N/A         #N/A         18         0.01         (0.0-0.0)           Other Monocytic         #N/A         #N/A         #N/A         14         0.01         (0.0-0.0)           Other Monocytic         #N/A         #N/A         #N/A         14         0.01         (0.0-0.0)           Other Monocytic         #N/A         #N/A         #N/A         14         0.01         (0.0-0.0)           Other Monocytic         #N/A         #N/A         #N/A         #N/A         14         0.01         (0.0-0.0)           Other Monocytic         #N/A         #N/A         #N/A         #N/A         14         0.01         (0.0-0.0)           Other         130         1.61         (1.3-1.9)         2,108         1.26         (1.2-1.3)           Other Chronic         #N/A         #N/A				, ,			,
Monocytic         #N/A         #N/A         #N/A         439         0.26         (0.2-0.3)           Acute Monocytic         17         0.19         (0.1-0.3)         407         0.24         (0.2-0.3)           Chronic Monocytic         #N/A         #N/A         #N/A         18         0.01         (0.0-0.0)           Other Monocytic         #N/A         #N/A         #N/A         14         0.01         (0.0-0.0)           Other Other Monocytic         130         1.61         (1.3-1.9)         2,108         1.26         (1.2-1.3)           Other Other Monocytic         49         0.61         (0.4-0.8)         775         0.47         (0.4-0.5)           Other Acute         49         0.61         (0.4-0.8)         775         0.47         (0.4-0.5)           Other Chronic         #N/A         #N/A         #N/A         50         0.03         (0.0-0.0)           Aleukemic, Subleukemic and NOS         81         1.01         (0.8-1.3)         1,283         0.76         (0.7-0.8)							
Acute Monocytic       17       0.19       (0.1-0.3)       407       0.24       (0.2-0.3)         Chronic Monocytic       #N/A       #N/A       #N/A       18       0.01       (0.0-0.0)         Other Monocytic       #N/A       #N/A       #N/A       14       0.01       (0.0-0.0)         Other       130       1.61       (1.3-1.9)       2,108       1.26       (1.2-1.3)         Other Acute       49       0.61       (0.4-0.8)       775       0.47       (0.4-0.5)         Other Chronic       #N/A       #N/A       #N/A       50       0.03       (0.0-0.0)         Aleukemic, Subleukemic and NOS       81       1.01       (0.8-1.3)       1,283       0.76       (0.7-0.8)							, ,
Chronic Monocytic         #N/A         #N/A         #N/A         18         0.01         (0.0-0.0)           Other Monocytic         #N/A         #N/A         #N/A         14         0.01         (0.0-0.0)           Other         130         1.61         (1.3-1.9)         2,108         1.26         (1.2-1.3)           Other Acute         49         0.61         (0.4-0.8)         775         0.47         (0.4-0.5)           Other Chronic         #N/A         #N/A         #N/A         50         0.03         (0.0-0.0)           Aleukemic, Subleukemic and NOS         81         1.01         (0.8-1.3)         1,283         0.76         (0.7-0.8)	•						, ,
Other Monocytic         #N/A         #N/A         #N/A         14         0.01         (0.0-0.0)           Other         130         1.61         (1.3-1.9)         2,108         1.26         (1.2-1.3)           Other Acute         49         0.61         (0.4-0.8)         775         0.47         (0.4-0.5)           Other Chronic         #N/A         #N/A         #N/A         50         0.03         (0.0-0.0)           Aleukemic, Subleukemic and NOS         81         1.01         (0.8-1.3)         1,283         0.76         (0.7-0.8)				, ,			, ,
Other         130         1.61         (1.3-1.9)         2,108         1.26         (1.2-1.3)           Other Acute         49         0.61         (0.4-0.8)         775         0.47         (0.4-0.5)           Other Chronic         #N/A         #N/A         #N/A         50         0.03         (0.0-0.0)           Aleukemic, Subleukemic and NOS         81         1.01         (0.8-1.3)         1,283         0.76         (0.7-0.8)	•						, ,
Other Acute       49       0.61       (0.4-0.8)       775       0.47       (0.4-0.5)         Other Chronic       #N/A       #N/A       #N/A       50       0.03       (0.0-0.0)         Aleukemic, Subleukemic and NOS       81       1.01       (0.8-1.3)       1,283       0.76       (0.7-0.8)	·						,
Other Chronic         #N/A         #N/A         #N/A         50         0.03         (0.0-0.0)           Aleukemic, Subleukemic and NOS         81         1.01         (0.8-1.3)         1,283         0.76         (0.7-0.8)							, ,
Aleukemic, Subleukemic and NOS 81 1.01 (0.8-1.3) 1,283 0.76 (0.7-0.8)							,
	•	1,201	13.98	(13.2-14.8)	19,585		(11.6-11.9)

<sup>\*</sup> Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Table 6. Nevada Incidence by Type of Cancer and Gender, Nevada, 1997-2001

	Total	*	Mal	е	Fema	ale
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**
Total	40,863	453.43	21,042	496.69	19,821	423.04
Lip, Oral Cavity and Pharynx	994	10.62	695	15.28	299	6.33
Lip	49	0.53	44	0.98	5	
Base of Tongue	140	1.44	112	2.34	28	0.58
Other & Unspecified Parts of Tongue	154	1.62	107	2.30	47	0.97
Parotid Gland	69	0.77	44	1.10	25	0.52
Other & Unspecified Major Salivary glands	29	0.32	17	0.41	12	0.25
Floor of Mouth	85	0.93	53	1.18	32	0.70
Gum	21	0.23	9		12	0.25
Palate	39	0.41	19	0.39	20	0.43
Other & Unspecified Parts of Mouth	52	0.58	32	0.76	20	0.43
Nasopharynx	50	0.54	38	0.79	12	0.26
Tonsil	125	1.31	90	1.88	35	0.74
Oropharynx	44	0.47	34	0.78	10	0.20
Pyriform Sinus	46	0.49	35	0.76	11	0.24
Hypopharynx	33	0.35	24	0.50	9	
Other & Unspecified Oral (Buccal) Cavity & Pharynx	58	0.65	37	0.91	21	0.45
Digestive System	7,357	84.57	4,155	100.59	3,202	70.46
Esophagus	481	5.30	363	8.38	118	2.54
Stomach Small Intestine	565 106	6.67	368	9.14	197 54	4.48
	106	1.17	52	1.17		1.16
Colon (excluding Rectum) Cecum	3,213 672	37.79 8.05	1,686 339	42.23 8.77	1,527 333	33.99 7.47
	35	0.39	17	0.36	18	0.39
Appendix Ascending Colon	424	5.09	214	5.43	210	4.76
——————————————————————————————————————	109	1.28	53	1.27	56	1.26
Hepatic Flexure Transverse Colon	245	2.88	124	3.15	121	2.68
Splenic Flexure	91	1.03	47	1.20	44	0.94
Descending Colon	147	1.63	75	1.72	72	1.55
Sigmoid Colon	917	10.35	510	12.15	407	8.81
Large Intestine, NOS	573	7.09	307	8.18	266	6.15
Rectum	770	8.62	446	10.58	324	6.96
Rectosigmoid Junction	421	4.68	248	5.70	173	3.73
Anus, Anal Canal and Anorectum	126	1.34	39	0.82	87	1.84
Liver	442	4.87	305	6.81	137	2.98
Intrahepatic Bile Ducts	73	0.85	42	1.05	31	0.68
Gallbladder	61	0.74	17	0.43	44	0.99
Other & Unspecified Biliary Tract	100	1.20	57	1.46	43	0.97
Pancreas	951	10.84	502	12.18	449	9.75
Retroperitoneum	32	0.35	21	0.45	11	0.24
Peritoneum, Omentum and Mesentery	3		2		1	
Other Digestive Organs	13	0.14	7		6	
Respiratory System	7,758	86.35	4,294	101.68	3,464	73.76
Nasal Cavity and Middle Ear	31	0.36	19	0.51	12	0.25
Accessory Sinuses	23	0.24	15	0.31	8	
Larynx	348	3.78	276	6.18	72	1.55
Lung and Bronchus	7,336	81.77	3,970	94.37	3,366	71.68
Pleura	3		2		1	
Trachea	4		3		1	
Mediastinum and Other Respiratory Organs	13	0.13	9		4	
Bones, Joints and Articular Cartilage	90	0.95	50	1.00	40	0.87
Bones, Joints & Articular Cartilage of Limbs	43	0.46	20	0.40	23	0.50
Bones, Joints & Articular Cartilage of Other & Unspec Sites	47	0.49	30	0.60	17	0.37
Soft Tissue (Including Heart)	215	2.32	124	2.72	91	1.93
Heart	1		0		1	
Peripheral Nerves & Autonomic Nervous System	8		4		4	
Connective, Subcutaneous & Other Soft Tissues	206	2.23	120	2.64	86	1.83

<sup>\*</sup> Those of unknown gender are not shown separately, but are included in the total.

<sup>\*\*</sup> Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Table 6. Nevada Incidence by Type of Cancer and Gender, Nevada, 1997-2001 (Continued)

	Tota	<b> </b> *	Mal	е	Fema	ale
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**
Total	40,863	453.43	21,042	496.69	19,821	423.04
Skin (Excluding Basal And Squamous)	1,189	12.82	699	15.74	490	10.35
Melanomas Of The Skin	1,083	11.59	634	14.09	449	9.45
Other Non-Epithelial Skin	106	1.23	65	1.65	41	0.90
Breast	6,493	70.45	73	1.82	6,420	135.20
Female Genital System	2,250	24.38	0		2,250	47.38
Cervix Uteri	497	5.22	0		497	10.39
Corpus Uteri	808	8.75	0		808	16.94
Uterus, NOS	44	0.52	0		44	0.96
Ovary	737	8.02	0		737	15.54
Vagina	39	0.43	0		39	0.83
Vulva	112	1.30	0		112	2.45
Placenta	1		0		1	
Other Female Genital Organs	12	0.12	0		12	0.24
Male Genital System	5,605	61.36	5,605	131.04	0	
Prostate	5,337	58.64	5,337	125.66	0	
Testis	237	2.37	237	4.63	0	
Penis	19	0.22	19	0.48	0	
Other Male Genital Organs	12	0.13	12	0.27	0	
Urinary System	3,218	36.33	2,317	56.15	901	19.49
Urinary Bladder	2,068	23.86	1,567	39.31	501	11.00
Kidney	1,014	10.96	656	14.55	358	7.60
Renal Pelvis	76	0.84	50	1.19	26	0.55
Ureter	38	0.44	28	0.74	10	0.21
Other Urinary Organs	22	0.23	16	0.36	6	
Eye and Orbit	50	0.54	29	0.65	21	0.44
Brain and Other Central Nervous System	580	6.21	338	7.36	242	5.11
Brain	540	5.78	316	6.90	224	4.73
Meninges	20	0.21	9		11	0.23
Spinal Cord, Cranial Nerves, & Other Parts of CNS	20	0.22	13	0.27	7	
Endocrine System	757	7.77	190	4.09	567	11.71
Thyroid Gland	696	7.12	157	3.29	539	11.15
Adrenal Gland	30	0.33	17	0.44	13	0.26
Other Endocrine (Including Thymus)	31	0.32	16	0.35	15	0.30
Hodgkin's Lymphoma	214	2.20	117	2.32	97	2.03
Non-Hodgkin's Lymphoma	1,316	14.65	737	17.38	579	12.42
Multiple Myeloma	372	4.20	216	5.32	156	3.33
Leukemia	1,059	12.05	629	14.97	430	9.44
Lymphocytic	451	5.03	280	6.62	171	3.68
Acute Lymphocytic	141	1.44	82	1.65	59	1.23
Chronic Lymphocytic	278	3.23	171	4.34	107	2.34
Other Lymphocytic	32	0.36	27	0.63	5	
Myeloid and Monocytic	478	5.40	276	6.42	202	4.43
Acute Myeloid	330	3.66	185	4.21	145	3.13
Acute Monocytic	17	0.19	9		8	
Chronic Myeloid	108	1.27	68	1.65	40	0.91
Other Myeloid/Monocytic	23	0.28	14	0.35	9	4 22
Other	130	1.61	73	1.94	57	1.33
Other Acute	49	0.61	30	0.83	19	0.43
Aleukemic, Subleukemic and NOS	81	1.01	43	1.11	38	0.90
Mesothelioma	91	1.08	71	1.97	20	0.42
Kaposi Sarcoma	54	0.58	52	1.15	2	40.00
Other, Ill-Defined and Unspecified Sites	1,201	13.98	651	15.46	550	12.32

<sup>\*</sup> Those of unknown gender are not shown separately, but are included in the total.

<sup>\*\*</sup> Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Table 7. Nevada Incidence by Type of Cancer and Stage of Cancer, Nevada, 1997-2001

Total	Type of Cancer	Total	In situ	Localized	Pagional	Distant	Unstaged
Lip, Oral Cavity and Pharynx	Type of Cancer				Regional	Distant	
Lip Base of Tongue Hid 0 0 37 5 2 9 1 1 2 2 1 1 2 1 1 2 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 1 2 1 1 1 1 2 1	lotal	40,863	1,560	15,503	7,420	7,688	8,692
Base of Tongue	Lip, Oral Cavity and Pharynx	994	0	322	372		210
Other & Unspecified Parts of Tongue         154         0         73         33         12         31           Parotid Gland         69         0         33         18         2         11           Other & Unspecified Major Salivary glands         29         0         8         12         2         15           Gum         21         0         6         8         3         3         12         3           Floor of Mouth         52         0         15         18         6         4         2         12         8         4         4         2         12         18         4         4         4         17         11         11         12         18         6         7         7         11         13         12         13         0         12         2         6         67         7         11         12         11         12         11         12         11         12         11         12         11         12         11         12         11         12         11         12         13         13         3         2         12         14         14         14         14         14         14	Lip	49				2	5
Parotid Cland   G9							22
Other & Unspecified Major Salivary glands         29         0         8         12         2         1         6         6         8         3         9         9         5         6         8         3         3         9         9         2         8         4         4         9         9         9         9         9         9         9         9         9         9         9         9         9         9         10         12         12         14         2         2         8         4         4         9         9         7         11         12         11         12         11         12         11         12         11         12         11         12         11         12         11         12         11         12         11         12         11         12         11         12         11         12         11         12         11         12	·						36
Floor of Mouth							16
Gum	· · · · · · · · · · · · · · · · · · ·						7
Palate							9
Other & Unspecified Parts of Mouth         52         0         15         18         6         11           Nasopharynx         50         0         56         67         7         22           Oropharynx         44         0         7         11         12         1           Pyriform Sinus         46         0         9         27         4         6           Hypopharynx         33         0         13         9         2         5           Hypopharynx         58         0         5         26         7         22           Digestive System         7,357         0         1,805         2268         1,565         1,70           Stomach         556         0         101         175         141         144           Stomach         556         0         101         175         141         144           Colon (excluding Rectum)         3,213         0         909         1,207         636         46           Appendix         35         0         111         11         10         1           Appendix         35         0         111         11         10         1							4
Nasopharynx							5
Tonsi	•						
Oropharynx         44         0         7         11         12         11         12         14         Pyriform Sinus         46         0         9         27         4         4         14	·						
Pyrtform Sinus							
Hypopharynx	·						6
Other & Unspecified Oral (Buccal) Cavity & Pharynx         58         0         5.65         2.266         1.565         1.70           Digestive System         7,357         0         1,865         2,286         1,565         1,70           Esophagus         481         0         74         99         1,19         188           Stomach         565         0         101         175         141         144           Small Intestine         106         0         23         36         31         111           Cocum         672         0         181         296         151         44           Appendix         35         0         111         111         10         3           Ascending Colon         424         0         136         193         69         22           Hepatic Flexure         109         0         32         50         21         6           Descending Colon         147         0         48         55         36         111           Sigmoid Colon         917         0         332         368         171         44           Large Intestine, NOS         573         0         65	•						9
Digestive System	** * *						20
Esophagus							1,701
Stomach   Sciomach   Sciomach   Sciomach   Small Intestine   106   0   23   36   31   144   14					•		189
Small Intestine         106         0         23         36         31         11           Colon (excluding Rectum)         3,213         0         909         1,207         636         46           Cecum         672         0         181         296         151         44           Appendix         35         0         11         11         10         5           Ascending Colon         424         0         136         193         69         22           Hepatic Flexure         109         0         32         50         21         60           Splenic Flexure         91         0         33         48         7         3           Splenic Flexure         91         0         33         48         7         3           Descending Colon         147         0         46         55         36         11           Sigmoid Colon         917         0         332         368         171         44           Large Intestine, NOS         573         0         65         74         123         31           Rectum         770         0         280         239         116	. •						148
Colon (excluding Rectum)         3,213         0         909         1,207         636         466           Cecum         672         0         181         296         151         446           Appendix         35         0         111         111         10         3           Ascending Colon         424         0         136         193         69         221           Hepatic Flexure         109         0         32         50         21         6           Splenic Flexure         91         0         33         48         7         3           Descending Colon         147         0         46         55         36         11           Sigmoid Colon         917         0         332         368         171         46           Large Intestine, NOS         573         0         65         74         123         31*           Rectum         770         0         280         239         116         13           Rectum         770         0         280         239         116         13           Rectum         770         0         280         239         17         25 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>16</td>							16
Cecum         672 by Appendix         0         181 by Cape By Appendix         44 by Appendix         45 by Appendix         45 by Appendix         46 by Appendix         47 by Appendix         47 by Appendix         47 by Appendix         48 by Appendix							461
Appendix Ascerding Colon	· • • • • • • • • • • • • • • • • • • •						44
Ascending Colon							3
Hepatic Flexure   109							26
Splenic Flexure         91         0         33         48         7         33           Descending Colon         147         0         46         55         36         11           Sigmoid Colon         917         0         332         368         171         44           Large Intestine, NOS         573         0         65         74         123         31*           Rectum         770         0         280         239         116         133           Rectosigmoid Junction         421         0         136         169         83         33           Anus, Anal Canal and Anorectum         126         0         67         23         15         22           Liver         442         0         84         29         77         25           Intrahepatic Bile Ducts         73         0         13         14         11         33           Gallbladder         61         0         18         21         18         4           Other & Unspecified Biliary Tract         100         0         22         28         15         38           Pactreas         951         0         69         240		109	0	32	50	21	6
Descending Colon	Transverse Colon	245	0	73	112	48	12
Sigmoid Colon         917         0         332         368         171         46           Large Intestine, NOS         573         0         65         74         123         31'           Rectum         770         0         280         239         116         133'           Rectosigmoid Junction         421         0         136         169         83         33'           Anus, Anal Canal and Anorectum         126         0         67         23         15         2'           Liver         442         0         84         29         77         25'           Intrahepatic Bile Ducts         73         0         13         14         11         3'           Gallbladder         61         0         18         21         18         -           Other & Unspecified Biliary Tract         100         0         22         28         15         3'           Pancreas         951         0         69         240         290         35'           Retroperitoneum         32         0         69         240         290         35'           Respiratoneum, Omentum and Mesentery         3         0         0 </td <td>Splenic Flexure</td> <td>91</td> <td>0</td> <td>33</td> <td>48</td> <td>7</td> <td>3</td>	Splenic Flexure	91	0	33	48	7	3
Large Intestine, NOS	Descending Colon	147	0	46	55	36	10
Rectum         770         0         280         239         116         133           Rectosigmoid Junction         421         0         136         169         83         33           Anus, Anal Canal and Anorectum         126         0         67         23         15         22           Liver         442         0         84         29         77         255           Intrahepatic Bile Ducts         73         0         13         14         11         33           Gallbladder         61         0         18         21         18         4           Other & Unspecified Biliary Tract         100         0         22         28         15         33           Pancreas         951         0         69         240         290         355           Retroperitoneum         32         0         9         5         6         12           Peritoneum, Omentum and Mesentery         3         0         0         0         5         8           Respiratory System         7,758         0         1,338         1,493         2,598         2,329           Respiratory Sinuses         23         0         8	Sigmoid Colon	917	0	332	368	171	46
Rectosigmoid Junction         421         0         136         169         83         33           Anus, Anal Canal and Anorectum         126         0         67         23         15         22           Liver         442         0         84         29         77         257           Intrahepatic Bile Ducts         73         0         13         14         11         38           Gallbladder         61         0         18         21         18         4           Other & Unspecified Biliary Tract         100         0         22         28         15         33           Pancreas         951         0         69         240         290         352           Retroperitoneum         32         0         9         5         6         12           Peritoneum, Omentum and Mesentery         3         0         0         0         5         6           Other Digestive Organs         13         0         0         0         5         6           Respiratory System         7,758         0         1,338         1,493         2,598         2,329           Accessory Sinuses         23         0         8	Large Intestine, NOS	573	0	65	74	123	311
Anus, Anal Canal and Anorectum 126 0 67 23 15 22 Liver 442 0 84 29 77 255 Intrahepatic Bile Ducts 73 0 13 14 11 33 Gallbladder 61 0 18 21 18 21 18 24 25 26 25 26 25 28 25 28 25 25 26 25 25 26	Rectum	770	0	280	239	116	135
Liver         442         0         84         29         77         252           Intrahepatic Bile Ducts         73         0         13         14         11         38           Gallbladder         61         0         18         21         18         4           Other & Unspecified Biliary Tract         100         0         22         28         15         38           Pancreas         951         0         69         240         290         352           Retroperitoneum         32         0         9         5         6         12           Peritoneum, Omentum and Mesentery         3         0         0         0         1         2         0           Other Digestive Organs         13         0         0         0         5         6         12           Respiratory System         7,758         0         1,338         1,493         2,598         2,322           Respiratory Sinuses         23         0         8         9         5         6           Larynx         348         0         135         78         24         11           Lung and Bronchus         7,336         0	Rectosigmoid Junction	421	0	136		83	33
Intrahepatic Bile Ducts	Anus, Anal Canal and Anorectum	126	0	67	23	15	21
Gallbladder         61         0         18         21         18         4           Other & Unspecified Biliary Tract         100         0         22         28         15         38           Pancreas         951         0         69         240         290         35           Retroperitoneum         32         0         9         5         6         12           Peritoneum, Omentum and Mesentery         3         0         0         1         2         0           Other Digestive Organs         13         0         0         0         5         6         12           Respiratory System         7,758         0         1,338         1,493         2,598         2,328           Nasal Cavity and Middle Ear         31         0         15         2         3         12           Accessory Sinuses         23         0         8         9         5         5           Larynx         348         0         135         78         24         11           Lung and Bronchus         7,336         0         1,176         1,401         2,563         2,196           Pleura         3         0         0	Liver	442	0	84	29	77	252
Other & Unspecified Biliary Tract         100         0         222         28         15         38           Pancreas         951         0         69         240         290         352           Retroperitoneum         32         0         9         5         6         12           Peritoneum, Omentum and Mesentery         3         0         0         1         2         0           Other Digestive Organs         13         0         0         0         1         2         0           Respiratory System         7,758         0         1,338         1,493         2,598         2,329           Nasal Cavity and Middle Ear         31         0         15         2         3         1           Accessory Sinuses         23         0         8         9         5         -           Larynx         348         0         135         78         24         11           Lung and Bronchus         7,336         0         1,176         1,401         2,563         2,196           Pleura         3         0         0         0         0         0         0           Mediastinum and Other Respiratory Organs	Intrahepatic Bile Ducts	73	0	13	14	11	35
Pancreas         951         0         69         240         290         352           Retroperitoneum         32         0         9         5         6         12           Peritoneum, Omentum and Mesentery         3         0         0         1         2         0           Other Digestive Organs         13         0         0         0         5         8           Respiratory System         7,758         0         1,338         1,493         2,598         2,328           Nasal Cavity and Middle Ear         31         0         15         2         3         1*           Accessory Sinuses         23         0         8         9         5         5           Larynx         348         0         135         78         24         11*           Lung and Bronchus         7,336         0         1,176         1,401         2,563         2,196           Pleura         3         0         0         0         0         0         0           Trachea         4         0         0         2         1         0           Mediastinum and Other Respiratory Organs         13         0         4							4
Retroperitoneum       32       0       9       5       6       12         Peritoneum, Omentum and Mesentery       3       0       0       1       2       0         Other Digestive Organs       13       0       0       0       5       8         Respiratory System       7,758       0       1,338       1,493       2,598       2,329         Nasal Cavity and Middle Ear       31       0       15       2       3       1°         Accessory Sinuses       23       0       8       9       5       6         Larynx       348       0       135       78       24       11°         Lung and Bronchus       7,336       0       1,176       1,401       2,563       2,196         Pleura       3       0       0       0       0       0       0       2       1       1         Trachea       4       0 <td< td=""><td>·</td><td></td><td></td><td></td><td></td><td></td><td>35</td></td<>	·						35
Peritoneum, Omentum and Mesentery       3       0       0       1       2       0         Other Digestive Organs       13       0       0       0       5       8         Respiratory System       7,758       0       1,338       1,493       2,598       2,329         Nasal Cavity and Middle Ear       31       0       15       2       3       1         Accessory Sinuses       23       0       8       9       5       2         Larynx       348       0       135       78       24       11         Lung and Bronchus       7,336       0       1,176       1,401       2,563       2,196         Pleura       3       0       0       0       0       0       0       3       2,196         Pleura       3       0       0       0       0       0       0       3       2,196       3       0       0       0       0       3       2,196       3       0       0       0       0       0       3       0       0       0       0       0       0       0       0       0       0       0       0       0       0       0							352
Other Digestive Organs         13         0         0         0         5         8           Respiratory System         7,758         0         1,338         1,493         2,598         2,329           Nasal Cavity and Middle Ear         31         0         15         2         3         1           Accessory Sinuses         23         0         8         9         5         2           Larynx         348         0         135         78         24         11           Lung and Bronchus         7,336         0         1,176         1,401         2,563         2,196           Pleura         3         0         0         0         0         0         0         0           Trachea         4         0         0         0         0         0         0         0         0         0           Mediastinum and Other Respiratory Organs         13         0         4         1         2         6         0         0         32         11         18         28         12         12         0         0         3         1         1         1         1         1         1         1         1							12
Respiratory System       7,758       0       1,338       1,493       2,598       2,329         Nasal Cavity and Middle Ear       31       0       15       2       3       17         Accessory Sinuses       23       0       8       9       5       2         Larynx       348       0       135       78       24       11         Lung and Bronchus       7,336       0       1,176       1,401       2,563       2,196         Pleura       3       0       0       0       0       0       0         Trachea       4       0       0       0       0       0         Mediastinum and Other Respiratory Organs       13       0       4       1       2       6         Bones, Joints and Articular Cartilage       90       0       32       11       18       28         Bones, Joints & Articular Cartilage of Limbs       43       0       23       4       5       17         Bones, Joints & Articular Cartilage of Other & Unspec Sites       47       0       9       7       13       18         Soft Tissue (Including Heart)       215       0       92       11       29       83 <td>· · · · · · · · · · · · · · · · · · ·</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>0</td>	· · · · · · · · · · · · · · · · · · ·						0
Nasal Cavity and Middle Ear       31       0       15       2       3       17         Accessory Sinuses       23       0       8       9       5       7         Larynx       348       0       135       78       24       117         Lung and Bronchus       7,336       0       1,176       1,401       2,563       2,196         Pleura       3       0       0       0       0       0       2       1       7         Trachea       4       0       0       0       2       1       7       1       7       1       1       2       6       6       6       1       1       1       2       6       6       1       1       1       2       1       1       2       1       1       2       1       1       2       1       1       2       1       1       2       1       1       2       1       1       2       1       1       2       1       1       2       1       2       1       2       1       2       1       2       1       2       1       2       1       1       2       2		13	0		0		8
Accessory Śinuses       23       0       8       9       5         Larynx       348       0       135       78       24       117         Lung and Bronchus       7,336       0       1,176       1,401       2,563       2,196         Pleura       3       0       0       0       0       0       0         Trachea       4       0       0       2       1       2         Mediastinum and Other Respiratory Organs       13       0       4       1       2       6         Bones, Joints and Articular Cartilage       90       0       32       11       18       25         Bones, Joints & Articular Cartilage of Limbs       43       0       23       4       5       17         Bones, Joints & Articular Cartilage of Other & Unspec Sites       47       0       9       7       13       18         Soft Tissue (Including Heart)       215       0       92       11       29       83	. , ,						
Larynx       348       0       135       78       24       117         Lung and Bronchus       7,336       0       1,176       1,401       2,563       2,196         Pleura       3       0       0       0       0       0       0         Trachea       4       0       0       2       1       0         Mediastinum and Other Respiratory Organs       13       0       4       1       2       6         Bones, Joints and Articular Cartilage       90       0       32       11       18       29         Bones, Joints & Articular Cartilage of Limbs       43       0       23       4       5       17         Bones, Joints & Articular Cartilage of Other & Unspec Sites       47       0       9       7       13       18         Soft Tissue (Including Heart)       215       0       92       11       29       83							11
Lung and Bronchus       7,336       0       1,176       1,401       2,563       2,196         Pleura       3       0       0       0       0       0       0         Trachea       4       0       0       2       1       0         Mediastinum and Other Respiratory Organs       13       0       4       1       2       6         Bones, Joints and Articular Cartilage       90       0       32       11       18       29         Bones, Joints & Articular Cartilage of Limbs       43       0       23       4       5       17         Bones, Joints & Articular Cartilage of Other & Unspec Sites       47       0       9       7       13       18         Soft Tissue (Including Heart)       215       0       92       11       29       83	•						1
Pleura       3       0       0       0       0       0       0       0       0       0       0       0       2       1       7       7       7       7       8       9       0       0       4       1       2       6       8       9       0       32       11       18       29       13       10       9       11       18       29       12       12       12       12       12       12       12       12       12       13       14       14       14       14       12       12       12       12       12       13       14       12       14       12       14       14       12       14       14       12       14       12       14       12       14       12       14       12       14       12       14       14       12       14       14       12       14       14       12       14       14       12       14       14       12       14       14       14       14       14       14       14       14       14       14       14       14       14       14       14       14       14       14       14							
Trachea         4         0         0         2         1         7           Mediastinum and Other Respiratory Organs         13         0         4         1         2         6           Bones, Joints and Articular Cartilage         90         0         32         11         18         29           Bones, Joints & Articular Cartilage of Limbs         43         0         23         4         5         17           Bones, Joints & Articular Cartilage of Other & Unspec Sites         47         0         9         7         13         18           Soft Tissue (Including Heart)         215         0         92         11         29         83	· · · · · · · · · · · · · · · · · · ·				•	•	•
Mediastinum and Other Respiratory Organs       13       0       4       1       2       6         Bones, Joints and Articular Cartilage       90       0       32       11       18       29         Bones, Joints & Articular Cartilage of Limbs       43       0       23       4       5       17         Bones, Joints & Articular Cartilage of Other & Unspec Sites       47       0       9       7       13       18         Soft Tissue (Including Heart)       215       0       92       11       29       83							3
Bones, Joints and Articular Cartilage       90       0       32       11       18       29         Bones, Joints & Articular Cartilage of Limbs       43       0       23       4       5       17         Bones, Joints & Articular Cartilage of Other & Unspec Sites       47       0       9       7       13       18         Soft Tissue (Including Heart)       215       0       92       11       29       83							1
Bones, Joints & Articular Cartilage of Limbs       43       0       23       4       5       13         Bones, Joints & Articular Cartilage of Other & Unspec Sites       47       0       9       7       13       18         Soft Tissue (Including Heart)       215       0       92       11       29       83	· · · · ·						6
Bones, Joints & Articular Cartilage of Other & Unspec Sites 47 0 9 7 13 18 Soft Tissue (Including Heart) 215 0 92 11 29 83							29
Soft Tissue (Including Heart)         215         0         92         11         29         83	•						
·							
Π <del>υ</del> αιι 1 U 1 U U	· · · · · · · · · · · · · · · · · · ·						
							0 5
· · · · · · · · · · · · · · · · · · ·							5 78

Table 7. Nevada Incidence by Type of Cancer and Stage of Cancer, Nevada, 1997-2001 (Continued)

Type of Cancer	Total	In situ	Localized	Regional	Distant	Unstaged
Total	40,863	1,560	15,503	7,420	7,688	8,692
Total	40,003	1,500	13,303	1,420	7,000	0,032
Skin (Excluding Basal And Squamous)	1,189	0	836	86	76	191
Melanomas Of The Skin	1,083	0	770	77	69	167
Other Non-Epithelial Skin	106	0	66	9	7	24
Breast	6,493	958	3,090	1,563	315	567
Female Genital System	2,250	0	1,127	412	472	239
Cervix Uteri	497	0	241	157	49	50
Corpus Uteri	808	0	616	92	44	56
Uterus, NOS	44	0	13	6	9	16
Ovary	737	0	162	124	352	99
Vagina	39	0	16	7	9	7
Vulva	112	0	76	24	3	9
Placenta	1	0	0	0	1	0
Other Female Genital Organs	12	0	3	2	5	2
Male Genital System	5,605	0	3,892	553	286	874
Prostate	5,337	0	3,726	516	247	848
Testis	237	0	150	35	38	14
Penis	19 12	0	9 7	1	1	8 4
Other Male Genital Organs		0				
Urinary System	3,218	602 602	1,616	325	256	419
Urinary Bladder	2,068		1,001	177	69	219
Kidney	1,014	0	538	117	179	180
Renal Pelvis Ureter	76 38	0	45 21	20 5	5 2	6 10
Other Urinary Organs	22	0	11	6	1	4
Eye and Orbit	50	0	12	0	1	37
Brain and Other Nervous System	580	0	381	14	6	179
Brain	540	0	368	12	5	179
Meninges	20	0	10	1	1	8
Spinal Cord, Cranial Nerves, & Other Parts of CNS	20	0	3	1	0	16
Endocrine System	757	0	485	142	43	87
Thyroid Gland	696	0	465	136	34	61
Adrenal Gland	30	0	8	4	7	11
Other Endocrine (Including Thymus)	31	0	12	2	2	15
Hodgkin's Lymphoma	214	0	83	30	51	50
Non-Hodgkin's Lymphoma	1,316	0	359	112	426	419
Multiple Myeloma	372	0	1	0	353	18
Leukemia	1,204	0	32	9	1,043	120
Lymphocytic	451	0	0	0	447	4
Acute Lymphocytic	141	0	0	0	141	0
Chronic Lymphocytic	278	0	0	0	275	3
Other Lymphocytic	32	0	0	0	31	1
Myeloid and Monocytic	478	0	Ö	Ö	468	10
Acute Myeloid	330	0	0	0	323	7
Acute Monocytic	17	0	0	0	17	0
Chronic Myeloid	108	0	0	0	107	1
Other Myeloid/Monocytic	23	0	0	0	21	2
Other	130	0	0	0	99	31
Other Acute	49	0	0	0	41	8
Aleukemic, Subleukemic and NOS	81	0	0	0	58	23
Mesothelioma	91	0	18	8	15	50
Kaposi Sarcoma	54	0	14	1	14	25
Other, Ill-Defined and Unspecified Sites	1,201	0	0	1	60	1,140
Carer, in Definited and Oriopeonical Office						1,170

Table 8. Top Ten Types of Cancer Incidence by County/Region of Residence, Nevada Residents, 1997-2001

		County/Region of Residence						
Rank	Type of Cancer		Nevada Total	Clark	Washoe	All Other Counties		
1	Lung and Bronchus	Incidence	7,336	5,117	1,102	1,113		
		Rate*	81.77	85.42	74.29	74.69		
		95% C.I.	(79.9-83.7)	(83.0-87.9)	(69.9-78.9)	(70.3-79.3)		
2	Breast*	Incidence	6,420	4,274	1,254	889		
		Rate*	135.20	134.37	154.28	118.04		
		95% C.I.	(131.9-138.6)	(130.3-138.5)	(145.8-163.1)	(110.4-126.1)		
3	Prostate*	Incidence	5,337	3,408	1,053	874		
		Rate*	125.66	119.84	151.02	123.95		
		95% C.I.	(122.1-129.4)	(115.5-124.3)	(141.6-161.0)	(115.5-133.0)		
4	Colorectal	Incidence	4,530	3,118	775	637		
		Rate*	52.43	54.15	53.32	44.71		
		95% C.I.	(50.9-54.0)	(52.2-56.2)	(49.6-57.3)	(41.2-48.4)		
5	Urinary Bladder	Incidence	2,068	1,376	337	354		
		Rate*	23.86	23.79	23.12	24.68		
		95% C.I.	(22.8-24.9)	(22.5-25.1)	(20.7-25.8)	(22.1-27.5)		
6	Non-Hodgkin's Lymphoma	Incidence	1,316	839	259	217		
		Rate*	14.65	14.10	16.86	14.84		
		95% C.I.	(13.9-15.5)	(13.1-15.1)	(14.8-19.1)	(12.9-17.0)		
7	Kidney and Renal Pelvis	Incidence	1,090	711	204	174		
		Rate*	11.80	11.49	13.07	11.78		
		95% C.I.	(11.1-12.5)	(10.6-12.4)	(11.3-15.0)	(10.1-13.7)		
8	Leukemia	Incidence	1,059	742	163	153		
		Rate*	12.05	12.64	10.90	10.94		
		95% C.I.	(11.3-12.8)	(11.7-13.6)	(9.3-12.8)	(9.2-12.9)		
9	Lip, Oral Cavity and Pharynx	Incidence	994	670	180			
		Rate*	10.62	10.68	11.50			
		95% C.I.	(10.0-11.3)	(9.9-11.6)	(9.9-13.4)			
10	Pancreas	Incidence	951		154	150		
		Rate*	10.84		10.49	10.42		
		95% C.I.	(10.1-11.6)		(8.9-12.3)	(8.8-12.3)		
	Total	Incidence	40,863	27,522	7,239	6,080		
		Rate*	453.43	456.94	476.32	415.82		
		95% C.I.	(448.9-457.9)	(451.4-462.5)	(465.3-487.6)	(405.3-426.6)		

<sup>\*</sup> Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Note: The "---" indicates that this type of cancer was not in the Top Ten for this specific region.

Table 9. Top Ten Types of Cancer Incidence by Age Group, Nevada Residents, 1997-2001

Ranking					Age Group				
Kalikiliy	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75+	Total
1	Leukemia	Thyroid Gland	Thyroid Gland	Breast	Breast	Lung and Bronchus	Lung and Bronchus	Lung and Bronchus	Lung and Bronchus
	115	42	125	668	1,393	1,699	2,806	2,052	7,336
	39.4%	14.6%	14.5%	29.5%	26.3%	18.5%	22.5%	20.2%	18.0%
2	Brain and OCNS	HL	Breast	Thyroid Gland	Lung and Bronchus	Breast	Prostate	Colorectal	Breast
	53	33	106	165	627	1,578	2,225	1,532	6,493
	18.2%	11.5%	12.3%	7.3%	11.8%	17.2%	17.8%	15.1%	15.9%
3	NHL	Leukemia	Skin	Colorectal	Colorectal	Prostate	Breast	Prostate	Prostate
	17	30	75	157	458	1,456	1,564	1,249	5,337
	5.8%	10.5%	8.7%	6.9%	8.6%	15.9%	12.5%	12.3%	13.1%
4	KRP	Skin	NHL	Skin	Prostate	Colorectal	Colorectal	Breast	Colorectal
	15	27	63	156	381	898	1,444	1,171	4,530
	5.1%	9.4%	7.3%	6.9%	7.2%	9.8%	11.6%	11.5%	11.1%
5	Liver and IBD	Brain and OCNS	Cervix Uteri	Lung and Bronchus	Skin	Urinary Bladder	Urinary Bladder	Urinary Bladder	Urinary Bladder
	8	20	57	129	209	390	717	727	2,068
	2.7%	7.0%	6.6%	5.7%	3.9%	4.3%	5.7%	7.2%	5.1%
6	HL	NHL	HL	Cervix Uteri	NHL	LOCP	NHL	NHL	NHL
	7	17	49	120	199	312	342	343	1,316
	2.4%	5.9%	5.7%	5.3%	3.8%	3.4%	2.7%	3.4%	3.2%
7	LOCP	Ovary	Brain and OCNS	NHL	KRP	KRP	Pancreas	Pancreas	KRP
	4	7	43	90	174	290	304	304	1,090
	1.4%	2.4%	5.0%	4.0%	3.3%	3.2%	2.4%	3.0%	2.7%
8	Urinary Bladder	Cervix Uteri	Leukemia	Ovary	LOCP	NHL	KRP	Leukemia	Skin
	3	6	38	74	172	243	302	300	1,083
	1.0%	2.1%	4.4%	3.3%	3.2%	2.6%	2.4%	3.0%	2.7%
9	Thyroid Gland	Breast	Colorectal	KRP	Urinary Bladder	CU & Uterus NOS	LOCP	KRP	Leukemia
	2	4	34	71	167	213	273	225	1,059
	0.7%	1.4%	3.9%	3.1%	3.1%	2.3%	2.2%	2.2%	2.6%
10	Breast	LOCP	Ovary	Leukemia	Thyroid Gland	Pancreas	Leukemia	Stomach	LOCP
	1	4	34	59	166	210	261	215	994
	0.3%	1.4%	3.9%	2.6%	3.1%	2.3%	2.1%	2.1%	2.4%
Sum	225	190	624	1,689	3,946	7,289	10,238	8,118	31,306
Percent	77.1%	66.2%	72.3%	74.7%	74.4%	79.4%	81.9%	80.0%	76.6%
Total	292	287	863	2,262	5,302	9,176	12,497	10,142	40,863
	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Abbreviations: Brain and OCNS = Brain and Other Central Nervous System, CU & Uterus NOS = Corpus Uteri and Uterus NOS, HL = Hodgkin's Lymphoma, KRP = Kidney and Renal Pelvis, LOCP = Lip, Oral Cavity and Pharynx, Liver and IBD = Liver and Intrahepatic Bile Ducts, NHL = Non-Hodgkin's Lymphoma. Note: Those cases with unknown ages are not shown separately, but are included in the total.

Table 10. Median Age at Time of Diagnosis by Leading Types of Cancer and Race/Ethnicity, Nevada Residents, 1997-2001

	Race/Ethnicity												
Type of Cancer	Whi	te	Bla	Black		Native American		Asian		Hispanic		Total	
	Number	Age	Number	Age	Number	Age	Number	Age	Number	Age	Number	Age	
Lung and Bronchus	6,623	69.0	329	66.0	41	68.0	137	67.0	183	68.0	7,329	69.0	
Breast	5,672	62.0	330	59.0	20	57.0	169	57.0	224	53.0	6,485	61.0	
Prostate	4,686	68.0	326	66.0	23	70.0	77	67.0	174	68.0	5,327	68.0	
Colorectal	4,022	70.0	224	67.0	15	64.0	106	64.0	129	67.0	4,525	70.0	
Urinary Bladder	1,896	71.0	68	69.0	9	61.0	22	72.0	63	67.0	2,067	71.0	
Non-Hodgkin's Lymphoma	1,175	66.0	44	54.0	5	41.0	29	63.0	55	59.0	1,314	65.0	
Kidney and Renal Pelvis	942	64.0	63	61.0	8	70.5	19	64.0	50	65.0	1,089	64.0	
Leukemia	919	68.0	39	59.0	3		24	58.5	68	35.0	1,058	66.0	
Lip, Oral Cavity and Pharynx	886	62.0	42	62.0	5	61.0	13	66.0	35	56.0	993	62.0	
Pancreas	817	69.0	61	67.0	5	67.0	18	69.0	47	66.0	951	69.0	
Skin	1,030	58.0	17	62.0	4		4		23	49.0	1,082	58.0	
Corpus Uteri & Uterus NOS	753	65.0	34	63.0	4		23	54.0	33	59.0	852	64.0	
Ovary	648	63.0	32	60.0	5	55.0	18	63.0	29	43.0	737	62.0	
Thyroid Gland	580	45.0	28	41.0	4		41	48.0	37	42.0	696	45.0	
Stomach	474	71.0	30	67.0	2		23	72.0	33	65.0	564	71.0	
Brain and Other Central Nervous System	493	59.0	21	57.0	2		20	55.0	40	38.0	580	58.0	
Cervix Uteri	397	49.0	27	50.0	0		24	55.0	43	52.0	497	50.0	
Liver and Intrahepatic Bile Ducts	406	68.0	36	63.5	4		39	57.0	29	60.0	515	67.0	
Esophagus	420	67.5	34	64.0	2		10	63.0	14	61.0	481	67.0	
Larynx	313	65.0	17	63.0	2		0		14	61.0	348	65.0	
Multiple Myeloma	311	68.0	22	64.0	6	74.5	10	68.0	20	63.0	369	67.0	
Hodgkin's Lymphoma	184	41.0	11	42.0	2		8	29.0	9	25.0	214	39.0	
All Other Sites	2,392	66.0	149	62.0	14	64.5	44	62.5	138	54.0	2,748	65.0	
Total	36,039	67.0	1,984	64.0	185	65.0	878	62.0	1,490	61.0	40,821	66.0	

Note: Those of other/unknown race/ethnicity are not shown separately, but are included in the total. Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

# INPATIENT HOSPITAL DISCHARGES HIGHLIGHTS

- ➤ Lung and Bronchus Cancer was the leading type of Cancer for inpatient discharges in Nevada from 1997 to 2001. This type of cancer accounted for 15.0% of all resident cancer inpatient hospital discharges. The second leading type of cancer was Colorectal Cancer, which accounted for 12.6% of all cancer inpatient discharges during this period.
- The two leading types of cancer for inpatient hospital discharges, Lung and Bronchus and Colorectal Cancer accounted for 305.2 million dollars in total billed amounts in Nevada from 1997 to 2001. This accounted for 32.8% of the total 1 billion dollars in billed amounts for cancer inpatient hospital discharges during this period.
- ➤ The five types of cancer that had the highest average total billed amount for Nevada from 1997 to 2001 were: Leukemia (\$60,984), Stomach (\$54,355), Esophagus (\$43,963), Ovary (\$41,285), and Larynx (\$41,256) Cancer.
- ➤ The five types of cancer that had the highest median total billed amount for Nevada from 1997 to 2001 were: Stomach (\$35,342), Larynx (\$30,842), Brain and Other Central Nervous System (\$30,345), Leukemia (\$29,255), and Colorectal (\$26,392) Cancer.
- ➤ The five types of cancer that had the highest average length of stay (days) for cancer inpatient hospital discharges for Nevada from 1997 to 2001 were: Leukemia (12.72), Stomach (11.07), Esophagus (10.01), Larynx (9.88), and Pancreas (9.58) Cancer.

Figure 9. Top Ten Leading Cancers in Total Inpatient Discharge Charges, Nevada Residents, 1997-2001




Figure 10. Top Ten Leading Cancers in Average Inpatient Discharge Charges, Nevada Residents, 1997-2001




Figure 11. Top Ten Leading Cancers in Median Inpatient Discharge Charges, Nevada Residents, 1997-2001




Figure 12. Top Ten Leading Cancers in Total Number of Days Stayed for Inpatient Hospital Discharges, Nevada Residents, 1997-2001




Figure 13. Top Ten Leading Cancers in Average Length of Stay (Days) for Inpatient Hospital Discharges, Nevada Residents, 1997-2001




Figure 14. Top Ten Leading Cancers in Median Length of Stay (Days) for Inpatient Hospital Discharges, Nevada Residents, 1997-2001




Table 11. Nevada Inpatient Hospital Discharges by Type of Cancer and Gender, Nevada, 1997-2001

	Total	*	Male	)	Female		
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**	
Total	33,235	364.78	16,125	372.79	17,110	363.40	
Lip, Oral Cavity and Pharynx	526	5.55	352	7.59	174	3.64	
Lip	8		7		1		
Base of Tongue	79	0.81	50	1.02	29	0.60	
Other & Unspecified Parts of Tongue	97	1.03	61	1.34	36	0.75	
Parotid Gland	47	0.50	30	0.66	17	0.36	
Other & Unspecified Major Salivary glands	9		7		2		
Floor of Mouth	59	0.60	37	0.75	22	0.45	
Gum	27	0.30	17	0.36	10	0.22	
Palate	12	0.13	5		7		
Other & Unspecified Parts of Mouth	27	0.29	18	0.42	9		
Nasopharynx	23	0.24	17	0.35	6	0.04	
Tonsil	46	0.48	35	0.70	11	0.24	
Oropharynx	23	0.23	20	0.40	3		
Pyriform Sinus	20	0.21	16	0.36	4		
Hypopharynx Other & Unapposition Oral (Russel) Cavity & Pharmay	25 24	0.28 0.26	15 17	0.32 0.40	10 7	0.22	
Other & Unspecified Oral (Buccal) Cavity & Pharynx Digestive System	6,591	75.45		87.08		65.08	
			3,624		2,967		
Esophagus Stomach	297 583	3.23 6.64	224 398	5.07 9.63	73 185	1.56 4.05	
	135			1.64	61		
Small Intestine	2,825	1.48 33.22	74 1,392	34.69	1,433	1.30	
Colon (excluding Rectum)	,					31.88	
Cecum	548	6.66	246	6.24	302	6.89	
Appendix	25	0.27	9		16	0.33	
Ascending Colon	543	6.44	259	6.55	284	6.35	
Hepatic Flexure	99	1.21	52	1.27	47	1.10	
Transverse Colon	250	2.95	120	3.09	130	2.87	
Splenic Flexure	101	1.18	43	1.20	58	1.24	
Descending Colon	155	1.73	89	2.17	66	1.40	
Sigmoid Colon	793	9.14	421	10.21	372	8.20	
Large Intestine, NOS	311	3.63	153	3.77	158	3.50	
Rectum	662	7.52	377	9.02	285	6.21	
Rectosigmoid Junction	576	6.41	329	7.51	247	5.34	
Anus, Anal Canal and Anorectum	133	1.47	71	1.68	62	1.32	
Liver	308	3.28	213	4.68	95	1.99	
Intrahepatic Bile Ducts	39	0.45	19	0.46	20	0.44	
Gallbladder	38	0.47	14	0.38	24	0.55	
Other & Unspecified Biliary Tract	145	1.73	76	2.03	69	1.52	
Pancreas	741 53	8.36 0.57	390 34	9.21 0.77	351 19	7.61 0.41	
Retroperitoneum	53 52			0.77			
Peritoneum, Omentum and Mesentery	52 4	0.56	11 2	0.23	41 2	0.86	
Other Digestive Organs	5,337	58.35	2,871	66.26			
Respiratory System Nasal Cavity and Middle Ear	5,33 <i>1</i> 11	0.12	2,071		2,466 5	51.93	
Accessory Sinuses							
•	17 203	0.18 2.18	12 160	0.25 3.60	5 43	0.00	
Larynx		54.28				0.90 49.79	
Lung and Bronchus Pleura	4,965	0.78	2,601	59.93	2,364		
	66		51	1.40	15	0.32	
Trachea Mediactinum and Other Respiratory Organs	18 57	0.19	10 31	0.21	8	0.54	
Mediastinum and Other Respiratory Organs Bones, Joints and Articular Cartilage	57 116	0.62 1.23	56	0.73 1.15	26 60	0.54 1.29	
•							
Bones, Joints & Articular Cartilage of Limbs	48	0.51	23	0.47	25 25	0.55	
Bones, Joints & Articular Cartilage of Other & Unspec Sites	68	0.71	33	0.67	35	0.74	
Soft Tissue (Including Heart)	125	1.38	61	1.47	64	1.36	
Heart	2		1		1		
Peripheral Nerves & Autonomic Nervous System	0	4.20	0		0	4 24	
Connective, Subcutaneous & Other Soft Tissues	123	1.36	60	1.45	63	1.34	

<sup>\*</sup> Those of unknown gender are not shown separately, but are included in the total.

<sup>\*\*</sup> Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Table 11. Nevada Inpatient Hospital Discharges by Type of Cancer and Gender, Nevada, 1997-2001 (Continued)

T	Tota	<b> </b> *	Mal	е	Female		
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**	
Total	33,235	364.78	16,125	372.79	17,110	363.40	
Skin (Excluding Basal And Squamous)	240	2.72	152	3.68	88	1.92	
Melanomas Of The Skin	83	0.91	54	1.28	29	0.61	
Other Non-Epithelial Skin	157	1.81	98	2.40	59	1.31	
Breast	2,608	28.45	19	0.52	2,589	54.69	
Female Genital System	2,349	25.18	0		2,349	49.24	
Cervix Uteri	646	6.65	0		646	13.39	
Corpus Uteri	801	8.60	0		801	16.73	
Uterus, NOS	27	0.30	0		27	0.58	
Ovary	669	7.21	0		669	14.04	
Vagina	53	0.59	0		53	1.13	
Vulva	117	1.45	0		117	2.63	
Placenta	1		0		1		
Other Female Genital Organs	35	0.36	0		35	0.71	
Male Genital System	2,605	27.49	2,605	57.52	0		
Prostate	2,536	26.77	2,536	56.03	0		
Testis	51	0.51	51	0.98	0		
Penis	15	0.19	15	0.45	0		
Other Male Genital Organs	3		3		0		
Urinary System	1,995	22.37	1,391	33.37	604	12.98	
Urinary Bladder	1,022	11.93	762	19.40	260	5.76	
Kidney	819	8.73	528	11.53	291	6.11	
Renal Pelvis	86	0.96	58	1.44	28	0.58	
Ureter	49	0.54	35	0.82	14	0.30	
Other Urinary Organs Eye and Orbit	19 4	0.20	8 2		11 2	0.22	
•							
Brain and Other Central Nervous System Brain	762 706	8.05 7.47	449 425	9.55 9.05	313 281	6.58 5.92	
Meninges	37	0.39	425 14	0.31	23	0.47	
Spinal Cord, Cranial Nerves, & Other Parts of CNS	19	0.39	10	0.20	9	0.47	
Endocrine System	1,032	10.56	235	4.93	797	16.48	
Thyroid Gland	985	10.06	216	4.47	769	15.92	
Adrenal Gland	21	0.22	9		12	0.24	
Other Endocrine (Including Thymus)	26	0.28	10	0.26	16	0.32	
Hodgkin's Lymphoma	116	1.19	63	1.25	53	1.11	
Non-Hodgkin's Lymphoma	988	11.01	550	12.84	438	9.44	
Multiple Myeloma	321	3.49	193	4.44	128	2.69	
Leukemia	1,080	11.77	628	14.22	452	9.60	
Lymphocytic	440	4.72	262	5.72	178	3.79	
Acute Lymphocytic	0		171	3.42	115	2.40	
Chronic Lymphocytic	150	1.76	88	2.22	62	1.37	
Other Lymphocytic	4		3		1		
Myeloid and Monocytic	573	6.30	333	7.75	240	5.08	
Acute Myeloid	458	5.00	256	5.79	202	4.28	
Acute Monocytic	9		5		4		
Chronic Myeloid	103	1.17	69	1.78	34	0.71	
Other Myeloid/Monocytic	3		3		0		
Other	67	0.75	33	0.76	34	0.73	
Other Acute	47	0.54	23	0.54	24	0.53	
Aleukemic, Subleukemic and NOS	20	0.21	10	0.22	10	0.20	
Mesothelioma	0		0		0		
Kaposi Sarcoma	2		1		1		
Other, III-Defined and Unspecified Sites	6,438	70.48	2,873	66.86	3,565	75.29	

<sup>\*</sup> Those of unknown gender are not shown separately, but are included in the total.

<sup>\*\*</sup> Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Table 12. Top Ten Types of Cancer Inpatient Hospital Discharges by County/Region of Residence, Nevada Residents, 1997-2001

			County/Region of Residence						
Rank	Type of Cance	Nevada Total	Clark	Washoe	All Other Counties				
1	Lung and Bronchus	Admissions	4,965	3,562	748	654			
		Rate*	54.28	58.13	49.49	43.60			
		95% C.I.	(52.8-55.8)	(56.2-60.1)	(46.0-53.2)	(40.3-47.2)			
2	Colorectal	Admissions	4,196	2,928	706	562			
		Rate*	48.62	50.70	49.21	39.44			
		95% C.I.	(47.1-50.2)	(48.8-52.7)	(45.6-53.1)	(36.2-42.9)			
3	Breast*	Admissions	2,589	1,787	459	341			
		Rate*	54.69	56.35	56.47	45.57			
		95% C.I.	(52.6-56.9)	(53.8-59.1)	(51.4-61.9)	(40.8-50.7)			
4	Prostate*	Admissions	2,536	1,679	426	431			
		Rate*	56.03	55.84	56.16	56.85			
		95% C.I.	(53.8-58.4)	(53.0-58.8)	(50.8-62.2)	(51.4-62.9)			
5	Leukemia	Admissions	1,080	807	138	134			
		Rate*	11.77	13.04	8.81	9.59			
		95% C.I.	(11.1-12.5)	(12.1-14.0)	(7.4-10.5)	(8.0-11.4)			
6	Urinary Bladder	Admissions	1,022	728	144	149			
		Rate*	11.93	12.85	10.05	10.22			
		95% C.I.	(11.2-12.7)	(11.9-13.9)	(8.5-11.9)	(8.6-12.1)			
7	Non-Hodgkin's Lymphoma	Admissions	988	673	182	133			
		Rate*	11.01	11.18	12.05	9.20			
		95% C.I.	(10.3-11.7)	(10.3-12.1)	(10.3-14.0)	(7.7-11.0)			
8	Corpus Uteri & Uterus NOS	Admissions	828	582	128	118			
	•	Rate*	17.31	18.04	15.81	15.85			
		95% C.I.	(16.1-18.5)	(16.6-19.6)	(13.2-18.8)	(13.1-19.0)			
9	Kidney and Renal Pelvis	Admissions	905	611	144	150			
	·	Rate*	9.70	9.77	9.18	9.95			
		95% C.I.	(9.1-10.4)	(9.0-10.6)	(7.7-10.9)	(8.4-11.7)			
10	Thyroid Gland	Admissions	985	757	151				
		Rate*	10.06	11.38	8.81				
		95% C.I.	(9.4-10.7)	(10.6-12.2)	(7.5-10.4)				
	Total	Admissions	33,235	23,445	5,453	4,325			
		Rate*	364.78	383.60	357.93	293.70			
		95% C.I.	(360.8-368.8)	(378.6-388.7)	(348.4-367.7)	(284.9-302.8)			

<sup>\*</sup> Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Note: The "---" indicates that this type of cancer was not in the Top Ten for this specific region.

## Table 13. Top Ten Types of Cancer Hospital Discharges by Age Group, Nevada Residents, 1997-2001

Abbreviations: Brain and OCNS = Brain and Other Central Nervous System, CU & Uterus NOS = Corpus Uteri and Uterus NOS, HL = Hodgkin's Lymphoma, KRP = Kidney and Renal Pelvis, LOCP = Lip, Oral Cavity and Pharynx, Liver and IBD = Liver and Intrahepatic Bile Ducts, NHL = Non-Hodgkin's Lymphoma. Note: Those cases with unknown ages are not shown separately, but are included in the total.

Ranking	Age Group									
Ranking	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75+	Total	
1	Leukemia	Leukemia	Thyroid Gland	Breast	Breast	Lung and Bronchus		Colorectal	Lung and Bronchus	
	216	58	179	293	523	1,267	1,870	1,456	9,930	
	48.0%	19.9%	22.3%	14.3%	11.7%	16.1%	19.1%	19.4%	14.9%	
2	Brain and OCNS	Thyroid Gland	Leukemia	Thyroid Gland	Lung and Bronchus	Prostate	Colorectal	Lung and Bronchus	Colorectal	
	68	57	66	268	480	941	1,347	1,211	8,392	
	15.1%	19.6%	8.2%	13.0%	10.8%	12.0%	13.7%	16.1%	12.6%	
3	KRP	Brain and OCNS	Cervix Uteri	Cervix Uteri	Colorectal	Colorectal	Prostate	Breast	Breast	
	24	22	62	179	414	824	963	518	5,216	
	5.3%	7.6%	7.7%	8.7%	9.3%	10.5%	9.8%	6.9%	7.8%	
4	NHL	NHL		Lung and Bronchus	Prostate	Breast	Breast	Urinary Bladder	Prostate	
	18	21	57	124	273	610	610	410	5,072	
	4.0%	7.2%	7.1%	6.0%	6.1%	7.8%	6.2%	5.5%	7.6%	
5	Liver and IBD	HL	NHL	Colorectal	Thyroid Gland	KRP	Urinary Bladder	Prostate	Leukemia	
	15	18	54	121	220	238	338	347	2,160	
	3.3%	6.2%	6.7%	5.9%	4.9%	3.0%	3.4%	4.6%	3.2%	
6	Thyroid Gland	Cervix Uteri	Breast	Brain and OCNS	Cervix Uteri	CU & Uterus NOS	NHL	NHL	Urinary Bladder	
	7	10	51	92	158	199	263	260	2,044	
	1.6%	3.4%	6.4%	4.5%	3.5%	2.5%	2.7%	3.5%	3.1%	
7	HL	Ovary	Colorectal	Ovary	KRP	Urinary Bladder	KRP	Pancreas	NHL	
	6	6	31	66	149	193	262	210	1,976	
	1.3%	2.1%	3.9%	3.2%	3.3%	2.5%	2.7%	2.8%	3.0%	
8	Breast	Lung and Bronchus	Ovary	KRP	CU & Uterus NOS	NHL	Pancreas	Leukemia	Thyroid Gland	
	2	5	29	62	147	188	254	198	1,970	
	0.4%	1.7%	3.6%	3.0%	3.3%	2.4%	2.6%	2.6%	3.0%	
9	Ovary	Stomach	CU & Uterus NOS	Leukemia	Ovary	LOCP	CU & Uterus NOS	Stomach	KRP	
	2	5	22	55	138	181	253	176	1,810	
	0.4%	1.7%	2.7%	2.7%	3.1%	2.3%	2.6%	2.3%	2.7%	
10	Urinary Bladder	Liver and IBD	HL	CU & Uterus NOS	NHL	Leukemia	Leukemia	KRP	CU & Uterus NOS	
	2	4	20	53	135	171	222	161	1,656	
	0.4%	1.4%	2.5%	2.6%	3.0%	2.2%	2.3%	2.1%	2.5%	
Sum	360	206	571	1,313	2,637	4,812	6,382	4,947	40,226	
Percent	80.0%	70.8%	71.1%	63.9%	59.1%	61.3%	65.0%	65.9%	60.5%	
Total	450	291	803	2,054	4,463	7,852	9,814	7,508	66,470	
	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	

## **MORTALITY**

## **HIGHLIGHTS**

- ➤ Lung and Bronchus Cancer was the leading type of cancer for cancer mortality in Nevada from 1997 to 2001. This type of cancer accounted for 32.0% of all resident cancer deaths during this period. The second leading type of cancer for mortality was Colorectal Cancer, which accounted for 10.8% of all cancer deaths.
- ▶ Blacks had the highest ratio of the remaining racial/ethnic groups when compared to the age-adjusted cancer mortality rates for Whites with a comparison ratio of 1.08. This means that for every 100 White cancer deaths Blacks would be expected to have 108 deaths. Native Americans, Asians and Hispanics had comparison ratios of 0.54, 0.54 and 0.46, respectively, for Nevada from 1997 to 2001.
- ➤ Stomach Cancer had the highest age-adjusted mortality rate comparison ratio for Blacks when compared to Whites in Nevada from 1997 to 2001 with a ratio of 1.91. This means that for every 100 White Stomach Cancer deaths, Blacks would be expected to have 191 deaths. The type of cancer with the highest comparison ratio for Native Americans was Stomach with a ratio of 1.61, and Asians was Liver and Intrahepatic Bile Ducts with a ratio of 1.87. Stomach also had the highest comparison ratio for Hispanics when compared to Whites with a ratio of 1.33.
- Skin Cancer had the lowest age-adjusted mortality rate comparison ratio for Blacks and Asians when compared to Whites in Nevada from 1997 to 2001 with ratios of 0.15 and 0.11. This means that for every 100 White cancer cases Blacks and Asians would be expected to have 15 and 11 deaths, respectively, from Skin Cancer. The type of cancer with the lowest age-adjusted mortality rate comparison ratio for Native Americans was Urinary Bladder Cancer with a ratio of 0.14 during this period. The type of cancer with the lowest age-adjusted mortality rate comparison ratio for Hispanics was Larynx Cancer with a ratio of 0.08.
- ➤ Cervical Cancer had the lowest median age at time of death for Nevada residents from 1997 to 2001 at 55 years. Prostate Cancer had the highest median age at time of death for Nevada residents at 77 years.
- ➤ Hodgkin's Lymphoma had the lowest median age at time of death for male Nevada residents from 1997 to 2001 at 55 years, while the highest median age at time of death for males in Nevada was Prostate Cancer at 76 years.
- ➤ Cervical Cancer had the lowest median age at time of death for Female Nevada Residents during this same period at 53 years, while the highest median age for females in Nevada was for Stomach and Urinary Bladder Cancer at 75 years.

Figure 15. Top Ten Leading Cancers by Percentage of Total Cancer Mortality, Nevada Residents, 1997-2001




Figure 16. Comparison of Age-Adjusted (2001) Mortality Rates of Blacks compared to Whites, Nevada Residents, 1997-2001






Figure 17. Comparison of Age-Adjusted (2001) Mortality Rates of Native Americans compared to Whites, Nevada Residents, 1997-2001



Note: "N/A" indicates that a comparison ratio could not be calculated.

Figure 18. Comparison of Age-Adjusted (2001) Mortality Rates of Asians compared to Whites, Nevada Residents, 1997-2001



Note: "N/A" indicates that a comparison ratio could not be calculated.

Figure 19. Comparison of Age-Adjusted (2001) Mortality Rates of Hispanics compared to Whites, Nevada Residents, 1997-2001




Table 14. Nevada Mortality by Type of Cancer and Gender, Nevada, 1997-2001

pe of Cancer	Total*		Male		Female	
	Number	Rate**	Number	Rate**	Number	Rate**
Total	17,459	204.62	9,476	242.86	7,983	175.83
Lip, Oral Cavity and Pharynx	225	2.53	142	3.24	83	1.84
Lip	1		0		1	
Base of Tongue	3		2		1	
Other & Unspecified Parts of Tongue	60	0.64	39	0.86	21	0.44
Parotid Gland	13	0.15	6		7	
Other & Unspecified Major Salivary glands	3		3		0	
Floor of Mouth	4		2		2	
Gum	3		1		2	
Palate	4		3		1	
Other & Unspecified Parts of Mouth	25	0.29	14	0.30	11	0.26
Nasopharynx	24	0.26	16	0.34	8	
Tonsil	15	0.16	10	0.21	5	
Oropharynx	8		5		3	
Pyriform Sinus	0		0		0	
Hypopharynx	3		3		0	
Other & Unspecified Oral (Buccal) Cavity & Pharynx	59	0.68	38	0.93	21	0.46
Digestive System	4,003	47.36	2,307	57.97	1,696	38.11
Esophagus	384	4.23	294	6.72	90	1.96
Stomach	325	3.94	201	5.15	124	2.86
Small Intestine	28	0.32	13	0.33	15	0.33
Colon (excluding Rectum)	1,603	19.53	888	23.16	715	16.38
Cecum	6		3		3	
Appendix	2		2		0	
Ascending Colon	3		1		2	
Hepatic Flexure	0		0		0	
Transverse Colon	1		0		1	
Splenic Flexure	0		0		0	
Descending Colon	0		0		0	
Sigmoid Colon	11	0.12	6		5	
Large Intestine, NOS	1,580	19.23	876	22.83	704	16.12
Rectum	200	2.31	119	2.99	81	1.77
Rectosigmoid Junction	64	0.77	35	0.83	29	0.68
Anus, Anal Canal and Anorectum	24	0.27	13	0.31	11	0.24
Liver	351	4.03	233	5.58	118	2.63
Intrahepatic Bile Ducts	64	0.74	39	0.95	25	0.55
Gallbladder	43	0.53	12	0.41	31	0.68
Other & Unspecified Biliary Tract	34	0.42	22	0.60	12	0.27
Pancreas	845	9.82	419	10.48	426	9.35
Retroperitoneum	6		4		2	
Peritoneum, Omentum and Mesentery	7		1		6	
Other Digestive Organs	25	0.31	14	0.36	11	0.25
Respiratory System	5,729	65.24	3,234	79.46	2,495	53.90
Nasal Cavity and Middle Ear	0		0		0	
Accessory Sinuses	11	0.12	8		3	
Larynx	124	1.41	93	2.22	31	0.68
Lung and Bronchus	5,582	63.56	3,125	76.78	2,457	53.07
Pleura	4		3		1	
Trachea	1		0		1	
Mediastinum and Other Respiratory Organs	7		5	0.50	2	
Bones, Joints and Articular Cartilage	37	0.44	20	0.52	17	0.38
Bones, Joints & Articular Cartilage of Limbs	1		0		1	
Bones, Joints & Articular Cartilage of Other & Unspec Sites	36	0.43	20	0.52	16	0.36
Soft Tissue (Including Heart)	121	1.34	73	1.70	48	1.02
Heart	8		4		4	
Peripheral Nerves & Autonomic Nervous System	3	4 00	2		1	
Connective, Subcutaneous & Other Soft Tissues	110	1.23	67	1.57	43	0.92

<sup>\*</sup> Those of unknown gender are not shown separately, but are included in the total.

Note: The "---" is used for rates calculated on numbers less than ten.

<sup>\*\*</sup>Rates are per 100,000 population and age-adjusted to the 2000 US Standard population.

Table 14. Nevada Mortality by Type of Cancer and Gender, Nevada, 1997-2001 (Continued)

	Tota	*	Mal	е	Female	
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**
Total	17,459	204.62	9,476	242.86	7,983	175.83
Skin (Excluding Basal And Squamous)	345	3.89	242	5.86	103	2.23
Melanomas Of The Skin	264	2.92	181	4.29	83	1.76
Other Non-Epithelial Skin	81	0.98	61	1.57	20	0.47
Breast	1,195	14.02	13	0.34	1,182	25.90
Female Genital System	690	7.99	0		690	15.03
Cervix Uteri	140	1.54	0		140	2.99
Corpus Uteri	59	0.70	0		59	1.30
Uterus, NOS	75	0.93	0		75	1.70
Ovary	376	4.33	0		376	8.16
Vagina	12	0.13	0		12	0.25
Vulva	15	0.20	0		15	0.35
Placenta	1		0		1	
Other Female Genital Organs	12	0.14	0		12	0.26
Male Genital System	943	12.36	943	29.68	0	
Prostate	922	12.14	922	29.21	0	
Testis	17	0.17	17	0.34	0	
Penis	4		4		0	
Other Male Genital Organs	0		0		0	
Urinary System	748	9.06	525	14.03	223	5.10
Urinary Bladder	401	5.09	288	8.29	113	2.67
Kidney	322	3.69	224	5.43	98	2.18
Renal Pelvis	5		2		3	
Ureter	12	0.14	5		7	
Other Urinary Organs	8		6		2	
Eye and Orbit	6		5		1	
Brain and Other Central Nervous System	338	3.71	205	4.60	133	2.86
Brain	335	3.68	204	4.58	131	2.82
Meninges	0		0		0	
Spinal Cord, Cranial Nerves, & Other Parts of CNS	3		1		2	
Endocrine System	53	0.61	28	0.72	25	0.54
Thyroid Gland	29	0.35	16	0.42	13	0.29
Adrenal Gland	15	0.17	7		8	
Other Endocrine (Including Thymus)	9		5		4	
Hodgkin's Lymphoma	38	0.40	22	0.46	16	0.34
Non-Hodgkin's Lymphoma	599	7.08	356	9.40	243	5.34
Multiple Myeloma	261	3.02	155	3.93	106	2.31
Leukemia	614	7.39	368	9.53	246	5.58
Lymphocytic	164	2.06	99	2.78	65	1.51
Acute Lymphocytic	32	0.34	19	0.44	13	0.27
Chronic Lymphocytic	120	1.55	72	2.10	48	1.14
Other Lymphocytic	12	0.17	8		4	
Myeloid and Monocytic	249	2.89	144	3.55	105	2.33
Acute Myeloid	180	2.07	100	2.42	80	1.77
Acute Monocytic	0		0		0	
Chronic Myeloid	53	0.63	31	0.78	22	0.50
Other Myeloid/Monocytic	16	0.19	13	0.36	3	
Other	201	2.43	125	3.20	76	1.74
Other Acute	88	1.02	59	1.46	29	0.64
Aleukemic, Subleukemic and NOS	113	1.41	66	1.73	47	1.10
Mesothelioma	46	0.56	35	1.03	11	0.23
Kaposi Sarcoma	0		0		0	
Other, III-Defined and Unspecified Sites	1,468	17.57	803	20.29	665	15.09
Tanana, and		17.07		20.20		10.00

<sup>\*</sup> Those of unknown gender are not shown separately, but are included in the total.

Note: The "---" is used for rates calculated on numbers less than ten.

<sup>\*\*</sup>Rates are per 100,000 population and age-adjusted to the 2000 US Standard population.

Table 15. Top Ten Types of Cancer Mortality by County/Region of Residence, Nevada Residents, 1997-2001

				County/Region	n of Residence	
Rank	Type of Cancer		Nevada Total	Clark	Washoe	All Other Counties
1	Lung and Bronchus	Mortality	5,582	3,823	911	848
		Rate*	63.56	65.57	62.16	57.64
·		95% C.I.	(61.9-65.3)	(63.4-67.8)	(58.1-66.4)	(53.8-61.8)
2	Colorectal	Mortality	1,891	1,291	328	272
		Rate*	22.88	23.49	23.31	19.99
-		95% C.I.	(21.8-24.0)	(22.2-24.9)	(20.8-26.1)	(17.6-22.6)
3	Breast*	Mortality	1,182	775	235	172
		Rate*	25.90	25.49	29.74	23.52
		95% C.I.	(24.4-27.4)	(23.7-27.4)	(26.0-33.8)	(20.1-27.4)
4	Prostate*	Mortality	922	606	170	146
		Rate*	29.21	28.41	33.68	27.02
		95% C.I.	(27.2-31.4)	(25.9-31.1)	(28.5-39.7)	(22.5-32.3)
5	Pancreas	Mortality	845	572	127	146
		Rate*	9.82	9.93	8.95	10.20
		95% C.I.	(9.1-10.5)	(9.1-10.8)	(7.4-10.7)	(8.6-12.1)
6	Non-Hodgkin's Lymphoma	Mortality	599	398	108	93
		Rate*	7.08	7.12	7.45	6.61
		95% C.I.	(6.5-7.7)	(6.4-7.9)	(6.1-9.1)	(5.3-8.2)
7	Leukemia	Mortality	614	419	104	91
		Rate*	7.39	7.61	7.16	6.85
		95% C.I.	(6.8-8.0)	(6.9-8.4)	(5.8-8.7)	(5.5-8.5)
8	Liver and Intrahepatic Bile Ducts	Mortality	415	299		57
		Rate*	4.77	5.21		4.02
		95% C.I.	(4.3-5.3)	(4.6-5.9)		(3.0-5.3)
9	Urinary Bladder	Mortality	401	272	62	67
		Rate*	5.09	5.33	4.48	4.91
		95% C.I.	(4.6-5.6)	(4.7-6.1)	(3.4-5.8)	(3.8-6.3)
10	Esophagus	Mortality	384	268	68	
		Rate*	4.23	4.45	4.48	
		95% C.I.	(3.8-4.7)	(3.9-5.0)	(3.5-5.7)	
	Total	Mortality	17,459	11,761	3,005	2,693
		Rate*	204.62	207.06	209.37	190.61
		95% C.I.	(201.5-207.8)	(203.2-211.0)	(201.8-217.2)	(183.3-198.1)

 $<sup>\</sup>ast$  Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Note: The "---" indicates that this type of cancer was not in the Top Ten for this specific region.

# Table 16. Top Ten Types of Cancer Mortality by Age Group, Nevada Residents, 1997-2001

Abbreviations: Brain and OCNS = Brain and Other Central Nervous System, CU & Uterus NOS = Corpus Uteri and Uterus NOS, HL = Hodgkin's Lymphoma, KRP = Kidney and Renal Pelvis, LOCP = Lip, Oral Cavity and Pharynx, Liver and IBD = Liver and Intrahepatic Bile Ducts, NHL = Non-Hodgkin's Lymphoma.

Ranking					Age Group				
Natikitig	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75+	Total
1	Leukemia	Leukemia	Brain and OCNS	Breast	Lung and Bronchus	Lung and Bronchus	Lung and Bronchus	Lung and Bronchus	Lung and Bronchi
	16	13	15	92	428	1,173	2,063	1,836	5,582
	32.7%	32.5%	13.6%	18.5%	27.7%	35.1%	37.4%	28.9%	32.0%
2	Brain and OCNS	NHL	Leukemia	Lung and Bronchus	Breast	Colorectal	Colorectal	Colorectal	Colorectal
	12	4	10	75	195	320	598	783	1,891
	24.5%	10.0%	9.1%	15.1%	12.6%	9.6%	10.8%	12.3%	10.8%
3	Liver and IBD	Brain and OCNS	NHL	Colorectal	Colorectal	Breast	Pancreas	Prostate	Breast
	3	3	10	52	128	250	281	569	1,195
	6.1%	7.5%	9.1%	10.4%	8.3%	7.5%	5.1%	8.9%	6.8%
4	KRP	Liver and IBD	Colorectal	Brain and OCNS	Pancreas	Pancreas	Prostate	Breast	Prostate
	1	3	9	29	77	169	275	380	922
	2.0%	7.5%	8.2%	5.8%	5.0%	5.1%	5.0%	6.0%	5.3%
5		Skin	Breast	Skin	Liver and IBD	Esophagus	Breast	Pancreas	Pancreas
		3	6	28	62	123	271	302	845
		7.5%	5.5%	5.6%	4.0%	3.7%	4.9%	4.7%	4.8%
6		HL	Cervix Uteri	Cervix Uteri	Ovary	NHL	NHL	Leukemia	Leukemia
		2	6	24	62	97	174	254	614
		5.0%	5.5%	4.8%	4.0%	2.9%	3.2%	4.0%	3.5%
7		Breast	Skin	Leukemia	NHL	Leukemia	Leukemia	NHL	NHL
		1	6	23	54	91	155	239	599
		2.5%	5.5%	4.6%	3.5%	2.7%	2.8%	3.8%	3.4%
8		Colorectal	HL	NHL	Leukemia	KRP	Liver and IBD	Urinary Bladder	Liver and IBD
		1	4	20	52	80	132	208	415
		2.5%	3.6%	4.0%	3.4%	2.4%	2.4%	3.3%	2.4%
9		LOCP	Lung and Bronchus	Ovary	Brain and OCNS	Liver and IBD	Esophagus	Stomach	Urinary Bladder
		1	4	15	43	77	118	141	401
		2.5%	3.6%	3.0%	2.8%	2.3%	2.1%	2.2%	2.3%
10		Pancreas & Skin	Pancreas	Stomach	Skin	Brain and OCNS	Ovary	Liver and IBD	Esophagus
		1 (each)	4	13	41	74	114	126	384
		2.5%	3.6%	2.6%	2.7%	2.2%	2.1%	2.0%	2.2%
Sum	32	31	74	371	1,142	2,454	4,181	4,838	12,848
Percent	65.3%	77.5%	67.3%	74.5%	74.0%	73.4%	75.9%	76.1%	73.6%
Total	49	40	110	498	1,543	3,345	5,512	6,360	17,459
	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Note: Those cases with unknown ages are not shown separately, but are included in the total.

Table 17. Median Age at Time of Death by Leading Types of Cancer and Race/Ethnicity, Nevada Residents, 1997-2001

						Race/E	thnicity					
Type of Cancer	Whi	ite	Bla	ck	Native A	merican	Asi	ian	Hispa	anic	Tot	al
	Number	Age	Number	Age	Number	Age	Number	Age	Number	Age	Number	Age
Lung and Bronchus	5,090	70.0	276	67.0	26	68.5	95	67.0	89	66.0	5,580	70.0
Breast	1,037	68.0	77	62.0	5	59.0	27	55.0	49	55.0	1,195	67.0
Prostate	810	77.0	69	75.0	4		13	74.0	26	74.5	922	77.0
Colorectal	1,650	72.0	120	67.0	13	68.0	45	66.0	62	69.0	1,891	72.0
Urinary Bladder	376	75.0	11	77.0	1		5	79.0	8	78.5	401	75.0
Non-Hodgkin's Lymphoma	535	72.0	17	66.0	3		20	72.0	24	69.0	599	72.0
Kidney and Renal Pelvis	284	71.0	13	72.0	2		7	61.0	19	65.0	327	71.0
Leukemia	539	73.0	26	65.0	3		12	63.5	32	62.5	614	72.0
Lip, Oral Cavity and Pharynx	201	67.0	13	64.0	1		3		7	72.0	225	67.0
Pancreas	726	71.0	50	68.0	7	68.0	17	68.0	42	68.0	845	70.0
Skin	257	64.0	2		1		2		2		264	64.0
Corpus Uteri & Uterus NOS	114	70.5	11	70.0	1		4		4		134	70.5
Ovary	332	70.0	20	65.5	2		7	59.0	15	61.0	376	69.0
Thyroid Gland	25	73.0	1		0		1		2		29	73.0
Stomach	246	74.0	25	68.0	4		20	63.0	30	62.5	325	73.0
Brain and Other Central Nervous System	295	64.0	13	66.0	1		11	58.0	18	47.5	338	63.5
Cervix Uteri	107	55.0	8	54.0	1		11	60.0	12	56.0	140	55.0
Liver and Intrahepatic Bile Ducts	323	71.0	26	55.0	5	67.0	33	58.0	27	60.0	415	69.0
Esophagus	337	68.0	28	62.0	0		8	62.5	11	61.0	384	67.5
Larynx	112	68.0	8	68.0	1		2		1		124	68.0
Multiple Myeloma	217	72.0	24	62.5	2		6	61.5	11	71.0	261	71.0
Hodgkin's Lymphoma	34	61.5	2		0		0		2		38	61.5
All Other Sites	1,799	71.0	96	65.0	17	71.0	36	66.0	80	62.5	2,030	71.0
Total	15,446	71.0	936	67.0	100	68.0	385	65.0	573	65.0	17,457	71.0

Note: Those of other/unknown race/ethnicity are not shown separately, but are included in the total. Those deaths of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

# SURVIVAL RATE

## **HIGHLIGHTS**

- ➤ Thyroid Gland Cancer had the highest one-year survival rate of all types of cancer in Nevada from 1997 to 2001 with a rate of 97.3%. This was followed by Breast, Uterine, Prostate, and Skin Cancers, which had one-year survival rates of 95.2%, 94.7%, 94.4%, and 91.6%, respectively.
- ➤ Pancreatic Cancer had the lowest one-year survival rate of all types of cancer in Nevada from 1997 to 2001 with a rate of 34.0%. This was followed by Liver and Intrahepatic Bile Ducts, Stomach, Lung and Bronchus, and Esophagus Cancer, which had One-Year Survival rates of 35.3%, 44.6%, 46.4%, and 48.6%, respectively.
- ➤ The five types of cancer with the highest five-year survival rates in Nevada from 1997 to 2001 were Thyroid Gland (96.1%), Breast (83.2%), Hodgkin's Lymphoma (81.7%), Prostate (80.4%), and Corpus Uteri & Uterus NOS (77.2%) Cancers.
- ➤ The five types of cancer with the lowest five-year survival rates in Nevada from 1997 to 2001 were Liver and Intrahepatic Bile Ducts (10.2%), Pancreatic (11.2%), Stomach (20.5%), Esophagus (21.5%), and Lung and Bronchus (22.1%) Cancers.

Figure 20. Ten Highest One-Year Survival Rates by Type of Cancer, Nevada Residents, 1997-2001




Figure 21. Ten Lowest One-Year Survival Rates by Type of Cancer, Nevada Residents, 1997-2001




Figure 22. Ten Highest Five-Year Survival Rates by Type of Cancer, Nevada Residents, 1997-2001




Figure 23. Ten Lowest Five-Year Survival Rates by Type of Cancer, Nevada Residents, 1997-2001




Table 18. One-Year, Five-Year and Median Survival Rates by Type of Cancer, Nevada Residents, 1997-2001

Type of Cancer	1-Year	5-Year	Median Survival (Years)
Lung and Bronchus	46.4%	22.1%	0.93
Colorectal	77.5%	53.2%	>5 years
Breast	95.2%	83.2%	>5 years
Prostate	94.4%	80.4%	>5 years
Pancreas	34.0%	11.2%	0.76
Non-Hodgkin's Lymphoma	74.9%	57.3%	>5 years
Leukemia	62.5%	46.7%	3.31
Liver and Intrahepatic Bile Ducts	35.3%	10.2%	0.77
Urinary Bladder	87.3%	74.9%	>5 years
Esophagus	48.6%	21.5%	0.97
Ovary	76.8%	51.9%	>5 years
Stomach	44.6%	20.5%	0.90
Kidney and Renal Pelvis	76.7%	64.0%	>5 years
Brain and Other Central Nervous System	57.1%	40.7%	1.64
Skin	91.6%	71.4%	>5 years
Multiple Myeloma	73.8%	48.8%	3.76
Lip, Oral Cavity and Pharynx	82.2%	55.0%	>5 years
Larynx	78.1%	58.3%	>5 years
Cervix Uteri	86.2%	74.6%	>5 years
Corpus Uteri & Uterus NOS	94.7%	77.2%	>5 years
Hodgkin's Lymphoma	91.0%	81.7%	>5 years
Thyroid Gland	97.3%	96.1%	>5 years
All Other Sites	67.1%	48.4%	3.37
Total	73.5%	54.7%	>5 years

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 19. One- and Five-Year Survival Rates by Type of Cancer and Gender, Nevada Residents, 1997-2001

	Gender								
Type of Cancer	Tot	al	Ma	ale	Fen	nale			
	1-Year	5-Year	1-Year	5-Year	1-Year	5-Year			
Lung and Bronchus	46.4%	22.1%	44.1%	21.3%	49.3%	23.1%			
Colorectal	77.5%	53.2%	76.2%	52.9%	78.8%	53.6%			
Breast	95.2%	83.2%			95.1%	83.1%			
Prostate	94.4%	80.4%	94.4%	80.4%					
Pancreas	34.0%	11.2%	35.5%	14.5%	32.4%	9.1%			
Non-Hodgkin's Lymphoma	74.9%	57.3%	74.6%	62.5%	75.3%	50.5%			
Leukemia	62.5%	46.7%	61.7%	49.1%	63.7%	43.5%			
Liver and Intrahepatic Bile Ducts	35.3%	10.2%	35.3%		35.2%	16.0%			
Urinary Bladder	87.3%	74.9%	88.2%	76.7%	84.6%	69.3%			
Esophagus	48.6%	21.5%	48.8%	21.8%	47.9%				
Ovary	76.8%	51.9%			76.8%	51.9%			
Stomach	44.6%	20.5%	45.3%	22.3%	43.2%	18.0%			
Kidney and Renal Pelvis	76.7%	64.0%	76.0%	64.4%	78.0%	63.4%			
Brain and Other Central		40 =0/		0.4.007		40.007			
Nervous System	57.1%	40.7%	55.9%	34.0%	58.7%	48.2%			
Skin	91.6%	71.4%	89.5%	67.1%	94.8%	78.2%			
Multiple Myeloma	73.8%	48.8%	70.0%	45.0%	79.8%	54.4%			
Lip, Oral Cavity and Pharynx	82.2%	55.0%	82.2%	52.9%	82.0%	61.3%			
Larynx	78.1%	58.3%	78.5%	56.8%	76.5%	62.6%			
Cervix Uteri	86.2%	74.6%			86.2%	74.6%			
Corpus Uteri & Uterus NOS	94.7%	77.2%			94.7%	77.2%			
Hodgkin's Lymphoma	91.0%	81.7%	87.8%	79.6%	94.7%	83.9%			
Thyroid Gland	97.3%	96.1%	93.1%	88.0%	98.4%	98.4%			
All Other Sites	67.1%	48.4%	69.9%	54.3%	62.9%	40.3%			
Total	73.5%	54.7%	70.6%	51.4%	76.4%	58.0%			

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 20. One- and Five-Year Survival Rates by Type of Cancer and Race/Ethnicity, Nevada Residents, 1997-2001

				Race/I	Ethnicity		
Type of Cance	r	Total	White	Black	Native American	Asian	Hispanic
Lung and Bronchus	1-Year	46.4%	45.7%	48.3%		53.8%	53.4%
	5-Year	22.1%	21.4%	23.0%		23.0%	36.8%
Colorectal	1-Year 5-Year	77.5% 53.2%	76.9% <u>52.4%</u>	78.6% <u>51.2%</u>		80.0% 66.4%	81.9% <u>56.8%</u>
Breast	1-Year	95.2%	95.3%	88.5%		96.9%	95.1%
Prostate	5-Year 1-Year	<u>83.2%</u> 94.4%	83.2%	<u>76.8%</u> 95.6%		90.6%	71.5%
Prostate	5-Year	94.4% 80.4%	94.0% 79.5%	75.3%			100.0%
Pancreas	1-Year	34.0%	32.9%	13.370			
Fancieas	5-Year	11.2%	9.8%				
Non-Hodgkin's Lymphoma	1-Year	74.9%	74.5%				
Non-Hougkin's Lymphoma	5-Year	<u>57.3%</u>	56.5%				
Leukemia	1-Year	62.5%	60.2%				73.2%
Leukeiiila	5-Year	46.7%	45.0%				45.4%
Liver and Intrahepatic Bile	1-Year	35.3%	34.1%				
Ducts	5-Year	10.2%	10.4%				
Urinary Bladder	1-Year	87.3%	87.1%				
Officery bladder	5-Year	74.9%	75.4%				
Esophagus	1-Year	48.6%	46.9%				
Loophagus	5-Year	21.5%	20.7%				
Ovary	1-Year	76.8%	76.5%				
Ovary	5-Year	51.9%	50.6%				
Stomach	1-Year	44.6%	44.8%				
	5-Year	20.5%	19.4%				
Kidney and Renal Pelvis	1-Year	76.7%	75.6%				
	5-Year	64.0%	61.5%				
Brain and Other Central	1-Year	57.1%	55.6%				
Nervous System	5-Year	40.7%	37.1%				
Skin	1-Year	91.6%	91.3%				
	5-Year	71.4%	71.0%				
Multiple Myeloma	1-Year	73.8%	72.8%				
	5-Year	48.8%	43.7%				
Lip, Oral Cavity and Pharynx	1-Year	82.2%	82.0%				
	5-Year	55.0%	54.2%				
Larynx	1-Year	78.1%	77.9%				
	5-Year	58.3%	<u>56.1%</u>				
Cervix Uteri	1-Year	86.2%	83.4%				
	5-Year	74.6%	74.8%				
Corpus Uteri & Uterus NOS	1-Year 5-Year	94.7% 77.2%	95.0% <u>78.6%</u>				
Hodgkin's Lymphoma	1-Year	91.0%	91.8%				
	5-Year	81.7%	81.0%				
Thyroid Gland	1-Year	97.3%	97.2%				
,	5-Year	96.1%	95.8%				
All Other Sites	1-Year	67.1%	66.5%	60.9%			71.2%
	5-Year	48.4%	48.9%	28.1%			47.3%
Total	1-Year	73.5%	72.9%	71.2%	59.0%	75.4%	78.4%
	5-Year	54.7%	53.9%	47.7%	46.5%	63.2%	62.0%
		<u> </u>	30.078		10.070	30.270	02.070

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

# ALL CANCERS

# **ALL CANCERS**

## **HIGHLIGHTS**

- ➤ The ratio of the cancer age-adjusted incidence rate, 453.4, to the age-adjusted mortality rate, 204.6 (per 100,000 2000 US Standard population), was 2.16 during the 1997 to 2001 period, which means that for every 2.16 cancer cases there was one death due to Cancer in Nevada during this period.
- Nevadan females had a higher ratio than males when the cancer incidence and cancer mortality age-adjusted rates were compared. For every female death due to cancer there were 2.48 female cases while there were 2.22 male cases for every male Cancer death in Nevada from 1997 to 2001.
- The median age at diagnosis of cancer was 66 years of age for Nevada residents from 1997 to 2001. The median age at time of death due to cancer was 71 years. The median age at diagnosis for females was lower than the age for males, 65 and 67 years, respectively, while the median age at time of death was 71 years for females and 70 years for males.

#### **INCIDENCE**

- Nevada's lower cancer incidence rate (453.4) was statistically significant when compared to the 1996-2001 National rate of 470.3 (per 100,000 2000 US Standard population) from 1997 to 2001.
- ➤ There were 40,863 resident cancer cases reported in Nevada from 1997 to 2001. Statistical significance tests show that Washoe County had the highest age-adjusted incidence rate of cancer once regional comparisons were made, with a rate of 476.3 Clark County and All Other Counties, as a region, followed with rates of 456.9 and 415.8 (per 100,000 population 2000 US Standard population), respectively. Washoe County's rate showed slight statistical significance over the 1995-1999 National rate of 470.3, while Clark County and All Other Counties were lower than the National rate.
- Whites, as a racial/ethnic group, accounted for 88.3% of all reported cancer cases in Nevada during the 1997 to 2001 period. Their statistically significant higher age-adjusted incidence rate of 490.1 was 153.8%, 140.7%, 94.1%, and 14.8 18.15% greater than the rates for Native Americans (194.6), Hispanics (226.3), Asians (240.9) and Blacks (458.2), respectively, during this period.
- Males had a statistically significant higher age-adjusted cancer incidence rate, 496.7 (489.6-503.9) over the female rate of 423.0 (417.1-429.0) during the 1997 to 2001 period. However, both had statistically significant lower rates when compared to their national counterparts who had rates of 554.3 (552.6-556.0) and 414.4 (413.1-415.7), respectively.

#### INPATIENT HOSPITAL DISCHARGES

- ➤ There were 33,235 hospital inpatient discharges for a primary diagnosis of cancer to Nevada Residents from 1997 to 2001. Clark County had the highest cancer age-adjusted inpatient discharge rate, 383.6 (378.6-388.7), once regional comparisons were made. Clark County's discharge rate showed statistical significance over the rates for Nevada overall, Washoe County, and All Other Counties who had rates of 364.8 (360.8-368.8) 357.9 (348.4-367.7), 293.7 (284.9-302.8), (per 100,000 2000 US standard population), respectively, during this period.
- ➤ Total billed charges for hospital inpatient discharges due to a primary diagnosis of cancer in Nevada totaled over 1.1 billion dollars from 1997 to 2001. Nevadans in the 1-4 year age group had the highest median total billed amount at \$36,331 during this period. The overall average billed charge per day for a hospital inpatient discharge due to Cancer was approximately \$4,420 in Nevada from 1996 to 2001.

### **MORTALITY**

- ➤ There were 17,459 resident deaths due to Cancer in Nevada from 1997 to 2001, which was the second leading cause of death during this period. Males had a 54.3% higher mortality rate (242.9 [237.6-248.3]), than females (175.8 [172.0-179.8]) in Nevada during this period. This difference is statistically significant and age-adjusted to the 2000 U.S. standard population.
- Racial/ethnic comparisons showed that Blacks and Whites, as racial/ethnic groups, had the highest statistically significant cancer age-adjusted mortality rates of 234.4 (218.5-251.4) and 216.0 (212.6-219.6), respectively, of all racial/ethnic groups. They were followed by Asians, Native Americans, and Hispanics who had age-adjusted mortality rates of 116.3 (101.8-133.4), 115.9 (93.1-143.3) and 99.2 (89.7-109.7), respectively from 1997 to 2001.


#### **SURVIVAL RATE**

- ➤ The one-year survival rate for all cancers in Nevada was 72.7% during the 1997 to 2001 period, while the five-year survival rate was 50.9% during this same time. The median survival rate in Nevada was >5 years.
- Females in Nevada had a higher one-year survival rate (75.3%) than males (70.2%) for all cancers during the 1997 to 2001 period. This trend was similar for the five-year survival rate and the median survival time with females and males at 54.5% and 47.2%, respectively, and > 5 years and 3.28 years, respectively.
- ➤ Hispanics, as a racial/ethnic group, had the highest One-Year Survival Rate for all cancers (75.9%) in the State, and were followed by Asians, Blacks, Whites, and Native Americans, with rates of 75.6%, 73.5%, 72.3%, and 61.7%, respectively, during the 1997 to 2001 period.

- Native Americans had both the lowest one-year survival and five-year survival rate for all cancers in Nevada at 61.7% and 46.6%, respectively during the 1997-2001 period.
- ➤ The five-year survival rate for those diagnosed at the in situ stage was 83.2% for Nevada from 1997 to 2001. The rate for those at the localized stage was 69.4%, while those recorded at the regional, distant and unstaged stages had rates of 51.9%, 26.6% and 29.8%, respectively.
- ➤ While the Median Survival time for those diagnosed at the in sit, localized, or regional stages was over five years for all types of cancer, those diagnosed at the distant and unstaged levels had median survival times of 1.20 and 1.47 years, respectively, for Nevada during the 1997 to 2001 period.

# **INCIDENCE**

Figure 24. Age-Adjusted (2001) Incidence Rates for All Cancers, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 25. All Cancers Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 26. All Cancers Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 21. All Cancers Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

		County/Region of Residence									
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)					
Total											
Cases	40,863	27,522	7,239	6,080	22	816,901					
Rate*	453.4	456.9	476.3	415.8		470.3					
95% C.I.	(448.9-457.9)	(451.4-462.5)	(465.3-487.6)	(405.3-426.6)		(469.3-471.3)					
Gender											
Male	21,042	14,080	3,624	3,327	11	416,773					
Rate*	496.7	498.5	515.9	472.6		554.3					
95% C.I.	(489.6-503.9)	(489.6-507.6)	(498.4-534.0)	(456.1-489.8)		(552.6-556.0)					
Female	19,821	13,442	3,615	2,753	11	400,128					
Rate*	423.0	428.8	450.6	369.3		414.4					
95% C.I.	(417.1-429.0)	(421.5-436.2)	(436.0-465.6)	(355.5-383.4)		(413.1-415.7)					
Other/Unknown	0	0	0	0	0	0					
Race/Ethnicity											
White	36,076	23,804	6,577	5,677	18	669,754					
Rate*	490.1	505.1	499.8	427.8		479.6					
95% C.I.	(485.0-495.3)	(498.5-511.7)	(487.7-512.2)	(416.5-439.3)		(478.5-480.8)					
Black	1,988	1,637	228	122	1	75,672					
Rate*	458.2	405.7	965.9	1,507.7		515.7					
95% C.I.	(436.9-480.6)	(384.8-427.7)	(840.0-1,107.3)	(1,249.0-1,808.3)		(512.0-519.5)					
Native American	185	72	50	62	1	3,867					
Rate*	194.6	191.7	271.5	159.0		237.7					
95% C.I.	(166.1-227.5)	(146.5-250.5)	(196.5-371.1)	(121.1-206.6)		(229.7-229.7)					
Asian	878	670	160	47	1	59,304					
Rate*	240.9	223.6	279.8	399.2		336.5					
95% C.I.	(221.2-262.9)	(202.4-247.9)	(231.2-341.8)	(274.3-578.4)		(333.8-339.3)					
Hispanic	1,491	1,114	217	159	1	62,567					
Rate*	226.3	220.3	234.0	261.0		346.2					
95% C.I.	(212.6-241.0)	(204.7-237.3)	(198.3-276.9)	(216.5-313.5)		(343.3-349.2)					
Other/Unknown	245	225	7	13	0	8,304					

<sup>\*</sup> Rates are per 100,000 population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 22. All Cancers Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

		County/Region of Residence									
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)					
Total											
Cases	40,863	27,522	7,239	6,080	22	816,901					
Rate*	419.6	413.1	431.3	435.1		441.1					
95% C.I.	(415.6-423.7)	(408.2-418.0)	(421.3-441.2)	(424.1-446.0)		(440.2-442.1)					
Age Group											
<1	31	20	5	6	0	632					
Rate*	21.3	19.5				22.8					
95% C.I.	(13.8-28.9)	(10.9-28.0)				(21.0-24.6)					
1-4	103	77	11	15	0	2,214					
Rate*	18.2	19.3	11.6	20.5		19.9					
95% C.I.	(14.6-21.7)	(15.0-23.6)	(4.8-18.5)	(10.1-30.9)		(19.0-20.7)					
5-14	158	98	34	25	1	3,418					
Rate*	11.4	10.4	14.8	11.9		12.8					
95% C.I.	(9.7-13.2)	(8.3-12.5)	(9.8-19.8)	(7.3-16.6)		(12.3-13.2)					
15-24	287	191	51	43	2	6,889					
Rate*	21.4	20.6	22.2	23.0		26.7					
95% C.I.	(18.9-23.8)	(17.7-23.5)	(16.1-28.3)	(16.2-29.9)		(26.0-27.3)					
25-34	863	621	142	98	2	19,627					
Rate*	58.5	58.4	55.7	62.3		67.1					
95% C.I.	(54.6-62.4)	(53.8-63.0)	(46.5-64.9)	(50.0-74.7)		(66.1-68.0)					
35-44	2,262	1,527	456	277	2	51,196					
Rate*	145.3	145.9	161.0	122.4		163.8					
95% C.I.	(139.3-151.3)	(138.6-153.2)	(146.2-175.7)	(107.9-136.8)		(162.4-165.3)					
45-54	5,302	3,571	990	739	2	108,163					
Rate*	413.0	421.8	418.7	368.0		472.6					
95% C.I.	(401.9-424.1)	(408.0-435.7)	(392.6-444.8)	(341.5-394.6)		(469.8-475.4)					
55-64	9,176	6,297	1,547	1,328	4	160,682					
Rate*	1,001.6	1,013.1	1,030.5	919.1		1,147.6					
95% C.I.	(981.1-1,022.1)	(988.1-1,038.2)	(979.2-1,081.9)	(869.7-968.5)		(1,142.0-1,153.2)					
65-74	12,497	8,385	2,171	1,938	3	220,368					
Rate*	1,945.9	1,938.7	2,117.7	1,807.8		1,910.1					
95% C.I.	(1,911.7-1,980.0)	(1,897.2-1,980.1)	(2,028.6-2,206.8)	(1,727.3-1,888.3)		(1,902.1-1,918.1)					
75-84	8,237	5,506	1,433	1,292	6	184,028					
Rate*	2,344.8	2,357.5	2,478.0	2,156.8		2,531.8					
95% C.I.	(2,294.2-2,395.5)	(2,295.3-2,419.8)	(2,349.7-2,606.3)	(2,039.2-2,274.4)		(2,520.3-2,543.4)					
85+	1,905	1,215	376	314	0	59,684					
Rate*	2,498.8	2,601.9	2,424.4	2,237.9		2,406.5					
95% C.I.	(2,386.6-2,611.0)	(2,455.6-2,748.2)	(2,179.3-2,669.4)	(1,990.3-2,485.4)		(2,387.2-2,425.8)					
Unknown	42	14_	23	5	0	0					

<sup>\*</sup>Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 23. All Cancers Cases by County of Residence at Diagnosis, Nevada Residents, 1997-2001

County of	1997-2001 Incidence							
Residence	0	Rat	e*	Age-Adjust	ted Rate**			
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	1,585	636.3	(605.0-667.6)	552.7	(525.7-581.0)			
Churchill	647	536.4	(495.1-577.8)	562.5	(519.7-608.3)			
Clark	27,522	413.1	(408.2-418.0)	456.9	(451.4-462.5)			
Douglas	885	431.8	(403.3-460.2)	365.9	(341.2-392.2)			
Elko	397	171.6	(154.7-188.4)	305.0	(272.6-340.8)			
Esmeralda	22	415.9	(242.1-589.7)	354.3	(213.8-587.8)			
Eureka	20	234.2	(131.6-336.9)	228.1	(137.9-385.2)			
Humboldt	214	254.9	(220.8-289.1)	339.9	(293.7-392.5)			
Lander	80	255.9	(199.8-312.0)	353.4	(275.6-449.0)			
Lincoln	67	330.8	(251.6-410.0)	265.6	(205.1-345.0)			
Lyon	910	535.0	(500.3-569.8)	466.6	(436.3-498.8)			
Mineral	157	594.9	(501.9-688.0)	450.6	(381.3-532.5)			
Nye	864	549.7	(513.0-586.4)	398.8	(371.0-428.7)			
Pershing	85	298.8	(235.3-362.3)	343.8	(273.9-427.8)			
Storey	46	255.8	(181.9-329.7)	223.2	(156.0-329.1)			
Washoe	7,239	431.3	(421.3-441.2)	476.3	(465.3-487.6)			
White Pine	101	240.4	(193.5-287.3)	203.1	(165.2-248.8)			
Unknown	22							
Total	40,863	419.6	(415.6-423.7)	453.4	(448.9-457.9)			

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 24. All Cancers Cases by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

			Ger	nder	
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total
White	Incidence	18,597	17,479	0	36,076
	Rate*	527.7	465.1		490.1
	95% C.I.	(519.7-535.7)	(458.2-472.1)		(485.0-495.3)
Black	Incidence	1,047	941	0	1,988
	Rate*	519.6	406.3		458.2
	95% C.I.	(484.7-557.7)	(379.6-434.6)		(436.9-480.6)
Native	Incidence	98	87	0	185
American	Rate*	235.1	167.1		194.6
	95% C.I.	(186.1-298.2)	(132.5-208.9)		(166.1-227.5)
Asian	Incidence	389	489	0	878
	Rate*	264.8	222.9		240.9
	95% C.I.	(232.7-302.6)	(198.7-251.2)		(221.2-262.9)
Hispanic	Incidence	795	696	0	1,491
·	Rate*	282.0	187.8		226.3
	95% C.I.	(256.9-310.0)	(171.9-205.2)		(212.6-241.0)
Other/Unkr	own	116	129	0	245
Total	Incidence	21,042	19,821	0	40,863
	Rate*	496.7	423.0		453.4
	95% C.I.	(489.6-503.9)	(417.1-429.0)		(448.9-457.9)

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population and age-adjusted to the 2001 US Standard population.

Table 25. All Cancers Cases by Age Group and Gender, Nevada Residents, 1997-2001

Age	Gender					
Group	Male	Female	Other/ Unknown	Total		
<1	20	11	0	31		
Rate*	26.9	15.5		21.3		
95% C.I.	(15.1-38.8)	(6.3-24.6)		(13.8-28.9)		
1-4	59	44	0	103		
Rate*	20.4	15.8		18.2		
95% C.I.	(15.2-25.6)	(11.2-20.5)		(14.6-21.7)		
5-14	90	68	0	158		
Rate*	12.7	10.2		11.4		
95% C.I.	(10.0-15.3)	(7.7-12.6)		(9.7-13.2)		
15-24	145	142	0	287		
Rate*	20.8	21.9		21.4		
95% C.I.	(17.4-24.2)	(18.3-25.6)		(18.9-23.8)		
25-34	327	536	0	863		
Rate*	42.6	75.8		58.5		
95% C.I.	(38.0-47.2)	(69.4-82.2)		(54.6-62.4)		
35-44	733	1,529	0	2,262		
Rate*	91.0	203.6		145.3		
95% C.I.	(84.4-97.6)	(193.4-213.8)		(139.3-151.3)		
45-54	2,230	3,072	0	5,302		
Rate*	343.0	484.8		413.0		
95% C.I.	(328.8-357.3)	(467.6-501.9)		(401.9-424.1)		
55-64	4,967	4,209	0	9,176		
Rate*	1,091.7	912.7		1,001.6		
95% C.I.	(1,061.3-1,122.1)	(885.1-940.2)		(981.1-1,022.1)		
65-74	7,239	5,258	0	12,497		
Rate*	2,283.9	1,616.4		1,945.9		
95% C.I.	(2,231.3-2,336.5)	(1,572.7-1,660.1)		(1,911.7-1,980.0)		
75-84	4,341	3,896	0	8,237		
Rate*	2,738.3	2,021.2		2,344.8		
95% C.I.	(2,656.9-2,819.8)	(1,957.8-2,084.7)		(2,294.2-2,395.5)		
85+	864	1,041	0	1,905		
Rate*	3,491.4	2,021.8		2,498.8		
95% C.I.	(3,258.5-3,724.2)	(1,898.9-2,144.6)		(2,386.6-2,611.0)		
Unknown	27	15	0	42		
Total	21,042	19,821	0	40,863		
Rate*	425.1	414.0		419.6		
95% C.I.	(419.3-430.8)	(408.2-419.8)		(415.6-423.7)		

Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 26. All Cancers Cases by Age Group and Stage, Nevada Residents, 1997-2001

		Stage					
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total
<1	Number	0	8	1	12	10	31
	Percent		25.8%	3.2%	38.7%	32.3%	100.0%
1-4	Number	0	23	2	62	16	103
	Percent		22.3%	1.9%	60.2%	15.5%	100.0%
5-14	Number	0	44	11	71	32	158
	Percent		27.8%	7.0%	44.9%	20.3%	100.0%
15-24	Number	2	128	43	75	39	287
	Percent	0.7%	44.6%	15.0%	26.1%	13.6%	100.0%
25-34	Number	15	423	165	132	128	863
	Percent	1.7%	49.0%	19.1%	15.3%	14.8%	100.0%
35-44	Number	99	1,024	495	343	301	2,262
	Percent	4.4%	45.3%	21.9%	15.2%	13.3%	100.0%
45-54	Number	343	2,110	1,052	928	869	5,302
	Percent	6.5%	39.8%	19.8%	17.5%	16.4%	100.0%
55-64	Number	354	3,544	1,836	1,764	1,678	9,176
	Percent	3.9%	38.6%	20.0%	19.2%	18.3%	100.0%
65-74	Number	441	4,845	2,222	2,377	2,612	12,497
	Percent	3.5%	38.8%	17.8%	19.0%	20.9%	100.0%
75-84	Number	261	2,816	1,301	1,588	2,271	8,237
	Percent	3.2%	34.2%	15.8%	19.3%	27.6%	100.0%
85+	Number	44	522	281	325	733	1,905
	Percent	2.3%	27.4%	14.8%	17.1%	38.5%	100.0%
Unknown	Number	1	16	11	11	3	42
	Percent	2.4%	38.1%	26.2%	26.2%	7.1%	100.0%
Total	Number	1,560	15,503	7,420	7,688	8,692	40,863
	Percent	3.8%	37.9%	18.2%	18.8%	21.3%	100.0%

Table 27. Cancer Incidence by Stage and Race/Ethnicity, Nevada Residents, 1997-2001

		Race/Ethnicity						
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total
In situ	Number	1,391	55	4	37	57	16	1,560
1	Percent	3.9%	2.8%	2.2%	4.2%	3.8%	6.5%	3.8%
Localized	Number	13,756	704	57	296	573	117	15,503
-	Percent	38.1%	35.4%	30.8%	33.7%	38.4%	47.8%	37.9%
Regional	Number	6,519	393	34	193	234	47	7,420
	Percent	18.1%	19.8%	18.4%	22.0%	15.7%	19.2%	18.2%
Distant	Number	6,736	395	41	180	315	21	7,688
	Percent	18.7%	19.9%	22.2%	20.5%	21.1%	8.6%	18.8%
Unstaged	Number	7,674	441	49	172	312	44	8,692
	Percent	21.3%	22.2%	26.5%	19.6%	20.9%	18.0%	21.3%
Total	Number	36,076	1,988	185	878	1,491	245	40,863
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%


Table 28. Median Age at Diagnosis of All Cancers by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

		Gender								
Race/Ethnicity	Ма	le	Fem	ale	Total					
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age				
White	18,572	68.0	17,467	66.0	36,039	67.0				
Black	1,046	65.0	938	63.0	1,984	64.0				
Native American	98	65.5	87	63.0	185	65.0				
Asian	389	65.0	489	59.0	878	62.0				
Hispanic	794	63.0	696	57.0	1,490	61.0				
Other/Unknown	116	64.0	129	60.0	245	62.0				
Total	21,015	67.0	19,806	65.0	40,821	66.0				

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

# INPATIENT HOSPITAL DISCHARGES

Figure 27. All Cancers Age-Adjusted (2001) Inpatient Discharge Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 28. All Cancers Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 29. Median Charges for All Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Figure 30. Average Length of Stay for All Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Table 29. All Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

		Coun	ty/Region of Reside	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	33,235	23,445	5,453	4,325	12
Rate*	364.8	383.6	357.9	293.7	
95% C.I.	(360.8-368.8)	(378.6-388.7)	(348.4-367.7)	(284.9-302.8)	
Gender					
Male	16,125	11,406	2,451	2,260	8
Rate*	372.8	395.3	343.5	314.0	
95% C.I.	(366.7-379.0)	(387.6-403.3)	(329.4-358.3)	(300.7-327.9)	
Female	17,110	12,039	3,002	2,065	4
Rate*	363.4	380.8	374.8	276.7	
95% C.I.	(357.9-368.9)	(373.9-387.7)	(361.4-388.5)	(264.8-289.0)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$1,013,692,130	\$158,970,196	\$158,970,196	\$107,192,310	\$981,706
Average Charges	\$30,501	\$31,843	\$29,153	\$24,784	\$81,809
Median Charges	\$20,115	\$20,459	\$21,874	\$15,992	\$27,389
Discharge Length of S	tay (LOS) (Days)				
Total LOS	230,939	166,768	37,545	26,467	159
Average LOS	6.9	7.1	6.9	6.1	13.3
Median LOS	5.0	5.0	5.0	4.0	7.0

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 30. Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		Cour	nty/Region of Reside	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	33,235	23,445	5,453	4,325	12
Rate*	341.3	351.9	324.9	309.5	
95% C.I.	(337.6-345.0)	(347.4-356.4)	(316.2-333.5)	(300.3-318.7)	
Age Group					
<1	29	25	0	4	0
Rate*	20.0	24.3			
95% C.I.	(12.7-27.2)	(14.8-33.9)			
1-4	146	128	4	14	0
Rate*	25.7	32.0		14.8	
95% C.I.	(21.6-29.9)	(26.5-37.6)		(7.0-22.6)	
5-14	275	244	18	13	0
Rate*	19.9	25.9	7.8	5.7	
95% C.I.	(17.6-22.3)	(22.7-29.2)	(4.2-11.5)	(2.6-8.7)	
15-24	291	221	42	28	0
Rate*	21.7	23.8	18.3	12.2	
95% C.I.	(19.2-24.1)	(20.7-27.0)	(12.8-23.8)	(7.7-16.7)	
25-34	803	629	107	67	0
Rate*	54.4	59.2	42.0	26.3	
95% C.I.	(50.7-58.2)	(54.6-63.8)	(34.0-49.9)	(20.0-32.6)	
35-44	2,054	1,504	339	210	1
Rate*	132.0	143.7	119.7	74.1	
95% C.I.	(126.3-137.7)	(136.4-151.0)	(106.9-132.4)	(64.1-84.1)	
45-54	4,463	3,214	735	513	1
Rate*	347.6	379.7	310.8	216.9	
95% C.I.	(337.4-357.8)	(366.5-392.8)	(288.4-333.3)	(198.2-235.7)	
55-64	7,852	5,621	1,230	997	4
Rate*	857.1	904.4	819.3	664.1	
95% C.I.	(838.1-876.0)	(880.7-928.0)	(773.6-865.1)	(622.9-705.4)	
65-74	9,814	6,736	1,633	1,441	4
Rate*	1,528.1	1,557.4	1,592.9	1,405.6	
95% C.I.	(1,497.9-1,558.3)	(1,520.2-1,594.6)	(1,515.7-1,670.2)	(1,333.0-1,478.2)	
75-84	6,197	4,286	1,078	831	2
Rate*	1,764.1	1,835.2	1,864.1	1,437.0	
95% C.I.	(1,720.2-1,808.0)	(1,780.2-1,890.1)	(1,752.8-1,975.4)	(1,339.3-1,534.7)	
85+	1,311	837	267	207	0
Rate*	1,719.6	1,792.4	1,721.6	1,334.7	
95% C.I.	(1,626.6-1,812.7)	(1,671.0-1,913.9)	(1,515.1-1,928.1)	(1,152.9-1,516.5)	
Unknown	0	0	0	0	0

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 31. All Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1997-2001

Age		Gender	
Group	Male	Female	Total
<1	13	16	29
Rate*	17.5	22.5	20.0
95% C.I.	(8.0-27.0)	(11.5-33.6)	(12.7-27.2)
1-4	85	61	146
Rate*	29.3	22.0	25.7
95% C.I.	(23.1-35.6)	(16.5-27.5)	(21.6-29.9)
5-14	135	140	275
Rate*	19.0	20.9	19.9
95% C.I.	(15.8-22.2)	(17.5-24.4)	(17.6-22.3)
15-24	135	156	291
Rate*	19.4	24.1	21.7
95% C.I.	(16.1-22.6)	(20.3-27.9)	(19.2-24.1)
25-34	261	542	803
Rate*	34.0	76.6	54.4
95% C.I.	(29.9-38.1)	(70.2-83.1)	(50.7-58.2)
35-44	637	1,417	2,054
Rate*	79.1	188.7	132.0
95% C.I.	(72.9-85.2)	(178.9-198.5)	(126.3-137.7)
45-54	1,886	2,577	4,463
Rate*	290.1	406.7	347.6
95% C.I.	(277.0-303.2)	(391.0-422.4)	(337.4-357.8)
55-64	4,180	3,672	7,852
Rate*	918.7	796.2	857.1
95% C.I.	(890.9-946.6)	(770.5-822.0)	(838.1-876.0)
65-74	5,280	4,534	9,814
Rate*	1,665.9	1,393.9	1,528.1
95% C.I.	(1,620.9-1,710.8)	(1,353.3-1,434.4)	(1,497.9-1,558.3)
75-84	2,950	3,247	6,197
Rate*	1,860.9	1,684.5	1,764.1
95% C.I.	(1,793.7-1,928.0)	(1,626.6-1,742.5)	(1,720.2-1,808.0)
85+	563	748	1,311
Rate*	2,275.0	1,452.7	1,719.6
95% C.I.	(2,087.1-2,463.0)	(1,348.6-1,556.8)	(1,626.6-1,812.7)
Unknown	0	0	0
Total	16,125	17,110	33,235
Rate*	325.7	357.4	341.3
95% C.I.	(320.7-330.8)	(352.0-362.7)	(337.6-345.0)

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 32. All Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001

2		al Discharges			
County of Residence	Number	Rat	e*	Age-Adjust	ted Rate**
	Number	Rate	95% C.I.	Rate	95% C.I.
Carson City	732	293.9	(272.6-315.2)	254.0	(235.8-273.3)
Churchill	423	350.7	(317.3-384.1)	366.2	(331.9-403.5)
Clark	23,445	351.9	(347.4-356.4)	383.6	(378.6-388.7)
Douglas	575	280.5	(257.6-303.5)	235.7	(216.1-257.1)
Elko	252	108.9	(95.5-122.4)	198.9	(172.6-228.6)
Esmeralda	36	680.6	(458.3-902.9)	550.4	(378.3-809.3)
Eureka	19	222.5	(122.5-322.6)	247.1	(146.5-416.6)
Humboldt	191	227.5	(195.2-259.8)	298.6	(255.8-347.7)
Lander	79	252.7	(197.0-308.4)	348.1	(271.1-442.8)
Lincoln	48	237.0	(169.9-304.0)	197.8	(144.9-270.3)
Lyon	933	548.6	(513.4-583.8)	482.3	(451.3-515.2)
Mineral	123	466.1	(383.7-548.5)	354.5	(293.2-428.6)
Nye	731	465.1	(431.4-498.8)	338.4	(312.8-366.1)
Pershing	66	232.0	(176.0-288.0)	261.9	(201.9-336.0)
Storey	18	100.1	(53.9-146.3)	100.5	(53.3-192.1)
Washoe	5,453	324.9	(316.2-333.5)	357.9	(348.4-367.7)
White Pine	99	235.6	(189.2-282.1)	199.0	(161.4-244.3)
Unknown	12				
Total	33,235	341.3	(337.6-345.0)	364.8	(360.8-368.8)


Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 33. All Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1997-2001

Age	Discharges		Charges (\$)		Len	gth of Stay (Da	ıys)
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	29	1,310,808	45,200	27,798	310	10.7	7.0
1-4	146	8,468,166	58,001	36,331	1,910	13.1	8.0
5-14	275	12,487,109	45,408	26,233	2,337	8.5	5.0
15-24	291	12,797,626	43,978	23,263	2,443	8.4	4.0
25-34	803	25,114,033	31,275	16,863	4,984	6.2	3.0
35-44	2,054	55,359,959	26,952	17,031	12,074	5.9	4.0
45-54	4,463	130,343,963	29,205	19,924	28,969	6.5	4.0
55-64	7,852	252,357,910	32,139	20,877	55,710	7.1	5.0
65-74	9,814	297,081,590	30,271	20,744	67,271	6.9	5.0
75-84	6,197	185,090,653	29,868	19,851	45,491	7.3	6.0
85+	1,311	33,280,313	25,385	17,148	9,440	7.2	6.0
Unknown	0						
Total	33,235	4,294,945	32,109	28,726	146	32,109.0	7.0

# **MORTALITY**

Figure 31. Cancer Age-Adjusted (2001) Mortality Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 32. Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 33. Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 34. All Cancers Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	17,459	11,761	3,005	2,693
Rate*	204.6	207.1	209.4	190.6
95% C.I.	(201.5-207.8)	(203.2-211.0)	(201.8-217.2)	(183.3-198.1)
Gender				
Male	9,476	6,383	1,571	1,522
Rate*	242.9	246.2	246.1	228.3
95% C.I.	(237.6-248.3)	(239.5-253.1)	(233.3-259.5)	(216.4-240.9)
Female	7,983	5,378	1,434	1,171
Rate*	175.8	178.0	183.9	158.9
95% C.I.	(172.0-179.8)	(173.2-182.9)	(174.4-193.7)	(149.8-168.3)
Other/Unknown	0	0	0	0
Race/Ethnicity				
White	15,447	10,113	2,770	2,564
Rate*	216.0	221.0	218.6	197.2
95% C.I.	(212.6-219.6)	(216.6-225.5)	(210.4-227.0)	(189.5-205.2)
Black	937	876	51	10
Rate*	234.4	237.7	230.9	130.6
95% C.I.	(218.5-251.4)	(220.9-255.8)	(170.0-308.2)	(62.2-246.2)
Native American	100	30	28	42
Rate*	115.9	82.5	171.7	115.6
95% C.I.	(93.1-143.3)	(53.8-125.6)	(110.4-259.5)	(82.5-159.0)
Asian	385	315	57	13
Rate*	116.3	116.5	120.6	111.8
95% C.I.	(101.8-133.4)	(100.0-136.3)	(86.1-170.2)	(53.3-230.3)
Hispanic	573	416	95	62
Rate*	99.2	93.9	114.4	114.4
95% C.I.	(89.7-109.7)	(83.3-105.9)	(89.2-147.3)	(84.4-153.1)
Other/Unknown	17	11	4	2

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 35. All Cancers Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	17,459	11,761	3,005	2,693
Rate*	179.3	176.5	179.0	192.7
95% C.I.	(176.6-181.9)	(173.3-179.7)	(172.6-185.4)	(185.4-200.0)
Age Group				
<1	4	3	0	1
Rate*				
95% C.I.				
1-4	14	9	2	3
Rate*	2.5			
95% C.I.	(1.2-3.8)			
5-14	31	19	9	3
Rate*	2.2	2.0		
95% C.I.	(1.5-3.0)	(1.1-2.9)		
15-24	40	27	6	7
Rate*	3.0	2.9		
95% C.I.	(2.1-3.9)	(1.8-4.0)		
25-34	110	88	13	9
Rate*	7.5	8.3	5.1	
95% C.I.	(6.1-8.9)	(6.5-10.0)	(2.3-7.9)	
35-44	498	357	86	55
Rate*	32.0	34.1	30.4	24.3
95% C.I.	(29.2-34.8)	(30.6-37.6)	(23.9-36.8)	(17.9-30.7)
45-54	1,543	1,101	247	195
Rate*	120.2	130.1	104.5	97.1
95% C.I.	(114.2-126.2)	(122.4-137.7)	(91.4-117.5)	(83.5-110.7)
55-64	3,345	2,276	549	520
Rate*	365.1	366.2	365.7	359.9
95% C.I.	(352.7-377.5)	(351.1-381.2)	(335.1-396.3)	(328.9-390.8)
65-74	5,512	3,690	952	870
Rate*	858.2	853.1	928.6	811.5
95% C.I.	(835.6-880.9)	(825.6-880.7)	(869.6-987.6)	(757.6-865.5)
75-84	4,836	3,245	832	759
Rate*	1,376.7	1,389.4	1,438.7	1,267.0
95% C.I.	(1,337.9-1,415.5)	(1,341.6-1,437.2)	(1,340.9-1,536.5)	(1,176.9-1,357.2)
85+	1,524	945	308	271
Rate*	1,999.0	2,023.7	1,985.9	1,931.4
95% C.I.	(1,898.7-2,099.4)	(1,894.7-2,152.7)	(1,764.1-2,207.7)	(1,701.4-2,161.4)
Unknown	2	1	1	0

Note: The "---" is used for rates calculated on numbers less than ten. \* Rates are per 100,000 age-specific population.

Table 36. Cancer Mortality by County of Residence, Nevada Residents, 1997-2001

	1997-2001 Mortality						
County of Residence		Rat	te*	Age-Adjust	ted Rate**		
	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	667	267.8	(247.4-288.1)	229.2	(212.0-247.5)		
Churchill	203	168.3	(145.2-191.5)	180.8	(156.6-208.2)		
Clark	11,761	176.5	(173.3-179.7)	207.1	(203.2-211.0)		
Douglas	374	182.5	(164.0-201.0)	160.9	(144.2-179.4)		
Elko	214	92.5	(80.1-104.9)	187.1	(160.6-217.1)		
Esmeralda	9						
Eureka	7						
Humboldt	110	131.0	(106.5-155.5)	195.3	(159.0-238.5)		
Lander	51	163.1	(118.4-207.9)	247.4	(180.6-332.9)		
Lincoln	48	237.0	(169.9-304.0)	192.4	(141.1-263.0)		
Lyon	383	225.2	(202.6-247.7)	203.8	(183.4-226.1)		
Mineral	74	280.4	(216.5-344.3)	215.6	(168.4-275.9)		
Nye	405	257.7	(232.6-282.8)	190.1	(170.7-211.7)		
Pershing	38	133.6	(91.1-176.1)	161.0	(113.4-223.4)		
Storey	28	155.7	(98.0-213.4)	139.6	(85.9-234.8)		
Washoe	3,005	179.0	(172.6-185.4)	209.4	(201.8-217.2)		
White Pine	82	195.2	(152.9-237.4)	160.3	(127.3-201.1)		
Unknown	0						
Total	17,459	179.3	(176.6-181.9)	204.6	(201.5-207.8)		

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 37. Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

		Gender		
Race/Ethnicity		Male	Female	Total
White	Mortality	8,400	7,047	15,447
	Rate*	254.1	187.2	216.0
	95% C.I.	(248.3-260.1)	(182.9-191.7)	(212.6-219.6)
Black	Mortality	500	437	937
	Rate*	280.8	200.1	234.4
	95% C.I.	(252.8-312.3)	(181.0-221.0)	(218.5-251.4)
Native	Mortality	57	43	100
American	Rate*	158.9	90.3	115.9
	95% C.I.	(114.7-218.8)	(64.6-123.5)	(93.1-143.3)
Asian	Mortality	186	199	385
	Rate*	130.3	105.8	116.3
	95% C.I.	(108.1-158.4)	(87.1-129.2)	(101.8-133.4)
Hispanic	Mortality	324	249	573
	Rate*	128.0	78.3	99.2
	95% C.I.	(110.5-148.5)	(67.6-90.7)	(89.7-109.7)
Other/Unknown		9	8	17
Total	Mortality	9,476	7,983	17,459
	Rate*	242.9	175.8	204.6
	95% C.I.	(237.6-248.3)	(172.0-179.8)	(201.5-207.8)

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 38. Cancer Mortality by Age Group and Gender, Nevada Residents, 1997-2001

Age		Gender	
Group	Male	Female	Total
<1	3	1	4
Rate*			
95% C.I.			
1-4	7	7	14
Rate*			2.5
95% C.I.			(1.2-3.8)
5-14	13	18	31
Rate*	1.8	2.7	2.2
95% C.I.	(0.8-2.8)	(1.4-3.9)	(1.5-3.0)
15-24	22	18	40
Rate*	3.2	2.8	3.0
95% C.I.	(1.8-4.5)	(1.5-4.1)	(2.1-3.9)
25-34	51	59	110
Rate*	6.6	8.3	7.5
95% C.I.	(4.8-8.5)	(6.2-10.5)	(6.1-8.9)
35-44	222	276	498
Rate*	27.6	36.8	32.0
95% C.I.	(23.9-31.2)	(32.4-41.1)	(29.2-34.8)
45-54	733	810	1,543
Rate*	112.8	127.8	120.2
95% C.I.	(104.6-120.9)	(119.0-136.6)	(114.2-126.2)
55-64	1,906	1,439	3,345
Rate*	418.9	312.0	365.1
95% C.I.	(400.1-437.7)	(295.9-328.2)	(352.7-377.5)
65-74	3,194	2,318	5,512
Rate*	1,007.7	712.6	858.2
95% C.I.	(972.8-1,042.7)	(683.6-741.6)	(835.6-880.9)
75-84	2,618	2,218	4,836
Rate*	1,651.4	1,150.7	1,376.7
95% C.I.	(1,588.2-1,714.7)	(1,102.8-1,198.6)	(1,337.9-1,415.5)
85+	705	819	1,524
Rate*	2,848.8 (2,638.6-3,059.1)	1,590.6 (1,481.7-1,699.5)	1,999.0 (1,898.7-2,099.4)
95% C.I.	(2,030.0-3,039.1)		(1,090.7-2,099.4)
Unknown Total	9,476	7,983	17,459
Rate*	9,476	7,983 166.7	17,459
95% C.I.	(187.6-195.3)	(163.1-170.4)	(176.6-181.9)
0070 0.11.	(107.0 100.0)	(100.1 170.4)	(176.6 161.6)

Note: The "---" is used for rates calculated on numbers less than ten. \* Rates are per 100,000 age-specific population.

Table 39. Median Age at Death from All Cancers by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

	Gender									
Race/Ethnicity	Ma	ile	Fem	nale	Total					
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age				
White	8,399	71.0	7,047	71.0	15,446	71.0				
Black	499	67.0	437	67.0	936	67.0				
Native American	57	68.0	43	68.0	100	68.0				
Asian	186	66.0	199	64.0	385	65.0				
Hispanic	324	65.0	249	64.0	573	65.0				
Other/Unknown	9	61.0	8	69.5	17	64.0				
Total	9,474	70.0	7,983	71.0	17,457	71.0				

Note: Those deaths of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

## **SURVIVAL RATE**

Figure 34. Survival Rates for All Cancers by Race/Ethnicity, Nevada Residents, 1997-2001




Figure 35. Survival Rates for All Cancers by Stage of Cancer at Diagnosis, Nevada Residents, 1997-2001




Table 40. Cause-Specific Survival Rates for All Cancers by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

Race/			Cause	Specific Survi	val Rate		Median
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	31,479	72.7%	61.3%	54.4%	50.9%	50.9%	>5 years
Male	16,164	70.2%	57.8%	51.1%	47.2%	47.2%	3.28
Female	15,315	75.3%	65.0%	57.8%	54.5%	54.5%	>5 years
Race/Ethnicity							
White	27,619	72.3%	60.7%	53.6%	50.0%	50.0%	4.00
Male	14,199	70.0%	57.4%	50.5%	46.5%	46.5%	3.13
Female	13,420	74.7%	64.1%	56.7%	53.5%	53.5%	>5 years
Black	1,562	73.5%	60.7%	55.1%	50.8%	50.8%	>5 years
Male	830	70.3%	56.9%	49.5%	45.2%	45.2%	2.93
Female	732	77.2%	64.9%	60.4%	56.0%	56.0%	>5 years
Native American	128	61.7%	53.1%	50.8%	46.6%	46.6%	3.20
Male	65	56.9%	48.1%	48.1%	38.5%	38.5%	1.78
Female	63	66.4%	57.7%	53.9%	53.9%	53.9%	>5 years
Asian	728	75.6%	67.7%	61.0%	59.4%	59.4%	>5 years
Male	308	68.4%	57.3%	49.9%	49.9%	49.9%	2.99
Female	420	80.9%	75.0%	68.7%	66.1%	66.1%	>5 years
Hispanic	1,207	75.9%	67.6%	61.9%	58.6%	58.6%	>5 years
Male	649	71.5%	62.2%	60.5%	56.7%	56.7%	>5 years
<u>Female</u>	558	81.0%	73.7%	64.2%	61.3%	61.3%	>5 years

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 41. Cause-Specific Survival Rates for All Cancers by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1997-2001


Surviv	/al Rate of Stage		Gender	
	at Diagnosis	Total	Male	Female
Total	Cases	31,479	16,164	15,315
	One Year	72.7%	70.2%	75.3%
	5 Years	50.9%	47.2%	54.5%
	Median Survival	>5 years	3.28	>5 years
Stage at D	iagnosis			
In situ	Cases	1,273	358	915
	One Year	92.3%	94.9%	91.2%
	5 Years	83.2%	76.2%	85.7%
	Median Survival	>5 years	>5 years	>5 years
Localized	Cases	12,673	6,710	5,963
	One Year	86.3%	85.5%	87.2%
	5 Years	69.4%	67.8%	70.9%
	Median Survival	>5 years	>5 years	>5 years
Regional	Cases	5,881	2,627	3,254
	One Year	77.2%	73.0%	80.6%
	5 Years	51.9%	44.8%	57.7%
	Median Survival	>5 years	2.89	>5 years
Distant	Cases	5,776	3,129	2,647
	One Year	53.1%	50.0%	56.9%
	5 Years	26.6%	24.7%	28.9%
	Median Survival	1.20	1.00	1.47
Unstaged	Cases	5,876	3,340	2,536
	One Year	57.0%	56.9%	57.1%
	5 Years	29.8%	29.7%	29.9%
	Median Survival	1.47	1.48	1.46

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

# LUNG AND BRONCHUS CANCER

# LUNG AND BRONCHUS CANCER GENERAL PROFILE<sup>4</sup>

Figure 36. Anatomy of the Respiratory Tract<sup>5</sup>



**General Anatomy:** The lungs, a pair of sponge-like, cone-shaped organs, are part of the respiratory system. The right lung has three sections, called lobes; it is a little larger than the left lung, which has two lobes. When we breathe in, the lungs take in oxygen, which our cells need to live and carry out their normal functions. When we breathe out, the lungs get rid of carbon dioxide, which is a waste product of the body's cells.

**Risk Factors:** Smoking is the most common factor in determining risk for Lung and Bronchus Cancer. Exposure to radon, asbestos, pollution, certain lung diseases, such as tuberculosis, and personal family history are also important risk factors.

**Signs and Symptoms:** Common signs and symptoms include: a cough that doesn't go away and worsens over time, constant chest pain, coughing up blood, shortness of breath, wheezing or hoarseness, repeated problems with pneumonia or bronchitis, swelling of the neck and face, loss of appetite or weight loss, and fatigue.

**Diagnosing the Cancer:** The most common ways of diagnosing Lung and Bronchus Cancer are: brochoscopy, needle aspiration, thoracentesis, thoracotomy.

**Treatment:** Treatment options include: surgery, chemotherapy, radiation therapy, and photodynamic therapy.

### **HIGHLIGHTS**

- Nevadan females had a higher ratio than males when the incidence and mortality ageadjusted rates for Lung and Bronchus Cancer were compared. Females had a ratio of 1.37 while the ratio for males was 1.27. This means that for every death due to Lung and Bronchus Cancer there would be 1.37 female cases, while only 1.27 cases for every male death.
- ➤ The median age at diagnosis of Lung and Bronchus Cancer for both female and male Nevada residents was 69 years of age from 1997 to 2001. The median age at time of death due to Lung and Bronchus Cancer was 70 years of age for both female and male Nevada residents.

#### **INCIDENCE**

- ➤ There were 7,336 cases of Lung and Bronchus Cancer reported in Nevada from 1997 to 2001, which was the highest of any type of cancer during this period. Clark County had a statistically significant higher incidence rate of Lung and Bronchus Cancer (85.4) during this period, with both Washoe County and All Other Counties as a region, slightly lower at rates of 74.3 and 74.7, respectively. However Nevada as a whole, as well as the three regions separately, had statistically significant higher rates than the National rate of 61.7 (per 100,000 2000 US Standard population).
- ➤ Whites and Blacks, as racial/ethnic groups, accounted for 94.6% of all reported Lung and Bronchus Cancer cases during the 1997 to 2001 period. Their higher age-adjusted incidence rates, 88.3 and 78.5 respectively, showed statistical significance over Asians, Native Americans and Hispanics who had age-adjusted incidence rates of 43.5, 44.1 and 32.9 (per 100,000 2000 US Standard population), respectively, during this same period.
- The higher age-adjusted incidence rate for males was statistically significant at 94.4 (91.3-97.6) over the rate for females (69.3-74.2) during the 1997 to 2001 period. However, both had statistically significant higher rates when compared to their national counterparts. The difference was considerably more for females, whose rate was 46.2% greater than the National rate, while the rate difference for Males was still a considerable 21.3% over the National rate during this period.

#### INPATIENT HOSPITAL DISCHARGES

➤ Billed charges from Lung and Bronchus Cancer inpatient discharges accounted for nearly 159 million dollars from 1997 to 2001. Nevadans in the 55-64 and 65-74 year age groups accounted for 63.2% of the total charges during this period. The median total bill charged for Lung and Bronchus Cancer discharges was approximately \$26,950 in Nevada during this period. Clark County had the highest median total billed charge, \$34,568, when compared to the amounts for Washoe County and All Other Counties of \$27,029 and \$25,091.

➤ There were 4,965 Inpatient Discharges for Lung and Bronchus Cancer in Nevada from 1997 to 2001. Clark County (58.1) had the highest age-adjusted inpatient discharge rate for Lung and Bronchus Cancer in Nevada, which showed statistical significance over the rates for Nevada overall, Washoe County, and All Other Counties who had rates of 54.3, 49.5 and 43.6 (per 100,000 – 2000 US Standard population), respectively.

#### **MORTALITY**


- ➤ There were 5,582 resident deaths due to Lung and Bronchus Cancer from 1997 to 2001. Clark County had a higher age-adjusted mortality rate (65.6) than Washoe County (62.2) and All Other Counties, as a region, (57.6) during the 1997 to 2001 period.
- Nevada males had a 59.0% higher statistically significant age-adjusted mortality rate (76.8) for Lung and Bronchus Cancer when compared to the female rate of 53.1 (per 100,000 2000 US Standard population) for the 1997 to 2001 period.
- ➤ Whites and Blacks, as racial/ethnic groups, accounted for 96.2% of all reported Lung and Bronchus Cancer cases during the 1997 to 2001 period. Their higher age-adjusted mortality rates, 68.9 and 67.4 respectively, showed statistical significance over Asians, Native Americans and Hispanics who had age-adjusted incidence rates of 30.6, 30.1 and 15.9 (per 100,000 2000 US Standard population), respectively, during this same period.

#### **SURVIVAL RATE**

- Females had a higher one-year survival rate (52.9%) than males (47.2%) for Lung and Bronchus Cancer in Nevada from 1997 to 2001. This trend was similar for the median survival time with females and males at 1.17 and 0.95 years, respectively. However, the difference decreased by the third-year survival rate where females had a slightly lower rate (25.7%) than males (25.9%) during the 1997-2001 period.
- Asians, as a racial/ethnic group, had the highest one-year survival rate for Lung and Bronchus Cancer (62.1%) as well as the highest five-year survival rate (47.0%) of those groups that had a rate calculated for Nevada from 1997 to 2001.
- ➤ The Lung and Bronchus Cancer Survival Rate varies greatly by the stage of the cancer at time of diagnosis. Those diagnosed at the localized stage had the highest one- and five-year survival rates with 76.2% and 50.6%, respectively. This was followed by those with Regional and then Distant diagnoses with rates of 62.8% and 29.7% for the one year period and 34.6% and 10.8% for the five year period.

# **INCIDENCE**

Figure 37. Lung and Bronchus Cancer Age-Adjusted (2001) Incidence Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 38. Lung and Bronchus Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 39. Lung and Bronchus Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 42. Lung and Bronchus Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)				
Total										
Cases	7,336	5,117	1,102	1,113	4	105,298				
Rate*	81.8	85.4	74.3	74.7		61.7				
95% C.I.	(79.9-83.7)	(83.0-87.9)	(69.9-78.9)	(70.3-79.3)		(61.3-62.1)				
Gender										
Male	3,970	2,766	576	625	3	58,192				
Rate*	94.4	98.6	84.7	87.7		79.1				
95% C.I.	(91.3-97.6)	(94.6-102.7)	(77.6-92.4)	(80.8-95.4)		(78.5-79.8)				
Female	3,366	2,351	526	488	1	47,106				
Rate*	71.7	74.9	66.6	63.7		49.1				
95% C.I.	(69.3-74.2)	(71.9-78.1)	(61.0-72.6)	(58.1-69.7)		(48.7-49.6)				
Other/Unknown	0	0	0	0	0	0				
Race/Ethnicity										
White	6,629	4,557	1,018	1,051	3	86,163				
Rate*	88.3	94.5	77.7	76.8		62.4				
95% C.I.	(86.2-90.5)	(91.8-97.4)	(73.0-82.7)	(72.1-81.7)		(62.0-62.8)				
Black	330	271	34	24	1	11,314				
Rate*	78.5	69.7	153.5	296.6		79.8				
95% C.I.	(69.9-88.2)	(61.3-79.5)	(105.0-218.7)	(189.4-447.8)		(78.4-81.4)				
Native American	41	19	11	11	0	467				
Rate*	44.1	48.7	58.2	31.3		33.1				
95% C.I.	(31.1-61.7)	(28.2-84.2)	(27.6-115.8)	(15.3-58.3)		(30.0-30.0)				
Asian	137	104	25	8	0	7,156				
Rate*	43.5	39.8	53.4			42.4				
95% C.I.	(34.5-55.2)	(30.3-52.9)	(30.7-93.0)			(41.4-43.4)				
Hispanic	183	151	14	18	0	4,919				
Rate*	32.9	35.0	23.3	32.1		32.2				
95% C.I.	(27.6-39.1)	(28.8-42.7)	(11.4-44.5)	(18.3-54.7)		(31.3-33.2)				
Other/Unknown	16	15	0	1	0	198				

<sup>\*</sup> Rates are per 100,000 population and age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 43. Lung and Bronchus Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

			County/Region	n of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)
Total						
Cases	7,336	5,117	1,102	1,113	4	105,298
Rate*	75.3	76.8	65.7	79.6		56.9
95% C.I.	(73.6-77.1)	(74.7-78.9)	(61.8-69.5)	(75.0-84.3)		(56.5-57.2)
Age Group						
<1	0	0	0	0	0	
Rate*						
95% C.I.						
1-4	0	0	0	0	0	
Rate*						
95% C.I.						
5-14	0	0	0	0	0	6
Rate*						
95% C.I.						
15-24	3	3	0	0	0	52
Rate*						0.2
95% C.I.						(0.1-0.3)
25-34	13	11	1	1	0	262
Rate*	0.9	1.0				0.9
95% C.I.	(0.4-1.4)	(0.4-1.6)				(0.8-1.0)
35-44	129	98	15	16	0	2,325
Rate*	8.3	9.4	5.3	7.1		7.4
95% C.I.	(6.9-9.7)	(7.5-11.2)	(2.6-8.0)	(3.6-10.5)		(7.1-7.7)
45-54	627	442	100	84	1	9,343
Rate*	48.8	52.2	42.3	41.8		40.8
95% C.I.	(45.0-52.7)	(47.3-57.1)	(34.0-50.6)	(32.9-50.8)		(40.0-41.7)
55-64	1,699	1,202	238	256	3	21,791
Rate*	185.4	193.4	158.5	177.2		155.6
95% C.I.	(176.6-194.3)	(182.5-204.3)	(138.4-178.7)	(155.5-198.9)		(153.6-157.7)
65-74	2,806	1,954	412	440	0	35,790
Rate*	436.9	451.8	401.9	410.4		310.2
95% C.I.	(420.7-453.1)	(431.7-471.8)	(363.1-440.7)	(372.1-448.8)		(307.0-313.4)
75-84	1,738	1,195	273	270	0	28,880
Rate*	494.8	511.7	472.1	450.7		397.3
95% C.I.	(471.5-518.0)	(482.7-540.7)	(416.1-528.1)	(397.0-504.5)		(392.7-401.9)
85+	314	211	58	45	0	6,843
Rate*	411.9	451.9	374.0	320.7		275.9
95% C.I.	(366.3-457.4)	(390.9-512.8)	(277.7-470.2)	(227.0-414.4)		(269.4-282.5)
Unknown	7	1	5	1	0	0

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 44. Lung and Bronchus Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1997-2001

County of	1997-2001 Incidence							
Residence	Cases	Rat	e*	Age-Adjus	sted Rate**			
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	253	101.6	(89.1-114.1)	85.4	(75.1-96.8)			
Churchill	112	92.9	(75.7-110.1)	97.3	(80.0-117.7)			
Clark	5,117	76.8	(74.7-78.9)	85.4	(83.0-87.9)			
Douglas	123	60.0	(49.4-70.6)	50.5	(41.6-61.1)			
Elko	73	31.5	(24.3-38.8)	56.0	(42.8-72.7)			
Esmeralda	3							
Eureka	4							
Humboldt	45	53.6	(37.9-69.3)	74.1	(53.2-101.7)			
Lander	20	64.0	(35.9-92.0)	106.3	(63.1-169.6)			
Lincoln	20	98.7	(55.5-142.0)	75.6	(46.0-125.8)			
Lyon	185	108.8	(93.1-124.4)	91.0	(78.2-105.7)			
Mineral	36	136.4	(91.9-181.0)	97.2	(67.5-140.4)			
Nye	204	129.8	(112.0-147.6)	88.9	(76.5-103.5)			
Pershing	16	56.2	(28.7-83.8)	67.9	(38.6-112.5)			
Storey	5							
Washoe	1,102	65.7	(61.8-69.5)	74.3	(69.9-78.9)			
White Pine	14	33.3	(15.9-50.8)	27.1	(14.8-48.0)			
Unknown	4							
Total	7,336	75.3	(73.6-77.1)	81.8	(79.9-83.7)			

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 45. Lung and Bronchus Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

			Gender							
Race/Ethnicity		Male	Female	Other/ Unknown	Total					
White	Incidence	3,544	3,085	0	6,629					
	Rate*	99.5	79.4		88.3					
	95% C.I.	(96.1-103.1)	(76.6-82.2)		(86.2-90.5)					
Black	Incidence	200	130	0	330					
	Rate*	98.9	59.7		78.5					
	95% C.I.	(84.6-116.5)	(49.6-71.7)		(69.9-88.2)					
Native	Incidence	20	21	0	41					
American	Rate*	50.0	41.2		44.1					
	95% C.I.	(28.7-87.6)	(25.0-64.9)		(31.1-61.7)					
Asian	Incidence	75	62	0	137					
	Rate*	59.0	31.9		43.5					
	95% C.I.	(43.0-81.6)	(22.3-46.6)		(34.5-55.2)					
Hispanic	Incidence	121	62	0	183					
	Rate*	47.9	20.9		32.9					
	95% C.I.	(38.0-60.9)	(15.5-28.0)		(27.6-39.1)					
Other/Unknown		10	6	0	16					
Total	Incidence	3,970	3,366	0	7,336					
	Rate*	94.4	71.7		81.8					
	95% C.I.	(91.3-97.6)	(69.3-74.2)		(79.9-83.7)					

<sup>\*</sup>Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 46. Lung and Bronchus Cancer Cases by Age Group and Gender, Nevada Residents, 1997-2001

Age	Gender								
Group	Male	Female	Other/ Unknown	Total					
<1	0	0	0	0					
Rate*									
95% C.I.									
1-4	0	0	0	0					
Rate*									
95% C.I.									
5-14 Poto*	0	0	0	0					
Rate* 95% C.I.	<del></del>								
15-24	1	2	0	3					
Rate*									
95% C.I.									
25-34	9	4	0	13					
Rate*		· 		0.9					
95% C.I.				(0.4-1.4)					
35-44	62	67	0	129					
Rate*	7.7	8.9		8.3					
95% C.I.	(5.8-9.6)	(6.8-11.1)		(6.9-9.7)					
45-54	319	308	0	627					
Rate*	49.1	48.6		48.8					
95% C.I.	(43.7-54.5)	(43.2-54.0)		(45.0-52.7)					
55-64	935	764	0	1,699					
Rate*	205.5	165.7		185.4					
95% C.I.	(192.3-218.7)	(153.9-177.4)		(176.6-194.3)					
65-74	1,576	1,230	0	2,806					
Rate*	497.2	378.1		436.9					
95% C.I.	(472.7-521.8)	(357.0-399.3)		(420.7-453.1)					
75-84 Rate*	908 572.8	830 430.6	0	1,738 494.8					
95% C.I.	(535.5-610.0)	(401.3-459.9)		(471.5-518.0)					
85+	156	158	0	314					
Rate*	630.4	306.9		411.9					
95% C.I.	(531.5-729.3)	(259.0-354.7)		(366.3-457.4)					
Unknown	4	3	0	7					
Total	3,970	3,366	0	7,336					
Rate*	80.2	70.3		75.3					
95% C.I.	(77.7-82.7)	(67.9-72.7)		(73.6-77.1)					

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 47. Lung and Bronchus Cancer Cases by Age Group and Stage, Nevada Residents, 1997-2001

•			Stage								
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total				
<1	Number	0	0	0	0	0	0				
	Percent										
1-4	Number	0	0	0	0	0	0				
	Percent										
5-14	Number	0	0	0	0	0	0				
	Percent										
15-24	Number	0	1	2	0	0	3				
	Percent		33.3%	66.7%			100.0%				
25-34	Number	0	4	2	6	1	13				
	Percent		30.8%	15.4%	46.2%	7.7%	100.0%				
35-44	Number	0	15	31	68	15	129				
	Percent		11.6%	24.0%	52.7%	11.6%	100.0%				
45-54	Number	0	72	124	292	139	627				
	Percent		11.5%	19.8%	46.6%	22.2%	100.0%				
55-64	Number	0	263	344	671	421	1,699				
	Percent		15.5%	20.2%	39.5%	24.8%	100.0%				
65-74	Number	0	496	573	920	817	2,806				
	Percent		17.7%	20.4%	32.8%	29.1%	100.0%				
75-84	Number	0	289	282	534	633	1,738				
	Percent		16.6%	16.2%	30.7%	36.4%	100.0%				
85+	Number	0	35	42	70	167	314				
	Percent		11.1%	13.4%	22.3%	53.2%	100.0%				
Unknown	Number	0	1	1	2	3	7				
	Percent		14.3%	14.3%	28.6%	42.9%	100.0%				
Total	Number	0	1,176	1,401	2,563	2,196	7,336				
	Percent		16.0%	19.1%	34.9%	29.9%	100.0%				

Table 48. Lung and Bronchus Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1997-2001

			Race/Ethnicity								
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total			
In situ	Number	0	0	0	0	0	0	0			
	Percent										
Localized	Number	1,082	50	2	20	18	4	1,176			
	Percent	16.3%	15.2%	4.9%	14.6%	9.8%	25.0%	16.0%			
Regional	Number	1,265	66	8	25	32	5	1,401			
	Percent	19.1%	20.0%	19.5%	18.2%	17.5%	31.3%	19.1%			
Distant	Number	2,301	112	20	52	73	5	2,563			
	Percent	34.7%	33.9%	48.8%	38.0%	39.9%	31.3%	34.9%			
Unstaged	Number	1,981	102	11	40	60	2	2,196			
	Percent	29.9%	30.9%	26.8%	29.2%	32.8%	12.5%	29.9%			
Total	Number	6,629	330	41	137	183	16	7,336			
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%			


Table 49. Median Age at Diagnosis of Lung and Bronchus Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

	Gender									
Race/Ethnicity	Ma	le	Fem	nale	Total					
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age				
White	3,540	69.0	3,083	69.0	6,623	69.0				
Black	200	66.0	129	68.0	329	66.0				
Native American	20	71.0	21	65.0	41	68.0				
Asian	75	70.0	62	66.0	137	67.0				
Hispanic	121	68.0	62	68.0	183	68.0				
Other/Unknown	10	57.5	6	73.5	16	71.5				
Total	3,966	69.0	3,363	69.0	7,329	69.0				

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

# **INPATIENT HOSPITAL DISCHARGES**

Figure 40. Lung and Bronchus Cancer Age-Adjusted (2001) Inpatient Hospital Discharge Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 41. Lung and Bronchus Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 42. Median Charges for Lung and Bronchus Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Figure 43. Average Length of Stay for Lung and Bronchus Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Table 50. Lung and Bronchus Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	4,965	3,562	748	654	1			
Rate*	54.3	58.1	49.5	43.6				
95% C.I.	(52.8-55.8)	(56.2-60.1)	(46.0-53.2)	(40.3-47.2)				
Gender								
Male	2,601	1,909	341	350	1			
Rate*	59.9	65.7	48.1	48.9				
95% C.I.	(57.5-62.4)	(62.6-69.0)	(43.0-53.9)	(43.7-54.7)				
Female	2,364	1,653	407	304	0			
Rate*	49.8	51.9	51.2	39.5				
95% C.I.	(47.8-51.9)	(49.5-54.6)	(46.3-56.4)	(35.1-44.2)				
Other/Unknown	0	0	0	0	0			
Inpatient Discharge Ch	narges (\$)							
Total Charges	\$159,839,368	\$20,217,725	\$20,217,725	\$16,409,825	\$79,089			
Average Charges	\$32,193	\$34,568	\$27,029	\$25,091	\$79,089			
Median Charges	\$25,196	\$26,950	\$20,904	\$18,839	\$79,089			
Discharge Length of S	tay (LOS) (Days)							
Total LOS	39,033	29,277	5,408	4,337	11			
Average LOS	7.9	8.2	7.2	6.6	11.0			
Median LOS	6.0	6.0	6.0	5.0	11.0			

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 51. Lung and Bronchus Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown				
Total									
Discharges	4,965	3,562	748	654	1				
Rate*	51.0	53.5	44.6	46.8					
95% C.I.	(49.6-52.4)	(51.7-55.2)	(41.4-47.8)	(43.2-50.4)					
Age Group									
<1	0	0	0	0	0				
Rate*									
95% C.I.									
1-4	0	0	0	0	0				
Rate*									
95% C.I.									
5-14	0	0	0	0	0				
Rate*									
95% C.I.									
15-24	5	5	0	0	0				
Rate*									
95% C.I.									
25-34	8	7	0	1	0				
Rate*									
95% C.I.									
35-44	124	95	14	15	0				
Rate*	8.0	9.1	4.9	5.3					
95% C.I.	(6.6-9.4)	(7.3-10.9)	(2.4-7.5)	(2.6-8.0)					
45-54	480	357	74	49	0				
Rate*	37.4	42.2	31.3	20.7					
95% C.I.	(34.0-40.7)	(37.8-46.5)	(24.2-38.4)	(14.9-26.5)					
55-64	1,267	932	182	153	0				
Rate*	138.3	149.9	121.2	101.9					
95% C.I.	(130.7-145.9)	(140.3-159.6)	(103.6-138.9)	(85.8-118.1)					
65-74	1,870	1,323	281	265	1				
Rate*	291.2	305.9	274.1	258.5					
95% C.I.	(278.0-304.4)	(289.4-322.4)	(242.1-306.2)	(227.4-289.6)					
75-84	1,071	748	174	149	0				
Rate*	304.9	320.3	300.9	257.7					
95% C.I.	(286.6-323.1)	(297.3-343.2)	(256.2-345.6)	(216.3-299.0)					
85+	140	95	23	22	0				
Rate*	183.6	203.4	148.3	141.9					
95% C.I.	(153.2-214.1)	(162.5-244.4)	(87.7-208.9)	(82.6-201.1)					
Unknown	0	0	0	0	0				

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 52. Lung and Bronchus Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1997-2001

Age		Gender							
Group	Male	Female	Total						
<1	0	0							
Rate*									
95% C.I.									
1-4	0	0	0						
Rate*									
95% C.I.									
5-14	0	0	0						
Rate*									
95% C.I.									
15-24	3	2	5						
Rate*									
95% C.I.									
25-34	5	3	8						
Rate*									
95% C.I.									
35-44	51	73	124						
Rate*	6.3	9.7	8.0						
95% C.I.	(4.6-8.1)	(7.5-12.0)	(6.6-9.4)						
45-54	235	245	480						
Rate* 95% C.I.	36.1	38.7	37.4 (34.0-40.7)						
	(31.5-40.8)	(33.8-43.5)							
55-64 Rate*	688 151.2	579 125.5	1,267 138.3						
95% C.I.	(139.9-162.5)	(115.3-135.8)	(130.7-145.9)						
65-74	1,009	861	1,870						
Rate*	318.3	264.7	291.2						
95% C.I.	(298.7-338.0)	(247.0-282.4)	(278.0-304.4)						
75-84	540	531	1,071						
Rate*	340.6	275.5	304.9						
95% C.I.	(311.9-369.4)	(252.0-298.9)	(286.6-323.1)						
85+	70	70	140						
Rate*	282.9	135.9	183.6						
95% C.I.	(216.6-349.1)	(104.1-167.8)	(153.2-214.1)						
Unknown	0	0	0						
Total	2,601	2,364	4,965						
Rate*	52.5	49.4	51.0						
95% C.I.	(50.5-54.6)	(47.4-51.4)	(49.6-52.4)						

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 53. Lung and Bronchus Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001

0 1 1	1997-2001 Inpatient Hospital Discharges						
County of Residence	Nemakan	Rat	e*	Age-Adjust	ed Rate**		
	Number	Rate	95% C.I.	Rate	95% C.I.		
Carson City	92	36.9	(29.4-44.5)	30.2	(24.3-37.3)		
Churchill	62	51.4	(38.6-64.2)	52.9	(40.5-68.4)		
Clark	3,562	53.5	(51.7-55.2)	58.1	(56.2-60.1)		
Douglas	72	35.1	(27.0-43.2)	30.3	(23.4-39.2)		
Elko	31	13.4	(8.7-18.1)	24.4	(16.0-36.3)		
Esmeralda	7						
Eureka	3						
Humboldt	33	39.3	(25.9-52.7)	50.6	(34.1-73.8)		
Lander	17	54.4	(28.5-80.2)	91.0	(51.4-151.0)		
Lincoln	14	69.1	(32.9-105.3)	53.6	(29.1-99.6)		
Lyon	147	86.4	(72.5-100.4)	73.7	(62.1-87.3)		
Mineral	18	68.2	(36.7-99.7)	52.6	(30.7-89.2)		
Nye	133	84.6	(70.2-99.0)	55.0	(45.8-66.5)		
Pershing	9						
Storey	2						
Washoe	748	44.6	(41.4-47.8)	49.5	(46.0-53.2)		
White Pine	14	33.3	(15.9-50.8)	27.0	(14.7-47.9)		
Unknown	1						
Total	4,965	51.0	(49.6-52.4)	54.3	(52.8-55.8)		


Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 54. Lung and Bronchus Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1997-2001

Age	Discharges	Charges (\$)			Length of Stay (Days)		
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	0						
1-4	0						
5-14	0						
15-24	5	139,302	27,860	24,201	34	6.8	4.0
25-34	8	717,499	89,687	31,627	80	10.0	7.0
35-44	124	3,367,700	27,159	21,990	911	7.3	6.0
45-54	480	14,947,683	31,141	26,808	3,858	8.0	6.0
55-64	1,267	43,958,433	34,695	26,574	10,517	8.3	6.0
65-74	1,870	61,873,412	33,087	26,117	14,549	7.8	6.0
75-84	1,071	31,475,587	29,389	22,868	8,063	7.5	6.0
85+	140	3,359,752	23,998	18,403	1,021	7.3	6.0
Unknown	0						
Total	4,965	457,600	4,895	30,481	121	4,895.0	8.0

# **MORTALITY**

Figure 44. Lung and Bronchus Cancer Age-Adjusted (2001) Mortality Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 p opulation and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 45. Lung and Bronchus Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 46. Lung and Bronchus Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 55. Lung and Bronchus Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1997-2001

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Mortality	5,582	3,823	911	848			
Rate*	63.6	65.6	62.2	57.6			
95% C.I.	(61.9-65.3)	(63.4-67.8)	(58.1-66.4)	(53.8-61.8)			
Gender							
Male	3,125	2,146	488	491			
Rate*	76.8	79.7	73.2	70.1			
95% C.I.	(73.9-79.8)	(76.0-83.5)	(66.6-80.6)	(63.8-77.1)			
Female	2,457	1,677	423	357			
Rate*	53.1	54.5	53.9	46.9			
95% C.I.	(51.0-55.2)	(51.9-57.2)	(48.9-59.3)	(42.2-52.1)			
Other/Unknown	0	0	0	0			
Race/Ethnicity							
White	5,091	3,403	859	829			
Rate*	68.9	72.1	66.2	61.1			
95% C.I.	(67.0-70.8)	(69.6-74.6)	(61.8-70.9)	(57.0-65.5)			
Black	277	257	18	2			
Rate*	67.4	67.3	81.7				
95% C.I.	(59.3-76.6)	(58.9-76.9)	(47.5-133.1)				
Native American	26	11	7	8			
Rate*	30.1	33.8					
95% C.I.	(19.2-46.0)	(15.9-68.0)					
Asian	95	75	19	1			
Rate*	30.6	31.2	37.5				
95% C.I.	(23.2-40.7)	(22.4-43.9)	(21.4-70.0)				
Hispanic	89	75	7	7			
Rate*	15.9	17.3					
95% C.I.	(12.3-20.5)	(13.1-23.0)					
Other/Unknown	4	2	1	1			

<sup>\*</sup>Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 56. Lung and Bronchus Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

Rate*         57.3         57.4         54.3         6.6           95% C.I.         (55.8-58.8)         (55.6-59.2)         (50.7-57.8)         (56.6-6           Age Group          (56.6-6)         6           <		County/Region of Residence						
Mortality         5,582         3,823         911           Rate*         57.3         57.4         54.3         6.6           95% C.I.         (55.8-58.8)         (55.6-59.2)         (50.7-57.8)         (56.6-6           Age Group           <1	Category	Nevada Total	Clark	Washoe				
Rate*         57.3         57.4         54.3         6.6           95% C.I.         (55.8-58.8)         (55.6-59.2)         (50.7-57.8)         (56.6-6           Age Group           <1         0         0         0           Rate*              95% C.I.              48ate*         4.8         5.3         4.2	Total							
Age Group         (55.8-58.8)         (55.6-59.2)         (50.7-57.8)         (56.6-6-6.6-6.6-6.6-6.6-6.6-6.6-6.6-6.6-6	Mortality	5,582	3,823	911	848			
Age Group  **1	Rate*	57.3	57.4	54.3	60.7			
<1	95% C.I.	(55.8-58.8)	(55.6-59.2)	(50.7-57.8)	(56.6-64.8)			
Rate* <td< td=""><td>Age Group</td><td></td><td></td><td></td><td></td></td<>	Age Group							
95% C.I.	<1	0	0	0	0			
1-4       0       0       0         Rate*            95% C.I.            5-14       0       0       0         Rate*            95% C.I.            95% C.I.            95% C.I.            95% C.I.            95% C.I.            95% C.I.            35-44       75       55       12         Rate*       4.8       5.3       4.2         95% C.I.       (3.7-5.9)       (3.9-6.6)       (1.8-6.6)         45-54       428       303       69         Rate*       33.3       35.8       29.2       2         95% C.I.       (30.2-36.5)       (31.8-39.8)       (22.3-36.1)       (20.6-3         55-64       1,173       804       186         Rate*       128.0       129.4       123.9       12         95% C.I.       (120.7-135.4)	Rate*							
Rate* <td< td=""><td>95% C.I.</td><td></td><td></td><td></td><td></td></td<>	95% C.I.							
95% C.I.		0	0	0	0			
5-14       0       0       0         Rate*            95% C.I.            15-24       1       1       0         Rate*            95% C.I.            25-34       4       4       0         Rate*            95% C.I.            35-44       75       55       12         Rate*       4.8       5.3       4.2         95% C.I.       (3.7-5.9)       (3.9-6.6)       (1.8-6.6)         45-54       428       303       69         Rate*       33.3       35.8       29.2       2         95% C.I.       (30.2-36.5)       (31.8-39.8)       (22.3-36.1)       (20.6-3         55-64       1,173       804       186         Rate*       128.0       129.4       123.9       12         95% C.I.       (120.7-135.4)       (120.4-138.3)       (106.1-141.7)       (108.3-14:         65-74       2,063       1,408       336         Rate*<								
Rate*           95% C.I.	95% C.I.							
95% C.I.		0	0	0	0			
15-24       1       1       0         Rate*            95% C.I.            25-34       4       4       0          95% C.I.            95% C.I.            35-44       75       55       12         Rate*       4.8       5.3       4.2         95% C.I.       (3.7-5.9)       (3.9-6.6)       (1.8-6.6)         45-54       428       303       69         Rate*       33.3       35.8       29.2       2         95% C.I.       (30.2-36.5)       (31.8-39.8)       (22.3-36.1)       (20.6-30.7)         55-64       1,173       804       186         Rate*       128.0       129.4       123.9       12         95% C.I.       (120.7-135.4)       (120.4-138.3)       (106.1-141.7)       (108.3-140.7)         65-74       2,063       1,408       336         Rate*       321.2       325.5       327.8       26         95% C.I.       (307.4-335.1)       (308.5-342.5)       (292.7-362.8)       (264.9-330.7)								
Rate*           95% C.I.								
95% C.I 25-34		1	1	0	0			
25-34       4       4       4       0         Rate*             95% C.I.             35-44       75       55       12         Rate*       4.8       5.3       4.2         95% C.I.       (3.7-5.9)       (3.9-6.6)       (1.8-6.6)         45-54       428       303       69         Rate*       33.3       35.8       29.2       2         95% C.I.       (30.2-36.5)       (31.8-39.8)       (22.3-36.1)       (20.6-30.6)         55-64       1,173       804       186         Rate*       128.0       129.4       123.9       12         95% C.I.       (120.7-135.4)       (120.4-138.3)       (106.1-141.7)       (108.3-140.6)         65-74       2,063       1,408       336         Rate*       321.2       325.5       327.8       26         95% C.I.       (307.4-335.1)       (308.5-342.5)       (292.7-362.8)       (264.9-330.7)         75-84       1,520       1,027       253         Rate*       432.7       439.7       437.5       40.7         95% C.I.								
Rate*           95% C.I.								
95% C.I.  35-44  75  55  12  Rate*  4.8  5.3  4.2  95% C.I.  (3.7-5.9)  (3.9-6.6)  (1.8-6.6)  45-54  428  303  69  Rate*  33.3  35.8  29.2  25.5  26.4  1,173  804  186  Rate*  128.0  129.4  123.9  129.6  120.4-138.3)  120.4-141.7)  120.7-135.4)  120.4-138.3)  120.4-141.7)  120.4-138.3  120.4-141.7)  120.4-138.3  120.4-141.7)  120.4-138.3  12		4	4	0	0			
35-44       75       55       12         Rate*       4.8       5.3       4.2         95% C.I.       (3.7-5.9)       (3.9-6.6)       (1.8-6.6)         45-54       428       303       69         Rate*       33.3       35.8       29.2       2         95% C.I.       (30.2-36.5)       (31.8-39.8)       (22.3-36.1)       (20.6-30.7)         55-64       1,173       804       186         Rate*       128.0       129.4       123.9       12         95% C.I.       (120.7-135.4)       (120.4-138.3)       (106.1-141.7)       (108.3-140.7)         65-74       2,063       1,408       336         Rate*       321.2       325.5       327.8       29         95% C.I.       (307.4-335.1)       (308.5-342.5)       (292.7-362.8)       (264.9-330.7)         75-84       1,520       1,027       253         Rate*       432.7       439.7       437.5       40         95% C.I.       (410.9-454.5)       (412.8-466.6)       (383.6-491.4)       (350.0-45								
Rate*       4.8       5.3       4.2         95% C.I.       (3.7-5.9)       (3.9-6.6)       (1.8-6.6)         45-54       428       303       69         Rate*       33.3       35.8       29.2       2         95% C.I.       (30.2-36.5)       (31.8-39.8)       (22.3-36.1)       (20.6-36.4)         55-64       1,173       804       186         Rate*       128.0       129.4       123.9       12         95% C.I.       (120.7-135.4)       (120.4-138.3)       (106.1-141.7)       (108.3-146.6)         65-74       2,063       1,408       336         Rate*       321.2       325.5       327.8       29.6         95% C.I.       (307.4-335.1)       (308.5-342.5)       (292.7-362.8)       (264.9-336.7)         75-84       1,520       1,027       253         Rate*       432.7       439.7       437.5       40.7         95% C.I.       (410.9-454.5)       (412.8-466.6)       (383.6-491.4)       (350.0-45.4)								
95% C.I. (3.7-5.9) (3.9-6.6) (1.8-6.6) 45-54 428 303 69  Rate* 33.3 35.8 29.2 2 95% C.I. (30.2-36.5) (31.8-39.8) (22.3-36.1) (20.6-3) 55-64 1,173 804 186  Rate* 128.0 129.4 123.9 12 95% C.I. (120.7-135.4) (120.4-138.3) (106.1-141.7) (108.3-14) 65-74 2,063 1,408 336  Rate* 321.2 325.5 327.8 29 95% C.I. (307.4-335.1) (308.5-342.5) (292.7-362.8) (264.9-33) 75-84 1,520 1,027 253  Rate* 432.7 439.7 437.5 40 95% C.I. (410.9-454.5) (412.8-466.6) (383.6-491.4) (350.0-45)		-			8			
45-54       428       303       69         Rate*       33.3       35.8       29.2       2         95% C.I.       (30.2-36.5)       (31.8-39.8)       (22.3-36.1)       (20.6-38.6)         55-64       1,173       804       186         Rate*       128.0       129.4       123.9       12         95% C.I.       (120.7-135.4)       (120.4-138.3)       (106.1-141.7)       (108.3-148.6)         65-74       2,063       1,408       336         Rate*       321.2       325.5       327.8       25         95% C.I.       (307.4-335.1)       (308.5-342.5)       (292.7-362.8)       (264.9-336.7)         75-84       1,520       1,027       253         Rate*       432.7       439.7       437.5       40         95% C.I.       (410.9-454.5)       (412.8-466.6)       (383.6-491.4)       (350.0-45								
Rate*       33.3       35.8       29.2       2         95% C.I.       (30.2-36.5)       (31.8-39.8)       (22.3-36.1)       (20.6-36.5)         55-64       1,173       804       186         Rate*       128.0       129.4       123.9       12         95% C.I.       (120.7-135.4)       (120.4-138.3)       (106.1-141.7)       (108.3-146.65.74         65-74       2,063       1,408       336         Rate*       321.2       325.5       327.8       29         95% C.I.       (307.4-335.1)       (308.5-342.5)       (292.7-362.8)       (264.9-336.7)         75-84       1,520       1,027       253         Rate*       432.7       439.7       437.5       40         95% C.I.       (410.9-454.5)       (412.8-466.6)       (383.6-491.4)       (350.0-45								
95% C.I.       (30.2-36.5)       (31.8-39.8)       (22.3-36.1)       (20.6-36.5)         55-64       1,173       804       186         Rate*       128.0       129.4       123.9       12         95% C.I.       (120.7-135.4)       (120.4-138.3)       (106.1-141.7)       (108.3-146.66.7)         65-74       2,063       1,408       336         Rate*       321.2       325.5       327.8       29         95% C.I.       (307.4-335.1)       (308.5-342.5)       (292.7-362.8)       (264.9-336.7)         75-84       1,520       1,027       253         Rate*       432.7       439.7       437.5       46         95% C.I.       (410.9-454.5)       (412.8-466.6)       (383.6-491.4)       (350.0-45					56			
55-64       1,173       804       186         Rate*       128.0       129.4       123.9       12         95% C.I.       (120.7-135.4)       (120.4-138.3)       (106.1-141.7)       (108.3-14)         65-74       2,063       1,408       336         Rate*       321.2       325.5       327.8       29         95% C.I.       (307.4-335.1)       (308.5-342.5)       (292.7-362.8)       (264.9-33)         75-84       1,520       1,027       253         Rate*       432.7       439.7       437.5       40         95% C.I.       (410.9-454.5)       (412.8-466.6)       (383.6-491.4)       (350.0-45					27.9			
Rate*       128.0       129.4       123.9       12         95% C.I.       (120.7-135.4)       (120.4-138.3)       (106.1-141.7)       (108.3-14)         65-74       2,063       1,408       336         Rate*       321.2       325.5       327.8       29         95% C.I.       (307.4-335.1)       (308.5-342.5)       (292.7-362.8)       (264.9-33)         75-84       1,520       1,027       253         Rate*       432.7       439.7       437.5       40         95% C.I.       (410.9-454.5)       (412.8-466.6)       (383.6-491.4)       (350.0-45					(20.6-35.2)			
95% C.I.       (120.7-135.4)       (120.4-138.3)       (106.1-141.7)       (108.3-14.6)         65-74       2,063       1,408       336         Rate*       321.2       325.5       327.8       29         95% C.I.       (307.4-335.1)       (308.5-342.5)       (292.7-362.8)       (264.9-336.7)         75-84       1,520       1,027       253         Rate*       432.7       439.7       437.5       40         95% C.I.       (410.9-454.5)       (412.8-466.6)       (383.6-491.4)       (350.0-45					183			
65-74       2,063       1,408       336         Rate*       321.2       325.5       327.8       29         95% C.I.       (307.4-335.1)       (308.5-342.5)       (292.7-362.8)       (264.9-33)         75-84       1,520       1,027       253         Rate*       432.7       439.7       437.5       40         95% C.I.       (410.9-454.5)       (412.8-466.6)       (383.6-491.4)       (350.0-45					126.7			
Rate*       321.2       325.5       327.8       29         95% C.I.       (307.4-335.1)       (308.5-342.5)       (292.7-362.8)       (264.9-336)         75-84       1,520       1,027       253         Rate*       432.7       439.7       437.5       40         95% C.I.       (410.9-454.5)       (412.8-466.6)       (383.6-491.4)       (350.0-45								
95% C.I.     (307.4-335.1)     (308.5-342.5)     (292.7-362.8)     (264.9-3362.8)       75-84     1,520     1,027     253       Rate*     432.7     439.7     437.5     40       95% C.I.     (410.9-454.5)     (412.8-466.6)     (383.6-491.4)     (350.0-458.8)					319			
75-84 1,520 1,027 253 Rate* 432.7 439.7 437.5 40 95% C.I. (410.9-454.5) (412.8-466.6) (383.6-491.4) (350.0-45					297.6			
Rate* 432.7 439.7 437.5 40 95% C.I. (410.9-454.5) (412.8-466.6) (383.6-491.4) (350.0-45								
95% C.I. (410.9-454.5) (412.8-466.6) (383.6-491.4) (350.0-45					240			
					400.6			
OUT 310 ZZU 34					(350.0-451.3)			
Rate* 414.5 471.1 348.2 29					299.3			
					(208.8-389.9)			
95% C.I. (368.6-460.2) (406.9-533.4) (255.3-441.1) (208.6-36) Unknown 2 1 1			(400.3-333.4)	(200.0-441.1)	(208.8-389.9)			

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 57. Lung and Bronchus Cancer Mortality by County of Residence, Nevada Residents, 1997-2001

	1997-2001 Mortality						
County of Residence	0	Ra	te*	Age-Adjusted Rate**			
	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	210	84.3	(72.9-95.7)	70.1	(60.9-80.5)		
Churchill	64	53.1	(40.1-66.1)	56.5	(43.4-72.8)		
Clark	3,823	57.4	(55.6-59.2)	65.6	(63.4-67.8)		
Douglas	115	56.1	(45.9-66.4)	47.4	(38.8-57.9)		
Elko	61	26.4	(19.7-33.0)	47.6	(35.4-63.2)		
Esmeralda	1						
Eureka	2						
Humboldt	40	47.6	(32.9-62.4)	69.3	(48.7-96.8)		
Lander	14	44.8	(21.3-68.2)	76.9	(40.7-133.9)		
Lincoln	12	59.2	(25.7-92.8)	43.7	(22.6-86.6)		
Lyon	124	72.9	(60.1-85.7)	60.9	(50.5-73.2)		
Mineral	20	75.8	(42.6-109.0)	55.4	(33.6-91.5)		
Nye	151	96.1	(80.7-111.4)	66.4	(55.7-79.4)		
Pershing	13	45.7	(20.9-70.5)	53.5	(28.3-94.2)		
Storey	8						
Washoe	911	54.3	(50.7-57.8)	62.2	(58.1-66.4)		
White Pine	13	30.9	(14.1-47.8)	25.7	(13.7-46.4)		
Unknown	0						
Total	5,582	57.3	(55.8-58.8)	63.6	(61.9-65.3)		

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 58. Lung and Bronchus Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

			Gender	
Race/Ethnicity		Male	Female	Total
White	Mortality Rate*	2,831 81.8	2,260 58.6	5,091 68.9
	95% C.I.	(78.6-85.1)	(56.2-61.1)	(67.0-70.8)
Black	Mortality	167	110	277
	Rate* 95% C.I.	89.5 (74.9-107.8)	50.3 (41.1-61.3)	67.4 (59.3-76.6)
Native	Mortality	16	10	26
American	Rate* 95% C.I.	46.7 (24.3-86.6)	20.5 (9.6-39.5)	30.1 (19.2-46.0)
Asian	Mortality	48	47	95
	Rate* 95% C.I.	35.5 (24.2-53.5)	26.9 (17.7-41.5)	30.6 (23.2-40.7)
Hispanic	Mortality	62	27	89
•	Rate* 95% C.I.	23.9 (17.2-33.9)	9.2 (5.7-14.5)	15.9 (12.3-20.5)
Other/Unkn		1	3	4
Total	Mortality	3,125	2,457	5,582
	Rate* 95% C.I.	76.8 (73.9-79.8)	53.1 (51.0-55.2)	63.6 (61.9-65.3)

<sup>\*</sup>Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 59. Lung and Bronchus Cancer Mortality by Age Group and Gender, Nevada Residents, 1997-2001

Age	Gender							
Group	Male	Female	Total					
<1	0							
Rate*								
95% C.I.								
1-4	0	0	0					
Rate*								
95% C.I.								
5-14	0	0	0					
Rate*								
95% C.I.								
15-24	0	1	1					
Rate*								
95% C.I.								
25-34	2	2	4					
Rate*								
95% C.I.								
35-44	34	41	75					
Rate*	4.2	5.5	4.8					
95% C.I.	(2.8-5.6)	(3.8-7.1)	(3.7-5.9)					
45-54	225	203	428					
Rate*	34.6	32.0	33.3					
95% C.I.	(30.1-39.1)	(27.6-36.4)	(30.2-36.5)					
55-64 Rate*	701 154.1	472 102.3	1,173 128.0					
95% C.I.	(142.7-165.5)	(93.1-111.6)	(120.7-135.4)					
65-74	1,181	882						
Rate*	372.6	271.1	2,063 321.2					
95% C.I.	(351.4-393.9)	(253.3-289.0)	(307.4-335.1)					
75-84	818	702	1,520					
Rate*	516.0	364.2	432.7					
95% C.I.	(480.6-551.4)	(337.3-391.1)	(410.9-454.5)					
85+	162	154	316					
Rate*	654.6	299.1	414.5					
95% C.I.	(553.8-755.4)	(251.8-346.3)	(368.8-460.2)					
Unknown	2	0	2					
Total	3,125	2,457	5,582					
Rate*	63.1	51.3	57.3					
95% C.I.	(60.9-65.3)	(49.3-53.3)	(55.8-58.8)					

<sup>\*</sup> Rates are per 100,000 age-specific population.


Table 60. Median Age at Death from Lung and Bronchus Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

		Gender									
Race/Ethnicity	Male		Fem	nale	Total						
,	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age					
White	2,830	70.0	2,260	71.0	5,090	70.0					
Black	166	66.5	110	67.5	276	67.0					
Native American	16	69.0	10	68.5	26	68.5					
Asian	48	67.0	47	68.0	95	67.0					
Hispanic	62	66.0	27	65.0	89	66.0					
Other/Unknown	1		3		4						
Total	3,123	70.0	2,457	70.0	5,580	70.0					

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

# **SURVIVAL RATE**

Figure 47. Survival Rates for Lung and Bronchus Cancer by Race/Ethnicity, Nevada Residents, 1997-2001



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 48. Survival Rates for Lung and Bronchus Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1997-2001




Table 61. Cause-Specific Survival Rates for Lung and Bronchus Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

Race/		Cause Specific Survival Rate					Median
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	5,168	49.8%	33.3%	25.8%	23.1%	23.1%	1.00
Male	2,774	47.2%	31.7%	25.9%	23.3%	23.3%	0.95
Female	2,394	52.9%	35.3%	25.7%	22.8%	22.8%	1.17
Race/Ethnicity							
White	4,642	49.1%	32.7%	25.0%	22.5%	22.5%	0.98
Male	2,451	46.5%	31.2%	25.5%	22.9%	22.9%	0.93
Female	2,191	52.0%	34.5%	24.6%	22.1%	22.1%	1.11
Black	245	59.2%	36.4%	29.8%	21.8%	21.8%	1.40
Male	151	52.7%	30.2%	21.1%	15.9%	15.9%	1.12
Female	94	70.1%	46.7%	46.7%	33.4%	33.4%	1.86
Native American	24						
Male	11						
Female	13						
Asian	100	62.1%	47.0%	47.0%	47.0%	47.0%	1.80
Male	53	61.0%	40.7%	40.7%			1.54
Female	47						
Hispanic	144	52.9%	40.1%	36.7%	36.7%	36.7%	1.23
Male	99	48.2%	38.3%	38.3%	38.3%	38.3%	0.97
Female	45						

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 62. Cause-Specific Survival Rates for Lung and Bronchus Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1997-2001


Survival Rate of Stage at Diagnosis		Gender		
		Total	Male	Female
Total	Cases	5,168	2,774	2,394
	One Year	49.8%	47.2%	52.9%
	5 Years	23.1%	23.3%	22.8%
	Median Survival	1.00	0.95	1.17
Stage at D	iagnosis			
In situ	Cases	0	0	0
	One Year			
	5 Years			
	Median Survival			
Localized	Cases	861	443	418
	One Year	76.2%	74.3%	78.3%
	5 Years	50.6%	56.1%	44.9%
	Median Survival	>5 years	>5 years	3.22
Regional	Cases	1,038	547	491
	One Year	62.8%	63.8%	61.8%
	5 Years	29.7%	28.9%	30.8%
	Median Survival	1.61	1.57	1.66
Distant	Cases	1,887	1,046	841
	One Year	34.6%	31.0%	39.2%
	5 Years	10.8%	10.7%	11.2%
	Median Survival	0.76	0.72	0.82
Unstaged	Cases	1,382	738	644
	One Year	45.5%	42.9%	48.5%
	5 Years	14.4%	13.4%	16.1%
	Median Survival	0.92	0.88	0.97

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

# BREAST CANCER

# BREAST CANCER GENERAL PROFILE<sup>4</sup>

Figure 49. Anatomy of the Breast<sup>5</sup>



**General Anatomy:** Each breast has 15 to 20 sections called lobes. Within each lobe are many smaller lobules, which end in dozens of tiny bulbs that can produce milk. The lobes, lobules, and bulbs are all linked by thin tubes called ducts. These ducts lead to the nipple in the center of a dark area of skin called the areola. Fat surrounds the lobules and ducts. Each breast also contains blood vessels and lymph vessels. The lymph vessels carry colorless fluid called lymph, and lead to small bean-shaped organs called lymph nodes. Clusters of lymph nodes are found near the breast in the axilla (under the arm), above the collarbone, and in the chest. Lymph nodes are also found in many other parts of the body.

**Risk Factors:** Personal, and/or family, history of Breast Cancer, atypical hyperplasia, lobular carcinoma in situ, prolonged levels of estrogen, later childbearing, breast density, radiation therapy, and alcohol use are all important risk factors.

**Signs and Symptoms:** Common signs and symptoms include: A lump or thickening in or near the breast or in the underarm area, change in the size or shape of the breast, nipple discharge or tenderness, nipple inverted into breast, ridges or pitting of the breast, and a change in the way the skin of the breast, areola, or nipple looks or feels (for example, warm, swollen, red, or scaly).

**Diagnosing the Cancer:** The most common ways of diagnosing Breast Cancer are: clinical breast exam, mammography, ultrasonography, fine-needle aspiration, and needle or surgical biopsy.

**Treatment:** Treatment options include: surgery (Lumpectomy, Segmental Mastectomy, Simple Mastectomy, and Radical Mastectomy), radiation therapy, chemotherapy, hormonal therapy, and biological therapy.

# **HIGHLIGHTS**

- ➤ The ratio of the age-adjusted incidence rate, 135.2, to the age-adjusted mortality rate, 25.9 (per 100,000 2000 US Standard female population), for Female Breast Cancer was 5.22 during the 1996 to 2001 period, which means that for every 5.22 Female Breast Cancer cases there was one female death due to Breast Cancer in Nevada during this period.
- ➤ The median age at diagnosis of Breast Cancer for Nevada females was 61 years of age from 1997 to 2001. The median age at time of death due to Breast Cancer for females was 67 years.

### **CANCER SCREENING**

- From 1997 to 2001, 93.9% of the 5,593 Nevadan females who responded had ever had a mammogram and/or a clinical breast exam to try and detect early signs of Breast Cancer.
- The percentage of women who stated their education level at less than high school, 89.8% (87.1%-92.5%), or high school, 91.3% (90.0%-92.6%), had a statistically significant lower rate of ever having had a mammogram and/or clinical breast exam than those who stated their education level at some post high school, 96.0% (95.1%-96.9%), or college graduate, 96.7% (95.7%-97.7%), during the 1996 to 2001 period.
- Those women whose age was 18 to 24 years, 80.7% (77.3%-84.1%), had the lowest statistically significant percentage of ever having a mammogram and/or a clinical breast exam of any age group surveyed from 1996 to 2001. However, those women 25 to 34 years of age also had a statistically significant lower percentage, 92.2% (90.6%-93.8%), than all other age groups surveyed.

### **INCIDENCE**

- ➤ There were 6,420 cases of Female Breast Cancer reported in Nevada from 1997 to 2001. Regional comparisons showed that Washoe County's age-adjusted incidence rate, 154.3 (145.8-163.1), was statistically higher than the rate for Clark County, 134.4 (145.8-163.7), and the All Other Counties region, 118.0 (110.4-126.1), during this period. Nevada and all three regions had similar rates compared to the National rate, 135.2 (134.4-135.9 per 100,000 2001 US Standard female population) during this period.
- ➤ Hispanic females were considerably lower than the statewide median age at time of diagnosis for Breast Cancer (61 years) with a median age of 53 years, the lowest of any racial/ethnic group. The racial/ethnic group with the highest median age at diagnosis was White females with a median age of 62 years for the 1997 to 2001 period.
- ➤ White females accounted for 88.4% of all reported Female Breast Cancer cases in Nevada from 1997 to 2001. They had a statistically significant higher rate, 76.6 (74.6-78.7), than Black females, 72.2 (64.1-81.5), Asian females, 38.0 (31.6-46.8), Hispanic

females, 28.6 (24.3-33.9), and Native American females, 18.8 (11.1-31.2), per 100,000 – 2001 US Standard population, during this period.

### **INPATIENT HOSPITAL DISCHARGES**

- There were 2,589 female hospital inpatient discharges with a primary diagnosis of Breast Cancer from 1997 to 2001. Washoe County had the highest age-adjusted inpatient discharge rate, 56.5, for Female Breast Cancer, and was followed by Clark County and the All Other Counties region with rates of 56.4 and 45.6 (per 100,000 2001 US Standard female population), respectively.
- Total billed charges for hospital inpatient discharges from Breast Cancer in Nevada totaled nearly 35 million dollars from 1997 to 2001. Washoe County had the highest median total charge (\$16,328) and average length of stay (2.5 days) during this time; once regional comparisons were made.
- ➤ The overall average billed charge per day for a Breast Cancer inpatient hospital discharge in Nevada was over \$5,900 from 1996 to 2001.

### **MORTALITY**

- ➤ There were 1,195 female deaths in Nevada due to Breast Cancer from 1997 to 2001. While Washoe County had a higher age-adjusted mortality rate for Female Breast Cancer (29.7) than Clark County (25.5) and All Other Counties (23.5), statistical analysis does not indicate a statistical difference between the three regions or the statewide rate of 25.9 (per 100,000 2000 US Standard female population) for this period.
- ➤ Racial/ethnic comparisons showed that Black and White females had higher age-adjusted mortality rates, 32.7 and 27.6, respectively, when compared to Asians and Hispanics who had rates of 12.1 and 12.8 (per 100,000 2000 US Standard female population), respectively, from 1997 to 2001.

### **SURVIVAL RATE**

- ➤ Hispanic females in Nevada had the highest one-year survival rate (91.6%) of any racial/ethnic group for Female Breast Cancer during the 1997 to 2001 period. They were followed by Asian, White and Black females with rates of 90.5%, 88.2% and 81.4%, respectively. Hispanic females also had the highest five-year survival rate (78.5%) for Female Breast Cancer during this time, while, Asian, White and Black females followed with rates of 73.6%, 72.3% and 67.3%, respectively.
- The five-year survival rate for females diagnosed with Breast Cancer at the in situ stage was 84.7% for Nevada from 1997 to 2001. The rate for those at the localized stage was 78.0%, while those recorded at the regional, distant and unstaged stages had rates of 71.6%, 36.7% and 47.5%, respectively.

# **SCREENING (BRFSS)**

Table 63. Female Breast Cancer Screening by County/Region of Residence, Education, Age Group, and Income, Nevada Residents, 1997-2001

			Answers			
	Yes			No		
Number	Percent*	95% C.I.	Number	Percent*	95% C.I.	Total
5,248	93.9%	(93.3%-94.5%)	345	6.1%	(5.5%-6.7%)	5,593
lence						
1,687	94.2%	(93.1%-95.3%)	110	5.8%	(4.7%-6.9%)	1,797
1,745	94.6%	(93.6%-95.6%)	105	5.4%	(4.4%-6.4%)	1,850
1,816	92.0%	(90.8%-93.2%)	130	8.0%	(6.8%-9.2%)	1,946
443	89.8%	(87.1%-92.5%)	56	10.2%	(7.5%-12.9%)	499
1,668	91.3%	(90.0%-92.6%)	146	8.7%	(7.4%-10.0%)	1,814
1,862	96.0%	(95.1%-96.9%)	104	4.0%	(3.1%-4.9%)	1,966
1,264	96.7%	(95.7%-97.7%)	38	3.3%	(2.3%-4.3%)	1,302
398	80.7%	(77.3%-84.1%)	110	19.3%	(15.9%-22.7%)	508
973	92.2%	(90.6%-93.8%)	66	7.8%	(6.2%-9.4%)	1,039
1,248	95.5%	(94.4%-96.6%)	59	4.5%	(3.4%-5.6%)	1,307
1,031	97.8%	(96.9%-98.7%)	23	2.2%	(1.3%-3.1%)	1,054
671	96.9%	(95.6%-98.2%)	21	3.1%	(1.8%-4.4%)	692
904	95.5%	(94.2%-96.8%)	63	4.5%	(3.2%-5.8%)	967
582	91.1%	(88.9%-93.3%)	69	8.9%	(6.7%-11.1%)	651
467	90.0%	(87.4%-92.6%)	59	10.0%	(7.4%-12.6%)	526
812	93.6%	(92.0%-95.2%)	52	6.4%	(4.8%-8.0%)	864
1,024	95.0%	(93.7%-96.3%)	40	5.0%	(3.7%-6.3%)	1,064
1,533	96.5%	(95.6%-97.4%)	36	3.5%	(2.6%-4.4%)	1,569
	5,248  lence  1,687 1,745 1,816  443 1,668 1,862 1,264  398 973 1,248 1,031 671 904  582 467 812 1,024	Number         Percent*           5,248         93.9%           lence         1,687         94.2%           1,745         94.6%         1,816         92.0%           443         89.8%         1,668         91.3%           1,862         96.0%         1,264         96.7%           398         80.7%         973         92.2%           1,248         95.5%         1,031         97.8%           671         96.9%         904         95.5%           582         91.1%         467         90.0%           812         93.6%         1,024         95.0%	Number         Percent*         95% C.I.           5,248         93.9%         (93.3%-94.5%)           lence         1,687         94.2%         (93.1%-95.3%)           1,745         94.6%         (93.6%-95.6%)           1,816         92.0%         (90.8%-93.2%)           443         89.8%         (87.1%-92.5%)           1,668         91.3%         (90.0%-92.6%)           1,862         96.0%         (95.1%-96.9%)           1,264         96.7%         (95.7%-97.7%)           398         80.7%         (77.3%-84.1%)           973         92.2%         (90.6%-93.8%)           1,248         95.5%         (94.4%-96.6%)           1,031         97.8%         (96.9%-98.7%)           671         96.9%         (95.6%-98.2%)           904         95.5%         (94.2%-96.8%)           582         91.1%         (88.9%-93.3%)           467         90.0%         (87.4%-92.6%)           812         93.6%         (92.0%-95.2%)           1,024         95.0%         (93.7%-96.3%)	Number         Percent*         95% C.I.         Number           5,248         93.9%         (93.3%-94.5%)         345           ence         1,687         94.2%         (93.1%-95.3%)         110           1,745         94.6%         (93.6%-95.6%)         105           1,816         92.0%         (90.8%-93.2%)         130           443         89.8%         (87.1%-92.5%)         56           1,668         91.3%         (90.0%-92.6%)         146           1,862         96.0%         (95.1%-96.9%)         104           1,264         96.7%         (95.7%-97.7%)         38           398         80.7%         (77.3%-84.1%)         110           973         92.2%         (90.6%-93.8%)         66           1,248         95.5%         (94.4%-96.6%)         59           1,031         97.8%         (96.9%-98.7%)         23           671         96.9%         (95.6%-98.2%)         21           904         95.5%         (94.2%-96.8%)         63           582         91.1%         (88.9%-93.3%)         69           467         90.0%         (87.4%-92.6%)         59           812         93.6%	Number   Percent*   95% C.I.   Number   Percent*	Number   Percent*   95% C.I.   Number   Percent*   95% C.I.


<sup>\*</sup>Denominator is persons age 18-64 and excludes missing, don't know, and refused responses.

Note: This table includes those respondents who answered "Yes" or "No" to either of the following questions:

- 1) A mammogram is an x-ray of each breast to look for breast cancer. Have you ever had a mammogram?
- 2) A clinical breast exam is when a doctor, nurse, or other health professional feels the breast for lumps. Have you ever had a clinical breast exam?

# **INCIDENCE**

Figure 50. Female Breast Cancer Age-Adjusted (2001) Incidence Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 female population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 51. Female Breast Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 52. Female Breast Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 64. Breast Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

			County/Regio	n of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)
Total						
Cases	6,493	4,314	1,269	907	3	129,844
Rate*	70.5	70.0	81.2	61.1		73.9
95% C.I.	(68.7-72.2)	(67.9-72.2)	(76.7-85.9)	(57.1-65.3)		(73.5-74.3)
Gender						
Male	73	40	15	18	0	876
Rate*	1.8	1.6	2.3	2.5		1.2
95% C.I.	(1.4-2.4)	(1.1-2.3)	(1.3-4.2)	(1.5-4.2)		(1.1-1.3)
Female	6,420	4,274	1,254	889	3	128,968
Rate*	135.2	134.4	154.3	118.0		135.2
95% C.I.	(131.9-138.6)	(130.3-138.5)	(145.8-163.1)	(110.4-126.1)		(134.4-135.9)
Other/Unknown	0	0	0	0	0	0
Race/Ethnicity						
White	5,678	3,664	1,158	853	3	107,678
Rate*	76.6	77.7	86.1	63.7		76.8
95% C.I.	(74.6-78.7)	(75.1-80.3)	(81.2-91.3)	(59.4-68.2)		(76.3-77.3)
Black	332	278	38	16	0	10,849
Rate*	72.2	64.9	153.6	194.6		69.2
95% C.I.	(64.1-81.5)	(56.9-74.2)	(106.6-216.7)	(110.4-323.7)		(67.9-70.6)
Native American	20	9	4	7	0	558
Rate*	18.8					29.2
95% C.I.	(11.1-31.2)					(26.6-26.6)
Asian	169	124	33	12	0	9,983
Rate*	38.0	33.4	48.6	83.4		52.8
95% C.I.	(31.6-46.8)	(27.0-43.2)	(32.3-80.2)	(35.3-193.0)		(51.8-53.9)
Hispanic	224	171	36	17	0	9,533
Rate*	28.6	28.1	34.2	23.7		48.5
95% C.I.	(24.3-33.9)	(23.3-34.3)	(22.3-54.1)	(12.7-43.4)		(47.5-49.6)
Other/Unknown	70	68	0	2	0	776

<sup>\*</sup> Rates are per 100,000 population and age-adjusted to the 2001 US Standard population. Rates for race/ethnicity groups are per 100,000 female population and age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 65. Female Breast Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)	
Total							
Cases	6,493	4,314	1,269	907	3	129,844	
Rate*	66.7	64.8	75.6	64.9		70.1	
95% C.I.	(65.1-68.3)	(62.8-66.7)	(71.4-79.8)	(60.7-69.1)		(69.7-70.5)	
Age Group							
<1	0	0	0	0	0		
Rate*							
95% C.I.							
1-4	0	0	0	0	0		
Rate*							
95% C.I.							
5-14	1	1	0	0	0		
Rate*							
95% C.I.							
15-24	4	4	0	0	0	98	
Rate*						0.4	
95% C.I.						(0.3-0.5)	
25-34	106	76	15	15	0	2,481	
Rate*	7.2	7.2	5.9	9.5		8.5	
95% C.I.	(5.8-8.6)	(5.5-8.8)	(2.9-8.9)	(4.7-14.4)		(8.1-8.8)	
35-44	668	459	134	75	0	13,997	
Rate*	42.9	43.9	47.3	33.1		44.8	
95% C.I.	(39.7-46.2)	(39.8-47.9)	(39.3-55.3)	(25.6-40.6)		(44.1-45.5)	
45-54	1,393	925	287	181	0	28,553	
Rate*	108.5	109.3	121.4	90.1		124.8	
95% C.I.	(102.8-114.2)	(102.2-116.3)	(107.3-135.4)	(77.0-103.3)		(123.3-126.2)	
55-64	1,578	1,067	279	231	1	27,877	
Rate*	172.2	171.7	185.9	159.9		199.1	
95% C.I.	(163.7-180.7)	(161.4-182.0)	(164.0-207.7)	(139.3-180.5)		(196.8-201.4)	
65-74	1,564	1,037	298	228	1	27,629	
Rate*	243.5	239.8	290.7	212.7		239.5	
95% C.I.	(231.5-255.6)	(225.2-254.4)	(257.7-323.7)	(185.1-240.3)		(236.7-242.3)	
75-84	950	601	201	147	1	21,949	
Rate*	270.4	257.3	347.6	245.4		302.0	
95% C.I.	(253.2-287.6)	(236.8-277.9)	(299.5-395.6)	(205.7-285.1)		(298.0-306.0)	
85+	221	142	50	29	0	7,256	
Rate*	289.9	304.1	322.4	206.7		292.6	
95% C.I.	(251.7-328.1)	(254.1-354.1)	(233.0-411.8)	(131.5-281.9)		(285.8-299.3)	
Unknown		2	5	1	0	0	

<sup>\*</sup>Rates are per 100,000 age-specific female population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 66. Female Breast Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1997-2001

County of	1997-2001 Incidence						
Residence	Cases	Rat	e*	Age-Adjust	ted Rate**		
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	266	209.9	(184.7-235.2)	174.2	(153.7-197.0)		
Churchill	90	149.7	(118.8-180.6)	152.0	(122.1-187.1)		
Clark	4,274	130.6	(126.7-134.5)	134.4	(130.3-138.5)		
Douglas	139	136.8	(114.0-159.5)	108.0	(90.6-128.8)		
Elko	51	46.1	(33.5-58.8)	62.4	(45.7-84.5)		
Esmeralda	4						
Eureka	3						
Humboldt	28	70.0	(44.0-95.9)	80.9	(52.9-120.1)		
Lander	11	72.4	(29.6-115.2)	93.2	(45.1-175.2)		
Lincoln	6						
Lyon	139	165.7	(138.1-193.2)	143.1	(120.1-169.7)		
Mineral	18	137.9	(74.2-201.5)	110.8	(64.8-185.3)		
Nye	98	128.2	(102.8-153.5)	88.6	(71.4-110.1)		
Pershing	15	108.7	(53.7-163.8)	116.7	(65.0-195.6)		
Storey	6						
Washoe	1,254	151.5	(143.1-159.9)	154.3	(145.8-163.1)		
White Pine	15	71.3	(35.2-107.4)	61.7	(34.2-107.0)		
Unknown	3						
Total	6,420	134.1	(130.8-137.4)	135.2	(131.9-138.6)		

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 female population. \*\*Rates are per 100,000 female population and are age-adjusted to the 2001 US Standard population.

Table 67. Breast Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

			Ger	nder	
Race/Ethnicity		Male	Female	Other/ Unknown	Total
White	Incidence Rate* 95% C.I.	66 2.0 (1.5-2.6)	5,612 148.7 (144.8-152.6)	0	5,678 76.6 (74.6-78.7)
Black	Incidence Rate* 95% C.I.	4	328 133.2 (118.6-149.4)	0	332 72.2 (64.1-81.5)
Native American	Incidence Rate* 95% C.I.	0 	20 35.0 (20.9-56.5)	0	20 18.8 (11.1-31.2)
Asian	Incidence Rate* 95% C.I.		167 65.1 (54.0-80.5)	0	169 38.0 (31.6-46.8)
Hispanic	Incidence Rate* 95% C.I.	1 	223 55.0 (47.2-64.3)	0	224 28.6 (24.3-33.9)
Other/Unkr	nown	0	70	0	70
Total	Incidence Rate* 95% C.I.	73 1.8 (1.4-2.4)	6,420 135.2 (131.9-138.6)	0 	6,493 70.5 (68.7-72.2)

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 female population and are age-adjusted to the 2001 US Standard population.

Table 68. Breast Cancer Cases by Age Group and Gender, Nevada Residents, 1997-2001

Age		Ger	nder	
Group	Male	Female	Other/ Unknown	Total
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14 Rate*	0	1	0	1
95% C.I.				
15-24	0	4	0	4
Rate*				
95% C.I.				
25-34	1	105	0	106
Rate*		14.8		7.2
95% C.I.		(12.0-17.7)		(5.8-8.6)
35-44	4	664	0	668
Rate*		88.4		42.9
95% C.I.		(81.7-95.1)		(39.7-46.2)
45-54	9	1,384	0	1,393
Rate*		218.4		108.5
95% C.I.		(206.9-229.9)		(102.8-114.2)
55-64	17	1,561	0	1,578
Rate*	3.7	338.5		172.2
95% C.I.	(2.0-5.5)	(321.7-355.3)		(163.7-180.7)
65-74	16	1,548	0	1,564
Rate* 95% C.I.	5.0 (2.6-7.5)	475.9 (452.2-499.6)		243.5 (231.5-255.6)
75-84	22	928	0	950
Rate*	13.9	481.4		270.4
95% C.I.	(8.1-19.7)	(450.5-512.4)		(253.2-287.6)
85+	4	217	0	221
Rate*		421.4		289.9
95% C.I.		(365.4-477.5)		(251.7-328.1)
Unknown	0	8	0	8
Total	73	6,420	0	6,493
Rate*	1.5	134.1		66.7
95% C.I.	(1.1-1.8)	(130.8-137.4)		(65.1-68.3)

Note: The "---" is used for rates calculated on numbers less than ten.

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 69. Breast Cancer Cases by Age Group and Stage, Nevada Residents, 1997-2001

<b>A</b>		Stage					
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total
<1	Number	0	0	0	0	0	0
	Percent						
1-4	Number	0	0	0	0	0	0
	Percent						
5-14	Number	0	0	0	1	0	1
	Percent				100.0%		100.0%
15-24	Number	0	2	1	0	1	4
	Percent		50.0%	25.0%		25.0%	100.0%
25-34	Number	12	40	41	3	10	106
	Percent	11.3%	37.7%	38.7%	2.8%	9.4%	100.0%
35-44	Number	85	283	220	33	47	668
	Percent	12.7%	42.4%	32.9%	4.9%	7.0%	100.0%
45-54	Number	275	612	346	57	103	1,393
	Percent	19.7%	43.9%	24.8%	4.1%	7.4%	100.0%
55-64	Number	241	743	403	77	114	1,578
	Percent	15.3%	47.1%	25.5%	4.9%	7.2%	100.0%
65-74	Number	234	791	323	76	140	1,564
	Percent	15.0%	50.6%	20.7%	4.9%	9.0%	100.0%
75-84	Number	99	514	185	59	93	950
	Percent	10.4%	54.1%	19.5%	6.2%	9.8%	100.0%
85+	Number	11	101	42	8	59	221
	Percent	5.0%	45.7%	19.0%	3.6%	26.7%	100.0%
Unknown	Number	1	4	2	1	0	8
	Percent	12.5%	50.0%	25.0%	12.5%		100.0%
Total	Number	958	3,090	1,563	315	567	6,493
	Percent	14.8%	47.6%	24.1%	4.9%	8.7%	100.0%

Table 70. Breast Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1997-2001

			Race/Ethnicity					
	Stage	White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total
In situ	Number	850	34	3	27	31	13	958
	Percent	15.0%	10.2%	15.0%	16.0%	13.8%	18.6%	14.8%
Localized	Number	2,715	140	11	80	107	37	3,090
	Percent	47.8%	42.2%	55.0%	47.3%	47.8%	52.9%	47.6%
Regional	Number	1,352	97	4	44	52	14	1,563
	Percent	23.8%	29.2%	20.0%	26.0%	23.2%	20.0%	24.1%
Distant	Number	266	28	1	7	11	2	315
	Percent	4.7%	8.4%	5.0%	4.1%	4.9%	2.9%	4.9%
Unstaged	Number	495	33	1	11	23	4	567
	Percent	8.7%	9.9%	5.0%	6.5%	10.3%	5.7%	8.7%
Total	Number	5,678	332	20	169	224	70	6,493
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%


Table 71. Median Age at Diagnosis of Breast Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

	Gender							
Race/Ethnicity	Ма	ile	Fen	nale	То	Total		
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age		
White	66	67.5	5,606	62.0	5,672	62.0		
Black	4		326	59.0	330	59.0		
Native American	0		20	57.0	20	57.0		
Asian	2		167	57.0	169	57.0		
Hispanic	1		223	53.0	224	53.0		
Other/Unknown	0		70	59.5	70	59.5		
Total	73	67.0	6,412	61.0	6,485	61.0		

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

# **INPATIENT HOSPITAL DISCHARGES**

Figure 53. Female Breast Cancer Age-Adjusted (2001) Inpatient Discharge Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 female population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 54. Female Breast Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 55. Median Charges for Breast Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Figure 56. Average Length of Stay for Breast Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Table 72. Breast Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	2,608	1,798	464	344	2
Rate*	28.4	29.3	29.7	23.5	
95% C.I.	(27.3-29.6)	(28.0-30.8)	(27.0-32.6)	(21.0-26.2)	
Gender					
Male	19	11	5	3	0
Rate*	0.5	0.5			
95% C.I.	(0.3-0.9)	(0.2-1.0)			
Female	2,589	1,787	459	341	2
Rate*	54.7	56.4	56.5	45.6	
95% C.I.	(52.6-56.9)	(53.8-59.1)	(51.4-61.9)	(40.8-50.7)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Cl	harges (\$)				
Total Charges	\$35,831,623	\$24,293,930	\$7,576,291	\$3,939,010	\$22,392
Average Charges	\$13,739	\$13,512	\$16,328	\$11,451	\$11,196
Median Charges	\$11,044	\$10,823	\$13,048	\$9,554	\$11,196
Discharge Length of S	Stay (LOS) (Days)				
Total LOS	6,043	4,198	1,162	680	
Average LOS	2.3	2.3	2.5	2.0	
Median LOS	1.0	1.0	2.0	1.0	

<sup>\*</sup> Rates are per 100,000 female population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 73. Female Breast Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Cases	2,589	1,787	459	341	2			
Rate*	54.1	54.6	55.5	49.6				
95% C.I.	(52.0-56.2)	(52.1-57.1)	(50.4-60.5)	(44.3-54.9)				
Age Group								
<1	0	0	0	0	0			
Rate*								
95% C.I.								
1-4	0	0	0	0	0			
Rate*								
95% C.I.								
5-14	2	2	0	0	0			
Rate*								
95% C.I.								
15-24	1	1	0	0	0			
Rate*								
95% C.I.								
25-34	51	36	10	5	0			
Rate*	7.2	7.1	8.1					
95% C.I.	(5.2-9.2)	(4.8-9.4)	(3.1-13.2)					
35-44	291	201	55	35	0			
Rate*	38.8	40.2	39.6	31.1				
95% C.I.	(34.3-43.2)	(34.7-45.8)	(29.2-50.1)	(20.8-41.5)				
45-54	521	370	91	60	0			
Rate*	82.2	88.2	78.6	60.9				
95% C.I.	(75.2-89.3)	(79.2-97.2)	(62.5-94.8)	(45.5-76.3)				
55-64	609	432	106	69	2			
Rate*	132.1	136.5	143.4	97.5				
95% C.I.	(121.6-142.5)	(123.6-149.4)	(116.1-170.7)	(74.5-120.5)				
65-74	608	411	105	92	0			
Rate*	186.9	187.7	199.1	171.8				
95% C.I.	(172.1-201.8)	(169.5-205.8)	(161.0-237.1)	(136.7-206.9)				
75-84	415	274	74	67	0			
Rate*	215.3	215.0	223.9	207.8				
95% C.I.	(194.6-236.0)	(189.5-240.4)	(172.9-274.9)	(158.0-257.5)				
85+	91	60	18	13	0			
Rate*	176.7	188.3	168.7	145.1				
95% C.I.	(140.4-213.0)	(140.6-235.9)	(90.8-246.7)	(66.2-224.0)				
Unknown	0	0	0	0	0			

<sup>\*</sup> Rates are per 100,000 female age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 74. Breast Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1997-2001

Age		Gender	
Group	Male	Female	Total
<1	0	0	0
Rate*			
95% C.I.		<u></u> ,	
1-4	0	0	0
Rate*			
95% C.I.	<del></del>		
5-14	0	2	2
Rate*			
95% C.I.			
15-24	0	1	1
Rate*			
95% C.I.			
25-34	0	51	51
Rate*		7.2	3.5
95% C.I.	<u></u>	(5.2-9.2)	(2.5-4.4)
35-44	2	291	293
Rate*		38.8	18.8
95% C.I.	<u></u>	(34.3-43.2)	(16.7-21.0)
45-54	2	521	523
Rate*		82.2	40.7
95% C.I.		(75.2-89.3)	(37.2-44.2)
55-64	1	609	610
Rate*		132.1	66.6
95% C.I.		(121.6-142.5)	(61.3-71.9)
65-74	2	608	610
Rate*		186.9	95.0
95% C.I.		(172.1-201.8)	(87.4-102.5)
75-84	11	415	426
Rate*	6.9	215.3	121.3
95% C.I.	(2.8-11.0)	(194.6-236.0)	(109.8-132.8)
85+	1	91	92
Rate*		176.7	120.7
95% C.I.		(140.4-213.0)	(96.0-145.3)
Unknown	0	0	0
Total	19	2,589	2,608
Rate*	0.4	54.1	26.8
95% C.I.	(0.2-0.6)	(52.0-56.2)	(25.8-27.8)

<sup>\*</sup> Rates are per 100,000 female age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 75. Female Breast Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001

•	1997-2001 Inpatient Hospital Discharges						
County of Residence	Nemakan	Rate	e*	Age-Adjusted Rate**			
	Number	Rate	95% C.I.	Rate	95% C.I.		
Carson City	49	19.7	(14.2-25.2)	17.4	(12.8-23.2)		
Churchill	46	38.1	(27.1-49.2)	39.9	(29.2-53.8)		
Clark	1,798	27.0	(25.7-28.2)	29.3	(28.0-30.8)		
Douglas	38	18.5	(12.6-24.4)	14.6	(10.3-20.7)		
Elko	31	13.4	(8.7-18.1)	20.7	(13.6-31.3)		
Esmeralda	2						
Eureka	2						
Humboldt	11	13.1	(5.4-20.8)	16.1	(7.7-31.6)		
Lander	8						
Lincoln	2						
Lyon	78	45.9	(35.7-56.0)	41.8	(32.9-52.7)		
Mineral	11	41.7	(17.1-66.3)	37.3	(18.4-71.9)		
Nye	48	30.5	(21.9-39.2)	22.2	(16.2-30.6)		
Pershing	6						
Storey	1						
Washoe	464	27.6	(25.1-30.2)	29.7	(27.0-32.6)		
White Pine	11	26.2	(10.7-41.7)	21.9	(10.9-41.8)		
Unknown	2						
Total	2,608	26.8	(25.8-27.8)	28.4	(27.3-29.6)		


Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 female population. \*\*Rates are per 100,000 female population and are age-adjusted to the 2001 US Standard population.

Table 76. Breast Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1997-2001

Age	Diaghargas	(	Charges (\$)	Length of Stay (Days)			
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	0						
1-4	0						
5-14	2						
15-24	1						
25-34	51	771,798	15,133	12,555	119	2.3	2.0
35-44	293	4,985,175	17,014	12,491	776	2.6	2.0
45-54	523	8,035,169	15,364	12,714	1,230	2.4	2.0
55-64	610	8,371,715	13,724	11,210	1,374	2.3	1.0
65-74	610	7,393,485	12,120	10,264	1,197	2.0	1.0
75-84	426	5,093,712	11,957	9,960	1,047	2.5	1.0
85+	92	1,142,837	12,422	9,555	295	3.2	2.0
Unknown	0						
Total	2,608	203,562	2,542	13,636	64	2,542.0	2.4

# **MORTALITY**

Figure 57. Female Breast Cancer Age-Adjusted (2001) Mortality Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 female population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 58. Female Breast Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 59. Female Breast Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 77. Breast Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1997-2001

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Mortality	1,195	785	236	174			
Rate*	14.0	13.8	16.2	12.5			
95% C.I.	(13.2-14.9)	(12.8-14.9)	(14.2-18.5)	(10.7-14.6)			
Gender							
Male	13	10	1	2			
Rate*	0.3	0.4					
95% C.I.	(0.2-0.7)	(0.2-0.9)					
Female	1,182	775	235	172			
Rate*	25.9	25.5	29.7	23.5			
95% C.I.	(24.4-27.4)	(23.7-27.4)	(26.0-33.8)	(20.1-27.4)			
Other/Unknown	0	0	0	0			
Race/Ethnicity							
White	1,037	647	222	168			
Rate*	14.8	14.4	17.4	13.3			
95% C.I.	(13.9-15.7)	(13.3-15.6)	(15.2-19.9)	(11.3-15.5)			
Black	77	72	3	2			
Rate*	18.7	19.3					
95% C.I.	(14.4-24.3)	(14.6-25.3)					
Native American	5	3	1	1			
Rate*							
95% C.I.							
Asian	27	24	2	1			
Rate*	7.0	7.8					
95% C.I.	(3.9-13.2)	(4.0-15.9)					
Hispanic	49	39	8	2			
Rate*	6.7	6.8					
95% C.I.	(4.7-9.9)	(4.5-10.7)					
Other/Unknown	<u></u>	0 _	0	0			

<sup>\*</sup> Rates are per 100,000 population and age-adjusted to the 2001 US Standard population. Rates for race/ethnicity groups are per 100,000 female population and age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 78. Female Breast Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Cases	1,182	775	235	172	0			
Rate*	24.7	23.7	28.4	25.0				
95% C.I.	(23.3-26.1)	(22.0-25.3)	(24.8-32.0)	(21.3-28.8)				
Age Group								
<1	0	0	0	0	0			
Rate*								
95% C.I.								
1-4	0	0	0	0	0			
Rate*								
95% C.I.								
5-14	0	0	0	0	0			
Rate*								
95% C.I.								
15-24	1	1	0	0	0			
Rate*								
95% C.I.								
25-34	6	5	0	1	0			
Rate*								
95% C.I.								
35-44	91	62	19	10	0			
Rate*	12.1	12.4	13.7	8.9				
95% C.I.	(9.6-14.6)	(9.3-15.5)	(7.5-19.9)	(3.4-14.4)				
45-54	194	124	38	32	0			
Rate*	30.6	29.6	32.8	32.5				
95% C.I.	(26.3-34.9)	(24.4-34.8)	(22.4-43.3)	(21.2-43.7)				
55-64	246	163	48	35	0			
Rate*	53.3	51.5	64.9	49.5				
95% C.I.	(46.7-60.0)	(43.6-59.4)	(46.6-83.3)	(33.1-65.8)				
65-74	269	188	46	35	0			
Rate*	82.7	85.9	87.2	65.4				
95% C.I.	(72.8-92.6)	(73.6-98.1)	(62.0-112.4)	(43.7-87.0)				
75-84	254	158	57	39	0			
Rate*	131.8	124.0	172.5	120.9				
95% C.I.	(115.6-148.0)	(104.6-143.3)	(127.7-217.2)	(83.0-158.9)				
85+	121	74	27	20	0			
Rate*	235.0	232.2	253.1	223.3				
95% C.I.	(193.1-276.9)	(179.3-285.1)	(157.6-348.6)	(125.4-321.1)				
Unknown	0	0	0	0	0			

<sup>\*</sup> Rates are per 100,000 female age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 79. Female Breast Cancer Mortality by County of Residence, Nevada Residents, 1997-2001

	1997-2001 Mortality						
County of Residence	Dootho	Rat	te*	Age-Adjus	ted Rate**		
	Deaths	Rate	95% C.I.	Rate	95% C.I.		
Carson City	39	30.8	(21.1-40.4)	24.8	(17.6-34.5)		
Churchill	13	21.6	(9.9-33.4)	22.0	(11.7-38.0)		
Clark	775	23.7	(22.0-25.3)	25.5	(23.7-27.4)		
Douglas	18	17.7	(9.5-25.9)	13.9	(8.2-23.6)		
Elko	11	9.9	(4.1-15.8)	14.8	(7.0-28.8)		
Esmeralda	1						
Eureka	1						
Humboldt	11	27.5	(11.2-43.7)	31.3	(15.3-58.7)		
Lander	4						
Lincoln	3						
Lyon	30	35.8	(23.0-48.5)	32.9	(22.1-47.7)		
Mineral	4						
Nye	25	32.7	(19.9-45.5)	23.8	(15.1-37.3)		
Pershing	2						
Storey	1						
Washoe	235	28.4	(24.8-32.0)	29.7	(26.0-33.8)		
White Pine	9						
Unknown	0						
Total	1,182	24.7	(23.3-26.1)	25.9	(24.4-27.4)		

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 female population. \*\*Rates are per 100,000 female population and are age-adjusted to the 2001 US Standard population.

Table 80. Breast Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

			Gender						
Race/Ethnicity		Male	Female	Total					
White	Mortality		1,026	1,037					
	Rate* 95% C.I.	0.3 (0.1-0.6)	27.6 (25.9-29.3)	14.8 (13.9-15.7)					
Black	Mortality	2	75	77					
	Rate* 95% C.I.		32.7 (25.4-41.8)	18.7 (14.4-24.3)					
Native American	Mortality Rate* 95% C.I.		5	5					
Asian	Mortality Rate* 95% C.I.	0	27 12.1 (6.8-23.1)	27 7.0 (3.9-13.2)					
Hispanic	Mortality Rate* 95% C.I.	0	49 12.8 (9.1-18.1)	49 6.7 (4.7-9.9)					
Other/Unknown		0	0	0					
Total	Mortality Rate* 95% C.I.	13 0.3 (0.2-0.7)	1,182 25.9 (24.4-27.4)	1,195 14.0 (13.2-14.9)					

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 81. Breast Cancer Mortality by Age Group and Gender, Nevada Residents, 1997-2001

Age	Gender					
Group	Male	Female	Total			
<1	0					
Rate*						
95% C.I.						
1-4	0	0	0			
Rate*						
95% C.I.						
5-14	0	0	0			
Rate*						
95% C.I.						
15-24	0	1	1			
Rate*						
95% C.I.						
25-34	0	6	6			
Rate*						
95% C.I.						
35-44	1	91	92			
Rate*		12.1	5.9			
95% C.I.		(9.6-14.6)	(4.7-7.1)			
45-54	1	194	195			
Rate*		30.6	15.2			
95% C.I.		(26.3-34.9)	(13.1-17.3)			
55-64	4	246	250			
Rate*		53.3	27.3			
95% C.I.		(46.7-60.0)	(23.9-30.7)			
65-74	2	269	271			
Rate*		82.7 (72.8-92.6)	42.2 (37.2-47.2)			
95% C.I.	4					
75-84 Rate*	4	254 131.8	258 73.4			
95% C.I.		(115.6-148.0)	(64.5-82.4)			
85+	1	121	122			
Rate*	I 	235.0	160.0			
95% C.I.		(193.1-276.9)	(131.6-188.4)			
Unknown	0	(193.1-270.9)	(131.0-100.4)			
Total	13	1,182	1,195			
Rate*	0.3	24.7	12.3			
95% C.I.	(0.1-0.4)	(23.3-26.1)	(11.6-13.0)			

Note: The "---" is used for rates calculated on numbers less than ten.

<sup>\*</sup> Rates are per 100,000 age-specific population.


Table 82. Median Age at Death from Breast Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

	Gender									
Race/Ethnicity	Ma	ale	Fen	nale	То	Total				
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age				
White	11	67.0	1,026	68.0	1,037	68.0				
Black	2		75	62.0	77	62.0				
Native American	0		5	59.0	5	59.0				
Asian	0		27	55.0	27	55.0				
Hispanic	0		49	55.0	49	55.0				
Other/Unknown	0		0		0					
Total	13	67.0	1,182	67.0	1,195	67.0				

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

# **SURVIVAL RATE**

Figure 60. Survival Rates for Breast Cancer by Race/Ethnicity, Nevada Residents, 1997-2001



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 61. Survival Rates for Breast Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1997-2001




Table 83. Cause-Specific Survival Rates for Breast Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

Race/			Median				
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	5,293	88.2%	81.0%	75.6%	72.4%	72.4%	>5 years
Male	60	86.4%	72.7%	72.7%	53.3%	53.3%	>5 years
Female	5,233	88.2%	81.1%	75.6%	72.7%	72.7%	>5 years
Race/Ethnicity							
White	4,598	88.2%	80.7%	75.2%	72.0%	72.0%	>5 years
Male	54	89.7%	74.4%	74.4%	54.5%	54.5%	>5 years
Female	4,544	88.2%	80.7%	75.2%	72.3%	72.3%	>5 years
Black	272	81.3%	75.9%	70.7%	67.3%	67.3%	>5 years
Male	4						
Female	268	81.4%	76.0%	70.7%	67.3%	67.3%	>5 years
Native American	12						
Male	0						
Female	12						
Asian	155	89.8%	85.0%	79.3%	73.0%	73.0%	>5 years
Male	2						
Female	153	90.5%	85.7%	80.0%	73.6%	73.6%	>5 years
Hispanic	187	91.6%	86.5%	78.5%	78.5%	78.5%	>5 years
Male	0						
Female	187	91.6%	86.5%	78.5%	78.5%	78.5%	>5 years

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 84. Cause-Specific Survival Rates for Breast Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1997-2001


Survival Rate of Stage at Diagnosis		Gender					
		Total	Male	Female			
Total	Cases	5,293	60	5,233			
	One Year	88.2%	86.4%	88.2%			
	5 Years	72.4%	53.3%	72.7%			
	Median Survival	>5 years	>5 years	>5 years			
Stage at D	iagnosis						
In situ	Cases	796	4	792			
	One Year	90.9%		90.8%			
	5 Years	84.7%		84.7%			
	Median Survival	>5 years		>5 years			
Localized	Cases	2,537	34	2,503			
	One Year	90.3%		90.4%			
	5 Years	77.9%		78.0%			
	Median Survival	>5 years		>5 years			
Regional	Cases	1,306	16	1,290			
	One Year	90.2%		90.2%			
	5 Years	70.7%		71.6%			
	Median Survival	>5 years		>5 years			
Distant	Cases	251	3	248			
	One Year	70.6%		70.3%			
	5 Years	37.7%		36.7%			
	Median Survival	2.68		2.64			
Unstaged	Cases	403	3	400			
	One Year	75.1%		75.2%			
	5 Years	47.0%		47.5%			
	Median Survival	3.28		3.41			

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

# PROSTATE CANCER

# PROSTATE CANCER GENERAL PROFILE<sup>4</sup>

Figure 62. Anatomy of the Male Urogenital System<sup>5</sup>



General Anatomy: The prostate is a gland in a man's reproductive system. It makes and stores seminal fluid, a milky fluid that nourishes sperm. This fluid is released to form part of semen. The prostate is about the size of a walnut. It is located below the bladder and in front of the rectum. It surrounds the upper part of the urethra, the tube that empties urine from the bladder. If the prostate grows too large, the flow of urine can be slowed or stopped. To work properly, the prostate needs male hormones (androgens), which are responsible for male sex characteristics. The main male hormone is testosterone, which is made mainly by the testicles. Some male hormones are produced in small amounts by the adrenal glands.

**Risk Factors:** Age, family history of Prostate Cancer, race, and dietary factors are all important risk factors for Prostate Cancer.

**Signs and Symptoms:** A need to urinate frequently, especially at night, difficulty starting urination or holding back urine, inability to urinate, weak or interrupted flow of urine, painful or burning urination, difficulty in having an erection, painful ejaculation, blood in urine or semen, or frequent pain or stiffness in the lower back, hips, or upper thighs.

**Diagnosing the Cancer:** Digital rectal exam, blood test for prostate-specific antigen (PSA test), transrectal ultrasonography, intravenous pyelogram, and cystoscopy.

**Treatment:** Treatment options include: watchful waiting, surgery (prostatectomy, orchiectomy), radiation therapy, and hormonal therapy.

# **HIGHLIGHTS**

- ➤ The ratio of the age-adjusted incidence rate, 125.7, to the age-adjusted mortality rate, 29.2 (per 100,000 2000 US Standard male population) for Prostate Cancer, was 4.30 during the 1996 to 2001 period, which means that for every 4.30 cancer cases there was one death due to Prostate Cancer in Nevada during this period.
- ➤ The median age at diagnosis of Prostate Cancer was 68 years of age for Nevada residents from 1997 to 2001. The median age at time of death due to Prostate Cancer was 77 years. Black males had the lowest median age at time of diagnosis of Prostate Cancer (66 years) and the largest difference (9 years) between the median age at diagnosis and median age at time of death (75 years) during this period.
- ➤ Native American males had the highest median age at diagnosis of Prostate Cancer (70 years).

### **CANCER SCREENING**

- ➤ Of the 815 men in Nevada who were surveyed in 1997, 1999 and 2001, 82.1% responded yes to ever having a Prostate-Specific Antigen (PSA) test and/or a digital rectal exam to try and detect early signs of Prostate Cancer.
- ➤ The percentage of men who stated their education level as high school had the lowest percentage (77.1%) of those ever having a PSA test and/or a digital rectal exam, while those who stated their education level as a college graduate had the highest percentage (90.3%).
- ➤ Those men whose income was either less than \$15,000 or more than \$50,000 a year had the highest percentage of respondents who stated that they had ever received a PSA test or a digital rectal exam with percentages of 80.8% and 84.8%, respectively.

### **INCIDENCE**

- Nevada's Prostate Cancer age-adjusted incidence rate, 125.7 (122.1-129.4), demonstrated statistical significance in being lower than the 1997-2001 National rate of 172.3 (171.4-173.3) (per 100,000 2000 US Standard male population) during this period.
- ➤ There were 5,337 resident Prostate Cancer cases reported in Nevada from 1997 to 2001. Statistically significant tests show that Washoe County had the highest age-adjusted incidence rate of cancer once regional comparisons were made, with a rate of 151.0 (141.6-161.0). The All Other Counties region and Clark County followed with rates of 123.9 (115.5-133.0) and 119.8 (115.5-124.3) (per 100,000 population 2000 US Standard population), respectively.
- Racial/ethnic comparisons showed that Blacks and Whites, as racial/ethnic groups, had the highest statistically significant age-adjusted incidence rates for Prostate Cancer with

rates of 75.8 (67.4-85.3) and 61.6 (59.9-63.5), respectively, of all racial/ethnic groups. Asians, Hispanics and Native Americans, followed with rates of 23.5 (17.4-32.4),31.3 (126.3-37.3) and 25.5 (15.8-40.1), respectively from 1997 to 2001.

### **INPATIENT HOSPITAL DISCHARGES**

- ➤ There were 2,536 hospital inpatient discharges for Prostate Cancer among Nevada Residents from 1997 to 2001, with an age-adjusted inpatient discharge rate of 56.0 (per 100,000 2000 US Standard male population). The 'All Other Counties' region had the highest cancer age-adjusted inpatient discharge rate, 56.9, once regional comparisons were made, and was followed by Washoe County and Clark County with rates of 56.2 and 55.8, respectively.
- ➤ Total billed charges for hospital inpatient discharges due to Prostate Cancer in Nevada totaled nearly 52 million dollars from 1997 to 2001. Nevadans in the 55-74 year age group accounted for 75.1% of the total number of inpatient discharges and 78.9% of the total billed charges.
- ➤ Washoe County had a considerably higher median total billed charge for Prostate Cancer inpatient discharges (\$24,134) than Clark County (\$21,206) and All Other Counties (\$16,000) from 1997 to 2001.
- ➤ The overall average billed charge per day for a hospital inpatient discharge due to Prostate Cancer was just over \$5,781 in Nevada from 1997 to 2001.

### **MORTALITY**

- ➤ There were 922 resident deaths due to Prostate Cancer in Nevada from 1997 to 2001. While Washoe County had the highest age-adjusted mortality rate from Prostate Cancer, 33.7, statistical analysis does not show statistical significance over the rates for Nevada overall, Clark County or All Other Counties, who had rates of 29.2, 28.4 and 27.0, respectively.
- ➤ Racial/ethnic comparisons showed that Blacks and Whites, as racial/ethnic groups, had the highest cancer age-adjusted mortality rates of 20.8 and 12.3, respectively, of all racial/ethnic groups. They were followed by Hispanics and Asians who had age-adjusted mortality rates of 7.0 and 5.0 (per 100,000 2000 US Standard male population), respectively, from 1997 to 2001.

### SURVIVAL RATE

- ➤ The one-year survival rate for Prostate Cancer in Nevada was 85.6% during the 1997 to 2001 period, while the five-year survival rate was 65.6% during this same period. The median survival rate for Prostate Cancer in Nevada was greater than five years.
- ➤ The one-year survival rate for those diagnosed with Prostate Cancer at the localized stage was 89.4%, while those diagnosed at the regional, distant and unstaged stages had rates of 82.0%, 75.0% and 73.3%, respectively.

- ➤ The five-year survival rate for those diagnosed with Prostate Cancer at the localized stage was 76.3%, while those recorded at the regional, distant and unstaged stages had rates of 64.4%, 23.0% and 41.5%, respectively.
- ➤ Those diagnosed with Prostate Cancer at the distant stage had a significantly lower median survival rate than those at all other stages with a rate of 2.15 years compared to over five years for the localized and regional stages.

# **SCREENING (BRFSS)**

Table 85. Prostate Cancer Screening by County/Region of Residence, Education, Age Group, and Income, Nevada Residents, 1997, 1999 and 2001

	Answers						
Responses		Yes			No		
	Number	Percent*	95% C.I.	Number	Percent*	95% C.I.	Total
Total							
Responses	686	82.1%	(79.5%-84.7%)	129	17.9%	(15.3%-20.5%)	815
County/Region of Resid	dence						
Clark County	216	79.7%	(74.9%-84.5%)	55	20.3%	(15.5%-25.1%)	271
Washoe County	213	85.7%	(81.4%-90.0%)	37	14.3%	(10.0%-18.6%)	250
All Other Counties	257	88.5%	(84.9%-92.1%)	37	11.5%	(7.9%-15.1%)	294
Education							
Less than High School	39	77.1%	(65.2%-89.0%)	9	22.9%	(11.0%-34.8%)	48
High School	173	69.2%	(63.2%-75.2%)	54	30.8%	(24.8%-36.8%)	227
Some Post High School	216	83.3%	(78.7%-87.9%)	38	16.7%	(12.1%-21.3%)	254
College Graduate	256	90.3%	(86.9%-93.7%)	37	9.7%	(6.3%-13.1%)	293
Age Group							
18-24 years old	0			0			0
25-34 years old	0			0			0
35-44 years old	103	61.3%	(53.4%-69.2%)	44	38.7%	(30.8%-46.6%)	147
45-54 years old	202	78.0%	(72.9%-83.1%)	54	22.0%	(16.9%-27.1%)	256
55-64 years old	175	90.8%	(86.8%-94.8%)	21	9.2%	(5.2%-13.2%)	196
65+ years old	206	94.0%	(90.8%-97.2%)	10	6.0%	(2.8%-9.2%)	216
Income							
Less than \$15,000	47	80.8%	(70.9%-90.7%)	14	19.2%	(9.3%-29.1%)	61
\$15,000 - \$24,999	40	74.0%	(62.0%-86.0%)	11	26.0%	(14.0%-38.0%)	51
\$25,000 - \$34,999	64	72.5%	(62.9%-82.1%)	19	27.5%	(17.9%-37.1%)	83
\$35,000 - \$49,999	120	74.8%	(67.8%-81.8%)	26	25.2%	(18.2%-32.2%)	146
\$50,000 or More	313	84.8%	(81.1%-88.5%)	41	15.2%	(11.5%-18.9%)	354

<sup>\*</sup>Denominator is persons age 18-64 and excludes missing, don't know, and refused responses.


Note: This table includes those respondents who answered "Yes" or "No" to either of the following questions:

<sup>1)</sup> A Prostate-Specific Antigen test, also called a PSA test, is a blood test used to check men for prostate cancer. Have you ever had a PSA test?

<sup>2)</sup> A digital rectal exam is an exam in which a doctor, nurse, or other health professional places a gloved finger into the rectum to feel the size, and hardness of the prostate gland. Have you ever had a digital rectal exam?

# **INCIDENCE**

Figure 63. Prostate Cancer Age-Adjusted (2001) Incidence Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 male population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 64. Prostate Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 65. Prostate Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 86. Prostate Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)	
Total							
Cases	5,337	3,408	1,053	874	2	127,779	
Rate*	58.6	55.8	69.7	59.0		75.0	
95% C.I.	(57.0-60.3)	(53.9-57.8)	(65.5-74.2)	(55.1-63.1)		(74.6-75.5)	
Gender							
Male	5,337	3,408	1,053	874	2	127,779	
Rate*	125.7	119.8	151.0	123.9		172.3	
95% C.I.	(122.1-129.4)	(115.5-124.3)	(141.6-161.0)	(115.5-133.0)		(171.4-173.3)	
Female	0	0	0	0	0	0	
Rate*							
95% C.I.							
Other/Unknown	0	0	0	0	0	0	
Race/Ethnicity							
White	4,696	2,907	973	814	2	100,957	
Rate*	61.6	59.1	73.2	59.7		73.5	
95% C.I.	(59.9-63.5)	(56.9-61.4)	(68.7-78.0)	(55.6-64.1)		(73.0-73.9)	
Black	326	278	31	17	0	15,708	
Rate*	75.8	70.2	130.4	204.4		111.3	
95% C.I.	(67.4-85.3)	(61.8-79.9)	(87.9-189.0)	(118.6-334.7)		(109.6-113.1)	
Native American	23	9	6	8	0	309	
Rate*	25.5					22.1	
95% C.I.	(15.8-40.1)					(19.6-19.6)	
Asian	77	54	17	6	0	7,359	
Rate*	23.5	19.2	28.4			43.8	
95% C.I.	(17.4-32.4)	(13.6-28.5)	(15.8-57.8)			(42.8-44.9)	
Hispanic	174	125	24	25	0	8,932	
Rate*	31.3	29.3	32.6	44.2		57.8	
95% C.I.	(26.3-37.3)	(23.8-36.2)	(19.6-54.1)	(27.4-69.6)		(56.6-59.1)	
Other/Unknown	41	35	2	4	0	3,446	

<sup>\*</sup>Rates are per 100,000 male population and age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 87. Prostate Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)			
Total									
Cases	5,337	3,408	1,053	874	2	119,272			
Rate*	107.8	100.6	123.7	123.1		130.9			
95% C.I.	(104.9-110.7)	(97.2-103.9)	(116.3-131.2)	(114.9-131.3)		(130.1-131.6)			
Age Group									
<1	0	0	0	0	0				
Rate*									
95% C.I.									
1-4	0	0	0	0	0				
Rate*									
95% C.I.									
5-14	0	0	0	0	0				
Rate*									
95% C.I.									
15-24	1	1	0	0	0	7			
Rate*									
95% C.I.									
25-34	1	1	0	0	0	11			
Rate*						0.1			
95% C.I.						(0.0-0.1)			
35-44	14	8	3	3	0	421			
Rate*	1.7					2.7			
95% C.I.	(0.8-2.6)					(2.4-3.0)			
45-54	381	255	65	60	1	7,828			
Rate*	58.6	59.7	53.9	58.7		69.5			
95% C.I.	(52.7-64.5)	(52.4-67.0)	(40.8-66.9)	(43.8-73.5)		(67.9-71.0)			
55-64	1,456	963	281	212	0	28,440			
Rate*	320.0	315.7	368.7	287.6		423.4			
95% C.I.	(303.6-336.5)	(295.7-335.6)	(325.6-411.9)	(248.9-326.3)		(418.4-428.3)			
65-74	2,225	1,409	460	356	0	48,387			
Rate*	702.0	659.9	924.2	663.6		938.8			
95% C.I.	(672.8-731.2)	(625.4-694.3)	(839.8-1,008.7)	(594.6-732.5)		(930.4-947.1)			
75-84	1,028	638	198	191	1	28,206			
Rate*	648.5	601.3	799.1	690.7		973.2			
95% C.I.	(608.8-688.1)	(554.7-648.0)	(687.8-910.4)	(592.7-788.6)		(961.9-984.6)			
85+	221	126	44	51	0	5,964			
Rate*	893.0	849.5	908.8	1,005.2		804.7			
95% C.I.	(775.3-1,010.8)	(701.2-997.9)	(640.3-1,177.3)	(729.3-1,281.1)		(784.2-825.1)			
Unknown	10	<u>7</u>	2	1	0	0			

<sup>\*</sup> Rates are per 100,000 age-specific male population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 88. Prostate Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1997-2001

County of	1997-2001 Incidence					
Residence	Cases	Rat	e*	Age-Adjus	Age-Adjusted Rate**	
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.	
Carson City	242	197.7	(172.8-222.6)	186.5	(163.5-212.4)	
Churchill	88	145.5	(115.1-175.9)	164.5	(131.1-205.8)	
Clark	3,408	100.6	(97.2-103.9)	119.8	(115.5-124.3)	
Douglas	141	136.5	(113.9-159.0)	116.0	(96.3-139.9)	
Elko	62	51.3	(38.6-64.1)	123.6	(89.7-168.6)	
Esmeralda	5					
Eureka	4					
Humboldt	30	68.3	(43.9-92.7)	109.9	(70.9-169.9)	
Lander	6					
Lincoln	10	95.9	(36.5-155.3)	73.5	(35.2-154.6)	
Lyon	129	149.7	(123.9-175.5)	128.8	(106.9-155.2)	
Mineral	25	187.5	(114.0-261.0)	140.4	(87.3-224.8)	
Nye	102	126.4	(101.9-150.9)	84.1	(67.9-105.3)	
Pershing	7					
Storey	9					
Washoe	1,053	123.7	(116.3-131.2)	151.0	(141.6-161.0)	
White Pine	14	66.7	(31.8-101.7)	61.6	(33.4-107.6)	
Unknown	2		<u></u>			
Total	5,337	107.8	(104.9-110.7)	125.7	(122.1-129.4)	

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 male population. \*\*Rates are per 100,000 male population and are age-adjusted to the 2001 US Standard population.

Table 89. Prostate Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

			Ge	nder	
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total
White	Incidence Rate*	4,696 130.4	0	0	4,696 61.6
	95% C.I.	(126.5-134.5)			(59.9-63.5)
Black	Incidence	326	0	0	326
	Rate*	167.2			75.8
<del></del>	95% C.I.	(147.5-190.4)			(67.4-85.3)
Native	Incidence	23	0	0	23
American	Rate* 95% C.I.	57.8 (34.7-96.8)			25.5 (15.8-40.1)
Asian	Incidence	77	0	0	77
	Rate*	55.4			23.5
:	95% C.I.	(41.3-76.0)			(17.4-32.4)
Hispanic	Incidence	174	0	0	174
	Rate*	70.4			31.3
	95% C.I.	(58.3-85.5)			(26.3-37.3)
Other/Unkr	nown	41	0	0	41
Total	Incidence	5,337	0	0	5,337
	Rate*	125.7			58.6
	95% C.I.	(122.1-129.4)			(57.0-60.3)

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 male population and are age-adjusted to the 2001 US Standard population.

Table 90. Prostate Cancer Cases by Age Group and Gender, Nevada Residents, 1997-2001

Age	Gender						
Group	Male	Female	Other/ Unknown	Total			
<1	0	0	0	0			
Rate*							
95% C.I.							
1-4	0	0	0	0			
Rate* 95% C.I.							
5-14	0		0				
Rate*		0		0			
95% C.I.							
15-24	1	0					
Rate*							
95% C.I.							
25-34	1	0	0	1			
Rate*							
95% C.I.							
35-44	14	0	0	14			
Rate*	1.7			0.9			
95% C.I.	(0.8-2.6)			(0.4-1.4)			
45-54	381	0	0	381			
Rate*	58.6			29.7			
95% C.I.	(52.7-64.5)			(26.7-32.7)			
55-64	1,456	0	0	1,456			
Rate* 95% C.I.	320.0 (303.6-336.5)			158.9 (150.8-167.1)			
65-74	2,225	0	0	2,225			
Rate*	702.0			346.4			
95% C.I.	(672.8-731.2)			(332.0-360.8)			
75-84	1,028	0	0	1,028			
Rate*	648.5			292.6			
95% C.I.	(608.8-688.1)			(274.8-310.5)			
85+	221	0	0	221			
Rate*	893.0			289.9			
95% C.I.	(775.3-1,010.8)			(251.7-328.1)			
Unknown	10	0	0	10			
Total	5,337	0	0	5,337			
Rate*	107.8			54.8			
95% C.I.	(104.9-110.7)			(53.3-56.3)			

Note: The "---" is used for rates calculated on numbers less than ten.

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 91. Prostate Cancer Cases by Age Group and Stage, Nevada Residents, 1997-2001

•		Stage					
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total
<1	Number	0	0	0	0	0	0
	Percent						
1-4	Number	0	0	0	0	0	0
	Percent						
5-14	Number	0	0	0	0	0	0
	Percent						
15-24	Number	0	1	0	0	0	1
	Percent		100.0%				100.0%
25-34	Number	0	1	0	0	0	1
	Percent		100.0%				100.0%
35-44	Number	0	11	2	0	1	14
	Percent		78.6%	14.3%		7.1%	100.0%
45-54	Number	0	283	50	7	41	381
	Percent		74.3%	13.1%	1.8%	10.8%	100.0%
55-64	Number	0	1,051	211	41	153	1,456
	Percent		72.2%	14.5%	2.8%	10.5%	100.0%
65-74	Number	0	1,631	197	105	292	2,225
	Percent		73.3%	8.9%	4.7%	13.1%	100.0%
75-84	Number	0	648	45	73	262	1,028
	Percent		63.0%	4.4%	7.1%	25.5%	100.0%
85+	Number	0	92	10	20	99	221
	Percent		41.6%	4.5%	9.0%	44.8%	100.0%
Unknown	Number	0	8	1	1	0	10
	Percent		80.0%	10.0%	10.0%		100.0%
Total	Number Percent	0	3,726 69.8%	516 <u>9.7%</u>	247 4.6%	848 15.9%	5,337 100.0%

Table 92. Prostate Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1997-2001

			Race/Ethnicity							
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total		
In situ	Number	0	0	0	0	0	0	0		
	Percent									
Localized	Number	3,296	223	12	47	125	23	3,726		
	Percent	70.2%	68.4%	52.2%	61.0%	71.8%	56.1%	69.8%		
Regional	Number	458	31	4	5	13	5	516		
	Percent	9.8%	9.5%	17.4%	6.5%	7.5%	12.2%	9.7%		
Distant	Number	217	13	0	7	10	0	247		
	Percent	4.6%	4.0%		9.1%	5.7%		4.6%		
Unstaged	Number	725	59	7	18	26	13	848		
	Percent	15.4%	18.1%	30.4%	23.4%	14.9%	31.7%	15.9%		
Total	Number	4,696	326	23	77	174	41	5,337		
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%		


Table 93. Median Age at Diagnosis of Prostate Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

	Gender								
Race/Ethnicity	Male		Fem	nale	Total				
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age			
White	4,686	68.0	0		4,686	68.0			
Black	326	66.0	0		326	66.0			
Native American	23	70.0	0		23	70.0			
Asian	77	67.0	0		77	67.0			
Hispanic	174	68.0	0		174	68.0			
Other/Unknown	41	66.0	0		41	66.0			
Total	5,327	68.0	0		5,327	68.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

# **INPATIENT HOSPITAL DISCHARGES**

Figure 66. Prostate Cancer Age-Adjusted (2001) Inpatient Discharge Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 male population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 67. Prostate Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 68. Median Charges for Prostate Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Figure 69. Average Length of Stay for Prostate Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Table 94. Prostate Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	2,536	1,679	426	431	0
Rate*	26.8	26.5	26.9	27.8	
95% C.I.	(25.7-27.9)	(25.2-27.8)	(24.4-29.6)	(25.2-30.7)	
Gender					
Male	2,536	1,679	426	431	0
Rate*	56.0	55.8	56.2	56.9	
95% C.I.	(53.8-58.4)	(53.0-58.8)	(50.8-62.2)	(51.4-62.9)	
Female	0	0	0	0	0
Rate*					
95% C.I.					
Other/Unknown	0	0	0	0	0
Inpatient Discharge Cl	harges (\$)				
Total Charges	\$52,781,802	\$35,604,697	\$10,281,114	\$6,895,991	
Average Charges	\$20,813	\$21,206	\$24,134	\$16,000	
Median Charges	\$17,334	\$17,127	\$23,541	\$13,962	
Discharge Length of S	Stay (LOS) (Days)				
Total LOS	9,007	6,123	1,489	1,395	
Average LOS	3.6	3.6	3.5	3.2	
Median LOS	3.0	3.0	3.0	3.0	

<sup>\*</sup> Rates are per 100,000 male population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 95. Prostate Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown		
Total							
Cases	2,536	1,679	426	431	0		
Rate*	51.2	49.5	50.1	60.7			
95% C.I.	(49.2-53.2)	(47.2-51.9)	(45.3-54.8)	(55.0-66.4)			
Age Group							
<1	0	0	0	0	0		
Rate*							
95% C.I.							
1-4	0	0	0	0	0		
Rate*							
95% C.I.							
5-14	0	0	0	0	0		
Rate*							
95% C.I.							
15-24	0	0	0	0	0		
Rate*							
95% C.I.							
25-34	0	0	0	0	0		
Rate*							
95% C.I.							
35-44	12	9	1	2	0		
Rate*	1.5						
95% C.I.	(0.6-2.3)						
45-54	273	180	51	42	0		
Rate*	42.0	42.1	42.3	41.1			
95% C.I.	(37.0-47.0)	(36.0-48.3)	(30.7-53.8)	(28.6-53.5)			
55-64	941	632	164	145	0		
Rate*	206.8	207.2	215.2	196.7			
95% C.I.	(193.6-220.0)	(191.0-223.3)	(182.3-248.1)	(164.7-228.7)			
65-74	963	612	162	189	0		
Rate*	303.8	286.6	325.5	352.3			
95% C.I. 75-84	(284.6-323.0)	(263.9-309.3)	(275.4-375.6)	(302.1-402.5)	0		
75-84 Rate*	283	206 194.2	38 153.4	39 141.0	0		
95% C.I.	178.5 (157.7-199.3)	(167.6-220.7)	(104.6-202.1)	(96.8-185.3)	<del></del>		
95% C.I.	(157.7-199.3)	(167.6-220.7)	(104.6-202.1)	(96.6-165.3)	0		
Rate*	258.6	269.7	206.5	275.9	0		
95% C.I.	(195.3-322.0)	(186.1-353.3)	(78.5-334.6)	(131.4-420.5)			
Unknown	(195.3-322.0)	(100.1-353.3)	(76.5-334.6)	(131.4-420.5)	0		

<sup>\*</sup> Rates are per 100,000 age-specific male population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 96. Prostate Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1997-2001

Age		Gender	
Group	Male	Female	Total
<1	0	0	
Rate*			
95% C.I.			
1-4	0	0	0
Rate*			
95% C.I.			
5-14	0	0	0
Rate*			
95% C.I.			
15-24	0	0	0
Rate*			
95% C.I.			
25-34	0	0	0
Rate*			
95% C.I.			
35-44	12	0	12
Rate*	1.5		0.8
95% C.I.	(0.6-2.3)		(0.3-1.2)
45-54	273	0	273
Rate*	42.0		21.3
95% C.I.	(37.0-47.0)		(18.7-23.8)
55-64	941	0	941
Rate*	206.8		102.7
95% C.I.	(193.6-220.0)		(96.1-109.3)
65-74	963	0	963
Rate*	303.8		149.9
95% C.I.	(284.6-323.0)		(140.5-159.4)
75-84	283	0	283
Rate*	178.5		80.6
95% C.I.	(157.7-199.3)		(71.2-89.9)
85+	64	0	64
Rate*	258.6		83.9
95% C.I.	(195.3-322.0)		(63.4-104.5)
Unknown	2.526	0	2.536
Total	2,536	Ü	2,536
Rate* 95% C.I.	51.2 (49.2-53.2)		26.0 (25.0-27.1)
უე% U.I.	(49.2-53.2)		(25.0-27.1)

<sup>\*</sup> Rates are per 100,000 male age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 97. Prostate Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001

	1997-2001 Inpatient Hospital Discharges						
County of Residence	Nombre	Rat	te*	Age-Adjus	sted Rate**		
	Number	Rate	95% C.I.	Rate	95% C.I.		
Carson City	88	35.3	(27.9-42.7)	30.5	(24.5-37.8)		
Churchill	42	34.8	(24.3-45.4)	35.6	(25.6-48.7)		
Clark	1,679	25.2	(24.0-26.4)	26.5	(25.2-27.8)		
Douglas	76	37.1	(28.7-45.4)	29.6	(23.1-38.0)		
Elko	27	11.7	(7.3-16.1)	19.0	(12.0-29.6)		
Esmeralda	2						
Eureka	1						
Humboldt	16	19.1	(9.7-28.4)	26.5	(14.8-45.4)		
Lander	2						
Lincoln	5						
Lyon	94	55.3	(44.1-66.4)	45.0	(36.3-55.7)		
Mineral	13	49.3	(22.5-76.0)	33.3	(17.6-63.6)		
Nye	55	35.0	(25.7-44.2)	23.6	(17.5-32.0)		
Pershing	5						
Storey	2						
Washoe	426	25.4	(23.0-27.8)	26.9	(24.4-29.6)		
White Pine	3						
Unknown	0						
Total	2,536	26.0	(25.0-27.1)	26.8	(25.7-27.9)		


Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 male population. \*\*Rates are per 100,000 male population and are age-adjusted to the 2001 US Standard population.

Table 98. Prostate Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1997-2001

Age	Discharges	Charges (\$)			Length of Stay (Days)		
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	0						
1-4	0						
5-14	0						
15-24	0						
25-34	0						
35-44	12	207,402	17,284	16,642	38	3.2	3.0
45-54	273	5,169,236	18,935	17,878	875	3.2	3.0
55-64	941	23,334,538	24,798	18,397	3,283	3.5	3.0
65-74	963	18,281,703	18,984	17,340	3,410	3.5	3.0
75-84	283	4,526,806	15,996	11,788	1,108	3.9	2.0
85+	64	1,262,117	19,721	11,337	293	4.6	3.0
Unknown	0						
Total	2,536	4,294,945	2,450	20,277	45	2,450.0	3.7

# **MORTALITY**

Figure 70. Prostate Cancer Age-Adjusted (2001) Mortality Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 male population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 71. Prostate Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 72. Prostate Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 99. Prostate Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	922	606	170	146
Rate*	12.1	11.9	13.3	11.6
95% C.I.	(11.3-13.0)	(10.9-12.9)	(11.3-15.5)	(9.7-13.7)
Gender				
Male	922	606	170	146
Rate*	29.2	28.4	33.7	27.0
95% C.I.	(27.2-31.4)	(25.9-31.1)	(28.5-39.7)	(22.5-32.3)
Female	0	0	0	0
Rate*				
95% C.I.				
Other/Unknown	0	0	0	0
Race/Ethnicity				
White	810	514	159	137
Rate*	12.3	12.0	13.7	11.7
95% C.I.	(11.5-13.2)	(11.0-13.2)	(11.6-16.1)	(9.8-13.9)
Black	69	66	2	1
Rate*	20.8	21.4		
95% C.I.	(16.0-27.0)	(16.3-28.0)		
Native American	4	1	1	2
Rate*				
95% C.I.				
Asian	13	10	1	2
Rate*	5.0	5.1		
95% C.I.	(2.2-11.2)	(1.9-13.3)		
Hispanic	26	15	7	4
Rate*	7.0	5.5		
95% C.I.	(4.3-10.9)	(2.8-10.0)		
Other/Unknown	0	0	0	0

Note: The "---" is used for rates calculated on numbers less than ten.

\*Rates are per 100,000 population and age-adjusted to the 2001 US Standard population. Rates for race/ethnicity groups are per 100,000 male population and age-adjusted to the 2001 US Standard population.

Table 100. Prostate Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region o	f Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	922	606	170	146
Rate*	9.5	9.1	10.1	10.4
95% C.I.	(8.9-10.1)	(8.4-9.8)	(8.6-11.7)	(8.8-12.1)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	0	0	0	0
Rate*				
95% C.I.				
25-34	0	0	0	0
Rate*				
95% C.I.				
35-44	0	0	0	0
Rate*				
95% C.I.				
45-54	8	5	2	1
Rate*				
95% C.I.				
55-64	70	50	13	7
Rate*	7.6	8.0	8.7	
95% C.I.	(5.9-9.4)	(5.8-10.3)	(4.0-13.4)	
65-74	275	194	43	38
Rate*	42.8	44.9	41.9	35.4
95% C.I.	(37.8-47.9)	(38.5-51.2)	(29.4-54.5)	(24.2-46.7)
75-84	398	265	69	64
Rate*	113.3	113.5	119.3	106.8
95% C.I.	(102.2-124.4)	(99.8-127.1)	(91.2-147.5)	(80.7-133.0)
85+	171	92	43	36
Rate*	224.3	197.0	277.3	256.6
95% C.I.	(190.7-257.9)	(156.8-237.3)	(194.4-360.1)	(172.8-340.4)
Unknown	0	0	0	0

<sup>\*</sup> Rates are per 100,000 age-specific male population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 101. Prostate Cancer Mortality by County of Residence, Nevada Residents, 1997-2001

	1997-2001 Mortality								
County of Residence	C	Rat	e*	Age-Adjusted Rate**					
	Cases	Rate	95% C.I.	Rate	95% C.I.				
Carson City	40	16.1	(11.1-21.0)	13.3	(9.5-18.4)				
Churchill	15	12.4	(6.1-18.7)	13.9	(7.7-23.6)				
Clark	606	9.1	(8.4-9.8)	11.9	(10.9-12.9)				
Douglas	18	8.8	(4.7-12.8)	10.4	(6.0-17.3)				
Elko	17	7.3	(3.9-10.8)	20.1	(11.5-33.0)				
Esmeralda	0								
Eureka	0								
Humboldt	7								
Lander	1								
Lincoln	4								
Lyon	14	8.2	(3.9-12.5)	7.8	(4.2-13.7)				
Mineral	4								
Nye	16	10.2	(5.2-15.2)	9.0	(4.8-16.1)				
Pershing	3								
Storey	1								
Washoe	170	10.1	(8.6-11.7)	13.3	(11.3-15.5)				
White Pine	6								
Unknown	0								
Total	922	9.5	(8.9-10.1)	12.1	(11.3-13.0)				

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 male population. \*\*Rates are per 100,000 male population and are age-adjusted to the 2001 US Standard population.

Table 102. Prostate Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

			Gender		
Rac	e/Ethnicity	Male	Female	Total	
White	Mortality	810	0	810	
	Rate*	29.5		12.3	
	95% C.I.	(27.3-31.9)		(11.5-13.2)	
Black	Mortality	69	0	69	
	Rate*	51.0		20.8	
	95% C.I.	(38.0-68.3)		(16.0-27.0)	
Native	Mortality	4	0	4	
American	Rate*				
	95% C.I.	<u> </u>			
Asian	Mortality	13	0	13	
	Rate*	11.6		5.0	
	95% C.I.	(5.1-26.1)		(2.2-11.2)	
Hispanic	Mortality	26	0	26	
	Rate*	17.6		7.0	
	95% C.I.	(10.5-28.6)		(4.3-10.9)	
Other/Unkn	nown	0	0	0	
Total	Mortality	922	0	922	
	Rate*	29.2		12.1	
	95% C.I.	(27.2-31.4)		(11.3-13.0)	

Note: The "---" is used for rates calculated on numbers less than ten.\*Rates are per 100,000 male population and are age-adjusted to the 2001 US Standard population.

Table 103. Prostate Cancer Mortality by Age Group and Gender, Nevada Residents, 1997-2001

Age		Gender	
Group	Male	Female	Total
<1	0		0
Rate*			
95% C.I.			
1-4	0	0	0
Rate*			
95% C.I.			
5-14	0	0	0
Rate*			
95% C.I.			
15-24	0	0	0
Rate*			
95% C.I.			
25-34	0	0	0
Rate*			
95% C.I.			
35-44 Rate*	0	0	0
95% C.I.		<b></b>	
45-54			8
Rate*	8	0	0
95% C.I.			
55-64	70	0	70
Rate*	15.4		7.6
95% C.I.	(11.8-19.0)		(5.9-9.4)
65-74	275	0	275
Rate*	86.8		42.8
95% C.I.	(76.5-97.0)		(37.8-47.9)
75-84	398	0	398
Rate*	251.1		113.3
95% C.I.	(226.4-275.7)		(102.2-124.4)
85+	171	0	171
Rate*	691.0		224.3
95% C.I.	(587.4-794.6)		(190.7-257.9)
Unknown	0	0	0
Total	922	0	922
Rate*	18.6		9.5
95% C.I.	(17.4-19.8)		(8.9-10.1)

Note: The "---" is used for rates calculated on numbers less than ten.

<sup>\*</sup> Rates are per 100,000 age-specific population.


Table 104. Median Age at Death from Prostate Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

		Gender									
Race/Ethnicity	Ma	ale	Fem	nale	То	Total					
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age					
White	810	77.0	0		810	77.0					
Black	69	75.0	0		69	75.0					
Native American	4		0		4						
Asian	13	74.0	0		13	74.0					
Hispanic	26	74.5	0		26	74.5					
Other/Unknown	0		0		0						
Total	922	77.0	0		922	77.0					

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

# **SURVIVAL RATE**

Figure 73. Survival Rates for Prostate Cancer by Race/Ethnicity, Nevada Residents, 1997-2001



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 74. Survival Rates for Prostate Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1997-2001




Table 105. Cause-Specific Survival Rates for Prostate Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

Race/	Name		Cause Specific Survival Rate				
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	4,518	85.6%	76.4%	70.2%	65.6%	65.6%	>5 years
Male	4,510	85.6%	76.5%	70.3%	65.6%	65.6%	>5 years
Female	8						
Race/Ethnicity							
White	3,947	85.5%	76.3%	69.9%	65.0%	65.0%	>5 years
Male	3,940	85.6%	76.5%	70.0%	65.0%	65.0%	>5 years
Female	7						
Black	289	87.7%	79.0%	74.5%	69.8%	69.8%	>5 years
Male	289	87.7%	79.0%	74.5%	69.8%	69.8%	>5 years
Female	0						
Native American	19						
Male	19						
Female	0						
Asian	68	76.2%	67.3%	50.5%	50.5%	50.5%	. E vooro
Male	67	76.2%	67.1%	50.3%	50.3%	50.3%	>5 years
Female	1	70.0%	07.1%	50.5%	50.5%	50.5%	>5 years
remaie	ı						
Hispanic	154	84.4%	70.5%	70.5%	70.5%		
Male	154	84.4%	70.5%	70.5%	70.5%		
<u>Female</u>	0						

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 106. Cause-Specific Survival Rates for Prostate Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1997-2001


Survival Rate of Stage			Gender	
	nt Diagnosis	Total	Male	Female
Total	Cases	4,518	4,510	8
	One Year	85.6%	85.6%	
	5 Years	65.6%	65.6%	
	Median Survival	>5 years	>5 years	
Stage at Di	iagnosis			
In situ	Cases	0	0	0
	One Year			
	5 Years			
	Median Survival			
Localized	Cases	3,246	3,240	6
	One Year	89.4%	89.5%	
	5 Years	76.3%	76.5%	
	Median Survival	>5 years	>5 years	
Regional	Cases	451	449	2
	One Year	82.0%	82.2%	
	5 Years	64.4%	64.3%	
	Median Survival	>5 years	>5 years	
Distant	Cases	208	208	0
	One Year	75.0%	75.0%	
	5 Years	23.0%	23.0%	
	Median Survival	2.15	2.15	
Unstaged	Cases	613	613	0
	One Year	73.3%	73.3%	
	5 Years	41.5%	41.5%	
	Median Survival	2.75	2.75	

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

# COLORECTAL CANCER

# COLORECTAL CANCER GENERAL PROFILE<sup>4</sup>

Figure 75. Anatomy of the Digestive System<sup>5</sup>



**General Anatomy:** The colon and rectum are parts of the body's digestive system, which removes nutrients from food and stores waste until it is passed out of the body. Together, the colon and rectum form a long, muscular tube called the large intestine (also called the large bowel). The colon makes up the proximal 6 feet of the large intestine, and the rectum is identified as the most distal 8 to 10 inches of the large intestine.

**Risk Factors:** Age, diet, polyps (benign growths on the inner wall of the colon and rectum), personal medical history, family medical history, and ulcerative colitis (the lining of the colon becomes inflamed).

**Signs and Symptoms:** A change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood (either bright red or very dark) in the stool, stools that are narrower than usual, general abdominal discomfort (frequent gas pains, bloating, fullness, and/or cramps), weight loss with no known reason, constant tiredness, and vomiting.

**Diagnosing the Cancer:** Fecal occult blood test, sigmoidoscopy, colonscopy, double contrast barium enema (DCBE), polypectomy, biopsy, and a digital rectal exam.

**Treatment:** Treatment options include: surgery (Colostomy), chemotherapy, radiation therapy, biological therapy, and clinical trials.

### **HIGHLIGHTS**

- ➤ The ratio of the age-adjusted incidence rate, 52.4, to the age-adjusted mortality rate, 22.9 (per 100,000 2000 US Standard population), for Colorectal Cancer was 2.29 during the 1997 to 2001 period, which means that for every 2.29 Colorectal Cancer cases diagnosed during this period, there was one death due to Colorectal Cancer in Nevada.
- Nevadan females had a higher ratio than males when the age-adjusted incidence and age-adjusted mortality rates for Colorectal Cancer were compared. For every female death due to Colorectal Cancer there was 2.43 female cases while there were 2.17 male cases for every male Colorectal Cancer death in Nevada from 1997 to 2001.
- ➤ The median age at diagnosis of Colorectal Cancer was 70 years of age for Nevada residents from 1996 to 2001, while the median age at time of death was 72 years.

#### **CANCER SCREENING**

- ➤ Of the 3,841 individuals in Nevada who were surveyed in 1997, 1999 and 2001, 51.9% responded no to ever having a blood stool test and/or a sigmoidoscopy or colonoscopy to try and detect early signs of Colorectal Cancer.
- Males had a lower percentage of respondents who said yes to ever having a blood stool test and/or a sigmoidoscopy or colonoscopy than females (49.3%) with a percentage of 46.9% when the questions were asked in 1997, 1999 and 2001.
- Each age group showed statistical significance over the next age group for those respondents who said that they had never had a blood stool test and/or a sigmoidoscopy or colonoscopy, with the 35 to 44 age group having the highest percentage at 85.1% (82.1%-88.1%); being followed by the 45 to 54, 55 to 64 and 65 and older age groups with percentages of 59.8% (57.0%-62.6%), 44.5% (41.3%-47.7%) and 34.6% (31.8%-37.4%), respectively, when these questions were included in the Behavorial Risk Factor Surveillance Survey.

#### **INCIDENCE**

- Nevada's incidence rate for Colorectal Cancer (52.4) was only slightly lower than the National rate of 55.0 (per 100,000 2000 US Standard population) from 1997 to 2001.
- ➤ There were 4,530 cases of Colorectal Cancer reported in Nevada from 1997 to 2001. Regional comparisons of Colorectal Cancer incidence showed that Clark County had the highest age-adjusted incidence rate, 54.1, followed by Washoe County, 53.3, and the All Other Counties region, 44.7 (per 100,000 2001 US Standard population), during the 1997 to 2001 period.
- Males had a statistically significant higher age-adjusted incidence rate for Colorectal Cancer 59.3 (56.8-62.0) than the female rate of 46.5 (44.5-48.6) during the 1997 to 2001

period.

➤ The Colorectal Cancer age-adjusted incidence rates for Blacks, 56.7 (49.0-65.6), and Whites, 55.8 (54.0-57.6), showed statistical significance over, and were nearly double, the rates for all other racial/ethnic groups from 1997 to 2001. They were followed by Asians, Hispanics and Native Americans with rates of 30.8 (24.0-40.2), 23.8 (19.3-29.4) and 15.9 (8.6-28.3), respectively.

#### INPATIENT HOSPITAL DISCHARGES

- ➤ There were 4,196 Nevada resident hospital inpatient discharges with a primary diagnosis of Colorectal Cancer from 1997 to 2001. Clark County had the highest cancer ageadjusted inpatient discharge rate, 50.7 (48.8-52.7), once regional comparisons were made. However, the rate was only statistically significant over the All Other Counties region which had the lowest age-adjusted discharge rate, 39.4 (36.2-42.9), during this same period.
- ➤ Total billed charges for Colorectal Cancer inpatient hospital discharges in Nevada totaled nearly 145.3 million dollars from 1997 to 2001. The overall average billed charge per day for a hospital inpatient discharge due to Colorectal Cancer was approximately \$4,122 in Nevada from 1997 to 2001.
- ➤ Clark County had the highest median total billed amount (\$35,855). Washoe County had the highest average length of stay, once regional comparisons were made (8.7 days) during this time.

#### **MORTALITY**

- ➤ There were 1,891 resident deaths due to Colorectal Cancer in Nevada from 1997 to 2001. Males had a higher statistically significant age-adjusted mortality rate, 27.3 (25.5-29.2), than females who had a rate of 19.1 (17.8-20.4), per 100,000 2000 US Standard population, during this period.
- ➤ Blacks, as a racial/ethnic group, had the highest age-adjusted mortality rate for Colorectal Cancer of any racial/ethnic group, 31.3, and were followed by Whites, Native Americans, Asians, and Hispanics with rates of 23.6, 15.6, 12.9, and 12.0, (per 100,000 2000 US Standard population) respectively, from 1997 to 2001.

#### **SURVIVAL RATE**

- The one-year survival rate for Colorectal Cancer in Nevada was 74.1% during the 1997 to 2001 period, while the five-year survival rate was 49.0% during this same time. The median survival rate in Nevada was 3.81 years.
- Females in Nevada had a slightly higher one-year survival rate (75.2%) than males (73.2%) for Colorectal Cancer during the 1997 to 2001 period. This trend was similar for the median survival time with females and males at over 5 years and 3.49 years,

- respectively. Females also had a higher five-year survival rate (50.3%) for Colorectal Cancer than males who had a rate of 48.1% during this time.
- ➤ Hispanics had a considerably higher median survival time than other racial/ethnic groups with a period of over five years, while Whites and Blacks had periods of 3.56 and 2.96 years, respectively.
- The five-year survival rate for those diagnosed at the localized stage for Colorectal Cancer was 67.8% for Nevada from 1997 to 2001, while those recorded at the regional, distant and unstaged stages had rates of 53.0%, 22.2% and 33.9%, respectively.
- ➤ While the median survival time for those diagnosed at the localized and Regional stages was over five years for Colorectal Cancer, those diagnosed at the distant and unstaged levels had median survival times of, 1.43 and 1.88 years, respectively, for Nevada during the 1997 to 2001 period.

## **SCREENING (BRFSS)**

Table 107. Colorectal Cancer Screening by County/Region of Residence, Gender, Education, Age Group, and Income, Nevada Residents, 1997, 1999 and 2001

				Answers			
Responses		Yes			No		
	Number	Percent*	95% C.I.	Number	Percent*	95% C.I.	Total
Total							
Responses	1,828	48.1%	(46.5%-49.7%)	2,013	51.9%	(50.3%-53.5%)	3,841
County/Region of Resid	lence						
Clark County	569	48.0%	(45.2%-50.8%)	662	52.0%	(49.2%-54.8%)	1,231
Washoe County	581	49.2%	(46.4%-52.0%)	612	50.8%	(48.0%-53.6%)	1,193
All Other Counties	678	47.7%	(45.1%-50.3%)	739	52.3%	(49.7%-54.9%)	1,417
Gender							
Male	881	46.9%	(44.6%-49.2%)	989	53.1%	(50.8%-55.4%)	1,870
Female	947	49.3%	(47.1%-51.5%)	1,024	50.7%	(48.5%-52.9%)	1,971
Education							
Less than High School	169	51.7%	(46.4%-57.0%)	170	48.3%	(43.0%-53.6%)	339
High School	483	41.9%	(39.0%-44.8%)	664	58.1%	(55.2%-61.0%)	1,147
Some Post High School	600	50.1%	(47.3%-52.9%)	659	49.9%	(47.1%-52.7%)	1,259
College Graduate	572	51.6%	(48.6%-54.6%)	513	48.4%	(45.4%-51.4%)	1,085
Age Group							
18-24 years old	0			0			0
25-34 years old	0			0			0
35-44 years old	89	14.9%	(11.9%-17.9%)	468	85.1%	(82.1%-88.1%)	557
45-54 years old	443	40.2%	(37.4%-43.0%)	740	59.8%	(57.0%-62.6%)	1,183
55-64 years old	529	55.5%	(52.3%-58.7%)	422	44.5%	(41.3%-47.7%)	951
65+ years old	762	65.4%	(62.6%-68.2%)	370	34.6%	(31.8%-37.4%)	1,132
Income							
Less than \$15,000	179	40.0%	(35.1%-44.9%)	201	60.0%	(55.1%-64.9%)	380
\$15,000 - \$24,999	172	50.6%	(45.3%-55.9%)	166	49.4%	(44.1%-54.7%)	338
\$25,000 - \$34,999	228	41.9%	(37.7%-46.1%)	297	58.1%	(53.9%-62.3%)	525
\$35,000 - \$49,999	317	46.4%	(42.7%-50.1%)	392	53.6%	(49.9%-57.3%)	709
\$50,000 or More	606	48.1%	(45.4%-50.8%)	664	51.9%	(49.2%-54.6%)	1,270


<sup>\*</sup>Denominator is persons age 18-64 and excludes missing, don't know, and refused responses.

Note: This table includes those respondents who answered "Yes" or "No" to either of the following questions:

- 1) A blood stool test is a test that may use a special kit at home to determine whether the stool contains blood. Have you ever had this test using a home kit?
- 2) A sigmoidoscopy or colonoscopy is when a tube is inserted in the rectum to view the bowel for signs of cancer and other health problems. Have you ever had this exam?

# **INCIDENCE**

Figure 76. Colorectal Cancer Age-Adjusted (2001) Incidence Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 77. Colorectal Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 78. Colorectal Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 108. Colorectal Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)	
Total							
Cases	4,530	3,118	775	637	0	94,216	
Rate*	52.4	54.1	53.3	44.7		55.0	
95% C.I.	(50.9-54.0)	(52.2-56.2)	(49.6-57.3)	(41.2-48.4)		(54.7-55.4)	
Gender							
Male	2,419	1,659	419	341	0	47,193	
Rate*	59.3	61.1	61.6	50.1		64.6	
95% C.I.	(56.8-62.0)	(58.0-64.5)	(55.6-68.4)	(44.7-56.2)		(64.0-65.2)	
Female	2,111	1,459	356	296	0	47,023	
Rate*	46.5	48.3	45.8	40.0		47.8	
95% C.I.	(44.5-48.6)	(45.8-50.9)	(41.2-50.9)	(35.6-44.9)		(47.3-48.2)	
Other/Unknown	0	0	0	0	0	0	
Race/Ethnicity							
White	4,026	2,714	712	600	0	76,262	
Rate*	55.8	58.6	55.7	45.8		54.8	
95% C.I.	(54.0-57.6)	(56.4-61.0)	(51.6-60.0)	(42.1-49.7)		(54.4-55.1)	
Black	225	187	25	13	0	9,007	
Rate*	56.7	50.4	112.1	172.7		64.6	
95% C.I.	(49.0-65.6)	(42.8-59.3)	(71.5-169.4)	(91.2-301.2)		(63.2-65.9)	
Native American	15	4	5	6	0	546	
Rate*	15.9					35.9	
95% C.I.	(8.6-28.3)					(32.7-32.7)	
Asian	106	87	16	3	0	7,948	
Rate*	30.8	31.5	30.0			46.8	
95% C.I.	(24.0-40.2)	(23.6-43.1)	(16.1-60.7)			(45.8-47.9)	
Hispanic	129	100	16	13	0	6,450	
Rate*	23.8	23.7	21.6	28.0		40.3	
95% C.I.	(19.3-29.4)	(18.5-30.4)	(11.7-40.2)	(14.0-51.8)		(39.3-41.4)	
Other/Unknown	29	<u>26</u>	1	2	0	453	

<sup>\*</sup> Rates are per 100,000 population and age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 109. Colorectal Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)				
Total										
Cases	4,530	3,118	775	637	0	94,216				
Rate*	46.5	46.8	46.2	45.6		50.9				
95% C.I.	(45.2-47.9)	(45.2-48.4)	(42.9-49.4)	(42.0-49.1)		(50.6-51.2)				
Age Group										
<1	0	0	0	0	0					
Rate*										
95% C.I.										
1-4	0	0	0	0	0					
Rate*										
95% C.I.										
5-14	1	0	1	0	0	12				
Rate*						0.0				
95% C.I.						(0.0-0.1)				
15-24	1	0	1	0	0	129				
Rate*						0.5				
95% C.I.						(0.4-0.6)				
25-34	34	26	6	2	0	835				
Rate*	2.3	2.4				2.9				
95% C.I.	(1.5-3.1)	(1.5-3.4)				(2.7-3.0)				
35-44	157	118	22	17	0	3,484				
Rate*	10.1	11.3	7.8	7.5		11.2				
95% C.I.	(8.5-11.7)	(9.2-13.3)	(4.5-11.0)	(3.9-11.1)		(10.8-11.5)				
45-54	458	310	78	70	0	9,602				
Rate*	35.7	36.6	33.0	34.9		42.0				
95% C.I.	(32.4-38.9)	(32.5-40.7)	(25.7-40.3)	(26.7-43.0)		(41.1-42.8)				
55-64	898	641	147	110	0	15,857				
Rate*	98.0	103.1	97.9	76.1		113.3				
95% C.I.	(91.6-104.4)	(95.1-111.1)	(82.1-113.8)	(61.9-90.4)		(111.5-115.0)				
65-74	1,444	979	253	212	0	25,272				
Rate*	224.8	226.3	246.8	197.8		219.1				
95% C.I.	(213.2-236.4)	(212.2-240.5)	(216.4-277.2)	(171.1-224.4)		(216.3-221.8)				
75-84	1,184	826	189	169	0	27,288				
Rate*	337.1	353.7	326.8	282.1		375.4				
95% C.I.	(317.9-356.3)	(329.6-377.8)	(280.2-373.4)	(239.6-324.7)		(371.0-379.9)				
85+	348	218	74	56	0	11,736				
Rate*	456.5	466.8	477.1	399.1		473.2				
95% C.I.	(408.5-504.4)	(404.9-528.8)	(368.4-585.9)	(294.6-503.6)		(464.6-481.8)				
Unknown		0	4	1	0	0				

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 110. Colorectal Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1997-2001

County of	1997-2001 Incidence					
Residence	Cases	Ra	te*	Age-Adjusted Rate**		
at Diagnosis		Rate	95% C.I.	Rate	95% C.I.	
Carson City	161	64.6	(54.6-74.6)	55.8	(47.5-65.4)	
Churchill	62	51.4	(38.6-64.2)	55.7	(42.6-72.0)	
Clark	3,118	46.8	(45.2-48.4)	54.1	(52.2-56.2)	
Douglas	90	43.9	(34.8-53.0)	37.8	(30.1-47.3)	
Elko	50	21.6	(15.6-27.6)	45.5	(32.7-62.1)	
Esmeralda	2					
Eureka	1					
Humboldt	20	23.8	(13.4-34.3)	36.7	(21.8-59.1)	
Lander	7					
Lincoln	10	49.4	(18.8-80.0)	39.1	(18.6-82.1)	
Lyon	88	51.7	(40.9-62.6)	45.2	(36.1-56.3)	
Mineral	21	79.6	(45.5-113.6)	61.8	(37.7-100.4)	
Nye	100	63.6	(51.2-76.1)	44.9	(36.1-56.1)	
Pershing	7					
Storey	2					
Washoe	775	46.2	(42.9-49.4)	53.3	(49.6-57.3)	
White Pine	16	38.1	(19.4-56.7)	32.9	(18.7-55.8)	
Unknown	0					
Total	4,530	46.5	(45.2-47.9)	52.4	(50.9-54.0)	

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 111. Colorectal Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

Race/Ethnicity			Gender					
		Male	Female	Other/ Unknown	Total			
White	Incidence	2,155	1,871	0	4,026			
	Rate* 95% C.I.	62.7 (60.0-65.7)	49.7 (47.5-52.0)		55.8 (54.0-57.6)			
Black	Incidence	116	109	0	225			
	Rate* 95% C.I.	62.2 (49.6-78.7)	52.0 (42.3-63.5)	 	56.7 (49.0-65.6)			
Native American	Incidence Rate* 95% C.I.	8 	7 	0	15 15.9 (8.6-28.3)			
Asian	Incidence Rate* 95% C.I.	58 42.7 (29.8-62.3)	48 21.8 (15.7-33.0)	0	106 30.8 (24.0-40.2)			
Hispanic	Incidence	69	60	0	129			
	Rate* 95% C.I.	26.2 (19.2-36.4)	21.4 (15.8-28.8)		23.8 (19.3-29.4)			
Other/Unknown		13	16	0	29			
Total	Incidence	2,419	2,111	0	4,530			
	Rate* 95% C.I.	59.3 (56.8-62.0)	46.5 (44.5-48.6)	 	52.4 (50.9-54.0)			

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 112. Colorectal Cancer Cases by Age Group and Gender, Nevada Residents, 1997-2001

Age	Gender					
Group	Male	Female	Other/ Unknown	Total		
<1	0	0	0			
Rate*						
95% C.I.						
1-4	0	0	0	0		
Rate*						
95% C.I.						
5-14	0	1	0	1		
Rate*						
95% C.I.						
15-24	0	1	0	1		
Rate*						
95% C.I.						
25-34	13	21	0	34		
Rate*	1.7	3.0		2.3		
95% C.I.	(0.8-2.6)	(1.7-4.2)		(1.5-3.1)		
35-44	77	80	0	157		
Rate*	9.6	10.7		10.1		
95% C.I.	(7.4-11.7)	(8.3-13.0)		(8.5-11.7)		
45-54	241	217	0	458		
Rate*	37.1	34.2		35.7		
95% C.I.	(32.4-41.8)	(29.7-38.8)		(32.4-38.9)		
55-64	536	362	0	898		
Rate*	117.8	78.5		98.0		
95% C.I.	(107.8-127.8)	(70.4-86.6)		(91.6-104.4)		
65-74	822	622	0	1,444		
Rate*	259.3	191.2		224.8		
95% C.I.	(241.6-277.1)	(176.2-206.2)		(213.2-236.4)		
75-84	595	589	0	1,184		
Rate*	375.3	305.6		337.1		
95% C.I.	(345.2-405.5)	(280.9-330.2)		(317.9-356.3)		
85+	131	217	0	348		
Rate*	529.4	421.4		456.5		
95% C.I.	(438.7-620.0)	(365.4-477.5)		(408.5-504.4)		
Unknown	4	1	0	5		
Total	2,419	2,111	0	4,530		
Rate*	48.9	44.1		46.5		
95% C.I.	(46.9-50.8)	(42.2-46.0)		(45.2-47.9)		

Note: The "---" is used for rates calculated on numbers less than ten.

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 113. Colorectal Cancer Cases by Age Group and Stage, Nevada Residents, 1997-2001

A O		Stage					
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total
<1	Number	0	0	0	0	0	0
	Percent						
1-4	Number	0	0	0	0	0	0
	Percent						
5-14	Number	0	0	100.0%	0	0	100.0%
15-24	Percent						100.076
15-24	Number Percent	0	0	0	100.0%	0	100.0%
25-34	Number	0	13	12	3	6	34
25-54	Percent		38.2%	35.3%	8.8%	17.6%	100.0%
35-44	Number	0	51	54	30	22	157
00 44	Percent		32.5%	34.4%	19.1%	14.0%	100.0%
45-54	Number		133	175	95	55	458
	Percent		29.0%	38.2%	20.7%	12.0%	100.0%
55-64	Number	0	278	317	190	113	898
	Percent		31.0%	35.3%	21.2%	12.6%	100.0%
65-74	Number	0	450	537	281	176	1,444
	Percent		31.2%	37.2%	19.5%	12.2%	100.0%
75-84	Number	0	376	416	191	201	1,184
	Percent		31.8%	35.1%	16.1%	17.0%	100.0%
85+	Number	0	91	123	57	77	348
	Percent		26.1%	35.3%	16.4%	22.1%	100.0%
Unknown	Number	0	0	3	2	0	5
	Percent			60.0%	40.0%		100.0%
Total	Number Percent	0 	1,392 30.7%	1,638 36.2%	850 18.8%	650 14.3%	4,530 100.0%

Table 114. Colorectal Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1997-2001

		Race/Ethnicity							
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total	
In situ	Number	0	0	0	0	0	0	0	
	Percent								
Localized	Number	1,246	56	7	27	47	9	1,392	
	Percent	30.9%	24.9%	46.7%	25.5%	36.4%	31.0%	30.7%	
Regional	Number	1,455	84	6	42	39	12	1,638	
	Percent	36.1%	37.3%	40.0%	39.6%	30.2%	41.4%	36.2%	
Distant	Number	752	47	0	21	26	4	850	
	Percent	18.7%	20.9%		19.8%	20.2%	13.8%	18.8%	
Unstaged	Number	573	38	2	16	17	4	650	
	Percent	14.2%	16.9%	13.3%	15.1%	13.2%	13.8%	14.3%	
Total	Number	4,026	225	15	106	129	29	4,530	
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	


Table 115. Median Age at Diagnosis of Colorectal Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

	Gender									
Race/Ethnicity	Ma	ile	Fem	nale	Total					
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age				
White	2,152	69.0	1,870	71.0	4,022	70.0				
Black	115	66.0	109	67.0	224	67.0				
Native American	8	56.5	7	75.0	15	64.0				
Asian	58	64.0	48	64.5	106	64.0				
Hispanic	69	66.0	60	69.0	129	67.0				
Other/Unknown	13	63.0	16	72.0	29	69.0				
Total	2,415	69.0	2,110	71.0	4,525	70.0				

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

# **INPATIENT HOSPITAL DISCHARGES**

Figure 79. Colorectal Cancer Age-Adjusted (2001) Inpatient Discharge Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 80. Colorectal Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 81. Median Charges for Colorectal Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Figure 82. Average Length of Stay for Colorectal Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Table 116. Colorectal Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown		
Total							
Discharges	4,196	2,928	706	562	0		
Rate*	48.6	50.7	49.2	39.4			
95% C.I.	(47.1-50.2)	(48.8-52.7)	(45.6-53.1)	(36.2-42.9)			
Gender							
Male	2,169	1,529	339	301	0		
Rate*	52.9	56.2	50.6	43.1			
95% C.I.	(50.5-55.4)	(53.1-59.4)	(45.0-56.8)	(38.2-48.7)			
Female	2,027	1,399	367	261	0		
Rate*	44.7	46.2	47.4	35.5			
95% C.I.	(42.8-46.8)	(43.7-48.7)	(42.7-52.6)	(31.3-40.2)			
Other/Unknown	0	0	0	0	0		
Inpatient Discharge Ch	narges (\$)						
Total Charges	\$145,312,024	\$104,984,223	\$23,941,559	\$16,386,242			
Average Charges	\$34,631	\$35,855	\$33,912	\$29,157			
Median Charges	\$26,392	\$26,324	\$28,892	\$22,237			
Discharge Length of S	tay (LOS) (Days)						
Total LOS	35,339	24,868	6,124	4,347			
Average LOS	8.4	8.5	8.7	7.7			
Median LOS	7.0	7.0	8.0	6.0			

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 117. Colorectal Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	4,196	2,928	706	562	0			
Rate*	43.1	44.0	42.1	40.2				
95% C.I.	(41.8-44.4)	(42.4-45.5)	(39.0-45.2)	(36.9-43.5)				
Age Group								
<1	0	0	0	0	0			
Rate*								
95% C.I.								
1-4	0	0	0	0	0			
Rate*								
95% C.I.								
5-14	1	0	1	0	0			
Rate*								
95% C.I.								
15-24	2	2	0	0	0			
Rate*								
95% C.I.								
25-34	31	23	3	5	0			
Rate*	2.1	2.2						
95% C.I.	(1.4-2.8)	(1.3-3.0)						
35-44	121	95	14	12	0			
Rate*	7.8	9.1	4.9	4.2				
95% C.I.	(6.4-9.2)	(7.3-10.9)	(2.4-7.5)	(1.8-6.6)				
45-54	414	292	71	51	0			
Rate*	32.2	34.5	30.0	21.6				
95% C.I.	(29.1-35.4)	(30.5-38.5)	(23.0-37.0)	(15.6-27.5)				
55-64	824	611	124	89	0			
Rate*	89.9	98.3	82.6	59.3				
95% C.I.	(83.8-96.1)	(90.5-106.1)	(68.1-97.1)	(47.0-71.6)				
65-74	1,347	914	236	197	0			
Rate*	209.7	211.3	230.2	192.2				
95% C.I.	(198.5-220.9)	(197.6-225.0)	(200.8-259.6)	(165.3-219.0)				
75-84	1,138	799	177	162	0			
Rate*	324.0	342.1	306.1	280.1				
95% C.I.	(305.1-342.8)	(318.4-365.8)	(261.0-351.2)	(237.0-323.3)				
85+	318	192	80	46	0			
Rate*	417.1	411.2	515.8	296.6				
95% C.I.	(371.3-463.0)	(353.0-469.3)	(402.8-628.9)	(210.9-382.3)				
Unknown	0	0	0	0	0			

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 118. Colorectal Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1997-2001

Age	Gender					
Group	Male	Female	Total			
<1	0	0				
Rate*						
95% C.I.						
1-4	0	0	0			
Rate*						
95% C.I.						
5-14	0	1	1			
Rate*						
95% C.I.						
15-24	0	2	2			
Rate*						
95% C.I.						
25-34	13	18	31			
Rate*	1.7	2.5	2.1			
95% C.I.	(0.8-2.6)	(1.4-3.7)	(1.4-2.8)			
35-44	58	63	121			
Rate*	7.2	8.4	7.8			
95% C.I.	(5.3-9.1)	(6.3-10.5)	(6.4-9.2)			
45-54	227	187	414			
Rate*	34.9	29.5	32.2			
95% C.I.	(30.4-39.5)	(25.3-33.7)	(29.1-35.4)			
55-64 Bata*	474	350	824			
Rate* 95% C.I.	104.2 (94.8-113.6)	75.9 (67.9-83.8)	89.9 (83.8-96.1)			
65-74						
Rate*	751 236.9	596 183.2	1,347 209.7			
95% C.I.	(220.0-253.9)	(168.5-197.9)	(198.5-220.9)			
75-84	536	602	1,138			
Rate*	338.1	312.3	324.0			
95% C.I.	(309.5-366.7)	(287.4-337.3)	(305.1-342.8)			
85+	110	208	318			
Rate*	444.5	404.0	417.1			
95% C.I.	(361.4-527.6)	(349.1-458.9)	(371.3-463.0)			
Unknown	0	0	0			
Total	2,169	2,027	4,196			
Rate*	43.8	42.3	43.1			
95% C.I.	(42.0-45.7)	(40.5-44.2)	(41.8-44.4)			

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 119. Colorectal Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001

	1997-2001 Inpatient Hospital Discharges						
County of Residence	Rate*			Age-Adjusted Rate**			
	Number	Rate	95% C.I.	Rate	95% C.I.		
Carson City	88	35.3	(27.9-42.7)	30.3	(24.2-37.5)		
Churchill	51	42.3	(30.7-53.9)	45.4	(33.7-60.3)		
Clark	2,928	44.0	(42.4-45.5)	50.7	(48.8-52.7)		
Douglas	71	34.6	(26.6-42.7)	29.8	(23.1-38.4)		
Elko	50	21.6	(15.6-27.6)	46.4	(33.4-63.1)		
Esmeralda	1						
Eureka	1						
Humboldt	18	21.4	(11.5-31.3)	31.0	(18.1-51.2)		
Lander	10	32.0	(12.2-51.8)	32.7	(15.4-68.2)		
Lincoln	4						
Lyon	120	70.6	(57.9-83.2)	64.7	(53.4-78.1)		
Mineral	26	98.5	(60.7-136.4)	76.1	(49.1-117.3)		
Nye	93	59.2	(47.1-71.2)	41.1	(32.8-51.7)		
Pershing	9						
Storey	2						
Washoe	706	42.1	(39.0-45.2)	49.2	(45.6-53.1)		
White Pine	18	42.8	(23.1-62.6)	36.7	(21.7-60.4)		
Unknown	0						
Total	4,196	43.1	(41.8-44.4)	48.6	(47.1-50.2)		


Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 120. Colorectal Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1997-2001

Age	Discharges	Charges (\$)		Length of Stay (Days)			
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	0						
1-4	0						
5-14	1						
15-24	2						
25-34	31	1,048,962	33,837	21,826	280	9.0	6.0
35-44	121	3,756,150	31,043	27,498	947	7.8	7.0
45-54	414	13,627,471	32,917	25,617	3,384	8.2	7.0
55-64	824	27,131,697	32,927	26,750	6,558	8.0	7.0
65-74	1,347	44,529,624	33,058	25,389	10,592	7.9	7.0
75-84	1,138	42,906,514	37,703	27,321	10,399	9.1	7.0
85+	318	12,075,184	37,972	28,894	3,137	9.9	8.0
Unknown	0						
Total	4,196	349,189	4,034	33,381	68	4,034.0	8.6

# **MORTALITY**

Figure 83. Colorectal Cancer Age-Adjusted (2001) Mortality Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 84. Colorectal Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 85. Colorectal Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 121. Colorectal Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1997-2001

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Mortality	1,891	1,291	328	272			
Rate*	22.9	23.5	23.3	20.0			
95% C.I.	(21.8-24.0)	(22.2-24.9)	(20.8-26.1)	(17.6-22.6)			
Gender							
Male	1,055	719	198	138			
Rate*	27.3	28.1	31.2	20.6			
95% C.I.	(25.5-29.2)	(25.9-30.6)	(26.8-36.4)	(17.2-24.7)			
Female	836	572	130	134			
Rate*	19.1	19.7	17.0	18.8			
95% C.I.	(17.8-20.4)	(18.1-21.4)	(14.2-20.2)	(15.7-22.3)			
Other/Unknown	0	0	0	0			
Race/Ethnicity							
White	1,650	1,093	300	257			
Rate*	23.6	24.5	24.1	20.4			
95% C.I.	(22.5-24.8)	(23.0-26.0)	(21.4-27.0)	(17.9-23.2)			
Black	120	115	4	1			
Rate*	31.3	32.7					
95% C.I.	(25.5-38.4)	(26.5-40.4)					
Native American	13	4	6	3			
Rate*	15.6						
95% C.I.	(8.0-28.6)						
Asian	45	33	10	2			
Rate*	12.9	10.7	22.2				
95% C.I.	(8.8-19.9)	(7.2-18.2)	(8.4-55.0)				
Hispanic	62	45	8	9			
Rate*	12.0	11.2					
95% C.I.	(8.8-16.4)	(7.6-16.5)					
Other/Unknown	1	1	0	0			

Note: The "---" is used for rates calculated on numbers less than ten.

<sup>\*</sup>Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 122. Colorectal Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region of	of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	1,891	1,291	328	272
Rate*	19.4	19.4	19.5	19.5
95% C.I.	(18.5-20.3)	(18.3-20.4)	(17.4-21.7)	(17.2-21.8)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	1	0	1	0
Rate*				
95% C.I.				
25-34	9	8	0	1
Rate*				
95% C.I.				
35-44	52	37	13	2
Rate*	3.3	3.5	4.6	
95% C.I.	(2.4-4.2)	(2.4-4.7)	(2.1-7.1)	
45-54	128	97	20	11
Rate*	10.0	11.5	8.5	5.5
95% C.I.	(8.2-11.7)	(9.2-13.7)	(4.8-12.2)	(2.2-8.7)
55-64	320	223	56	41
Rate*	34.9	35.9	37.3	28.4
95% C.I.	(31.1-38.8)	(31.2-40.6)	(27.5-47.1)	(19.7-37.1)
65-74	598	410	103	85
Rate*	93.1	94.8	100.5	79.3
95% C.I.	(85.6-100.6)	(85.6-104.0)	(81.1-119.9)	(62.4-96.1)
75-84	557	375	90	92
Rate*	158.6	160.6	155.6	153.6
95% C.I.	(145.4-171.7)	(144.3-176.8)	(123.5-187.8)	(122.2-185.0)
85+	226	141	45	40
Rate*	296.4	302.0	290.2	285.1
95% C.I.	(257.8-335.1)	(252.1-351.8)	(205.4-374.9)	(196.7-373.4)
Unknown Note: The " "is used for	0	0	0	0

Note: The "---" is used for rates calculated on numbers less than ten.

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 123. Colorectal Cancer Mortality by County of Residence, Nevada Residents, 1997-2001

•		1997-2001 Mortality				
County of Residence	Casas	Rat	e*	Age-Adjusted Rate**		
	Cases	Rate	95% C.I.	Rate	95% C.I.	
Carson City	57	22.9	(16.9-28.8)	19.8	(14.9-25.8)	
Churchill	25	20.7	(12.6-28.9)	22.8	(14.7-34.2)	
Clark	1,291	19.4	(18.3-20.4)	23.5	(22.2-24.9)	
Douglas	32	15.6	(10.2-21.0)	14.2	(9.5-21.0)	
Elko	27	11.7	(7.3-16.1)	28.7	(18.4-43.0)	
Esmeralda	1					
Eureka	1					
Humboldt	10	11.9	(4.5-19.3)	19.9	(9.2-38.4)	
Lander	7					
Lincoln	6					
Lyon	35	20.6	(13.8-27.4)	19.4	(13.3-27.6)	
Mineral	14	53.1	(25.3-80.8)	43.0	(23.2-77.9)	
Nye	46	29.3	(20.8-37.7)	20.6	(14.8-28.8)	
Pershing	3					
Storey	0					
Washoe	328	19.5	(17.4-21.7)	23.3	(20.8-26.1)	
White Pine	8					
Unknown	0					
Total	1,891	19.4	(18.5-20.3)	22.9	(21.8-24.0)	

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 124. Colorectal Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

			Gender					
Race/Ethnicity		Male	Female	Total				
White	Mortality	917	733	1,650				
	Rate*	27.9	19.8	23.6				
	95% C.I.	(26.0-30.0)	(18.4-21.4)	(22.5-24.8)				
Black	Mortality	70	50	120				
	Rate*	41.0	23.7	31.3				
	95% C.I.	(30.4-55.8)	(17.3-32.1)	(25.5-38.4)				
Native	Mortality	7	6	13				
American	Rate*			15.6				
	95% C.I.			(8.0-28.6)				
Asian	Mortality	25	20	45				
	Rate*	16.6	10.2	12.9				
	95% C.I.	(10.4-29.8)	(5.1-21.2)	(8.8-19.9)				
Hispanic	Mortality	36	26	62				
	Rate*	14.8	9.6	12.0				
	95% C.I.	(9.4-23.8)	(5.9-15.2)	(8.8-16.4)				
Other/Unkr	nown	0	1	1				
Total	Mortality	1,055	836	1,891				
	Rate*	27.3	19.1	22.9				
	95% C.I.	(25.5-29.2)	(17.8-20.4)	(21.8-24.0)				

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 125. Colorectal Cancer Mortality by Age Group and Gender, Nevada Residents, 1997-2001

Age	Gender					
Group	Male	Female	Total			
<1	0		0			
Rate*						
95% C.I.						
1-4	0	0	0			
Rate*						
95% C.I.						
5-14	0	0	0			
Rate*						
95% C.I.						
15-24	0	1	1			
Rate*						
95% C.I.						
25-34	2	7	9			
Rate*						
95% C.I.						
35-44 Rate*	29 3.6	23 3.1	52 3.3			
95% C.I.	(2.3-4.9)	(1.8-4.3)	(2.4-4.2)			
45-54	72	56	128			
Rate*	11.1	8.8	10.0			
95% C.I.	(8.5-13.6)	(6.5-11.2)	(8.2-11.7)			
55-64	205	115	320			
Rate*	45.1	24.9	34.9			
95% C.I.	(38.9-51.2)	(20.4-29.5)	(31.1-38.8)			
65-74	368	230	598			
Rate*	116.1	70.7	93.1			
95% C.I.	(104.2-128.0)	(61.6-79.8)	(85.6-100.6)			
75-84	296	261	557			
Rate*	186.7	135.4	158.6			
95% C.I.	(165.4-208.0)	(119.0-151.8)	(145.4-171.7)			
85+	83	143	226			
Rate*	335.4	277.7	296.4			
95% C.I.	(263.2-407.6)	(232.2-323.2)	(257.8-335.1)			
Unknown	0	0	0			
Total	1,055	836	1,891			
Rate*	21.3	17.5	19.4			
95% C.I.	(20.0-22.6)	(16.3-18.6)	(18.5-20.3)			

Note: The "---" is used for rates calculated on numbers less than ten.

<sup>\*</sup> Rates are per 100,000 age-specific population.


Table 126. Median Age at Death from Colorectal Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

		Gender						
Race/Ethnicity	Ma	ile	Fem	nale	То	tal		
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age		
White	917	71.0	733	75.0	1,650	72.0		
Black	70	66.5	50	68.0	120	67.0		
Native American	7	56.0	6	75.0	13	68.0		
Asian	25	69.0	20	59.5	45	66.0		
Hispanic	36	66.5	26	70.0	62	69.0		
Other/Unknown	0		1		1			
Total	1,055	70.0	836	74.0	1,891	72.0		

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

# **SURVIVAL RATE**

Figure 86. Survival Rates for Colorectal Cancer by Race/Ethnicity, Nevada Residents, 1997-2001



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 87. Survival Rates for Colorectal Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1997-2001




Table 127. Cause-Specific Survival Rates for Colorectal Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

Race/			Cause Specific Survival Rate						
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)		
Total	3,404	74.1%	61.0%	54.0%	49.0%	49.0%	3.81		
Male	1,820	73.2%	59.2%	51.8%	48.1%	48.1%	3.49		
Female	1,584	75.2%	63.0%	56.7%	50.3%	50.3%	>5 years		
Race/Ethnicity	,								
White	3,004	73.6%	60.0%	53.0%	47.6%	47.6%	3.56		
Male	1,609	72.6%	57.9%	50.8%	46.9%	46.9%	3.20		
Female	1,395	74.7%	62.6%	55.9%	48.5%	48.5%	3.80		
Black	180	74.0%	58.3%	49.7%	46.1%	46.1%	2.96		
Male	91	74.5%	62.6%	46.2%	36.0%	36.0%	2.77		
Female	89	73.6%	54.9%	51.4%	51.4%	51.4%	>5 years		
Native American	10								
Male	6								
Female	4								
Asian	85	75.4%	68.4%	62.4%	62.4%	62.4%	>5 years		
Male	46								
Female	39								
Hispanic	99	82.7%	76.4%	69.1%	69.1%	69.1%	>5 years		
Male	57	82.8%	75.3%	68.4%	68.4%	68.4%	>5 years		
Female	42								

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 128. Cause-Specific Survival Rates for Colorectal Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1997-2001

Survi	/al Rate of Stage		Gender					
	at Diagnosis	Total	Male	Female				
Total	Cases	3,404	1,820	1,584				
	One Year	74.1%	73.2%	75.2%				
	5 Years	49.0%	48.1%	50.3%				
	Median Survival	3.81	3.49	>5 years				
Stage at D	iagnosis							
In situ	Cases	0	0	0				
	One Year							
	5 Years							
	Median Survival							
Localized	Cases	1,063	566	497				
	One Year	85.3%	84.8%	85.8%				
	5 Years	67.8%	69.3%	65.9%				
	Median Survival	>5 years	>5 years	>5 years				
Regional	Cases	1,274	658	616				
	One Year	80.1%	80.6%	79.6%				
	5 Years	53.0%	52.3%	54.1%				
	Median Survival	>5 years	>5 years	>5 years				
Distant	Cases	650	371	279				
	One Year	55.6%	53.9%	57.8%				
	5 Years	22.2%	21.3%	22.8%				
	Median Survival	1.30	1.21	1.43				
Unstaged	Cases	417	225	192				
	One Year	59.2%	56.8%	62.2%				
	5 Years	33.9%	30.0%	39.2%				
	Median Survival	1.48	1.30	1.88				


Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

# URINARY BLADDER CANCER

# URINARY BLADDER CANCER

# GENERAL PROFILE<sup>4</sup>

Figure 88. Anatomy of the Urinary System<sup>5</sup>



**General Anatomy:** The bladder is a hollow organ in the lower abdomen. It stores urine, the liquid waste produced by the kidneys. Urine passes from each kidney into the bladder through a tube called a ureter. An outer layer of muscle surrounds the inner lining of the bladder. When the bladder is full, the muscles in the bladder wall can tighten to allow urination. Urine leaves the bladder through another tube, the urethra.

**Risk Factors:** Age, tobacco use, occupation (due to amount of carcinogens in the workplace), infection, treatment with cyclophosphamide or arsenic, race, being a man, family history, and personal history with Bladder Cancer.

**Signs and Symptoms:** Blood in the urine (making the urine slightly rusty to deep red), pain during urination, and frequent urination, or feeling the need to urinate without results.

**Diagnosing the Cancer:** Physical exams, urine tests, intravenous pyelogram, and cystoscopy.

**Treatment:** Treatment options include: surgery (Transurethral resection, Radical cystectomy, and Segmental cystectomy), radiation therapy (internal or external), chemotherapy, and biological therapy.

### **HIGHLIGHTS**

- Nevadan males had a considerably higher ratio than females when the incidence and mortality age-adjusted rates for Urinary Bladder Cancer were compared. Males had a ratio of 5.44 while the ratio for females was 4.43. This means that for every death due to Urinary Bladder Cancer there would be 5.44 male cases while only 4.43 cases for every female death.
- ➤ The median age at diagnosis of Urinary Bladder Cancer for Nevada residents and males was 70 years of age for Nevada Residents from 1997 to 2001 while the median age for females was 71 years. However, the median age at time of death due to Urinary Bladder Cancer was 75 years for Nevada overall, 77 years for females and 74 years of age for males.

#### **INCIDENCE**

- ➤ There were 2,068 cases of Urinary Bladder Cancer reported in Nevada from 1997 to 2001. Nevada's age-adjusted incidence rate (23.9) for Urinary Bladder Cancer was only slightly higher than the National rate of 20.4 (per 100,000 2000 US Standard population).
- ➤ While there was little regional variation between All Other Counties (24.7), Clark County (23.8), Washoe County (23.1), and in the age-adjusted incidence rate for Urinary Bladder Cancer, the rate for males (39.3) was more than three times the rate for Nevada females (11.0, per 100,000 2000 US Standard population) for the 1997 to 2001 period.
- ➤ Similar to the National rates, Nevada Whites, as a racial/ethnic group, had an age-adjusted incidence rate (26.0, per 100,000 2000 US Standard population) nearly double the rates for all other racial/ethnic groups from 1997 to 2001.

#### **INPATIENT HOSPITAL DISCHARGES**

- ➤ Billed charges from Urinary Bladder Cancer inpatient hospital discharges accounted for over 32.3 million dollars from 1997 to 2001. Nevadans in the 65-74 and 75-84 age groups accounted for 66.2% of the total inpatient discharges and 66.4% of the total billed charges during this period. The overall daily billed amount for these discharges was over \$4,872 in Nevada during this period.
- ➤ There were 1,022 Inpatient Discharges for Urinary Bladder Cancer to Nevada residents in Nevada from 1997 to 2001. Clark County had the highest age-adjusted inpatient discharge rate, 12.8 (11.9-13.9), for Urinary Bladder Cancer in Nevada, and showed statistical significance over the Washoe County rate of 10.1 (8.5-11.9) who had the lowest age-adjusted inpatient discharge rate during the 1997 to 2001 period.
- ➤ The median total billed charges in Nevada for inpatient discharges due to Urinary Bladder Cancer were \$17,544 from 1997 to 2001. Washoe County had the highest median

total billed charge, \$19,622, when compared to the billed amounts for Clark County and All Other Counties of \$17,949 and \$15,362.

#### **MORTALITY**


- ➤ There were 401 resident deaths due to Urinary Bladder Cancer from 1997 to 2001. Regional comparisons were fairly similar between Clark, All Other Counties and, Washoe, as a region, with rates of 5.3, 4.9 and 4.5 (per 100,000 2000 US Standard population), respectively.
- Nevadan males had a 34.4% higher statistically significant age-adjusted mortality rate, 8.3 (7.3-9.5), for Urinary Bladder Cancer when compared to the female rate of 2.7 (2.2-3.2) (per 100,000 2001 US Standard population) for the 1997 to 2001 period.

#### **SURVIVAL RATE**

- Nevada's one-year survival rate for males with Urinary Bladder Cancer was higher than the rate for females during the 1997 to 2001 period, with rates of 83.0% and 79.2%, respectively. This difference lessened by the five-year rate where males had a rate of 60.5% and females had a rate of 59.5%.
- The one-year survival rate for those diagnosed with Urinary Bladder Cancer at the in situ stage was 94.6%, with those at the localized stage at 82.3%, and those recorded at the regional, distant and unstaged stages had rates of 70.7%, 42.5% and 70.1%, respectively.
- ➤ The median survival time for those diagnosed at the in situ and localized stages was over five years, while those diagnosed at the regional, distant and unstaged levels had median survival times of 2.61, 0.87 and 3.90 years, respectively.

# **INCIDENCE**

Figure 89. Urinary Bladder Cancer Age-Adjusted (2001) Incidence Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 90. Urinary Bladder Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 91. Urinary Bladder Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 129. Urinary Bladder Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

			County/Region	n of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)
Total						
Cases	2,068	1,376	337	354	1	34,766
Rate*	23.9	23.8	23.1	24.7		20.4
95% C.I.	(22.8-24.9)	(22.5-25.1)	(20.7-25.8)	(22.1-27.5)		(20.2-20.6)
Gender						
Male	1,567	1,044	248	274	1	25,847
Rate*	39.3	38.9	38.0	41.2		36.1
95% C.I.	(37.2-41.5)	(36.4-41.7)	(33.2-43.6)	(36.2-46.9)		(35.7-36.6)
Female	501	332	89	80	0	8,919
Rate*	11.0	11.0	11.4	10.6		9.1
95% C.I.	(10.0-12.0)	(9.8-12.3)	(9.1-14.0)	(8.4-13.3)		(8.9-9.3)
Other/Unknown	0	0	0	0	0	0
Race/Ethnicity						
White	1,897	1,255	308	334	0	31,167
Rate*	26.0	26.7	24.1	25.3		22.5
95% C.I.	(24.9-27.3)	(25.2-28.3)	(21.4-27.0)	(22.6-28.3)		(22.2-22.7)
Black	68	53	7	8	0	1,678
Rate*	17.4	15.2				12.6
95% C.I.	(13.3-22.7)	(11.2-20.7)				(12.0-13.2)
Native American	9	4	4	0	1	79
Rate*						5.6
95% C.I.						(4.4-4.4)
Asian	22	14	4	4	0	1,573
Rate*	8.6	6.4				9.6
95% C.I.	(4.6-15.9)	(2.8-14.6)				(9.1-10.1)
Hispanic	63	41	14	8	0	1,574
Rate*	12.0	9.9	19.1			10.5
95% C.I.	(8.8-16.4)	(6.5-14.9)	(9.4-37.9)			(10.0-11.1)
Other/Unknown	9	9	0	0	0	269

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 130. Urinary Bladder Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

			County/Region	on of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)
Total						
Cases	2,068	1,376	337	354	1	34,766
Rate*	21.2	20.7	20.1	25.3		18.8
95% C.I.	(20.3-22.2)	(19.6-21.7)	(17.9-22.2)	(22.7-28.0)		(18.6-19.0)
Age Group						
<1	2	0	2	0	0	
Rate*						
95% C.I.						
1-4	1	1	0	0	0	6
Rate*						
95% C.I.						
5-14	0	0	0	0	0	7
Rate*						
95% C.I.						
15-24	3	3	0	0	0	42
Rate*						0.2
95% C.I.						(0.1-0.2)
25-34	12	8	4	0	0	188
Rate*	0.8					0.6
95% C.I.	(0.4-1.3)					(0.6-0.7)
35-44	48	28	8	11	1	882
Rate*	3.1	2.7		4.9		2.8
95% C.I.	(2.2-4.0)	(1.7-3.7)		(2.0-7.7)		(2.6-3.0)
45-54	167	109	34	24	0	2,813
Rate*	13.0	12.9	14.4	12.0		12.3
95% C.I.	(11.0-15.0)	(10.5-15.3)	(9.5-19.2)	(7.2-16.7)		(11.8-12.7)
55-64	390	266	57	67	0	5,731
Rate*	42.6	42.8	38.0	46.4		40.9
95% C.I.	(38.3-46.8)	(37.7-47.9)	(28.1-47.8)	(35.3-57.5)		(39.9-42.0)
65-74	717	471	118	128	0	10,371
Rate*	111.6	108.9	115.1	119.4		89.9
95% C.I.	(103.5-119.8)	(99.1-118.7)	(94.3-135.9)	(98.7-140.1)		(88.2-91.6)
75-84	588	410	84	94	0	10,921
Rate*	167.4	175.6	145.3	156.9		150.2
95% C.I.	(153.9-180.9)	(158.6-192.5)	(114.2-176.3)	(125.2-188.6)		(147.4-153.1)
85+	139	80	29	30	0	3,803
Rate*	182.3	171.3	187.0	213.8		153.3
95% C.I.	(152.0-212.6)	(133.8-208.9)	(118.9-255.0)	(137.3-290.3)		(148.5-158.2)
Unknown	1	0	1	0	0	0

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 131. Urinary Bladder Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1997-2001

County of			1997-2001 Incidence					
Residence	Cases	Ra	te*	Age-Adjus	sted Rate**			
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	102	40.9	(33.0-48.9)	34.9	(28.4-42.6)			
Churchill	28	23.2	(14.6-31.8)	24.4	(16.1-35.8)			
Clark	1,376	20.7	(19.6-21.7)	23.8	(22.5-25.1)			
Douglas	65	31.7	(24.0-39.4)	28.5	(21.6-37.4)			
Elko	11	4.8	(1.9-7.6)	9.8	(4.4-19.3)			
Esmeralda	0							
Eureka	1							
Humboldt	13	15.5	(7.1-23.9)	20.9	(10.6-38.5)			
Lander	5							
Lincoln	2							
Lyon	63	37.0	(27.9-46.2)	32.5	(24.8-42.2)			
Mineral	5							
Nye	51	32.4	(23.5-41.4)	24.5	(17.8-33.6)			
Pershing	3							
Storey	2							
Washoe	337	20.1	(17.9-22.2)	23.1	(20.7-25.8)			
White Pine	3							
Unknown	1							
Total	2,068	21.2	(20.3-22.2)	23.9	(22.8-24.9)			

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 132. Urinary Bladder Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

			Gen	der					
Race/Ethnicity		Male	Female	Other/ Unknown	Total				
White	Incidence Rate*	1,434 42.3	463 12.2	0	1,897 26.0				
Black	95% C.I. Incidence Rate* 95% C.I.	(40.0-44.8) 49 26.7 (19.1-38.2)	(11.1-13.4) 19 9.4 (5.5-15.3)	0	(24.9-27.3) 68 17.4 (13.3-22.7)				
Native American	Incidence Rate* 95% C.I.	8	1	0	9				
Asian	Incidence Rate* 95% C.I.	15 14.4 (6.4-30.6)	7 	0	22 8.6 (4.6-15.9)				
Hispanic	Incidence Rate* 95% C.I.	52 22.1 (14.9-32.8)	11 4.4 (2.0-8.8)	0	63 12.0 (8.8-16.4)				
Other/Unknown		9	0	0	9				
Total	Incidence Rate* 95% C.I.	1,567 39.3 <u>(37.2-41.5)</u>	501 11.0 (10.0-12.0)	0  	2,068 23.9 (22.8-24.9)				

Note: The "---" is used for rates calculated on numbers less than ten.

\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 133. Urinary Bladder Cancer Cases by Age Group and Gender, Nevada Residents, 1997-2001

Age		Gen	der	
Group	Male	Female	Other/ Unknown	Total
<1	2	0	0	2
Rate*				
95% C.I.				
1-4	1	0	0	1
Rate*				
95% C.I.				
5-14 Rate*	0	0	0	0
95% C.I.				
15-24		2	0	3
Rate*	' 			
95% C.I.				
25-34	8	4	0	12
Rate*				0.8
95% C.I.				(0.4-1.3)
35-44	33	15	0	48
Rate*	4.1	2.0		3.1
95% C.I.	(2.7-5.5)	(1.0-3.0)		(2.2-4.0)
45-54	127	40	0	167
Rate*	19.5	6.3		13.0
95% C.I.	(16.1-22.9)	(4.4-8.3)		(11.0-15.0)
55-64	308	82	0	390
Rate*	67.7	17.8		42.6
95% C.I.	(60.1-75.3)	(13.9-21.6)		(38.3-46.8)
65-74	558	159	0	717
Rate* 95% C.I.	176.1	48.9 (41.3-56.5)		111.6
	<u>(161.4-190.7)</u> 432	156		(103.5-119.8)
75-84 Rate*	432 272.5	80.9	0	588 167.4
95% C.I.	(246.8-298.2)	(68.2-93.6)		(153.9-180.9)
85+	96	43	0	139
Rate*	387.9	83.5		182.3
95% C.I.	(310.3-465.5)	(58.6-108.5)		(152.0-212.6)
Unknown	1	0	0	1
Total	1,567	501	0	2,068
Rate*	31.7	10.5		21.2
95% C.I.	(30.1-33.2)	(9.5-11.4)		(20.3-22.2)

Note: The "---" is used for rates calculated on numbers less than ten.

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 134. Urinary Bladder Cancer Cases by Age Group and Stage, Nevada Residents, 1997-2001

<b>A</b>	0		Stage						
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total		
<1	Number	0	1	0	0	1	2		
	Percent		50.0%			50.0%	100.0%		
1-4	Number	0	0	0	0	1	1		
	Percent					100.0%	100.0%		
5-14	Number	0	0	0	0	0	0		
	Percent								
15-24	Number	2	1	0	0	0	3		
	Percent	66.7%	33.3%				100.0%		
25-34	Number	3	6	0	1	2	12		
	Percent	25.0%	50.0%		8.3%	16.7%	100.0%		
35-44	Number	14	27	2	2	3	48		
	Percent	29.2%	56.3%	4.2%	4.2%	6.3%	100.0%		
45-54	Number	68	73	11	5	10	167		
	Percent	40.7%	43.7%	6.6%	3.0%	6.0%	100.0%		
55-64	Number	113	183	44	17	33	390		
	Percent	29.0%	46.9%	11.3%	4.4%	8.5%	100.0%		
65-74	Number	207	351	56	26	77	717		
	Percent	28.9%	49.0%	7.8%	3.6%	10.7%	100.0%		
75-84	Number	162	291	55	14	66	588		
	Percent	27.6%	49.5%	9.4%	2.4%	11.2%	100.0%		
85+	Number	33	67	9	4	26	139		
	Percent	23.7%	48.2%	6.5%	2.9%	18.7%	100.0%		
Unknown	Number	0	1	0	0	0	1		
	Percent		100.0%				100.0%		
Total	Number	602	1,001	177	69	219	2,068		
	Percent	29.1%	48.4%	8.6%	3.3%	10.6%	100.0%		

Table 135. Urinary Bladder Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1997-2001

			Race/Ethnicity						
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total	
In situ	Number	541	21	1	10	26	3	602	
	Percent	28.5%	30.9%	11.1%	45.5%	41.3%	33.3%	29.1%	
Localized	Number	929	30	4	6	27	5	1,001	
	Percent	49.0%	44.1%	44.4%	27.3%	42.9%	55.6%	48.4%	
Regional	Number	164	5	1	3	4	0	177	
	Percent	8.6%	7.4%	11.1%	13.6%	6.3%		8.6%	
Distant	Number	62	4	0	1	2	0	69	
	Percent	3.3%	5.9%		4.5%	3.2%		3.3%	
Unstaged	Number	201	8	3	2	4	1	219	
	Percent	10.6%	11.8%	33.3%	9.1%	6.3%	11.1%	10.6%	
Total	Number	1,897	68	9	22	63	9	2,068	
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	


Table 136. Median Age at Diagnosis of Urinary Bladder Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

	Gender							
Race/Ethnicity	Ma	ile	Fen	nale	То	tal		
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age		
White	1,433	71.0	463	71.0	1,896	71.0		
Black	49	69.0	19	74.0	68	69.0		
Native American	8	66.0	1		9	61.0		
Asian	15	71.0	7	76.0	22	72.0		
Hispanic	52	65.0	11	70.0	63	67.0		
Other/Unknown	9	70.0	0		9	70.0		
Total	1,566	70.0	501	71.0	2,067	71.0		

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

# **INPATIENT HOSPITAL DISCHARGES**

Figure 92. Urinary Bladder Cancer Age-Adjusted (2001) Inpatient Discharge Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 93. Urinary Bladder Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 94. Median Charges for Urinary Bladder Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Figure 95. Average Length of Stay for Urinary Bladder Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Table 137. Urinary Bladder Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	1,022	728	144	149	1
Rate*	11.9	12.8	10.1	10.2	
95% C.I.	(11.2-12.7)	(11.9-13.9)	(8.5-11.9)	(8.6-12.1)	
Gender					
Male	762	559	92	110	1
Rate*	19.4	21.6	14.2	16.3	
95% C.I.	(17.9-21.0)	(19.7-23.7)	(11.3-17.7)	(13.2-20.0)	
Female	260	169	52	39	0
Rate*	5.8	5.7	6.7	5.1	
95% C.I.	(5.1-6.5)	(4.9-6.7)	(5.0-8.8)	(3.6-7.0)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Cl	harges (\$)				
Total Charges	\$32,369,616	\$22,724,052	\$5,542,994	\$4,067,369	\$35,201
Average Charges	\$31,673	\$31,214	\$38,493	\$27,298	\$35,201
Median Charges	\$17,544	\$17,949	\$19,622	\$15,362	\$35,201
Discharge Length of S	Stay (LOS) (Days)				
Total LOS	6,672	4,639	1,088	933	12
Average LOS	6.5	6.4	7.6	6.3	12.0
Median LOS	4.0	4.0	5.5	4.0	12.0

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 138. Urinary Bladder Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	
Total						
Discharges	1,022	728	144	149	1	
Rate*	10.5	10.9	8.6	10.7		
95% C.I.	(9.9-11.1)	(10.1-11.7)	(7.2-10.0)	(9.0-12.4)		
Age Group						
<1	0	0	0	0	0	
Rate*						
95% C.I.						
1-4	2	2	0	0	0	
Rate*						
95% C.I.						
5-14	0	0	0	0	0	
Rate*						
95% C.I.						
15-24	0	0	0	0	0	
Rate*						
95% C.I.						
25-34	5	5	0	0	0	
Rate*						
95% C.I.						
35-44	16	12	2	2	0	
Rate*	1.0	1.1				
95% C.I.	(0.5-1.5)	(0.5-1.8)				
45-54	58	41	11	6	0	
Rate*	4.5	4.8	4.7			
95% C.I.	(3.4-5.7)	(3.4-6.3)	(1.9-7.4)			
55-64	193	139	22	32	0	
Rate*	21.1	22.4	14.7	21.3		
95% C.I.	(18.1-24.0)	(18.6-26.1)	(8.5-20.8)	(13.9-28.7)		
65-74	338	231	51	56	0	
Rate*	52.6	53.4	49.7	54.6		
95% C.I.	(47.0-58.2)	(46.5-60.3)	(36.1-63.4)	(40.3-68.9)		
75-84	339	247	47	44	1	
Rate*	96.5	105.8	81.3	76.1		
95% C.I.	(86.2-106.8)	(92.6-118.9)	(58.0-104.5)	(53.6-98.6)		
85+	71	51	11	9	0	
Rate*	93.1	109.2	70.9			
95% C.I.	(71.5-114.8)	(79.2-139.2)	(29.0-112.8)			
Unknown	0	0	0	0	0	

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 139. Urinary Bladder Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1997-2001

Age	Gender					
Group	Male	Female	Total			
<1	0	0	0			
Rate*						
95% C.I.	<u></u> , _					
1-4	2	0	2			
Rate*						
95% C.I.						
5-14	0	0	0			
Rate*						
95% C.I.						
15-24	0	0	0			
Rate*						
95% C.I.	<u></u>					
25-34	3	2	5			
Rate*						
95% C.I.						
35-44	11	5	16			
Rate*	1.4		1.0			
95% C.I.	(0.6-2.2)		(0.5-1.5)			
45-54	37	21	58			
Rate*	5.7	3.3	4.5			
95% C.I.	(3.9-7.5)	(1.9-4.7)	(3.4-5.7)			
55-64	156	37	193			
Rate*	34.3	8.0	21.1			
95% C.I.	(28.9-39.7)	(5.4-10.6)	(18.1-24.0)			
65-74	259	79	338			
Rate* 95% C.I.	81.7 (71.8-91.7)	24.3 (18.9-29.6)	52.6 (47.0-58.2)			
75-84	247					
Rate*	155.8	92 47.7	339 96.5			
95% C.I.	(136.4-175.2)	(38.0-57.5)	(86.2-106.8)			
85+	47	24	71			
Rate*	189.9	46.6	93.1			
95% C.I.	(135.6-244.2)	(28.0-65.3)	(71.5-114.8)			
Unknown	0	0	0			
Total	762	260	1,022			
Rate*	15.4	5.4	10.5			
95% C.I.	(14.3-16.5)	(4.8-6.1)	(9.9-11.1)			

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 140. Urinary Bladder Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001

Country of	1997-2001 Inpatient Hospital Discharges							
County of Residence	Number	Rat	te*	Age-Adjusted Rate**				
	Number	Rate	95% C.I.	Rate	95% C.I.			
Carson City	22	8.8	(5.1-12.5)	7.2	(4.5-11.2)			
Churchill	11	9.1	(3.7-14.5)	9.5	(4.7-17.8)			
Clark	728	10.9	(10.1-11.7)	12.8	(11.9-13.9)			
Douglas	19	9.3	(5.1-13.4)	7.6	(4.5-12.8)			
Elko	11	4.8	(1.9-7.6)	11.7	(5.5-22.2)			
Esmeralda	1							
Eureka	0							
Humboldt	4							
Lander	2							
Lincoln	1							
Lyon	33	19.4	(12.8-26.0)	16.5	(11.3-23.8)			
Mineral	4							
Nye	32	20.4	(13.3-27.4)	15.0	(9.9-22.9)			
Pershing	2							
Storey	0							
Washoe	144	8.6	(7.2-10.0)	10.1	(8.5-11.9)			
White Pine	7							
Unknown	1							
Total	1,022	10.5	(9.9-11.1)	11.9	(11.2-12.7)			


Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 141. Urinary Bladder Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1997-2001

Age Discharges			Charges (\$)	Len	gth of Stay (Da	ays)	
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	0						
1-4	2						
5-14	0						
15-24	0						
25-34	5	180,094	36,019	23,729	36	7.2	6.0
35-44	16	468,039	29,252	24,128	98	6.1	5.5
45-54	58	1,846,879	31,843	22,956	374	6.4	5.5
55-64	193	6,993,859	36,238	23,931	1,397	7.2	6.0
65-74	338	10,619,146	31,418	19,613	2,170	6.4	5.0
75-84	339	10,899,799	32,153	15,479	2,176	6.4	4.0
85+	71	1,241,630	17,488	12,431	393	5.5	3.0
Unknown	0						
Total	1,022	516,075	989	30,741	87	989.0	6.6

## **MORTALITY**

Figure 96. Urinary Bladder Cancer Age-Adjusted (2001) Mortality Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 97. Urinary Bladder Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 98. Urinary Bladder Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 142. Urinary Bladder Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1997-2001

	County/Region of Residence							
Category	Nevada Total	Nevada Total Clark Washoe		All Other Counties				
Total								
Mortality	401	272	62	67				
Rate*	5.1	5.3	4.5	4.9				
95% C.I.	(4.6-5.6)	(4.7-6.1)	(3.4-5.8)	(3.8-6.3)				
Gender								
Male	288	199	40	49				
Rate*	8.3	8.7	6.8	8.2				
95% C.I.	(7.3-9.5)	(7.4-10.3)	(4.8-9.7)	(5.9-11.2)				
Female	113	73	22	18				
Rate*	2.7	2.7	2.8	2.4				
95% C.I.	(2.2-3.2)	(2.1-3.5)	(1.8-4.3)	(1.4-3.9)				
Other/Unknown	0	0	0	0				
Race/Ethnicity								
White	376	251	58	67				
Rate*	5.5	5.9	4.7	5.3				
95% C.I.	(5.0-6.1)	(5.1-6.7)	(3.5-6.1)	(4.1-6.8)				
Black	11	11	0	0				
Rate*	3.6	4.0						
95% C.I.	(1.7-7.0)	(1.9-7.8)						
Native American	1	0	1	0				
Rate*								
95% C.I.								
Asian	5	4	1	0				
Rate*								
95% C.I.								
Hispanic	8	6	2	0				
Rate*								
95% C.I.								
Other/Unknown	for rates calculated on num	0	0	0				

<sup>\*</sup>Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 143. Urinary Bladder Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region of	of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	401	272	62	67
Rate*	4.1	4.1	3.7	4.8
95% C.I.	(3.7-4.5)	(3.6-4.6)	(2.8-4.6)	(3.6-5.9)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	0	0	0	0
Rate*				
95% C.I.				
25-34	1	1	0	0
Rate*				
95% C.I.				
35-44	4	1	2	1
Rate*				
95% C.I.				
45-54	10	8	2	0
Rate*	0.8			
95% C.I.	(0.3-1.3)			
55-64	67	44	13	10
Rate*	7.3	7.1	8.7	6.9
95% C.I.	(5.6-9.1)	(5.0-9.2)	(4.0-13.4)	(2.6-11.2)
65-74	111	70	17	24
Rate*	17.3	16.2	16.6	22.4
95% C.I.	(14.1-20.5)	(12.4-20.0)	(8.7-24.5)	(13.4-31.3)
75-84	142	102	18	22
Rate*	40.4	43.7	31.1	36.7
95% C.I.	(33.8-47.1)	(35.2-52.1)	(16.7-45.5)	(21.4-52.1)
85+	66	46	10	10
Rate*	86.6	98.5	64.5	71.3
95% C.I.	(65.7-107.5)	(70.0-127.0)	(24.5-104.4)	(27.1-115.4)
Unknown Note: The " " is used f	0	0	0	0

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 144. Urinary Bladder Cancer Mortality by County of Residence, Nevada Residents, 1997-2001

	1997-2001 Mortality							
County of Residence	Casas Rate*			Age-Adjus	sted Rate**			
	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	19	7.6	(4.2-11.1)	6.5	(3.9-10.3)			
Churchill	2							
Clark	272	4.1	(3.6-4.6)	5.3	(4.7-6.1)			
Douglas	16	7.8	(4.0-11.6)	7.6	(4.2-13.3)			
Elko	4							
Esmeralda	0							
Eureka	0							
Humboldt	4							
Lander	2							
Lincoln	0							
Lyon	5							
Mineral	1							
Nye	10	6.4	(2.4-10.3)	5.5	(2.4-11.7)			
Pershing	1							
Storey	0							
Washoe	62	3.7	(2.8-4.6)	4.5	(3.4-5.8)			
White Pine	3							
Unknown	0							
Total	401	4.1	(3.7-4.5)	5.1	(4.6-5.6)			

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 145. Urinary Bladder Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

		Gender						
Rac	e/Ethnicity	Male	Female	Total				
White	Mortality	271	105	376				
	Rate* 95% C.I.	9.0 (7.9-10.3)	2.9 (2.4-3.5)	5.5 (5.0-6.1)				
Black	Mortality Rate*	7	4	11 3.6				
	95% C.I.			(1.7-7.0)				
Native	Mortality	1	0	1				
American	Rate* 95% C.I.	 	 					
Asian	Mortality	3	2	5				
	Rate* 95% C.I.							
Hispanic	Mortality Rate*	6	2	8				
	95% C.I.							
Other/Unkn	iown	0	0	0				
Total	Mortality	288	113	401				
	Rate* 95% C.I.	8.3 (7.3-9.5)	2.7 (2.2-3.2)	5.1 (4.6-5.6)				

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 146. Urinary Bladder Cancer Mortality by Age Group and Gender, Nevada Residents, 1997-2001

Age		Gender	
Group	Male	Female	Total
<1			0
Rate*			
95% C.I.			
1-4	0	0	0
Rate*			
95% C.I.			
5-14	0	0	0
Rate*			
95% C.I.			
15-24	0	0	0
Rate*			
95% C.I.			
25-34	1	0	1
Rate*			
95% C.I.			
35-44 Rate*	1	3	4
95% C.I.			
45-54	6	4	10
Rate*			0.8
95% C.I.			(0.3-1.3)
55-64	53	14	67
Rate*	11.6	3.0	7.3
95% C.I.	(8.5-14.8)	(1.4-4.6)	(5.6-9.1)
65-74	87	24	111
Rate*	27.4	7.4	17.3
95% C.I.	(21.7-33.2)	(4.4-10.3)	(14.1-20.5)
75-84	101	41	142
Rate*	63.7	21.3	40.4
95% C.I.	(51.3-76.1)	(14.8-27.8)	(33.8-47.1)
85+	39	27	66
Rate*	157.6	52.4	86.6
95% C.I.	(108.1-207.1)	(32.7-72.2)	(65.7-107.5)
Unknown	0	0	0
Total	288	113	401
Rate*	5.8 (5.1.6.5)	2.4	4.1
95% C.I.	(5.1-6.5)	(1.9-2.8)	(3.7-4.5)

<sup>\*</sup> Rates are per 100,000 age-specific population.


Table 147. Median Age at Death from Urinary Bladder Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

		Gender									
Race/Ethnicity	Male		Fem	nale	Total						
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age					
White	271	74.0	105	76.0	376	75.0					
Black	7	72.0	4		11	77.0					
Native American	1		0		1						
Asian	3		2		5	79.0					
Hispanic	6	69.0	2		8	78.5					
Other/Unknown	0		0		0						
Total	288	74.0	113	77.0	401	75.0					

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

## **SURVIVAL RATE**

Figure 99. Survival Rates for Urinary Bladder Cancer by Race/Ethnicity, Nevada Residents, 1997-2001



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 100. Survival Rates for Urinary Bladder Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1997-2001




Table 148. Cause-Specific Survival Rates for Urinary Bladder Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

Race/		Cause Specific Survival Rate					Median
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	1,603	82.1%	72.6%	65.2%	60.4%	60.4%	>5 years
Male	1,209	83.0%	73.8%	66.5%	60.5%	60.5%	>5 years
Female	394	79.2%	69.1%	61.3%	59.5%	59.5%	>5 years
Race/Ethnicity							
White	1,464	82.2%	73.2%	65.3%	60.5%	60.5%	>5 years
Male	1,099	82.9%	74.1%	66.5%	60.6%	60.6%	>5 years
Female	365	80.0%	70.4%	61.7%	59.7%	59.7%	>5 years
Black	50	81.3%	65.1%	56.9%	56.9%	56.9%	>5 years
Male	37						
Female	13						
Native American	6						
Male	5						
Female	1						
Asian	19						
Male	13						
Female	6						
Hispanic	55	75.6%	55.4%	55.4%	55.4%	55.4%	>5 years
Male	46						
Female	9						

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 149. Cause-Specific Survival Rates for Urinary Bladder Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1997-2001

Survi	/al Rate of Stage	Gender					
	at Diagnosis	Total	Male	Female			
Total	Cases	1,603	1,209	394			
	One Year	82.1%	83.0%	79.2%			
	5 Years	60.4%	60.5%	59.5%			
	Median Survival	>5 years	>5 years	>5 years			
Stage at D	iagnosis						
In situ	Cases	477	354	123			
	One Year	94.6%	94.8%	93.9%			
	5 Years	80.0%	76.1%	93.9%			
	Median Survival	>5 years	>5 years	>5 years			
Localized	Cases	783	604	179			
	One Year	82.3%	83.2%	79.4%			
	5 Years	60.4%	60.7%	58.7%			
	Median Survival	>5 years	>5 years	>5 years			
Regional	Cases	128	90	38			
	One Year	70.7%	73.8%				
	5 Years	33.0%	37.9%				
	Median Survival	2.61	2.87				
Distant	Cases	53	37	16			
	One Year	42.5%					
	5 Years						
	Median Survival	0.87					
Unstaged	Cases	162	124	38			
	One Year	70.1%	71.0%				
	5 Years	49.0%	47.5%				
	Median Survival	3.90	3.83				


Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

# NON-HODGKIN'S LYMPHOMA

## NON-HODGKIN'S LYMPHOMA

## GENERAL PROFILE<sup>4</sup>

Figure 101. Anatomy of the Lymphatic System



General Anatomy: Lymphoma is a general term for cancers that develop in the lymphatic system. The lymphatic system is part of the body's immune system that helps the body fight disease and infection and includes a network of thin tubes (lymphatic vessels) that branch, like blood vessels, into tissues throughout the body. Lymphatic vessels carry lymph, a colorless, watery fluid that contains infection fighting cells called lymphocytes. Along this network of vessels are small organs called lymph nodes that are found in the underarms, groin, neck, chest, and abdomen. Other parts of the lymphatic system are the spleen, thymus, tonsils, and bone marrow. Lymphatic tissue is also found in other parts of the body, including the stomach, intestines, and skin.

In non-Hodgkin's lymphoma, cells in the lymphatic system become abnormal. They divide and grow without any order or control, or old cells do not die as cells normally do. Non-Hodgkin's lymphoma can start almost anywhere in the body and may occur in a single lymph node, a group of lymph nodes, or in another organ. This type of cancer can spread to almost any part of the body, including the liver, bone marrow, and spleen.

**Risk Factors:** Age, male gender, weakened immune system, viruses (Human T-lymphotropic virus type I [HTLV-1] and Epstein-Barr virus), and environment (chemical exposure).

**Signs and Symptoms:** Unexplained fever, night sweats, constant fatigue, unexplained weight loss, itchy skin, and reddened patches on the skin.

**Diagnosing the Cancer:** X-rays, computed tomography (CAT) scan, magnetic resonance imaging (MRI), and lymphangiogram.

**Treatment:** Treatment options include: chemotherapy, radiation therapy, bone marrow transplantation (BMT), biological therapy, surgery, and clinical trials.

### **HIGHLIGHTS**

- ➤ The ratio of the age-adjusted incidence rate, 14.7, to the age-adjusted mortality rate, 7.1 (per 100,000 2000 US Standard population), for Non-Hodgkin's Lymphoma was 2.01 during the 1997 to 2001 period, which means that for every 2.07 Non-Hodgkin's Lymphoma cases during this period, there was one death due to Non-Hodgkin's Lymphoma in Nevada.
- Nevadan females had a higher ratio than males when the age-adjusted incidence and age-adjusted mortality rates for Non-Hodgkin's Lymphoma were compared. For every female death due to Non-Hodgkin's Lymphoma, there was 2.38 female cases. There were 2.07 male cases for every male Non-Hodgkin's Lymphoma death in Nevada from 1997 to 2001.
- ➤ The median age at diagnosis of Non-Hodgkin's Lymphoma was 65 years of age for Nevada residents from 1997 to 2001; the median age at time of death was 72 years.

#### **INCIDENCE**

- ➤ There were 1,316 cases of Non-Hodgkin's Lymphoma in Nevada from 1997 to 2001. Nevada's lower incidence rate, 14.7 (1.9-15.5), for Non-Hodgkin's Lymphoma showed statistical significance when compared to the National rate, 19.1 (18.9-19.3), per 100,000 2000 US Standard population.
- ➤ While regional comparisons showed that Washoe County's age-adjusted incidence rate, 16.9, was higher than the rate for All Other Counties (14.8) and Clark County (14.1) from 1997 to 2001, these differences were not statistically significant (adjusted to the 2000 US Standard Population).
- ➤ Males had a higher, and statistically significant, age-adjusted incidence rate, 17.4 (16.1-18.8), than females who had a rate of 12.4 (11.4-13.5), per 100,000 2000 US Standard population.
- ➤ Whites had the highest age-adjusted incidence rate, 16.3, for Non-Hodgkin's Lymphoma of all racial/ethnic groups and were followed by Blacks, Hispanics, and Asians with rates of 8.7, 8.1 and 8.10 (per 100,000 2000 US Standard population), respectively, during this period.

#### INPATIENT HOSPITAL DISCHARGES

➤ There were 988 Inpatient Discharges for Non-Hodgkin's Lymphoma to Nevada residents from 1997 to 2001. Regional comparisons showed little difference between the ageadjusted inpatient discharge rates and average length of stay between Clark County, Washoe County and All Other Counties, as a region.

- ➤ Total billed charges for hospital inpatient discharges from Non-Hodgkin's Lymphoma in Nevada totaled just over 38.7 million dollars from 1997 to 2001. Clark County had the highest median total billed charge (\$41,132) once regional comparisons were made.
- The overall average billed charge per day for an inpatient hospital discharge for Non-Hodgkin's Lymphoma was approximately \$4,309 in Nevada from 1997 to 2001.

#### **MORTALITY**


- There were 599 deaths in Nevada due to Non-Hodgkin's Lymphoma from 1997 to 2001. Regional comparisons showed little difference between the age-adjusted mortality rates for Washoe County, Clark County, and All Other Counties, as a region, with rates of 7.5, 7.1 and 6.6 (per 100,000 2000 US Standard population), respectively.
- ➤ While racial/ethnic comparisons showed that Whites had highest age-adjusted mortality rate (7.6) for Non-Hodgkin's Lymphoma, and were followed by Asians, Hispanics and Blacks with rates of 5.8, 4.7 and 4.0 (per 100,000 2001 US Standard population), respectively; statistical analysis does not show any statistical significance between any of the racial/ethnic groups during the 1997 to 2001 period.

#### **SURVIVAL RATE**

- Females in Nevada had a slightly higher one-year survival rate (78.4%) than males (74.4%) for Non-Hodgkin's Lymphoma during the 1997 to 2001 period. By the five-year survival period females had a survival rate of 53.4% and males had a rate of 51.3%.
- ➤ The Non-Hodgkin's Lymphoma survival rate varies greatly by the stage of the cancer at time of diagnosis. Those diagnosed at the localized stage had the highest one- and five-year survival rates with 88.1% and 60.4%, respectively. This was followed by those with regional and then distant diagnoses with rates of 72.3% and 46.3% for the one-year period and 72.6% and 53.7% for the five-year period.

## **INCIDENCE**

Figure 102. Non-Hodgkin's Lymphoma Age-Adjusted (2001) Incidence Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 103. Non-Hodgkin's Lymphoma Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 104. Non-Hodgkin's Lymphoma Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 150. Non-Hodgkin's Lymphoma Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)	
Total							
Cases	1,316	839	259	217	1	33,470	
Rate*	14.7	14.1	16.9	14.8		19.1	
95% C.I.	(13.9-15.5)	(13.1-15.1)	(14.8-19.1)	(12.9-17.0)		(18.9-19.3)	
Gender							
Male	737	468	144	125	0	18,156	
Rate*	17.4	16.8	20.2	17.3		23.3	
95% C.I.	(16.1-18.8)	(15.1-18.6)	(16.8-24.2)	(14.3-21.0)		(22.9-23.6)	
Female	579	371	115	92	1	15,314	
Rate*	12.4	12.0	14.3	12.5		15.7	
95% C.I.	(11.4-13.5)	(10.8-13.3)	(11.8-17.3)	(10.0-15.3)		(15.5-16.0)	
Other/Unknown	0	0	0	0	0	0	
Race/Ethnicity							
White	1,177	751	225	200	1	28,196	
Rate*	16.3	16.3	17.2	15.2		20.1	
95% C.I.	(15.3-17.2)	(15.2-17.6)	(15.0-19.7)	(13.2-17.6)		(19.8-20.3)	
Black	44	29	11	4	0	2,353	
Rate*	8.7	6.0	41.2			14.6	
95% C.I.	(6.2-12.4)	(3.9-9.4)	(19.7-79.7)			(14.0-15.2)	
Native American	5	2	2	1	0	150	
Rate*						8.7	
95% C.I.						(7.2-7.2)	
Asian	29	20	7	2	0	2,422	
Rate*	8.0	7.1				13.7	
95% C.I.	(4.7-14.3)	(3.5-15.2)				(13.2-14.3)	
Hispanic	55	32	13	10	0	2,989	
Rate*	8.1	6.1	13.9	14.7		15.6	
95% C.I.	(5.6-11.8)	(3.7-10.2)	(5.7-31.7)	(6.0-33.1)		(15.0-16.2)	
Other/Unknown	6	5	1	0	0	349	

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 151. Non-Hodgkin's Lymphoma Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)				
Total										
Cases	1,316	839	259	217	1	33,470				
Rate*	13.5	12.6	15.4	15.5		18.1				
95% C.I.	(12.8-14.2)	(11.7-13.4)	(13.6-17.3)	(13.5-17.6)		(17.9-18.3)				
Age Group										
<1	0	0	0	0	0					
Rate*										
95% C.I.										
1-4	5	2	2	1	0	67				
Rate*						0.6				
95% C.I.						(0.5-0.7)				
5-14	12	4	6	2	0	293				
Rate*	0.9					1.1				
95% C.I.	(0.4-1.4)					(1.0-1.2)				
15-24	17	13	3	1	0	510				
Rate*	1.3	1.4				2.0				
95% C.I.	(0.7-1.9)	(0.6-2.2)				(1.8-2.1)				
25-34	63	42	11	10	0	1,392				
Rate*	4.3	4.0	4.3	6.4		4.8				
95% C.I.	(3.2-5.3)	(2.8-5.1)	(1.8-6.9)	(2.4-10.3)		(4.5-5.0)				
35-44	90	53	25	12	0	3,000				
Rate*	5.8	5.1	8.8	5.3		9.6				
95% C.I.	(4.6-7.0)	(3.7-6.4)	(5.4-12.3)	(2.3-8.3)		(9.3-9.9)				
45-54	199	130	35	34	0	4,604				
Rate*	15.5	15.4	14.8	16.9		20.1				
95% C.I.	(13.3-17.7)	(12.7-18.0)	(9.9-19.7)	(11.2-22.6)		(19.5-20.7)				
55-64	243	149	52	42	0	5,600				
Rate*	26.5	24.0	34.6	29.1		40.0				
95% C.I.	(23.2-29.9)	(20.1-27.8)	(25.2-44.1)	(20.3-37.9)		(38.9-41.0)				
65-74	342	215	63	64	0	7,803				
Rate*	53.3	49.7	61.5	59.7		67.6				
95% C.I.	(47.6-58.9)	(43.1-56.4)	(46.3-76.6)	(45.1-74.3)		(66.1-69.1)				
75-84	282	190	48	43	1	7,607				
Rate*	80.3	81.4	83.0	71.8		104.7				
95% C.I.	(70.9-89.6)	(69.8-92.9)	(59.5-106.5)	(50.3-93.2)		(102.3-107.0)				
85+	61	41	13	7	0	2,590				
Rate*	80.0	87.8	83.8			104.4				
95% C.I.	(59.9-100.1)	(60.9-114.7)	(38.3-129.4)			(100.4-108.5)				
Unknown	2	Ó	1	1	0	, ,				

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 152. Non-Hodgkin's Lymphoma Cases by County of Residence at Diagnosis, Nevada Residents, 1997-2001

County of	1997-2001 Incidence					
Residence	Cases	Ra	te*	Age-Adjus	ted Rate**	
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.	
Carson City	70	28.1	(21.5-34.7)	25.3	(19.7-32.1)	
Churchill	24	19.9	(11.9-27.9)	20.1	(12.9-30.5)	
Clark	839	12.6	(11.7-13.4)	14.1	(13.1-15.1)	
Douglas	48	23.4	(16.8-30.0)	19.9	(14.5-27.2)	
Elko	9					
Esmeralda	0					
Eureka	0					
Humboldt	6					
Lander	1					
Lincoln	0					
Lyon	22	12.9	(7.5-18.3)	11.4	(7.1-17.9)	
Mineral	4					
Nye	27	17.2	(10.7-23.7)	13.4	(8.5-21.0)	
Pershing	3					
Storey	1					
Washoe	259	15.4	(13.6-17.3)	16.9	(14.8-19.1)	
White Pine	2					
Unknown	1					
Total	1,316	13.5	(12.8-14.2)	14.7	(13.9-15.5)	

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 153. Non-Hodgkin's Lymphoma Cases by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

			Gei	nder	
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total
White	Incidence Rate*	647 18.8	530 14.2	0	1,177 16.3
	95% C.I.	(17.3-20.4)	(13.0-15.5)		(15.3-17.2)
Black	Incidence	29	15	0	44
	Rate* 95% C.I.	11.6 (7.5-19.9)	6.0 (3.3-10.7)	, 	8.7 (6.2-12.4)
Native American	Incidence Rate* 95% C.I.	3	2	0	5
Asian	Incidence Rate* 95% C.I.	18 10.1 (5.7-22.0)	11 6.3 (2.2-17.0)	0	29 8.0 (4.7-14.3)
Hispanic	Incidence Rate* 95% C.I.	36 12.5 (7.2-21.6)	19 5.2 (2.8-9.4)	0	55 8.1 (5.6-11.8)
Other/Unkr	nown	4	2	0	6
Total	Incidence Rate*	737	579 12.4	0	1,316 14.7
	95% C.I.	(16.1-18.8)	(11.4-13.5)		(13.9-15.5)

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population and are agaadjusted to the 2001 US Standard population.

Table 154. Non-Hodgkin's Lymphoma Cases by Age Group and Gender, Nevada Residents, 1997-2001

Age		Gender Gender							
Group	Male	Female	Other/ Unknown	Total					
<1	0	0	0	0					
Rate*									
95% C.I.									
1-4	2	3	0	5					
Rate*									
95% C.I.									
5-14	8	4	0	12					
Rate*				0.9					
95% C.I.				(0.4-1.4)					
15-24 Rate*	8	9	0	17					
95% C.I.				1.3 (0.7-1.9)					
25-34	38	25	0	-					
Rate*	4.9	3.5		63 4.3					
95% C.I.	(3.4-6.5)	(2.1-4.9)		(3.2-5.3)					
35-44	57	33	0	90					
Rate*	7.1	4.4		5.8					
95% C.I.	(5.2-8.9)	(2.9-5.9)		(4.6-7.0)					
45-54	120	79	0	199					
Rate*	18.5	12.5		15.5					
95% C.I.	(15.2-21.8)	(9.7-15.2)		(13.3-17.7)					
55-64	144	99	0	243					
Rate*	31.6	21.5		26.5					
95% C.I.	(26.5-36.8)	(17.2-25.7)		(23.2-29.9)					
65-74	187	155	0	342					
Rate*	59.0	47.7		53.3					
95% C.I.	(50.5-67.5)	(40.1-55.2)		(47.6-58.9)					
75-84	137	145	0	282					
Rate*	86.4	75.2		80.3					
95% C.I.	(71.9-100.9)	(63.0-87.5)		(70.9-89.6)					
85+	34	27	0	61					
Rate*	137.4	52.4		80.0					
95% C.I.	(91.2-183.6)	(32.7-72.2)		(59.9-100.1)					
Unknown	2	<u> </u>	0	1 216					
Total Rate*	737 14.9	579 12.1	0	1,316 13.5					
95% C.I.	(13.8-16.0)	(11.1-13.1)		(12.8-14.2)					
	(10.0 10.0)	(		(12.0 11.2)					

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 155. Non-Hodgkin's Lymphoma Cases by Age Group and Stage, Nevada Residents, 1997-2001

<b>A</b>		Stage						
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total	
<1	Number	0	0	0	0	0	0	
	Percent							
1-4	Number	0	1	0	2	2	5	
	Percent		20.0%		40.0%	40.0%	100.0%	
5-14	Number	0	1	0	5	6	12	
	Percent		8.3%		41.7%	50.0%	100.0%	
15-24	Number	0	6	0	6	5	17	
	Percent		35.3%		35.3%	29.4%	100.0%	
25-34	Number	0	17	8	19	19	63	
	Percent		27.0%	12.7%	30.2%	30.2%	100.0%	
35-44	Number	0	28	5	32	25	90	
-	Percent		31.1%	5.6%	35.6%	27.8%	100.0%	
45-54	Number	0	58	15	70	56	199	
	Percent		29.1%	7.5%	35.2%	28.1%	100.0%	
55-64	Number	0	70	25	84	64	243	
	Percent		28.8%	10.3%	34.6%	26.3%	100.0%	
65-74	Number	0	101	26	105	110	342	
	Percent		29.5%	7.6%	30.7%	32.2%	100.0%	
75-84	Number	0	64	28	82	108	282	
	Percent		22.7%	9.9%	29.1%	38.3%	100.0%	
85+	Number	0	13	4	20	24	61	
	Percent		21.3%	6.6%	32.8%	39.3%	100.0%	
Unknown	Number	0	0	1	1	0	2	
	Percent			50.0%	50.0%		100.0%	
Total	Number	0	359	112	426	419	1,316	
	Percent		27.3%	8.5%	32.4%	31.8%	100.0%	

Table 156. Non-Hodgkin's Lymphoma Cases by Stage and Race/Ethnicity, Nevada Residents, 1997-2001

				ty				
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total
In situ	Number	0	0	0	0	0	0	0
	Percent							
Localized	Number	317	12	2	8	16	4	359
	Percent	26.9%	27.3%	40.0%	27.6%	29.1%	66.7%	27.3%
Regional	Number	101	1	0	4	5	1	112
	Percent	8.6%	2.3%		13.8%	9.1%	16.7%	8.5%
Distant	Number	378	21	2	10	14	1	426
	Percent	32.1%	47.7%	40.0%	34.5%	25.5%	16.7%	32.4%
Unstaged	Number	381	10	1	7	20	0	419
	Percent	32.4%	22.7%	20.0%	24.1%	36.4%		31.8%
Total	Number	1,177	44	5	29	55	6	1,316
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%


Table 157. Median Age at Diagnosis of Non-Hodgkin's Lymphoma by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

		Gender									
Race/Ethnicity	Ma	ale	Fen	nale	Total						
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age					
White	645	65.0	530	67.0	1,175	66.0					
Black	29	51.0	15	59.0	44	54.0					
Native American	3		2		5	41.0					
Asian	18	60.5	11	64.0	29	63.0					
Hispanic	36	59.0	19	59.0	55	59.0					
Other/Unknown	4		2		6	75.0					
Total	735	64.0	579	66.0	1,314	65.0					

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

## **INPATIENT HOSPITAL DISCHARGES**

Figure 105. Non-Hodgkin's Lymphoma Age-Adjusted (2001) Inpatient Discharge Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 106. Non-Hodgkin's Lymphoma Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 107. Median Charges for Non-Hodgkin's Lymphoma Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Figure 108. Average Length of Stay for Non-Hodgkin's Lymphoma Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Table 158. Non-Hodgkin's Lymphoma Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

		Coun	ty/Region of Reside	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	988	673	182	133	0
Rate*	11.0	11.2	12.1	9.2	
95% C.I.	(10.3-11.7)	(10.3-12.1)	(10.3-14.0)	(7.7-11.0)	
Gender					
Male	550	382	93	75	0
Rate*	12.8	13.5	13.1	10.1	
95% C.I.	(11.7-14.1)	(12.0-15.1)	(10.5-16.5)	(7.9-13.0)	
Female	438	291	89	58	0
Rate*	9.4	9.3	11.2	8.0	
95% C.I.	(8.6-10.4)	(8.3-10.5)	(9.0-13.8)	(6.1-10.5)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Cl	narges (\$)				
Total Charges	\$38,747,537	\$27,682,072	\$6,420,369	\$4,645,096	
Average Charges	\$39,218	\$41,132	\$35,277	\$34,926	
Median Charges	\$23,526	\$26,354	\$21,057	\$16,626	
Discharge Length of S	tay (LOS) (Days)				
Total LOS	8,990	6,259	1,533	1,198	
Average LOS	9.1	9.3	8.4	9.0	
Median LOS	6.0	7.0	6.0	6.0	

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 159. Non-Hodgkin's Lymphoma Discharges by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		Count	y/Region of Residen	ce	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	988	673	182	133	C
Rate*	10.1	10.1	10.8	9.5	
95% C.I.	(9.5-10.8)	(9.3-10.9)	(9.3-12.4)	(7.9-11.1)	
Age Group					
<1	1	1	0	0	C
Rate*					
95% C.I.					
1-4	4	2	0	2	0
Rate*					
95% C.I.					
5-14	13	10	2	1	C
Rate*	0.9	1.1			
95% C.I.	(0.4-1.5)	(0.4-1.7)			
15-24	21	17	2	2	C
Rate*	1.6	1.8			
95% C.I.	(0.9-2.2)	(1.0-2.7)			
25-34	54	39	10	5	0
Rate*	3.7	3.7	3.9		
95% C.I.	(2.7-4.6)	(2.5-4.8)	(1.5-6.4)		
35-44	49	40	7	2	0
Rate*	3.1	3.8			
95% C.I.	(2.3-4.0)	(2.6-5.0)			
45-54	135	98	22	15	0
Rate*	10.5	11.6	9.3	6.3	
95% C.I.	(8.7-12.3)	(9.3-13.9)	(5.4-13.2)	(3.1-9.6)	
55-64	188	118	44	26	C
Rate*	20.5	19.0	29.3	17.3	
95% C.I.	(17.6-23.5)	(15.6-22.4)	(20.6-38.0)	(10.7-24.0)	
65-74	263	169	44	50	C
Rate*	41.0	39.1	42.9	48.8	
95% C.I.	(36.0-45.9)	(33.2-45.0)	(30.2-55.6)	(35.3-62.3)	
75-84	211	152	39	20	C
Rate*	60.1	65.1	67.4	34.6	
95% C.I.	(52.0-68.2)	(54.7-75.4)	(46.3-88.6)	(19.4-49.7)	
85+	49	27	12	10	C
Rate*	64.3	57.8	77.4	64.5	
95% C.I.	(46.3-82.3)	(36.0-79.6)	(33.6-121.2)	(24.5-104.4)	
Unknown		0	0	0	0

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 160. Non-Hodgkin's Lymphoma Discharges by Age Group and Gender, Nevada Residents, 1997-2001

Age		Gender	
Group	Male	Female	Total
<1	0		1
Rate*			
95% C.I.			
1-4	3	1	4
Rate*			
95% C.I.			
5-14	4	9	13
Rate*			0.9
95% C.I.			(0.4-1.5)
15-24	12	9	21
Rate*	1.7		1.6
95% C.I.	(0.7-2.7)		(0.9-2.2)
25-34	36	18	54
Rate*	4.7	2.5	3.7
95% C.I.	(3.2-6.2)	(1.4-3.7)	(2.7-4.6)
35-44 Rate*	37 4.6	12	49 3.1
95% C.I.	(3.1-6.1)	1.6 (0.7-2.5)	(2.3-4.0)
45-54 Rate*	76 11.7	59 9.3	135 10.5
95% C.I.	(9.1-14.3)	(6.9-11.7)	(8.7-12.3)
55-64	109	79	188
Rate*	24.0	17.1	20.5
95% C.I.	(19.5-28.5)	(13.4-20.9)	(17.6-23.5)
65-74	152	111	263
Rate*	48.0	34.1	41.0
95% C.I.	(40.3-55.6)	(27.8-40.5)	(36.0-45.9)
75-84	97	114	211
Rate*	61.2	59.1	60.1
95% C.I.	(49.0-73.4)	(48.3-70.0)	(52.0-68.2)
85+	24	25	49
Rate*	97.0	48.6	64.3
95% C.I.	(58.2-135.8)	(29.5-67.6)	(46.3-82.3)
Unknown	0	0	0
Total	550	438	988
Rate*	11.1	9.1	10.1
95% C.I.	(10.2-12.0)	(8.3-10.0)	(9.5-10.8)

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 161. Non-Hodgkin's Lymphoma Discharges by County/Region of Residence, Nevada Residents, 1997-2001

		1997-2001 Inpatient Hospital Discharges						
County of Residence	Number	Rat	e*	Age-Adjust	ed Rate**			
	Number	Rate	95% C.I.	Rate	95% C.I.			
Carson City	30	12.0	(7.7-16.4)	10.5	(7.0-15.2)			
Churchill	22	18.2	(10.6-25.9)	18.7	(11.7-29.0)			
Clark	673	10.1	(9.3-10.9)	11.2	(10.3-12.1)			
Douglas	21	10.2	(5.9-14.6)	9.1	(5.5-14.9)			
Elko	1							
Esmeralda	0							
Eureka	0							
Humboldt	6							
Lander	0							
Lincoln	1							
Lyon	24	14.1	(8.5-19.8)	13.2	(8.3-20.3)			
Mineral	3							
Nye	22	14.0	(8.1-19.8)	11.1	(6.7-18.3)			
Pershing	2							
Storey	0							
Washoe	182	10.8	(9.3-12.4)	12.1	(10.3-14.0)			
White Pine	1							
Unknown	0							
Total	988	10.1	(9.5-10.8)	11.0	(10.3-11.7)			


Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 162. Non-Hodgkin's Lymphoma Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1997-2001

Age	- · ·		Charges (\$)		Length of Stay (Days)		
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	1						
1-4	4						
5-14	13	535,164	41,166	37,868	105	8.1	8.0
15-24	21	2,216,272	105,537	62,882	357	17.0	12.0
25-34	54	2,423,345	44,877	33,358	639	11.8	7.0
35-44	49	2,562,859	52,303	24,214	523	10.7	6.0
45-54	135	4,957,572	36,723	24,622	1,118	8.3	6.0
55-64	188	7,088,232	37,703	24,707	1,637	8.7	6.0
65-74	263	10,143,639	38,569	22,365	2,396	9.1	6.0
75-84	211	6,998,059	33,166	21,401	1,746	8.3	7.0
85+	49	1,485,744	30,321	23,552	408	8.3	6.0
Unknown	0						
Total	988	501,834	966	36,539	81	966.0	9.1

## **MORTALITY**

Figure 109. Non-Hodgkin's Lymphoma Age-Adjusted (2001) Mortality Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 110. Non-Hodgkin's Lymphoma Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 111. Non-Hodgkin's Lymphoma Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 163. Non-Hodgkin's Lymphoma Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region	of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	599	398	108	93
Rate*	7.1	7.1	7.5	6.6
95% C.I.	(6.5-7.7)	(6.4-7.9)	(6.1-9.1)	(5.3-8.2)
Gender				
Male	356	233	60	63
Rate*	9.4	9.5	9.4	9.4
95% C.I.	(8.4-10.6)	(8.2-11.0)	(7.0-12.5)	(7.1-12.4)
Female	243	165	48	30
Rate*	5.3	5.5	6.1	4.1
95% C.I.	(4.7-6.1)	(4.6-6.4)	(4.5-8.2)	(2.7-5.9)
Other/Unknown	0	0	0	0
Race/Ethnicity				
White	535	350	99	86
Rate*	7.6	7.8	7.7	6.7
95% C.I.	(6.9-8.3)	(7.0-8.7)	(6.3-9.5)	(5.3-8.3)
Black	17	16	1	0
Rate*	4.0	4.1		
95% C.I.	(2.3-7.1)	(2.3-7.4)		
Native American	3	0	1	2
Rate*				
95% C.I.				
Asian	20	17	2	1
Rate*	5.8	6.0		
95% C.I.	(3.4-11.3)	(3.3-13.0)		
Hispanic	24	15	5	4
Rate*	4.7	4.0		
95% C.I.	(2.8-7.8)	(2.0-7.8)		
Other/Unknown	0	0	0	0

<sup>\*</sup>Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 164. Non-Hodgkin's Lymphoma Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

	County/Region of Residence				
Category	Nevada Total	Clark	Washoe	All Other Counties	
Total					
Mortality	599	398	108	93	
Rate*	6.2	6.0	6.4	6.7	
95% C.I.	(5.7-6.6)	(5.4-6.6)	(5.2-7.6)	(5.3-8.0)	
Age Group					
<1	0	0	0	0	
Rate*					
95% C.I.					
1-4	0	0	0	0	
Rate*					
95% C.I.					
5-14	1	1	0	0	
Rate*					
95% C.I.					
15-24	4	4	0	0	
Rate*					
95% C.I.					
25-34	10	7	2	1	
Rate*	0.7				
95% C.I.	(0.3-1.1)				
35-44	20	12	5	3	
Rate*	1.3	1.1			
95% C.I.	(0.7-1.8)	(0.5-1.8)			
45-54	54	37	8	9	
Rate*	4.2	4.4			
95% C.I.	(3.1-5.3)	(3.0-5.8)			
55-64	97	60	18	19	
Rate*	10.6	9.7	12.0	13.1	
95% C.I.	(8.5-12.7)	(7.2-12.1)	(6.5-17.5)	(7.2-19.1)	
65-74	174	109	37	28	
Rate*	27.1	25.2	36.1	26.1	
95% C.I.	(23.1-31.1)	(20.5-29.9)	(24.5-47.7)	(16.4-35.8)	
75-84	187	136	28	23	
Rate*	53.2	58.2	48.4	38.4	
95% C.I.	(45.6-60.9)	(48.4-68.0)	(30.5-66.4)	(22.7-54.1)	
85+	52	32	10	10	
Rate*	68.2	68.5	64.5	71.3	
95% C.I.	(49.7-86.7)	(44.8-92.3)	(24.5-104.4)	(27.1-115.4)	
* Rates are per 100 000 as	0	0	0	0	

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 165. Non-Hodgkin's Lymphoma Mortality by County of Residence, Nevada Residents, 1997-2001

	1997-2001 Mortality				
County of Residence	Rate*		Age-Adjusted Rate**		
	Cases	Rate	95% C.I.	Rate	95% C.I.
Carson City	26	10.4	(6.4-14.4)	9.4	(6.1-14.0)
Churchill	9				
Clark	398	6.0	(5.4-6.6)	7.1	(6.4-7.9)
Douglas	14	6.8	(3.3-10.4)	6.7	(3.5-12.2)
Elko	9				
Esmeralda	0				
Eureka	0				
Humboldt	3				
Lander	0				
Lincoln	1				
Lyon	12	7.1	(3.1-11.0)	6.0	(3.1-11.1)
Mineral	3				
Nye	13	8.3	(3.8-12.8)	6.3	(3.1-12.2)
Pershing	1				
Storey	0				
Washoe	108	6.4	(5.2-7.6)	7.5	(6.1-9.1)
White Pine	2				
Unknown	0				
Total	599	6.2	(5.7-6.6)	7.1	(6.5-7.7)

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 166. Non-Hodgkin's Lymphoma Mortality by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

Race/Ethnicity			Gender			
		Male	Female	Total		
White	Mortality Rate*	319 10.1	216 5.7	535 7.6		
	95% C.I.	(8.9-11.4)	(5.0-6.5)	(6.9-8.3)		
Black	Mortality Rate* 95% C.I.	10 5.5 (2.5-13.3)	7 	17 4.0 (2.3-7.1)		
Native American	Mortality Rate* 95% C.I.	1	2 	3		
Asian	Mortality Rate* 95% C.I.	12 7.6 (3.7-19.5)	8 	20 5.8 (3.4-11.3)		
Hispanic	Mortality Rate* 95% C.I.	14 4.5 (2.2-10.8)	10 4.5 (2.0-9.0)	24 4.7 (2.8-7.8)		
Other/Unkr	nown	0	0	0		
Total	Mortality Rate*	356 9.4 (8.4.10.6)	243 5.3 (4.7.6.1)	599 7.1 (6.5.7.7)		
	95% C.I.	(8.4-10.6)	(4.7-6.1)	(6.5-7.7)		

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 167. Non-Hodgkin's Lymphoma Mortality by Age Group and Gender, Nevada Residents, 1997-2001

Age	Gender			
Group	Male	Female	Total	
<1				
Rate*				
95% C.I.				
1-4	0	0	0	
Rate*				
95% C.I.				
5-14	1	0	1	
Rate*				
95% C.I.				
15-24	3	1	4	
Rate*				
95% C.I.				
25-34	8	2	10	
Rate*			0.7	
95% C.I.			(0.3-1.1)	
35-44 Pata*	13	7	20	
Rate* 95% C.I.	1.6 (0.7-2.5)	<b></b>	1.3 (0.7-1.8)	
45-54	36	18	54	
Rate*	5.5	2.8	4.2	
95% C.I.	(3.7-7.3)	(1.5-4.2)	(3.1-5.3)	
55-64	58	39	97	
Rate*	12.7	8.5	10.6	
95% C.I.	(9.5-16.0)	(5.8-11.1)	(8.5-12.7)	
65-74	100	74	174	
Rate*	31.6	22.7	27.1	
95% C.I.	(25.4-37.7)	(17.6-27.9)	(23.1-31.1)	
75-84	105	82	187	
Rate*	66.2	42.5	53.2	
95% C.I.	(53.6-78.9)	(33.3-51.7)	(45.6-60.9)	
85+	32	20	52	
Rate*	129.3	38.8	68.2	
95% C.I.	(84.5-174.1)	(21.8-55.9)	(49.7-86.7)	
Unknown	0	0	0	
Total	356	243	599	
Rate*	7.2	5.1	6.2	
95% C.I.	(6.4-7.9)	(4.4-5.7)	(5.7-6.6)	

<sup>\*</sup> Rates are per 100,000 age-specific population.


Table 168. Median Age at Death from Non-Hodgkin's Lymphoma by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

			Gen	der			
Race/Ethnicity	Ma	ale	Female		Total		
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age	
White	319	71.0	216	73.0	535	72.0	
Black	10	70.0	7	64.0	17	66.0	
Native American	1		2		3		
Asian	12	66.5	8	73.0	20	72.0	
Hispanic	14	63.0	10	76.5	24	69.0	
Other/Unknown	0		0		0		
Total	356	70.0	243	73.0	599	72.0	

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

# **SURVIVAL RATE**

Figure 112. Survival Rates for Non-Hodgkin's Lymphoma by Race/Ethnicity, Nevada Residents, 1997-2001



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 113. Survival Rates for Non-Hodgkin's Lymphoma by Stage of Cancer at Diagnosis, Nevada Residents, 1997-2001




Table 169. Cause-Specific Survival Rates for Non-Hodgkin's Lymphoma by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

Race/	Number		Cause Specific Survival Rate						
Ethnicity and Gender	Ethnicity of Cases		Two Years	Three Years	Four Years	Five Years	Survival Time (years)		
Total	1,042	76.1%	65.7%	56.1%	52.3%	52.3%	>5 years		
Male	586	74.4%	61.7%	52.9%	51.3%	51.3%	>5 years		
Female	456	78.4%	71.2%	60.5%	53.4%	53.4%	>5 years		
Race/Ethnicity									
White	924	76.3%	66.5%	56.5%	52.0%	52.0%	>5 years		
Male	508	75.5%	63.0%	53.7%	51.8%	51.8%	>5 years		
Female	416	77.3%	71.2%	60.1%	51.9%	51.9%	>5 years		
Black	35								
Male	25								
Female	10								
Native American	4								
Male	3								
Female	1								
Asian	24								
Male	15								
Female	9								
Hispanic	49								
Male	31								
Female	18								

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 170. Cause-Specific Survival Rates for Non-Hodgkin's Lymphoma by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1997-2001


Surviv	/al Rate of Stage		Gender	
a	at Diagnosis	Total	Male	Female
Total	Cases	1,042	586	456
	One Year	76.1%	74.4%	78.4%
	5 Years	52.3%	51.3%	53.4%
	Median Survival	>5 years	>5 years	>5 years
Stage at D	iagnosis			
In situ	Cases	0	0	0
	One Year			
	5 Years			
	Median Survival			
Localized	Cases	303	160	143
	One Year	88.1%	89.7%	86.4%
	5 Years	60.4%	69.5%	51.9%
	Median Survival	>5 years	>5 years	>5 years
Regional	Cases	85	53	32
	One Year	72.3%	69.0%	
	5 Years	46.3%	52.5%	
	Median Survival	3.64	>5 years	
Distant	Cases	331	187	144
	One Year	72.6%	70.6%	75.2%
	5 Years	53.7%	49.4%	59.6%
	Median Survival	>5 years	2.93	>5 years
Unstaged	Cases	323	186	137
	One Year	69.9%	67.5%	73.4%
	5 Years	43.8%	37.8%	
	Median Survival	2.76	2.37	

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

# KIDNEY AND RENAL PELVIS CANCER

# KIDNEY AND RENAL PELVIS CANCER GENERAL PROFILE<sup>4</sup>

Figure 114. Anatomy of the Urinary System<sup>5</sup>



**General Anatomy:** The kidneys are two reddish-brown, bean-shaped organs located just above the waist, one on each side of the spine. They are part of the urinary system. Their main function is to filter blood and produce urine to rid the body of waste. As blood flows through the kidneys, they remove waste products and unneeded water. The resulting liquid, urine, collects in the middle of each kidney in an area called the renal pelvis. Urine drains from each kidney through a long tube, the ureter, into the bladder, where it is stored. Urine leaves the body through another tube, called the urethra. The kidneys also produce substances that help control blood pressure and regulate the formation of red blood cells.

**Risk Factors:** Tobacco use, obesity, occupational exposure, radiation, phenacetin (prolonged heavy use of this painkiller), dialysis, and Von Hippel-Lindau (VHL) disease.

**Signs and Symptoms:** Blood in the urine, a lump or mass in the kidney area, and other less common symptoms may include: fatigue, loss of appetite, weight loss, recurrent fevers, a pain in the side that doesn't go away, or a general feeling of poor health.

**Diagnosing the Cancer:** Health exams, intravenous pyelogram (IVP), arteriography, computed tomography (CAT) scan, magnetic resonance imaging (MRI), and ultrasonography.

**Treatment:** Surgery (Simple or Radical Nephrectomy), arterial embolization, radiation therapy, biological therapy, chemotherapy, and hormone therapy.

### **HIGHLIGHTS**

- ➤ The ratio of the age-adjusted incidence rate, 11.8, to the age-adjusted mortality rate, 3.7 (per 100,000 2000 US Standard population), for Kidney and Renal Pelvis Cancer was 3.19 during the 1997 to 2001 period, which means that for every 3.19 Kidney and Renal Pelvis Cancer cases diagnosed during this period, there was one death caused by this type of cancer in Nevada.
- Nevadan females had a higher ratio than males when the age-adjusted incidence and age-adjusted mortality rates for Kidney and Renal Pelvis Cancer were compared. For every female death due to this type of cancer there were 3.73 female cases diagnosed, while there were 2.85 male cases for every male Kidney and Renal Pelvis Cancer death in Nevada from 1997 to 2001.
- ➤ The median age at diagnosis of Kidney and Renal Pelvis Cancer for Nevada residents and females was 65 years of age from 1997 to 2001 while the median age for males was 64 years. The median age at time of death due to Kidney and Renal Pelvis Cancer was 71 years for Nevada overall, 68.5 years of age for males and 73 years of age for females.

#### **INCIDENCE**

- ➤ There were 1,090 cases of Kidney and Renal Pelvis Cancer in Nevada from 1997 to 2001. Nevada's incidence rate for Kidney and Renal Pelvis Cancer (11.8) was only slightly higher than the National rate of 11.3 (per 100,000 2000 US Standard population) from 1997 to 2001. Regional comparisons showed variation between Washoe County (13.1), All Other Counties (11.8) and Clark County (11.5) from 1997 to 2001. Through statistical analysis, none of these differences were found to be significantly different from the National rate of 11.3 (per 100,000 2000 US Standard population).
- ➤ The higher age-adjusted incidence rate for male Kidney and Renal Pelvis Cancer, 15.7 (14.6-17.0), was statistically significant over the female rate of 8.2 (7.4-9.0), per 100,000 2000 US Standard population, during the 1997 to 2001 period.
- ➤ Blacks had the highest age-adjusted incidence rate, 13.8, for Kidney and Renal Pelvis Cancer of all racial/ethnic groups and were followed by Whites, Hispanics and Asians with rates of 12.6, 7.9 and 4.8 (per 100,000 2000 US Standard population), respectively, during the 1997 to 2001 period.
- ➤ The median age at diagnosis for Other/Unknown (56 years) was the lowest of any racial/ethnic group and was significantly lower than the statewide median age of 64 years for the 1997 to 2001 period.

#### INPATIENT HOSPITAL DISCHARGES

➤ There were 905 hospital inpatient discharges with a primary diagnosis of Kidney and Renal Pelvis Cancer to Nevada Residents from 1997 to 2001. Regional comparisons

- showed little difference between the age-adjusted inpatient discharge rates between All Other Counties (10.0), Clark County (9.8) and Washoe County (9.2) (per 100,000 2000 US Standard population).
- ➤ Total billed charges for Kidney and Renal Pelvis Cancer inpatient hospital discharges in Nevada totaled nearly 26.8 million dollars from 1997 to 2001. The overall average billed charge per day for a hospital inpatient discharge due to this type of cancer was approximately \$4,703 in Nevada from 1997 to 2001.
- ➤ Washoe County had the highest median total billed amount (\$33,101), while the statewide median billed amount was \$29,630 from 1997 to 2001; with Clark County and All Other Counties with median billed amounts of \$31,002 and \$20,710.

#### **MORTALITY**


- ➤ There were 327 resident deaths due to Kidney and Renal Pelvis Cancer from 1997 to 2001. Males had a statistically significant age-adjusted mortality rate, 5.5 (4.7-6.3), more than double the female rate of 2.2 (1.8-2.7), per 100,000 2000 US Standard population, during this period.
- ▶ Blacks, as a racial/ethnic group, had the highest age-adjusted mortality rate for Kidney and Renal Pelvis Cancer of any racial/ethnic group, 30.0, and were followed by Whites, Asians, Native Americans, and Hispanics with rates of 23.7, 12.5, 12.0, and 11.3, (per 100,000 2001 US Standard population) respectively, from 1997 to 2001.
- ➤ Males had a median age at death from Kidney and Renal Pelvis Cancer five years earlier than females in Nevada from 1997 to 2001 with a median age at death of 68.5 and 73 years, respectively.

#### **SURVIVAL RATE**

- ➤ The one-year survival rate for Kidney and Renal Pelvis Cancer in Nevada was 71.9% during the 1997 to 2001 period, while the five-year survival rate was 52.9% during this same time. The median survival rate in Nevada was greater than five years for Kidney and Renal Pelvis Cancer.
- Females in Nevada had a slightly higher one-year survival rate (75.4%) than males (70.0%) for Kidney and Renal Pelvis Cancer during the 1997 to 2001 period. This trend continued for the five-year survival rate with females and males at 49.5% and 59.1%, respectively. Males had a median survival time of 3.91, and females had median survival times of over five years.
- ➤ The Kidney and Renal Pelvis Cancer Survival rate varies greatly by the stage of the cancer at time of diagnosis. Those diagnosed at the localized stage had the highest one-and five-year survival rates with 83.8% and 65.1%, respectively. This was followed by those with regional, and then distant diagnoses with rates of 78.4% and 61.0% for the one-year period.

# **INCIDENCE**

Figure 115. Kidney and Renal Pelvis Cancer Age-Adjusted (2001) Incidence Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 116. Kidney and Renal Pelvis Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 117. Kidney and Renal Pelvis Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 171. Kidney and Renal Pelvis Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

			County/Region	n of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)
Total						
Cases	1,090	711	204	174	1	19,693
Rate*	11.8	11.5	13.1	11.8		11.3
95% C.I.	(11.1-12.5)	(10.6-12.4)	(11.3-15.0)	(10.1-13.7)		(11.2-11.5)
Gender						
Male	706	459	128	118	1	12,165
Rate*	15.7	15.3	16.9	16.3		15.7
95% C.I.	(14.6-17.0)	(13.8-16.9)	(14.0-20.5)	(13.4-19.8)		(15.4-16.0)
Female	384	252	76	56	0	7,528
Rate*	8.2	8.0	9.5	7.5		7.8
95% C.I.	(7.4-9.0)	(7.0-9.1)	(7.5-12.0)	(5.7-9.9)		(7.7-8.0)
Other/Unknown	0	0	0	0	0	0
Race/Ethnicity						
White	943	597	186	159	1	16,311
Rate*	12.6	12.4	13.8	11.9		11.7
95% C.I.	(11.8-13.4)	(11.4-13.5)	(11.9-16.0)	(10.1-14.0)		(11.5-11.9)
Black	63	55	6	2	0	2,019
Rate*	13.8	13.2				13.3
95% C.I.	(10.3-18.4)	(9.6-18.1)				(12.7-13.9)
Native American	8	2	2	4	0	165
Rate*						10.0
95% C.I.						(8.5-8.5)
Asian	19	17	1	1	0	1,132
Rate*	4.8	5.1				6.4
95% C.I.	(2.8-10.1)	(2.9-11.9)				(6.0-6.8)
Hispanic	50	33	9	8	0	2,019
Rate*	7.9	7.3				11.0
95% C.I.	(5.6-11.2)	(4.8-11.5)				(10.5-11.5)
Other/Unknown	7	7	0	0	0	66

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 172. Kidney and Renal Pelvis Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

			County/Region	on of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)
Total						
Cases	1,090	711	204	174	1	19,693
Rate*	11.2	10.7	12.2	12.5		10.6
95% C.I.	(10.5-11.9)	(9.9-11.5)	(10.5-13.8)	(10.6-14.3)		(10.5-10.8)
Age Group						
<1	0	0	0	0	0	49
Rate*						1.8
95% C.I.						(1.3-2.3)
1-4	11	9	2	0	0	215
Rate*	1.9					1.9
95% C.I.	(0.8-3.1)					(1.7-2.2)
5-14	4	3	1	0	0	106
Rate*						0.4
95% C.I.						(0.3-0.5)
15-24	2	1	0	0	1	58
Rate*						0.2
95% C.I.						(0.2-0.3)
25-34	10	8	0	2	0	236
Rate*	0.7					0.8
95% C.I.	(0.3-1.1)					(0.7-0.9)
35-44	71	36	19	16	0	1,258
Rate*	4.6	3.4	6.7	7.1		4.0
95% C.I.	(3.5-5.6)	(2.3-4.6)	(3.7-9.7)	(3.6-10.5)		(3.8-4.2)
45-54	174	110	38	26	0	3,062
Rate*	13.6	13.0	16.1	12.9		13.4
95% C.I.	(11.5-15.6)	(10.6-15.4)	(11.0-21.2)	(8.0-17.9)		(12.9-13.9)
55-64	290	199	44	47	0	4,395
Rate*	31.7	32.0	29.3	32.5		31.4
95% C.I.	(28.0-35.3)	(27.6-36.5)	(20.6-38.0)	(23.2-41.8)		(30.5-32.3)
65-74	302	204	56	42	0	5,229
Rate*	47.0	47.2	54.6	39.2		45.3
95% C.I.	(41.7-52.3)	(40.7-53.6)	(40.3-68.9)	(27.3-51.0)		(44.1-46.6)
75-84	196	121	40	35	0	3,979
Rate*	55.8	51.8	69.2	58.4		54.7
95% C.I.	(48.0-63.6)	(42.6-61.0)	(47.7-90.6)	(39.1-77.8)		(53.0-56.4)
85+	29	20	3	6	0	1,106
Rate*	38.0	42.8				44.6
95% C.I.	(24.2-51.9)	(24.1-61.6)				(42.0-47.2)
Unknown	1	0	1	0	0	0

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 173. Kidney and Renal Pelvis Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1997-2001

County of			1997-2001 Incide	-2001 Incidence					
Residence	Cases	Ra	te*	Age-Adjus	Age-Adjusted Rate**				
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.				
Carson City	42	16.9	(11.8-22.0)	14.7	(10.6-20.1)				
Churchill	19	15.8	(8.7-22.8)	16.1	(9.7-25.9)				
Clark	711	10.7	(9.9-11.5)	11.5	(10.6-12.4)				
Douglas	25	12.2	(7.4-17.0)	9.8	(6.3-15.2)				
Elko	18	7.8	(4.2-11.4)	13.1	(7.3-22.6)				
Esmeralda	1								
Eureka	2								
Humboldt	4								
Lander	2								
Lincoln	2								
Lyon	30	17.6	(11.3-24.0)	15.9	(10.6-23.2)				
Mineral	2								
Nye	22	14.0	(8.1-19.8)	10.5	(6.4-17.2)				
Pershing	2								
Storey	2								
Washoe	204	12.2	(10.5-13.8)	13.1	(11.3-15.0)				
White Pine	1								
Unknown	1								
Total	1,090	11.2	(10.5-11.9)	11.8	(11.1-12.5)				

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 174. Kidney and Renal Pelvis Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

			Gei	nder	
Race/Ethnicity		Male	Female	Other/ Unknown	Total
White	Incidence	614	329	0	943
	Rate* 95% C.I.	16.7 (15.4-18.2)	8.7 (7.8-9.7)		12.6 (11.8-13.4)
Black	Incidence	39	24	0	63
	Rate*	18.0	10.1		13.8
	95% C.I.	(12.1-28.1)	(6.3-15.8)		(10.3-18.4)
Native	Incidence	4	4	0	8
American	Rate*				
	95% C.I.				
Asian	Incidence	12	7	0	19
	Rate*	7.0			4.8
	95% C.I.	(3.5-18.6)			(2.8-10.1)
Hispanic	Incidence	32	18	0	50
	Rate*	9.3	6.2		7.9
	95% C.I.	(6.1-15.9)	(3.5-10.9)		(5.6-11.2)
Other/Unkr	nown	5	2	0	7
Total	Incidence	706	384	0	1,090
	Rate*	15.7	8.2		11.8
	95% C.I.	(14.6-17.0)	(7.4-9.0)		(11.1-12.5)

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 175. Kidney and Renal Pelvis Cancer Cases by Age Group and Gender, Nevada Residents, 1997-2001

Age		Gen	der	
Group	Male	Female	Other/ Unknown	Total
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	6	5	0	11
Rate*				1.9
95% C.I.				(0.8-3.1)
5-14	2	2	0	4
Rate*				
95% C.I.	2			
15-24 Rate*	2	0	0	2
95% C.I.	<del></del>			
				10
25-34 Rate*	6	4	0	0.7
95% C.I.				(0.3-1.1)
35-44	44	27	0	71
Rate*	5.5	3.6		4.6
95% C.I.	(3.8-7.1)	(2.2-5.0)		(3.5-5.6)
45-54	116	58	0	174
Rate*	17.8	9.2		13.6
95% C.I.	(14.6-21.1)	(6.8-11.5)		(11.5-15.6)
55-64	200	90	0	290
Rate*	44.0	19.5		31.7
95% C.I.	(37.9-50.1)	(15.5-23.5)		(28.0-35.3)
65-74	202	100	0	302
Rate*	63.7	30.7		47.0
95% C.I.	(54.9-72.5)	(24.7-36.8)		(41.7-52.3)
75-84	114	82	0	196
Rate*	71.9	42.5		55.8
95% C.I.	(58.7-85.1)	(33.3-51.7)		(48.0-63.6)
85+	14	15	0	29
Rate*	56.6	29.1		38.0
95% C.I.	(26.9-86.2)	(14.4-43.9)		(24.2-51.9)
Unknown	0	1	0	1 222
Total	706	384	0	1,090
Rate* 95% C.I.	14.3 (13.2-15.3)	8.0 (7.2-8.8)		11.2 (10.5-11.9)
30 /0 U.I.	(13.2-13.3)	(1.2-0.0)		(10.5-11.9)

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 176. Kidney and Renal Pelvis Cancer Cases by Age Group and Stage, Nevada Residents, 1997-2001

•		Stage							
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total		
<1	Number	0	0	0	0	0	0		
	Percent								
1-4	Number	0	6	1	2	2	11		
	Percent		54.5%	9.1%	18.2%	18.2%	100.0%		
5-14	Number	0	2	1	1	0	4		
	Percent		50.0%	25.0%	25.0%		100.0%		
15-24	Number	0	0	1	0	1	2		
	Percent			50.0%		50.0%	100.0%		
25-34	Number	0	8	0	1	1	10		
	Percent		80.0%		10.0%	10.0%	100.0%		
35-44	Number	0	48	8	6	9	71		
	Percent		67.6%	11.3%	8.5%	12.7%	100.0%		
45-54	Number	0	106	23	24	21	174		
	Percent		60.9%	13.2%	13.8%	12.1%	100.0%		
55-64	Number	0	156	43	49	42	290		
	Percent		53.8%	14.8%	16.9%	14.5%	100.0%		
65-74	Number	0	162	34	59	47	302		
	Percent		53.6%	11.3%	19.5%	15.6%	100.0%		
75-84	Number	0	89	19	37	51	196		
	Percent		45.4%	9.7%	18.9%	26.0%	100.0%		
85+	Number	0	6	6	5	12	29		
	Percent		20.7%	20.7%	17.2%	41.4%	100.0%		
Unknown	Number	0	0	1	0	0	1		
	Percent			100.0%			100.0%		
Total	Number Percent	0	583 53.5%	137 12.6%	184 16.9%	186 17.1%	1,090 100.0%		

Table 177. Kidney and Renal Pelvis Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1997-2001

			Race/Ethnicity						
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total	
In situ	Number	0	0	0	0	0	0	0	
	Percent								
Localized	Number	501	40	3	9	27	3	583	
	Percent	53.1%	63.5%	37.5%	47.4%	54.0%	42.9%	53.5%	
Regional	Number	123	4	1	3	4	2	137	
	Percent	13.0%	6.3%	12.5%	15.8%	8.0%	28.6%	12.6%	
Distant	Number	164	8	2	4	6	0	184	
-	Percent	17.4%	12.7%	25.0%	21.1%	12.0%		16.9%	
Unstaged	Number	155	11	2	3	13	2	186	
	Percent	16.4%	17.5%	25.0%	15.8%	26.0%	28.6%	17.1%	
Total	Number	943	63	8	19	50	7	1,090	
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	


Table 178. Median Age at Diagnosis of Kidney and Renal Pelvis Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

	Gender							
Race/Ethnicity	Ma	ile	Fen	nale	Total			
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age		
White	614	64.0	328	65.0	942	64.0		
Black	39	61.0	24	61.5	63	61.0		
Native American	4		4		8	70.5		
Asian	12	67.0	7	62.0	19	64.0		
Hispanic	32	63.5	18	68.0	50	65.0		
Other/Unknown	5	54.0	2		7	56.0		
Total	706	64.0	383	65.0	1,089	64.0		

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

# **INPATIENT HOSPITAL DISCHARGES**

Figure 118. Kidney and Renal Pelvis Cancer Age-Adjusted (2001) Inpatient Discharge Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 119. Kidney and Renal Pelvis Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 120. Median Charges for Kidney and Renal Pelvis Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Figure 121. Average Length of Stay for Kidney and Renal Pelvis Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Table 179. Kidney and Renal Pelvis Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

		Cour	ty/Region of Resid	lence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	905	611	144	150	0
Rate*	9.7	9.8	9.2	10.0	
95% C.I.	(9.1-10.4)	(9.0-10.6)	(7.7-10.9)	(8.4-11.7)	
Gender					
Male	586	390	91	105	0
Rate*	13.0	12.8	12.1	14.2	
95% C.I.	(11.9-14.2)	(11.5-14.3)	(9.6-15.2)	(11.5-17.4)	
Female	319	221	53	45	0
Rate*	6.7	6.9	6.6	6.0	
95% C.I.	(6.0-7.5)	(6.0-7.9)	(4.9-8.7)	(4.3-8.0)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$26,815,356	\$18,942,286	\$4,766,512	\$3,106,558	
Average Charges	\$29,630	\$31,002	\$33,101	\$20,710	
Median Charges	\$22,290	\$22,018	\$29,261	\$17,881	
Discharge Length of S	tay (LOS) (Days)				
Total LOS	5,715	4,000	934	781	
Average LOS	6.3	6.5	6.5	5.2	
Median LOS	5.0	5.0	5.0	4.0	

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 180. Kidney and Renal Pelvis Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown				
Total									
Discharges	905	611	144	150	0				
Rate*	9.3	9.2	8.6	10.7					
95% C.I.	(8.7-9.9)	(8.4-9.9)	(7.2-10.0)	(9.0-12.5)					
Age Group									
<1	2	1	0	1	0				
Rate*									
95% C.I.									
1-4	12	12	0	0	0				
Rate*	2.1	3.0							
95% C.I.	(0.9-3.3)	(1.3-4.7)							
5-14	10	10	0	0	0				
Rate*	0.7	1.1							
95% C.I.	(0.3-1.2)	(0.4-1.7)							
15-24	1	1	0	0	0				
Rate*									
95% C.I.									
25-34	8	7	0	1	0				
Rate*									
95% C.I.									
35-44	62	36	14	12	0				
Rate*	4.0	3.4	4.9	4.2					
95% C.I.	(3.0-5.0)	(2.3-4.6)	(2.4-7.5)	(1.8-6.6)					
45-54	149	99	28	22	0				
Rate*	11.6	11.7	11.8	9.3					
95% C.I.	(9.7-13.5)	(9.4-14.0)	(7.5-16.2)	(5.4-13.2)					
55-64	238	159	34	45	0				
Rate*	26.0	25.6	22.6	30.0					
95% C.I.	(22.7-29.3)	(21.6-29.6)	(15.0-30.3)	(21.2-38.7)					
65-74	262	183	41	38	0				
Rate*	40.8	42.3	40.0	37.1					
95% C.I.	(35.9-45.7)	(36.2-48.4)	(27.8-52.2)	(25.3-48.9)					
75-84	142	89	24	29	0				
Rate*	40.4	38.1	41.5	50.1					
95% C.I.	(33.8-47.1)	(30.2-46.0)	(24.9-58.1)	(31.9-68.4)					
85+	19	14	3	2	0				
Rate*	24.9	30.0							
95% C.I.	(13.7-36.1)	(14.3-45.7)							
Unknown	0	0	0	0	0				

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 181. Kidney and Renal Pelvis Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1997-2001

Age	Gender						
Group	Male	Female	Total				
<1	0	2	2				
Rate*							
95% C.I.							
1-4	9	3	12				
Rate*			2.1				
95% C.I.			(0.9-3.3)				
5-14	4	6	10				
Rate*			0.7				
95% C.I.	<u></u>		(0.3-1.2)				
15-24	1	0	1				
Rate*							
95% C.I.							
25-34	5	3	8				
Rate*							
95% C.I.							
35-44	41	21	62				
Rate*	5.1	2.8	4.0				
95% C.I.	(3.5-6.6)	(1.6-4.0)	(3.0-5.0)				
45-54	95	54	149				
Rate*	14.6	8.5	11.6				
95% C.I.	(11.7-17.6)	(6.2-10.8)	(9.7-13.5)				
55-64	159	79	238				
Rate*	34.9	17.1	26.0				
95% C.I.	(29.5-40.4)	(13.4-20.9)	(22.7-29.3)				
65-74	176	86	262				
Rate*	55.5	26.4	40.8				
95% C.I.	(47.3-63.7)	(20.9-32.0)	(35.9-45.7)				
75-84	85	57	142				
Rate*	53.6	29.6	40.4				
95% C.I.	(42.2-65.0)	(21.9-37.2)	(33.8-47.1)				
85+	11	8	19				
Rate*	44.5		24.9				
95% C.I.	(18.2-70.7)		(13.7-36.1)				
Unknown	0	0	0				
Total	586	319	905				
Rate*	11.8	(5.0.7.4)	9.3				
95% C.I.	(10.9-12.8)	(5.9-7.4)	(8.7-9.9)				

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 182. Kidney and Renal Pelvis Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001

2		1997-2001 Inpatient Hospital Discharges						
County of Residence	Neverlean	Rate*			Age-Adjusted Rate**			
	Number	Rate	95% C.I.	Rate	95% C.I.			
Carson City	25	10.0	(6.1-14.0)	8.7	(5.6-13.1)			
Churchill	9							
Clark	611	9.2	(8.4-9.9)	9.8	(9.0-10.6)			
Douglas	18	8.8	(4.7-12.8)	7.1	(4.2-12.0)			
Elko	11	4.8	(1.9-7.6)	7.2	(3.5-14.5)			
Esmeralda	1							
Eureka	6							
Humboldt	5							
Lander	5							
Lincoln	2							
Lyon	37	21.8	(14.7-28.8)	19.4	(13.6-27.3)			
Mineral	1							
Nye	23	14.6	(8.7-20.6)	10.8	(6.7-17.6)			
Pershing	3							
Storey	2							
Washoe	144	8.6	(7.2-10.0)	9.2	(7.7-10.9)			
White Pine	2							
Unknown	0							
Total	905	9.3	(8.7-9.9)	9.7	(9.1-10.4)			


Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 183. Kidney and Renal Pelvis Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1997-2001

Age		Charges (\$)			Length of Stay (Days)		
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	2						
1-4	12	399,892	33,324	38,481	90	7.5	7.0
5-14	10	986,495	98,650	39,568	160	16.0	6.5
15-24	1						
25-34	8	151,123	18,890	19,239	36	4.5	4.0
35-44	62	1,721,379	27,764	21,189	336	5.4	4.0
45-54	149	3,816,522	25,614	21,446	812	5.4	4.0
55-64	238	7,000,087	29,412	22,866	1,549	6.5	5.0
65-74	262	7,082,511	27,032	22,145	1,512	5.8	5.0
75-84	142	5,039,695	35,491	24,270	1,061	7.5	6.0
85+	19	519,233	27,328	20,081	131	6.9	6.0
Unknown	0						
Total	905	486,469	842	27,742	65	842.0	6.4

# **MORTALITY**

Figure 122. Kidney and Renal Pelvis Cancer Age-Adjusted (2001) Mortality Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 123. Kidney and Renal Pelvis Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 124. Kidney and Renal Pelvis Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 184. Kidney and Renal Pelvis Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region of Residence						
Category	Category  Nevada Total  Clark		Washoe	All Other Counties				
Total								
Mortality	327	223	50	54				
Rate*	3.7	3.9	3.3	3.8				
95% C.I.	(3.3-4.2)	(3.4-4.4)	(2.5-4.5)	(2.8-5.0)				
Gender								
Male	226	154	34	38				
Rate*	5.5	5.7	4.9	5.4				
95% C.I.	(4.7-6.3)	(4.7-6.8)	(3.3-7.2)	(3.7-7.7)				
Female	101	69	16	16				
Rate*	2.2	2.3	2.1	2.2				
95% C.I.	(1.8-2.7)	(1.8-2.9)	(1.2-3.4)	(1.2-3.7)				
Other/Unknown	0	0	0	0				
Race/Ethnicity								
White	284	191	45	48				
Rate*	3.9	4.1	3.5	3.7				
95% C.I.	(3.4-4.4)	(3.5-4.7)	(2.5-4.7)	(2.7-5.0)				
Black	13	12	1	0				
Rate*	3.5	3.6						
95% C.I.	(1.8-6.6)	(1.7-7.0)						
Native American	2	0	2	0				
Rate*								
95% C.I.								
Asian	7	6	1	0				
Rate*								
95% C.I.								
Hispanic	19	13	1	5				
Rate*	3.0	3.0						
95% C.I.	(1.7-5.6)	(1.4-6.5)						
Other/Unknown	2	1	0	1				

<sup>\*</sup>Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 185. Kidney and Renal Pelvis Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Mortality	327	223	50	54				
Rate*	3.4	3.3	3.0	3.9				
95% C.I.	(3.0-3.7)	(2.9-3.8)	(2.2-3.8)	(2.8-4.9)				
Age Group								
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	1	0	1	0				
Rate*								
95% C.I.								
15-24	0	0	0	0				
Rate*								
95% C.I.								
25-34	0	0	0	0				
Rate*								
95% C.I.								
35-44	7	6	0	1				
Rate*								
95% C.I.								
45-54	25	17	5	3				
Rate*	1.9	2.0						
95% C.I.	(1.2-2.7)	(1.1-3.0)						
55-64	80	55	10	15				
Rate*	8.7	8.8	6.7	10.4				
95% C.I.	(6.8-10.6)	(6.5-11.2)	(2.5-10.8)	(5.1-15.6)				
65-74	105	66	20	19				
Rate*	16.3	15.3	19.5	17.7				
95% C.I.	(13.2-19.5)	(11.6-18.9)	(11.0-28.1)	(9.8-25.7)				
75-84	87	65	12	10				
Rate*	24.8	27.8	20.8	16.7				
95% C.I.	(19.6-30.0)	(21.1-34.6)	(9.0-32.5)	(6.3-27.0)				
85+	22	14	2	6				
Rate*	28.9	30.0						
95% C.I.	(16.8-40.9)	(14.3-45.7) 0	0	0				

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 186. Kidney and Renal Pelvis Cancer Mortality by County of Residence, Nevada Residents, 1997-2001

	1997-2001 Mortality							
County of Residence	Rate*			Age-Adjusted Rate**				
	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	16	6.4	(3.3-9.6)	5.8	(3.3-9.6)			
Churchill	4							
Clark	223	3.3	(2.9-3.8)	3.9	(3.4-4.4)			
Douglas	9							
Elko	5							
Esmeralda	0							
Eureka	1							
Humboldt	1							
Lander	2							
Lincoln	1							
Lyon	9							
Mineral	0							
Nye	4							
Pershing	0							
Storey	1							
Washoe	50	3.0	(2.2-3.8)	3.3	(2.5-4.5)			
White Pine	1							
Unknown	0							
Total	327	3.4	(3.0-3.7)	3.7	(3.3-4.2)			

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 187. Kidney and Renal Pelvis Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

			Gender					
Rad	e/Ethnicity	Male	Female	Total				
White	Mortality	197	87	284				
	Rate* 95% C.I.	5.7 (4.9-6.7)	2.3 (1.8-2.8)	3.9 (3.4-4.4)				
Black	Mortality	7	6	13				
	Rate*			3.5				
	95% C.I.	<u> </u>		(1.8-6.6)				
Native	Mortality	0	2	2				
American	Rate*							
	95% C.I.	<u> </u>						
Asian	Mortality	7	0	7				
	Rate*							
	95% C.I.							
Hispanic	Mortality	14	5	19				
	Rate*	4.3		3.0				
	95% C.I.	(2.2-10.3)		(1.7-5.6)				
Other/Unkr	nown	1	1	2				
Total	Mortality	226	101	327				
	Rate*	5.5	2.2	3.7				
Tr " ":	95% C.I.	(4.7-6.3)	(1.8-2.7)	(3.3-4.2)				

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 188. Kidney and Renal Pelvis Cancer Mortality by Age Group and Gender, Nevada Residents, 1997-2001

Age	Gender						
Group	Male	Female	Total				
<1	0	0	0				
Rate*							
95% C.I.							
1-4	0	0	0				
Rate*							
95% C.I.							
5-14	0	1	1				
Rate*							
95% C.I.							
15-24	0	0	0				
Rate*							
95% C.I.							
25-34	0	0	0				
Rate*							
95% C.I.							
35-44	6	1	7				
Rate*							
95% C.I.							
45-54	19	6	25				
Rate*	2.9		1.9				
95% C.I.	(1.6-4.2)		(1.2-2.7)				
55-64	63	17	80				
Rate*	13.8	3.7	8.7				
95% C.I.	(10.4-17.3)	(1.9-5.4)	(6.8-10.6)				
65-74	72	33	105				
Rate*	22.7	10.1	16.3				
95% C.I. 75-84	(17.5-28.0) 55	(6.7-13.6)	(13.2-19.5) 87				
Rate*	34.7	16.6	24.8				
95% C.I.	(25.5-43.9)	(10.8-22.4)	(19.6-30.0)				
85+	<u>(23.5-43.9)</u> 11	11	22				
Rate*	44.5	21.4	28.9				
95% C.I.	(18.2-70.7)	(8.7-34.0)	(16.8-40.9)				
Unknown	0	0.7 54.0)	0				
Total	226	101	327				
Rate*	4.6	2.1	3.4				
95% C.I.	(4.0-5.2)	(1.7-2.5)	(3.0-3.7)				

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.


Table 189. Median Age at Death from Kidney and Renal Pelvis Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

	Gender								
Race/Ethnicity	Ma	le	Fem	ale	Total				
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age			
White	197	69.0	87	73.0	284	71.0			
Black	7	68.0	6	76.0	13	72.0			
Native American	0		2		2				
Asian	7	61.0	0		7	61.0			
Hispanic	14	62.5	5	67.0	19	65.0			
Other/Unknown	1		1		2				
Total	226	68.5	101	73.0	327	71.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

# **SURVIVAL RATE**

Figure 125. Survival Rates for Kidney and Renal Pelvis Cancer by Race/Ethnicity, Nevada Residents, 1997-2001



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 126. Survival Rates for Kidney and Renal Pelvis Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1997-2001




Table 190. Cause-Specific Survival Rates for Kidney and Renal Pelvis Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

Race/	Manufact	Cause Specific Survival Rate					Median
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	816	71.9%	61.2%	56.3%	52.9%	52.9%	>5 years
Male	522	70.0%	57.7%	54.8%	49.5%	49.5%	3.91
Female	294	75.4%	67.3%	59.1%	59.1%	59.1%	>5 years
Race/Ethnicity							
White	706	71.0%	59.3%	53.8%	51.3%	51.3%	>5 years
Male	454	68.4%	54.9%	51.6%	47.9%	47.9%	3.44
Female	252	75.7%	67.3%	57.9%	57.9%	57.9%	>5 years
Black	46						
Male	25						
Female	21						
Native American	7						
Male	4						
Female	3						
Asian	13						
Male	9						
Female	4						
Hispanic	38						
Male	25						
Female	13						

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 191. Cause-Specific Survival Rates for Kidney and Renal Pelvis Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1997-2001

Surviv	/al Rate of Stage		Gender				
	at Diagnosis	Total	Male	Female			
Total	Cases	816	522	294			
	One Year	71.9%	70.0%	75.4%			
	5 Years	52.9%	49.5%	59.1%			
	Median Survival	>5 years	3.91	>5 years			
Stage at D	iagnosis						
In situ	Cases	0	0	0			
	One Year						
	5 Years						
	Median Survival						
Localized	Cases	445	276	169			
	One Year	83.8%	81.8%	87.0%			
	5 Years	65.1%	62.2%	70.8%			
	Median Survival	>5 years	>5 years	>5 years			
Regional	Cases	102	65	37			
	One Year	78.4%	74.5%				
	5 Years	61.0%	60.1%				
	Median Survival	>5 years	>5 years				
Distant	Cases	145	100	45			
	One Year	40.9%	42.0%				
	5 Years						
	Median Survival	0.85	0.86				
Unstaged	Cases	124	81	43			
	One Year	64.7%	64.2%				
	5 Years	44.1%	45.2%				
	Median Survival	2.00	1.75				


Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

# **LEUKEMIA**

#### LEUKEMIA

# GENERAL PROFILE<sup>4</sup>

Figure 127. Anatomy of Stem Cell Maturation



**General Anatomy:** Blood cells form in the bone marrow, which is the soft material in the center of most bones. Immature blood cells are called stem cells and blasts. Most blood cells mature in the bone marrow and then move into the blood vessels. The bone marrow makes different types of blood cells; each with a special function: White blood cells fight infection, red blood cells carry oxygen to body tissues, and platelets help form blood clots to speed healing. With leukemia, the bone marrow produces abnormal white blood cells. At first, leukemia cells function almost normally. In time, they may crowd out normal white blood cells, red blood cells, and platelets.

**Risk Factors:** Very high levels of radiation, working with certain chemicals (e.g. Benzene, Formaldehyde), chemotherapy, Down's syndrome, human T-cell leukemia virus-I (HTLV-I), and myelodysplastic syndrome.

**Signs and Symptoms:** Fevers or night sweats, frequent infections, feeling weak or tired, headache, bleeding and bruising easily (bleeding gums, purplish patches in the skin, or tiny red spots under the skin), pain in the bones or joints, swelling or discomfort in the abdomen (from an enlarged spleen), swollen lymph nodes, especially in the neck or armpit, and weight loss.

**Diagnosing the Cancer:** Health exams, blood tests (High level of white blood cells, low levels of red blood cells and platelets), bone marrow aspiration, bone marrow biopsy, cytogenetics, spinal tap, and chest x-ray.

**Treatment:** chemotherapy (intrathecal), biological therapy, radiation therapy, or stem cell transplantation (bone marrow, peripheral stem cell and umbilical cord blood transplantations).

### **HIGHLIGHTS**

- ➤ The ratio of the age-adjusted incidence rate, 12.0, to the age-adjusted mortality rate, 7.4 (per 100,000 2000 US Standard population), for Leukemia was 1.62 during the 1997 to 2001 period. This means that for every 1.62 Leukemia cases during this period, there was one Leukemia death in Nevada.
- Nevadan females had a slighlty higher ratio than males when the age-adjusted incidence and age-adjusted mortality rates for Leukemia were compared. For every female death due to Leukemia there were 1.75 female cases while only 1.71 male cases for every male Leukemia death in Nevada from 1997 to 2001.
- The median age at diagnosis of Leukemia was 66 years of age for Nevada residents from 1997 to 2001; the median age at time of death was 72 years.

#### **INCIDENCE**

- ➤ There were 1,059 cases of Leukemia in Nevada from 1997 to 2001. Regional comparisons showed little variation between Clark County (12.6), All Other Counties (10.9) and Washoe County (10.9) from 1997 to 2001. Churchill County had the highest age adjusted rate (19.2). While the age-adjusted incidence rates for All Other Counties and Washoe County were slightly lower than the National rate of 12.1 (per 100,000 − 2000 US Standard population) statistical analysis does not show a significant difference between any of the areas.
- ➤ The age-adjusted incidence rate for male Leukemia, 15.0 (13.7-16.3), was statistically significant over the rate for females, 9.4 (8.5-10.4), during the 1997 to 2001 period.
- ➤ Whites, as a racial/ethnic group, had the highest age-adjusted incidence rate from Leukemia during the 1997 to 2001 period at 13.3 (12.5-14.3). They were followed by Blacks, Hispanics and Asians, who had rates of 8.7, 6.7 and 5.2, (per 100,000 2000 US Standard population), respectively.

#### INPATIENT HOSPITAL DISCHARGES

- ➤ Statistical regional comparisons indicate that Clark County had the highest age-adjusted inpatient discharge rate for Leukemia, 13.0 (12.1-14.0), and was followed by All Other Counties, 9.6 (8.0-11.4), and Washoe County, 8.8 (7.4-10.5) (per 100,000 2000 US Standard population), from 1997 to 2001.
- Clark County had the highest median total charge (\$65,670) followed by All Other Counties (\$53,299) and Washoe County (\$41,157) as a region, during the 1997 to 2001 period.
- ➤ Total billed charges for hospital inpatient discharges from Leukemia in Nevada totaled approximately 65.8 million dollars from 1997 to 2001. The overall average billed charge

per day for an inpatient hospital discharge for Leukemia was approximately \$4,802 in Nevada during this time. The average length of stay for an inpatient hospital discharge for Leukemia as 12.7 days during this time period.

### **MORTALITY**


- ➤ There were 614 Leukemia deaths from 1997 to 2001. While, Clark County as a region, had a higher age-adjusted mortality rate (7.6), than Washoe County (7.2) and All Other Counties (6.8), (per 100,000 2000 US Standard population), none of the rates show any statistically significant difference exists between the three regions.
- Males had a statistically higher age-adjusted mortality rate due to Leukemia, 9.5 (8.5-10.7), than their Female counterparts' rate, 5.6 (4.9-6.3), in Nevada from 1997 to 2001.

### **SURVIVAL RATE**

- ➤ The one-year survival rate for Leukemia in Nevada was 55.9% during the 1996 to 2001 period, while the five-year survival rate was 30.5%. The median survival rate in Nevada for Leukemia was 1.60 years.
- While females in Nevada diagnosed with Leukemia had a higher one-year survival rate (57.1%) than males (55.2%), their five-year survival rate (27.3%) was lower than the rate for males (33.3%) during the 1997 to 2001 period.
- Nevadan females had a slightly higher median survival time than their male counterparts with median survival times of 1.65 and 1.58 years, respectively, during the 1997 to 2001 period.

# **INCIDENCE**

Figure 128. Leukemia Age-Adjusted (2001) Incidence Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 129. Leukemia Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 130. Leukemia Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 192. Leukemia Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)	
Total							
Cases	1,059	742	163	153	1	21,418	
Rate*	12.0	12.6	10.9	10.9		12.1	
95% C.I.	(11.3-12.8)	(11.7-13.6)	(9.3-12.8)	(9.2-12.9)		(12.0-12.3)	
Gender							
Male	629	449	92	87	1	12,200	
Rate*	15.0	16.3	12.8	12.5		15.9	
95% C.I.	(13.7-16.3)	(14.7-18.2)	(10.2-15.9)	(9.9-15.7)		(15.6-16.2)	
Female	430	293	71	66	0	9,218	
Rate*	9.4	9.6	9.0	9.3		9.4	
95% C.I.	(8.6-10.4)	(8.5-10.8)	(7.0-11.4)	(7.2-11.9)		(9.2-9.6)	
Other/Unknown	0	0	0	0	0	0	
Race/Ethnicity							
White	920	640	143	137	0	18,176	
Rate*	13.3	14.6	11.4	11.0		12.9	
95% C.I.	(12.5-14.3)	(13.5-15.8)	(9.6-13.4)	(9.2-13.1)		(12.7-13.1)	
Black	39	31	5	3	0	1,530	
Rate*	8.7	7.5				9.9	
95% C.I.	(5.9-12.8)	(4.8-11.7)				(9.4-10.4)	
Native American	3	2	1	0	0	112	
Rate*						5.0	
95% C.I.						(4.0-4.0)	
Asian	24	17	6	1	0	1,376	
Rate*	5.2	4.6				7.5	
95% C.I.	(3.3-10.4)	(2.6-11.2)				(7.1-8.0)	
Hispanic	68	49	7	11	1	2,307	
Rate*	6.7	5.9		13.1		9.1	
95% C.I.	(4.7-9.8)	(3.9-9.4)		(5.3-30.2)		(8.7-9.5)	
Other/Unknown	5	3	1	1	0	224	

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 193. Leukemia Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)			
Total									
Cases	1,059	742	163	153	1	21,418			
Rate*	10.9	11.1	9.7	10.9		11.6			
95% C.I.	(10.2-11.5)	(10.3-11.9)	(8.2-11.2)	(9.2-12.7)		(11.4-11.7)			
Age Group									
<1	7	6	0	1	0	123			
Rate*						4.4			
95% C.I.						(3.7-5.2)			
1-4	53	40	4	9	0	944			
Rate*	9.3	10.0				8.5			
95% C.I.	(6.8-11.9)	(6.9-13.1)				(7.9-9.0)			
5-14	55	37	10	8	0	998			
Rate*	4.0	3.9	4.4			3.7			
95% C.I.	(2.9-5.0)	(2.7-5.2)	(1.7-7.1)			(3.5-4.0)			
15-24	30	22	2	6	0	665			
Rate*	2.2	2.4				2.6			
95% C.I.	(1.4-3.0)	(1.4-3.4)				(2.4-2.8)			
25-34	38	29	6	2	1	819			
Rate*	2.6	2.7				2.8			
95% C.I.	(1.8-3.4)	(1.7-3.7)				(2.6-3.0)			
35-44	59	41	14	4	0	1,293			
Rate*	3.8	3.9	4.9			4.1			
95% C.I.	(2.8-4.8)	(2.7-5.1)	(2.4-7.5)			(3.9-4.4)			
45-54	97	71	13	13	0	2,069			
Rate*	7.6	8.4	5.5	6.5		9.0			
95% C.I.	(6.1-9.1)	(6.4-10.3)	(2.5-8.5)	(3.0-10.0)		(8.7-9.4)			
55-64	158	111	25	22	0	2,914			
Rate*	17.2	17.9	16.7	15.2		20.8			
95% C.I.	(14.6-19.9)	(14.5-21.2)	(10.1-23.2)	(8.9-21.6)		(20.1-21.6)			
65-74	261	181	37	43	0	4,509			
Rate*	40.6	41.8	36.1	40.1		39.1			
95% C.I.	(35.7-45.6)	(35.8-47.9)	(24.5-47.7)	(28.1-52.1)		(37.9-40.2)			
75-84	226	151	44	31	0	4,931			
Rate*	64.3	64.7	76.1	51.8		67.8			
95% C.I.	(55.9-72.7)	(54.3-75.0)	(53.6-98.6)	(33.5-70.0)		(65.9-69.7)			
85+	74	52	8	14	0	2,153			
Rate*	97.1	111.4		99.8		86.8			
95% C.I.	(75.0-119.2)	(81.1-141.6)		(47.5-152.0)		(83.1-90.5)			
Unknown	1	1	0	0	0	0			

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 194. Leukemia Cases by County of Residence at Diagnosis, Nevada Residents, 1997-2001

County of	1997-2001 Incidence						
Residence	Canada	Rat	te*	Age-Adjust	ted Rate**		
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	40	16.1	(11.1-21.0)	14.6	(10.4-20.1)		
Churchill	23	19.1	(11.3-26.9)	19.2	(12.1-29.5)		
Clark	742	11.1	(10.3-11.9)	12.6	(11.7-13.6)		
Douglas	23	11.2	(6.6-15.8)	9.7	(6.0-15.4)		
Elko	13	5.6	(2.6-8.7)	10.0	(4.9-18.9)		
Esmeralda	0						
Eureka	0						
Humboldt	3						
Lander	2						
Lincoln	2						
Lyon	15	8.8	(4.4-13.3)	8.0	(4.4-13.9)		
Mineral	5						
Nye	19	12.1	(6.7-17.5)	8.8	(5.2-15.1)		
Pershing	1						
Storey	4						
Washoe	163	9.7	(8.2-11.2)	10.9	(9.3-12.8)		
White Pine	3						
Unknown	1						
Total	1,059	10.9	(10.2-11.5)	12.0	(11.3-12.8)		

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 195. Leukemia Cases by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

			Gei	nder	
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total
White	Incidence	548	372	0	920
	Rate* 95% C.I.	16.5 (15.1-18.1)	10.5 (9.4-11.6)		13.3 (12.5-14.3)
Black	Incidence	22	17	0	39
	Rate*	10.1	7.5		8.7
	95% C.I.	(5.6-19.2)	(4.1-12.8)		(5.9-12.8)
Native	Incidence	2	1	0	3
American	Rate*				
	95% C.I.				
Asian	Incidence	14	10	0	24
	Rate*	6.7	4.0		5.2
	95% C.I.	(3.5-18.0)	(1.9-12.7)		(3.3-10.4)
Hispanic	Incidence	39	29	0	68
	Rate*	8.5	5.5		6.7
	95% C.I.	(4.8-15.9)	(3.3-9.4)		(4.7-9.8)
Other/Unkr	nown	4	1	0	5
Total	Incidence	629	430	0	1,059
	Rate*	15.0	9.4		12.0
71 66 66 *	95% C.I.	(13.7-16.3)	(8.6-10.4)	100,000	(11.3-12.8)

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 196. Leukemia Cases by Age Group and Gender, Nevada Residents, 1997-2001

Age		Gen	der	
Group	Male	Female	Other/ Unknown	Total
<1	5	2	0	7
Rate*				
95% C.I.				
1-4	31	22	0	53
Rate*	10.7	7.9		9.3
95% C.I.	(6.9-14.5)	(4.6-11.2)		(6.8-11.9)
5-14	35	20	0	55
Rate*	4.9	3.0		4.0
95% C.I.	(3.3-6.6)	(1.7-4.3)		(2.9-5.0)
15-24	19	11	0	30
Rate*	2.7	1.7		2.2
95% C.I.	(1.5-4.0)	(0.7-2.7)		(1.4-3.0)
25-34	17	21	0	38
Rate*	2.2	3.0		2.6
95% C.I.	(1.2-3.3)	(1.7-4.2)		(1.8-3.4)
35-44	34	25	0	59
Rate*	4.2	3.3		3.8
95% C.I.	(2.8-5.6)	(2.0-4.6)		(2.8-4.8)
45-54	60	37	0	97
Rate*	9.2	5.8		7.6
95% C.I.	(6.9-11.6)	(4.0-7.7)		(6.1-9.1)
55-64	97	61	0	158
Rate*	21.3	13.2		17.2
95% C.I.	(17.1-25.6)	(9.9-16.5)		(14.6-19.9)
65-74	168	93	0	261
Rate*	53.0	28.6		40.6
95% C.I.	(45.0-61.0)	(22.8-34.4)		(35.7-45.6)
75-84	133	93	0	226
Rate*	83.9	48.2		64.3
95% C.I.	(69.6-98.2)	(38.4-58.1)		(55.9-72.7)
85+	29	45	0	74
Rate*	117.2	87.4		97.1
95% C.I.	(74.5-159.8)	(61.9-112.9)		(75.0-119.2)
Unknown	1	0	0	1
Total	629	430	0	1,059
Rate*	12.7	9.0		10.9
95% C.I.	(11.7-13.7)	(8.1-9.8)		(10.2-11.5)

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 197. Leukemia Incidence by Age Group and Stage, Nevada Residents, 1997-2001

A	0	Stage					
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total
<1	Number	0	0	0	6	1	7
	Percent				85.7%	14.3%	100.0%
1-4	Number	0	0	0	53	0	53
	Percent				100.0%		100.0%
5-14	Number	0	0	0	55	0	55
	Percent				100.0%		100.0%
15-24	Number	0	0	0	30	0	30
	Percent				100.0%		100.0%
25-34	Number	0	0	0	37	1	38
	Percent				97.4%	2.6%	100.0%
35-44	Number	0	0	0	57	2	59
	Percent				96.6%	3.4%	100.0%
45-54	Number	0	0	0	92	5	97
	Percent				94.8%	5.2%	100.0%
55-64	Number	0	0	0	157	1	158
	Percent				99.4%	0.6%	100.0%
65-74	Number	0	0	0	251	10	261
	Percent				96.2%	3.8%	100.0%
75-84	Number	0	0	0	211	15	226
	Percent				93.4%	6.6%	100.0%
85+	Number	0	0	0	64	10	74
	Percent				86.5%	13.5%	100.0%
Unknown	Number	0	0	0	1	0	1
	Percent				100.0%		100.0%
Total	Number	0	0	0	1,014	45	1,059
	Percent				95.8%	4.2%	100.0%

Table 198. Leukemia Cases by Stage and Race/Ethnicity, Nevada Residents, 1997-2001

			Race/Ethnicity							
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total		
In situ	Number	0	0	0	0	0	0	0		
	Percent									
Localized	Number	0	0	0	0	0	0	0		
	Percent									
Regional	Number	0	0	0	0	0	0	0		
	Percent									
Distant	Number	879	38	3	24	65	5	1,014		
	Percent	95.5%	97.4%	100.0%	100.0%	95.6%	100.0%	95.8%		
Unstaged	Number	41	1	0	0	3	0	45		
	Percent	4.5%	2.6%			4.4%		4.2%		
Total	Number	920	39	3	24	68	5	1,059		
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%		


Table 199. Median Age at Diagnosis of Leukemia by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

	Gender								
Race/Ethnicity	Male		Fem	nale	Total				
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age			
White	547	68.0	372	69.0	919	68.0			
Black	22	57.5	17	64.0	39	59.0			
Native American	2		1		3				
Asian	14	51.5	10	58.5	24	58.5			
Hispanic	39	22.0	29	41.0	68	35.0			
Other/Unknown	4		1		5	65.0			
Total	628	66.0	430	66.0	1,058	66.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

# **INPATIENT HOSPITAL DISCHARGES**

Figure 131. Leukemia Age-Adjusted (2001) Inpatient Discharge Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 132. Leukemia Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 133. Median Charges for Leukemia Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Figure 134. Average Length of Stay for Leukemia Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Table 200. Leukemia Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	1,080	807	138	134	1
Rate*	11.8	13.0	8.8	9.6	
95% C.I.	(11.1-12.5)	(12.1-14.0)	(7.4-10.5)	(8.0-11.4)	
Gender					
Male	628	468	77	82	1
Rate*	14.2	15.9	10.2	11.6	
95% C.I.	(13.1-15.5)	(14.4-17.6)	(8.0-13.0)	(9.2-14.8)	
Female	452	339	61	52	0
Rate*	9.6	10.6	7.6	7.5	
95% C.I.	(8.7-10.5)	(9.5-11.8)	(5.8-9.7)	(5.6-9.9)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$65,862,427	\$52,995,897	\$5,679,631	\$7,142,022	\$44,877
Average Charges	\$60,984	\$65,670	\$41,157	\$53,299	\$44,877
Median Charges	\$29,255	\$33,756	\$18,674	\$18,957	\$44,877
Discharge Length of S	tay (LOS) (Days)				
Total LOS	13,736	10,764	1,293	1,670	9
Average LOS	12.7	13.3	9.4	12.5	9.0
Median LOS	7.0	8.0	5.5	7.0	9.0

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 201. Leukemia Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		Count	ty/Region of Reside	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	1,080	807	138	134	1
Rate*	11.1	12.1	8.2	9.6	
95% C.I.	(10.4-11.8)	(11.3-12.9)	(6.8-9.6)	(8.0-11.2)	
Age Group					
<1	8	8	0	0	0
Rate*					
95% C.I.					
1-4	73	62	3	8	0
Rate*	12.9	15.5			
95% C.I.	(9.9-15.8)	(11.7-19.4)			
5-14	135	119	10	6	0
Rate*	9.8	12.6	4.4		
95% C.I.	(8.1-11.4)	(10.4-14.9)	(1.7-7.1)		
15-24	58	38	9	11	0
Rate*	4.3	4.1		4.8	
95% C.I.	(3.2-5.4)	(2.8-5.4)		(2.0-7.6)	
25-34	66	50	7	9	0
Rate*	4.5	4.7			
95% C.I.	(3.4-5.6)	(3.4-6.0)			
35-44	55	42	9	4	0
Rate*	3.5	4.0			
95% C.I.	(2.6-4.5)	(2.8-5.2)			
45-54	94	61	18	15	0
Rate*	7.3	7.2	7.6	6.3	
95% C.I.	(5.8-8.8)	(5.4-9.0)	(4.1-11.1)	(3.1-9.6)	
55-64	171	120	26	24	1
Rate*	18.7	19.3	17.3	16.0	
95% C.I.	(15.9-21.5)	(15.9-22.8)	(10.7-24.0)	(9.6-22.4)	
65-74	222	163	27	32	0
Rate*	34.6	37.7	26.3	31.2	
95% C.I.	(30.0-39.1)	(31.9-43.5)	(16.4-36.3)	(20.4-42.0)	
75-84	152	111	27	14	0
Rate*	43.3	47.5	46.7	24.2	
95% C.I.	(36.4-50.1)	(38.7-56.4)	(29.1-64.3)	(11.5-36.9)	
85+	46	33	2	11	0
Rate*	60.3	70.7		70.9	
95% C.I.	(42.9-77.8)	(46.6-94.8)		(29.0-112.8)	
Unknown	0	0	0	0	0

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 202. Leukemia Inpatient Discharges by Age Group and Gender, Nevada Residents, 1997-2001

Age		Gender	
Group	Male	Female	Total
<1		3	8
Rate*			
95% C.I.	<u></u>		
1-4	43	30	73
Rate*	14.8	10.8	12.9
95% C.I.	(10.4-19.3)	(6.9-14.7)	(9.9-15.8)
5-14	80	55	135
Rate*	11.3	8.2	9.8
95% C.I.	(8.8-13.7)	(6.0-10.4)	(8.1-11.4)
15-24	36	22	58
Rate*	5.2	3.4	4.3
95% C.I.	(3.5-6.9)	(2.0-4.8)	(3.2-5.4)
25-34	29	37	66
Rate*	3.8	5.2	4.5
95% C.I.	(2.4-5.2)	(3.5-6.9)	(3.4-5.6)
35-44	39	16	55
Rate*	4.8	2.1	3.5
95% C.I.	(3.3-6.4)	(1.1-3.2)	(2.6-4.5)
45-54	60	34	94
Rate*	9.2	5.4	7.3
95% C.I.	(6.9-11.6)	(3.6-7.2)	(5.8-8.8)
55-64	97	74	171
Rate*	21.3	16.0	18.7
95% C.I.	(17.1-25.6)	(12.4-19.7)	(15.9-21.5)
65-74	125	97	222
Rate*	39.4	29.8	34.6
95% C.I.	(32.5-46.4)	(23.9-35.8)	(30.0-39.1)
75-84	93	59	152
Rate*	58.7	30.6	43.3
95% C.I.	(46.7-70.6)	(22.8-38.4)	(36.4-50.1)
85+	21	25	46
Rate*	84.9	48.6	60.3
95% C.I.	(48.6-121.2)	(29.5-67.6)	(42.9-77.8)
Unknown	0	0	0
Total	628	452	1,080
Rate*	12.7	9.4	11.1
95% C.I.	(11.7-13.7)	(8.6-10.3)	(10.4-11.8)

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 203. Leukemia Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001

0 / (	1997-2001 Inpatient Hospital Discharges						
County of Residence	Number Rate*			Age-Adjus	Age-Adjusted Rate**		
	Number	Rate	95% C.I.	Rate	95% C.I.		
Carson City	25	10.0	(6.1-14.0)	9.8	(6.3-14.6)		
Churchill	18	14.9	(8.0-21.8)	14.7	(8.6-24.0)		
Clark	807	12.1	(11.3-12.9)	13.0	(12.1-14.0)		
Douglas	17	8.3	(4.4-12.2)	8.7	(5.0-14.7)		
Elko	3						
Esmeralda	3						
Eureka	3						
Humboldt	1						
Lander	1						
Lincoln	0						
Lyon	26	15.3	(9.4-21.2)	14.4	(9.2-21.7)		
Mineral	2						
Nye	30	19.1	(12.3-25.9)	15.1	(9.8-23.0)		
Pershing	1						
Storey	1						
Washoe	138	8.2	(6.8-9.6)	8.8	(7.4-10.5)		
White Pine	3						
Unknown	1						
Total	1,080	11.1	(10.4-11.8)	11.8	(11.1-12.5)		


Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 204. Leukemia Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1997-2001

Age	Discharges	Charges (\$)			Len	gth of Stay (Da	ıys)
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	8	556,633	69,579	47,004	111	13.9	7.0
1-4	73	2,788,065	38,193	33,300	650	8.9	8.0
5-14	135	6,287,314	46,573	27,120	1,186	8.8	6.0
15-24	58	3,963,881	68,343	43,611	893	15.4	9.5
25-34	66	5,524,571	83,706	49,527	1,032	15.6	7.0
35-44	55	4,469,412	81,262	57,144	975	17.7	13.0
45-54	94	7,168,510	76,261	39,948	1,556	16.6	10.0
55-64	171	12,657,275	74,019	36,155	2,523	14.8	9.0
65-74	222	15,693,670	70,692	36,421	3,094	13.9	8.0
75-84	152	5,996,789	39,453	18,729	1,446	9.5	6.5
85+	46	756,307	16,441	13,916	270	5.9	5.0
Unknown	0						
Total	1,080	471,810	1,040	53,265	85	1,040.0	12.3

# **MORTALITY**

Figure 135. Leukemia Age-Adjusted (2001) Mortality Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 136. Leukemia Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 137. Leukemia Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 205. Leukemia Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties					
Total									
Mortality	614	419	104	91					
Rate*	7.4	7.6	7.2	6.8					
95% C.I.	(6.8-8.0)	(6.9-8.4)	(5.8-8.7)	(5.5-8.5)					
Gender									
Male	368	256	60	52					
Rate*	9.5	10.2	8.9	7.9					
95% C.I.	(8.5-10.7)	(8.9-11.8)	(6.7-11.8)	(5.8-10.7)					
Female	246	163	44	39					
Rate*	5.6	5.5	5.7	5.7					
95% C.I.	(4.9-6.3)	(4.7-6.5)	(4.1-7.6)	(4.0-7.8)					
Other/Unknown	0	0	0	0					
Race/Ethnicity									
White	539	360	96	83					
Rate*	7.9	8.3	7.7	6.9					
95% C.I.	(7.2-8.6)	(7.4-9.2)	(6.2-9.4)	(5.4-8.6)					
Black	26	25	0	1					
Rate*	6.2	6.6							
95% C.I.	(3.9-9.9)	(4.0-10.6)							
Native American	3	1	0	2					
Rate*									
95% C.I.									
Asian	12	11	1	0					
Rate*	3.2	3.7							
95% C.I.	(1.5-8.3)	(1.7-10.4)							
Hispanic	32	22	5	5					
Rate*	4.4	4.3							
95% C.I.	(2.8-7.2)	(2.4-7.8)							
Other/Unknown	2	0	2	0					

\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 206. Leukemia Mortality by Age Group and County/Region of Residence, Neva da Residents, 1997-2001

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties					
Total									
Mortality	614	419	104	91					
Rate*	6.3	6.3	6.2	6.5					
95% C.I.	(5.8-6.8)	(5.7-6.9)	(5.0-7.4)	(5.2-7.8)					
Age Group									
<1	2	1	0	1					
Rate*									
95% C.I.									
1-4	5	2	2	1					
Rate*									
95% C.I.									
5-14	9	7	2	0					
Rate*									
95% C.I.									
15-24	13	9	2	2					
Rate*	1.0								
95% C.I.	(0.4-1.5)								
25-34	10	7	1	2					
Rate*	0.7								
95% C.I.	(0.3-1.1)								
35-44	23	18	4	1					
Rate*	1.5	1.7							
95% C.I.	(0.9-2.1)	(0.9-2.5)							
45-54	52	36	10	6					
Rate*	4.1	4.3	4.2						
95% C.I.	(2.9-5.2)	(2.9-5.6)	(1.6-6.9)						
55-64	91	60	17	14					
Rate*	9.9	9.7	11.3	9.7					
95% C.I.	(7.9-12.0)	(7.2-12.1)	(5.9-16.7)	(4.6-14.8)					
65-74	155	106	26	23					
Rate*	24.1	24.5	25.4	21.5					
95% C.I.	(20.3-27.9)	(19.8-29.2)	(15.6-35.1)	(12.7-30.2)					
75-84	187	130	32	25					
Rate*	53.2	55.7	55.3	41.7					
95% C.I.	(45.6-60.9)	(46.1-65.2)	(36.2-74.5)	(25.4-58.1)					
85+	67	43	8	16					
Rate*	87.9	92.1		114.0					
95% C.I.	(66.8-108.9)	(64.6-119.6)		(58.2-169.9)					
Unknown	0	0	0	0					

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 207. Leukemia Mortality by County of Residence, Nevada Residents, 1997-2001

• • •	1997-2001 Mortality							
County of Residence	Cases	Rat	te*	Age-Adjus	Age-Adjusted Rate**			
	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	20	8.0	(4.5-11.5)	7.5	(4.5-11.7)			
Churchill	7							
Clark	419	6.3	(5.7-6.9)	7.6	(6.9-8.4)			
Douglas	13	6.3	(2.9-9.8)	6.1	(3.1-11.2)			
Elko	9							
Esmeralda	1							
Eureka	0							
Humboldt	2							
Lander	2							
Lincoln	4							
Lyon	11	6.5	(2.6-10.3)	6.0	(2.9-11.4)			
Mineral	3							
Nye	14	8.9	(4.2-13.6)	6.9	(3.6-12.9)			
Pershing	0							
Storey	1							
Washoe	104	6.2	(5.0-7.4)	7.2	(5.8-8.7)			
White Pine	4							
Unknown	0							
Total	614	6.3	(5.8-6.8)	7.4	(6.8-8.0)			

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 208. Leukemia Mortality by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

			Gender						
Rac	ce/Ethnicity	Male	Female	Total					
White	Mortality	322	217	539					
	Rate* 95% C.I.	10.0 (8.9-11.3)	6.0 (5.2-6.9)	7.9 (7.2-8.6)					
Black	Mortality	14	12	26					
	Rate* 95% C.I.	7.5 (3.4-16.4)	5.4 (2.7-10.2)	6.2 (3.9-9.9)					
Native	Mortality	2	1	3					
American	Rate* 95% C.I.		<del></del>						
Asian	Mortality	8	4	12					
	Rate* 95% C.I.	 		3.2 (1.5-8.3)					
Hispanic	Mortality	20	12	32					
	Rate* 95% C.I.	6.4 (3.5-13.0)	2.8 (1.3-6.3)	4.4 (2.8-7.2)					
Other/Unkn	nown	2	0	2					
Total	Mortality	368	246	614					
Th. " ":	Rate* 95% C.I.	9.5 (8.5-10.7)	5.6 (4.9-6.3)	7.4 (6.8-8.0)					

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 209. Leukemia Mortality by Age Group and Gender, Nevada Residents, 1997-2001

Age	Gender						
Group	Male	Female	Total				
<1			2				
Rate*							
95% C.I.							
1-4	1	4	5				
Rate*							
95% C.I.							
5-14	4	5	9				
Rate*							
95% C.I.							
15-24	9	4	13				
Rate*			1.0				
95% C.I.			(0.4-1.5)				
25-34	4	6	10				
Rate*			0.7				
95% C.I.			(0.3-1.1)				
35-44	14	9	23				
Rate*	1.7		1.5				
95% C.I.	(0.8-2.6)		(0.9-2.1)				
45-54	35	17	52				
Rate*	5.4	2.7	4.1				
95% C.I.	(3.6-7.2)	(1.4-4.0)	(2.9-5.2)				
55-64	57	34	91				
Rate*	12.5	7.4	9.9				
95% C.I.	(9.3-15.8)	(4.9-9.9)	(7.9-12.0)				
65-74	99	56	155				
Rate* 95% C.I.	31.2 (25.1-37.4)	17.2 (12.7-21.7)	24.1 (20.3-27.9)				
75-84	116	71	187				
Rate*	73.2	36.8	53.2				
95% C.I.	(59.9-86.5)	(28.3-45.4)	(45.6-60.9)				
85+	27	40	67				
Rate*	109.1	77.7	87.9				
95% C.I.	(68.0-150.3)	(53.6-101.8)	(66.8-108.9)				
Unknown	0	0	0				
Total	368	246	614				
Rate*	7.4	5.1	6.3				
95% C.I.	(6.7-8.2)	(4.5-5.8)	(5.8-6.8)				

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.


Table 210. Median Age at Death from Leukemia by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

	Gender									
Race/Ethnicity	Ma	ale	Fen	nale	Total					
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age				
White	322	72.0	217	74.0	539	73.0				
Black	14	62.5	12	68.0	26	65.0				
Native American	2		1		3					
Asian	8	63.5	4		12	63.5				
Hispanic	20	66.0	12	55.0	32	62.5				
Other/Unknown	2		0		2					
Total	368	71.0	246	73.0	614	72.0				

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

# **SURVIVAL RATE**

Figure 138. Survival Rates for Leukemia by Race/Ethnicity, Nevada Residents, 1997-2001



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 139. Survival Rates for Leukemia by Stage of Cancer at Diagnosis, Nevada Residents, 1997-2001




Table 211. Cause-Specific Survival Rates for Leukemia by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

Race/		Cause Specific Survival Rate					Median
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	560	55.9%	46.1%	41.1%	36.3%	30.5%	1.60
Male	338	55.2%	46.2%	41.0%	38.8%	33.3%	1.58
Female	222	57.1%	46.1%	41.4%	33.4%	27.3%	1.65
Race/Ethnicity							
White	461	53.5%	43.3%	37.9%	33.0%	28.3%	1.34
Male	282	52.9%	44.9%	38.7%	35.7%	35.7%	1.36
Female	179	54.4%	41.3%	37.1%	29.7%	21.2%	1.34
Black	15						
Male	9						
Female	6						
Native American	5						
Male	1						
Female	4						
Asian	18						
Male	9						
Female	9						
Hispanic	58	67.3%	63.8%	58.0%	50.8%	38.1%	4.06
Male	36						
Female	22						

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 212. Cause-Specific Survival Rates for Leukemia by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1997-2001


Survival Rate of Stage			Gender					
	at Diagnosis	Total	Male	Female				
Total	Cases	560	338	222				
	One Year	55.9%	55.2%	57.1%				
	5 Years	30.5%	33.3%	27.3%				
	Median Survival	1.60	1.58	1.65				
Stage at D	iagnosis							
In situ	Cases	0	0	0				
	One Year							
	5 Years							
	Median Survival							
Localized	Cases	0	0	0				
	One Year							
	5 Years							
	Median Survival							
Regional	Cases	0	0	0				
	One Year							
	5 Years							
	Median Survival							
Distant	Cases	560	338	222				
	One Year	55.9%	55.2%	57.1%				
	5 Years	30.5%	33.3%	27.3%				
	Median Survival	1.60	1.58	1.65				
Unstaged	Cases	0	0	0				
	One Year							
	5 Years							
	Median Survival							

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

# LIP, ORAL CAVITY AND PHARYNYX CANCER

# LIP, ORAL CAVITY AND PHARYNX CANCER GENERAL PROFILE<sup>4</sup>

Figure 140. Anatomy of the Oral Cavity<sup>5</sup>



**General Anatomy:** The oral cavity includes many parts: the lips; the lining inside the lips and cheeks, called the buccal mucosa; the teeth; the bottom (floor) of the mouth under the tongue; the front two-thirds of the tongue; the bony top of the mouth (hard palate); the gums; and the small area behind the wisdom teeth. The oropharynx includes the back one-third of the tongue, the soft palate, the tonsils, and the part of the throat behind the mouth. Salivary glands throughout the oral cavity make saliva, which keeps the mouth moist and helps digest food.

**Risk Factors:** Tobacco use (especially smokeless tobacco), chronic and/or heavy alcohol use, sun exposure (Lip), history of leukoplakia (whitish patch inside the mouth associated with tobacco use), and erythroplakia (reddish patches usually in those over 60 years old)

**Signs and Symptoms:** Oral cancer usually occurs in people over the age of 45 but can develop at any age. These are some symptoms to watch for: A sore on the lip or in the mouth that does not heal, a lump on the lip or in the mouth or throat, a white or red patch on the gums, tongue, or lining of the mouth, unusual bleeding, pain, or numbness in the mouth, a sore throat that does not go away, or a feeling that something is caught in the throat, difficulty or pain with chewing or swallowing, swelling of the jaw that causes dentures to fit poorly or become uncomfortable, a change in the voice, and/or, pain in the ear.

**Diagnosing the Cancer:** Health exam, dental x-rays, head and chest x-rays, computed tomography (CAT) scan, ultrasonography, magnetic resonance imaging (MRI).

**Treatment:** Surgery, radiation therapy, chemotherapy, and clinical trials.

### **HIGHLIGHTS**

- ➤ The ratio of the age-adjusted incidence rate, 10.6, to the age-adjusted mortality rate, 2.5 (per 100,000 2000 US Standard population), for Lip, Oral Cavity and Pharynx Cancer was 4.24 during the 1996 to 2001 period, which means that for every 4.24 cases of Lip, Oral Cavity and Pharynx Cancer there was one death for this type of cancer in Nevada during this period.
- Nevadan males had a higher ratio than females when the age-adjusted incidence and age-adjusted mortality rates for Lip, Oral Cavity and Pharynx Cancer were compared. For every male death due to this type of cancer there were 4.89 male cases, while there were 3.60 female cases for every female death due to Lip, Oral Cavity and Pharynx Cancer from 1997 to 2001.
- ➤ The median age at diagnosis of Lip, Oral Cavity and Pharynx Cancer for Nevada residents was 62 years of age from 1997 to 2001 while the median age for males and females was 62 and 65 years, respectively. The median age at time of death due to Lip, Oral Cavity and Pharynx Cancer was 67 years statewide, 65.5 years of age for males and 72 years of age for females.

### **INCIDENCE**

- ➤ Nevada's age-adjusted incidence rate for Lip, Oral Cavity and Pharynx Cancer (10.6) was only slightly lower than the National rate of 10.7 (per 100,000 2000 US Standard population) from 1997 to 2001.
- ➤ The statistically significant age-adjusted incidence rate for male Lip, Oral Cavity and Pharynx Cancer, 15.3 (14.1-16.6), was more than double the rate for females, 6.3 (5.6-7.1), per 100,000 2000 US Standard population, during the 1997 to 2001 period.
- ➤ While regional comparisons showed that Washoe County's age-adjusted incidence rate for Lip, Oral Cavity and Pharynx Cancer (11.5) was higher than the rate for Clark County (10.7) and All Other Counties (9.6) (per 100,000 2000 US Standard population) from 1997 to 2001, these differences were not statistically significant.
- ➤ Whites had the highest age-adjusted incidence rate of all racial/ethnic groups at 11.7, and were followed by Blacks, Hispanics and Asians with rates of 9.4, 4.6 and 4.1 (per 100,000 2000 US Standard population), respectively.

#### INPATIENT HOSPITAL DISCHARGES

➤ There were 526 Lip, Oral Cavity and Pharynx Cancer inpatient discharges in Nevada from 1997 to 2001. The statistically significant age-adjusted inpatient discharge rate for males, 7.6 (6.8-8.5), was twice the inpatient discharge rate for females, 3.6 (3.1-4.2) (per 100,000 – 2000 US Standard population), in Nevada during this period.

- Total billed charges for hospital inpatient discharges from Lip, Oral Cavity and Pharynx Cancer in Nevada totaled over 18.3 million dollars from 1997 to 2001. Clark County had the highest median total charge (\$34,388), and also had the longest average length of stay (7.7 days) during this time period.
- The overall average billed charge per day for an inpatient hospital discharge for Lip, Oral Cavity, and Pharynx Cancer in Nevada was nearly \$4,643 from 1997 to 2001.

### **MORTALITY**


- There were 225 deaths due to Lip, Oral Cavity and Pharynx Cancer in Nevada from 1997 to 2001. While age-adjusted mortality rates were higher in All Other Counties (2.9) and Clark County (2.5), compared to Washoe County (2.3), statistical analysis shows that there is not a statistically significant difference between the three regions.
- Males had a statistically significant higher age-adjusted mortality rate due to Lip, Oral Cavity and Pharynx Cancer, 3.2 (2.7-3.9), than their female counterparts, 1.8 (1.5-2.3) (per 100,000 2000 US Standard population), during the 1997 to 2001 period.

### **SURVIVAL RATE**

- Females in Nevada had a slightly higher one- and five year survival rate (78.7% and 53.5%) than males (78.5% and 47.6%) for Lip, Oral Cavity and Pharynx Cancer during the 1997 to 2001 period. Females median survival time was greater than the survival time for males at over five years and 3.73 years, respectively.
- The one-year survival rate for those diagnosed with Lip, Oral Cavity and Pharynx Cancer at the localized stage was 86.9%, while those diagnosed at the regional, distant and unstaged stages had rates of 81.6%, 63.8% and 66.4%, respectively.
- ➤ The five-year survival rate for Lip, Oral Cavity and Pharynx Cancer with those at the localized stage was 64.7%, and was followed by those at the regional stage with rates of 49.2%.
- ➤ The median survival time for those diagnosed with Lip, Oral Cavity and Pharynx Cancer at the localized and regional stage was over five years, while those diagnosed at the unstaged levels had median survival times of 1.23 years.

# **INCIDENCE**

Figure 141. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted (2001) Incidence Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 142. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 143. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 213. Lip, Oral Cavity and Pharynx Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)				
Total										
Cases	994	670	180	143	1	18,668				
Rate*	10.6	10.7	11.5	9.6		10.7				
95% C.I.	(10.0-11.3)	(9.9-11.6)	(9.9-13.4)	(8.1-11.3)		(10.5-10.8)				
Gender										
Male	695	472	119	104	0	12,452				
Rate*	15.3	15.6	15.7	13.9		15.7				
95% C.I.	(14.1-16.6)	(14.1-17.3)	(12.9-19.2)	(11.3-17.2)		(15.5-16.0)				
Female	299	198	61	39	1	6,216				
Rate*	6.3	6.2	7.6	5.3		6.4				
95% C.I.	(5.6-7.1)	(5.4-7.2)	(5.8-9.8)	(3.7-7.2)		(6.3-6.6)				
Other/Unknown	0	0	0	0	0	0				
Race/Ethnicity										
White	887	596	157	133	1	14,890				
Rate*	11.7	12.3	11.6	10.0		10.7				
95% C.I.	(11.0-12.5)	(11.3-13.3)	(9.9-13.7)	(8.3-11.9)		(10.5-10.8)				
Black	42	32	8	2	0	1,888				
Rate*	9.4	7.8				11.9				
95% C.I.	(6.6-13.3)	(5.2-11.8)				(11.3-12.4)				
Native American	5	1	3	1	0	121				
Rate*						6.8				
95% C.I.						(5.6-5.6)				
Asian	13	9	4	0	0	1,618				
Rate*	4.1					8.7				
95% C.I.	(1.6-10.2)					(8.3-9.1)				
Hispanic	35	20	8	7	0	1,190				
Rate*	4.6	3.3				6.4				
95% C.I.	(3.0-7.3)	(1.8-6.4)				(6.0-6.8)				
Other/Unknown	12	12	0	0	0	151				

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 214. Lip, Oral Cavity and Pharynx Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)				
Total										
Cases	994	670	180	143	1	18,668				
Rate*	10.2	10.1	10.7	10.2		10.1				
95% C.I.	(9.6-10.8)	(9.3-10.8)	(9.2-12.3)	(8.6-11.9)		(9.9-10.2)				
Age Group										
<1	0	0	0	0	0					
Rate*										
95% C.I.										
1-4	0	0	0	0	0	6				
Rate* 95% C.I.										
5-14	4	3	0	1	0	48				
Rate*						0.2				
95% C.I.						(0.1-0.2)				
15-24	4	2	1	1	0	129				
Rate*						0.5				
95% C.I.						(0.4-0.6)				
25-34	17	8	3	6	0	461				
Rate*	1.2					1.6				
95% C.I.	(0.6-1.7)					(1.4-1.7)				
35-44	57	41	11	5	0	1,463				
Rate*	3.7	3.9	3.9			4.7				
95% C.I.	(2.7-4.6)	(2.7-5.1)	(1.6-6.2)			(4.4-4.9)				
45-54	172	109	33	30	0	3,657				
Rate*	13.4	12.9	14.0	14.9		16.0				
95% C.I.	(11.4-15.4)	(10.5-15.3)	(9.2-18.7)	(9.6-20.3)		(15.5-16.5)				
55-64	312	217	53	42	0	4,159				
Rate*	34.1	34.9	35.3	29.1		29.7				
95% C.I.	(30.3-37.8)	(30.3-39.6)	(25.8-44.8)	(20.3-37.9)		(28.8-30.6)				
65-74	273	192	46	34	1	4,494				
Rate*	42.5	44.4	44.9	31.7		39.0				
95% C.I.	(37.5-47.6)	(38.1-50.7)	(31.9-57.8)	(21.1-42.4)		(37.8-40.1)				
75-84	124	79	24	21	0	3,223				
Rate*	35.3	33.8	41.5	35.1		44.3				
95% C.I.	(29.1-41.5)	(26.4-41.3)	(24.9-58.1)	(20.1-50.1)		(42.8-45.9)				
85+	30	19	8	3	0	1,025				
Rate*	39.4	40.7				41.3				
95% C.I. Unknown	(25.3-53.4)	(22.4-59.0) 0	 1	0	0	(38.8-43.9)				
UTIKHOWH	- <del></del> -	<u> </u>				0				

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 215. Lip, Oral Cavity and Pharynx Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1997-2001

County of	1997-2001 Incidence							
Residence	Cases	Ra	Age-Adjus	Age-Adjusted Rate**				
at Diagnosis		Rate	95% C.I.	Rate	95% C.I.			
Carson City	31	12.4	(8.1-16.8)	10.8	(7.3-15.5)			
Churchill	20	16.6	(9.3-23.8)	17.3	(10.5-27.3)			
Clark	670	10.1	(9.3-10.8)	10.7	(9.9-11.6)			
Douglas	19	9.3	(5.1-13.4)	7.2	(4.3-12.1)			
Elko	10	4.3	(1.6-7.0)	7.7	(3.2-16.1)			
Esmeralda	0							
Eureka	1							
Humboldt	5							
Lander	3							
Lincoln	0							
Lyon	22	12.9	(7.5-18.3)	11.1	(6.9-17.4)			
Mineral	4							
Nye	21	13.4	(7.6-19.1)	10.3	(6.2-17.2)			
Pershing	2							
Storey	0							
Washoe	180	10.7	(9.2-12.3)	11.5	(9.9-13.4)			
White Pine	5							
Unknown	1							
Total	994	10.2	(9.6-10.8)	10.6	(10.0-11.3)			

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are a ge-adjusted to the 2001 US Standard population.

Table 216. Lip, Oral Cavity and Pharynx Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

Race/Ethnicity			Gender				
		Male	Female	Other/ Unknown	Total		
White	Incidence	617	270	0	887		
	Rate* 95% C.I.	16.6 (15.2-18.0)	7.1 (6.2-8.0)		11.7 (11.0-12.5)		
Black	Incidence	29	13	0	42		
	Rate*	14.9	5.2		9.4		
	95% C.I.	(9.3-24.7)	(2.7-9.6)		(6.6-13.3)		
Native	Incidence	4	1	0	5		
American	Rate*						
	95% C.I.						
Asian	Incidence	12	1	0	13		
	Rate*	9.1			4.1		
	95% C.I.	(3.4-23.0)			(1.6-10.2)		
Hispanic	Incidence	22	13	0	35		
	Rate*	6.9	2.8		4.6		
	95% C.I.	(3.9-13.5)	(1.4-6.0)		(3.0-7.3)		
Other/Unknown		11	1	0	12		
Total	Incidence	695	299	0	994		
	Rate*	15.3	6.3		10.6		
	95% C.I.	(14.1-16.6)	(5.6-7.1)		(10.0-11.3)		

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 217. Lip, Oral Cavity and Pharynx Cancer Cases by Age Group and Gender, Nevada Residents, 1997-2001

Age	Gender					
Group	Male	Female	Other/ Unknown	Total		
<1	0	0	0	0		
Rate*						
95% C.I.						
1-4	0	0	0	0		
Rate*						
95% C.I.		<u></u>				
5-14	3	1	0	4		
Rate*						
95% C.I.						
15-24	1	3	0	4		
Rate* 95% C.I.	<del></del>					
25-34 Rate*	11 1.4	6	0	17 1.2		
95% C.I.	(0.6-2.3)			(0.6-1.7)		
35-44	37	20	0	57		
Rate*	4.6	2.7		3.7		
95% C.I.	(3.1-6.1)	(1.5-3.8)		(2.7-4.6)		
45-54	131	41	0	172		
Rate*	20.2	6.5		13.4		
95% C.I.	(16.7-23.6)	(4.5-8.5)		(11.4-15.4)		
55-64	243	69	0	312		
Rate*	53.4	15.0		34.1		
95% C.I.	(46.7-60.1)	(11.4-18.5)		(30.3-37.8)		
65-74	185	88	0	273		
Rate*	58.4	27.1		42.5		
95% C.I.	(50.0-66.8)	(21.4-32.7)		(37.5-47.6)		
75-84	64	60	0	124		
Rate*	40.4	31.1		35.3		
95% C.I.	(30.5-50.3)	(23.3-39.0)		(29.1-41.5)		
85+	19	11	0	30		
Rate*	76.8	21.4		39.4		
95% C.I.	(42.3-111.3)	(8.7-34.0)		(25.3-53.4)		
Unknown	1	0	0	1		
Total	695	299	0	994		
Rate*	14.0	6.2		10.2		
95% C.I.	(13.0-15.1)	(5.5-7.0)		(9.6-10.8)		

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 218. Lip, Oral Cavity and Pharynx Cancer Cases by Age Group and Stage, Nevada Residents, 1997-2001

•	Age Group						
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total
<1	Number	0	0	0	0	0	0
	Percent						
1-4	Number	0	0	0	0	0	0
	Percent						
5-14	Number	0	0	1	0	3	4
	Percent			25.0%		75.0%	100.0%
15-24	Number	0	2	1	1	0	4
	Percent		50.0%	25.0%	25.0%		100.0%
25-34	Number	0	7	5	3	2	17
	Percent		41.2%	29.4%	17.6%	11.8%	100.0%
35-44	Number	0	24	22	4	7	57
	Percent		42.1%	38.6%	7.0%	12.3%	100.0%
45-54	Number	0	50	75	13	34	172
	Percent		29.1%	43.6%	7.6%	19.8%	100.0%
55-64	Number	0	88	122	33	69	312
	Percent		28.2%	39.1%	10.6%	22.1%	100.0%
65-74	Number	0	100	100	21	52	273
	Percent		36.6%	36.6%	7.7%	19.0%	100.0%
75-84	Number	0	41	35	13	35	124
	Percent		33.1%	28.2%	10.5%	28.2%	100.0%
85+	Number	0	9	11	2	8	30
	Percent		30.0%	36.7%	6.7%	26.7%	100.0%
Unknown	Number	0	1	0	0	0	1
	Percent		100.0%				100.0%
Total	Number	0	322	372	90	210	994
	Percent		32.4%	37.4%	9.1%	21.1%	100.0%

Table 219. Lip, Oral Cavity and Pharynx Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1997-2001

		Race/Ethnicity						
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total
In situ	Number	0	0	0	0	0	0	0
	Percent							
Localized	Number	290	14	2	4	9	3	322
	Percent	32.7%	33.3%	40.0%	30.8%	25.7%	25.0%	32.4%
Regional	Number	329	17	1	5	16	4	372
	Percent	37.1%	40.5%	20.0%	38.5%	45.7%	33.3%	37.4%
Distant	Number	79	5	1	2	3	0	90
	Percent	8.9%	11.9%	20.0%	15.4%	8.6%		9.1%
Unstaged	Number	189	6	1	2	7	5	210
	Percent	21.3%	14.3%	20.0%	15.4%	20.0%	41.7%	21.1%
Total	Number	887	42	5	13	35	12	994
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%


Table 220. Median Age at Diagnosis of Lip, Oral Cavity and Pharynx Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

	Gender									
Race/Ethnicity	Male		Fem	nale	Total					
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age				
White	616	61.0	270	66.0	886	62.0				
Black	29	63.0	13	62.0	42	62.0				
Native American	4		1		5	61.0				
Asian	12	64.5	1		13	66.0				
Hispanic	22	61.0	13	54.0	35	56.0				
Other/Unknown	11	66.0	1		12	65.0				
Total	694	62.0	299	65.0	993	62.0				

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

# **INPATIENT HOSPITAL DISCHARGES**

Figure 144. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted (2001) Inpatient Discharge Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 145. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 146. Median Charges for Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Figure 147. Average Length of Stay for Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Table 221. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

		Coun	ty/Region of Resid	lence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	526	387	84	54	1
Rate*	5.6	6.1	5.4	3.5	
95% C.I.	(5.1-6.1)	(5.5-6.8)	(4.3-6.8)	(2.6-4.7)	
Gender					
Male	352	265	49	37	1
Rate*	7.6	8.6	6.3	5.0	
95% C.I.	(6.8-8.5)	(7.5-9.9)	(4.6-8.6)	(3.4-7.2)	
Female	174	122	35	17	0
Rate*	3.6	3.8	4.4	2.2	
95% C.I.	(3.1-4.2)	(3.1-4.6)	(3.1-6.2)	(1.3-3.6)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$18,319,594	\$13,308,001	\$2,742,849	\$1,702,357	\$566,387
Average Charges	\$34,828	\$34,388	\$32,653	\$31,525	\$566,387
Median Charges	\$20,891	\$20,935	\$23,031	\$16,066	\$566,387
Discharge Length of S	tay (LOS) (Days)				
Total LOS	3,951	2,964	596	325	66
Average LOS	7.5	7.7	7.1	6.0	66.0
Median LOS	4.0	4.0	5.0	3.5	66.0

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 222. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		Cour	nty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	526	387	84	54	1
Rate*	5.4	5.8	5.0	3.9	
95% C.I.	(4.9-5.9)	(5.2-6.4)	(3.9-6.1)	(2.8-4.9)	
Age Group					
<1	0	0	0	0	0
Rate*					
95% C.I.					
1-4	0	0	0	0	0
Rate*					
95% C.I.					
5-14	1	1	0	0	0
Rate*					
95% C.I.					
15-24	0	0	0	0	0
Rate*					
95% C.I.					
25-34	4	4	0	0	0
Rate*					
95% C.I.					
35-44	27	21	4	2	0
Rate*	1.7	2.0			
95% C.I.	(1.1-2.4)	(1.1-2.9)			
45-54	85	67	8	10	0
Rate*	6.6	7.9		4.2	
95% C.I.	(5.2-8.0)	(6.0-9.8)		(1.6-6.9)	
55-64	181	132	25	23	1
Rate*	19.8	21.2	16.7	15.3	
95% C.I.	(16.9-22.6)	(17.6-24.9)	(10.1-23.2)	(9.1-21.6)	
65-74	155	113	30	12	0
Rate*	24.1	26.1	29.3	11.7	
95% C.I.	(20.3-27.9)	(21.3-30.9)	(18.8-39.7)	(5.1-18.3)	
75-84	62	41	16	5	0
Rate*	17.6	17.6	27.7		
95% C.I.	(13.3-22.0)	(12.2-22.9)	(14.1-41.2)		
85+	11	8	1	2	0
Rate*	14.4				
95% C.I.	(5.9-23.0)				
Unknown	0	0	0	0	0

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 223. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1997-2001

Age		Gender	
Group	Male	Female	Total
<1	0	0	0
Rate*			
95% C.I.			
1-4	0	0	0
Rate*			
95% C.I.			
5-14	1	0	1
Rate*			
95% C.I.			
15-24	0	0	0
Rate*			
95% C.I.			
25-34	1	3	4
Rate*			
95% C.I.			
35-44	19	8	27
Rate* 95% C.I.	2.4 (1.3-3.4)		1.7 (1.1-2.4)
45-54		40	
45-54 Rate*	66 10.2	19 3.0	85 6.6
95% C.I.	(7.7-12.6)	(1.7-4.3)	(5.2-8.0)
55-64	140	41	181
Rate*	30.8	8.9	19.8
95% C.I.	(25.7-35.9)	(6.2-11.6)	(16.9-22.6)
65-74	93	62	155
Rate*	29.3	19.1	24.1
95% C.I.	(23.4-35.3)	(14.3-23.8)	(20.3-27.9)
75-84	24	38	62
Rate*	15.1	19.7	17.6
95% C.I.	(9.1-21.2)	(13.4-26.0)	(13.3-22.0)
85+	8	3	11
Rate*			14.4
95% C.I.			(5.9-23.0)
Unknown	0	0	0
Total	352	174	526
Rate*	7.1	3.6	5.4
95% C.I.	(6.4-7.9)	(3.1-4.2)	(4.9-5.9)

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 224. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001

	1997-2001 Inpatient Hospital Discharges						
County of Residence	Normalis and	Rat	te*	Age-Adjus	ted Rate**		
	Number	Rate	95% C.I.	Rate	95% C.I.		
Carson City	9						
Churchill	4						
Clark	387	5.8	(5.2-6.4)	6.1	(5.5-6.8)		
Douglas	5						
Elko	3						
Esmeralda	0						
Eureka	0						
Humboldt	5						
Lander	0						
Lincoln	0						
Lyon	11	6.5	(2.6-10.3)	5.4	(2.7-10.3)		
Mineral	2						
Nye	15	9.5	(4.7-14.4)	7.3	(3.9-13.5)		
Pershing	0						
Storey	0						
Washoe	84	5.0	(3.9-6.1)	5.4	(4.3-6.8)		
White Pine	0						
Unknown	1						
Total 1.6	526	5.4	(4.9-5.9)	5.6	(5.1-6.1)		


Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 225. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1997-2001

Age	Disabarras	Charges (\$)			Length of Stay (Days)		
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	0						
1-4	0						
5-14	1						
15-24	0						
25-34	4						
35-44	27	681,766	25,251	17,785	116	4.3	3.0
45-54	85	2,270,755	26,715	21,283	559	6.6	4.0
55-64	181	7,579,784	41,877	22,047	1,744	9.6	5.0
65-74	155	5,217,946	33,664	20,948	997	6.4	4.0
75-84	62	1,990,007	32,097	18,724	414	6.7	4.0
85+	11	304,879	27,716	19,252	62	5.6	5.0
Unknown	0						
Total	526	566,387	505	33,790	134	505.0	7.6

# **MORTALITY**

Figure 148. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted (2001) Mortality Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 149. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 150. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 226. Lip, Oral Cavity and Pharynx Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	225	137	43	45
Rate*	2.5	2.3	2.9	3.1
95% C.I.	(2.2-2.9)	(1.9-2.7)	(2.1-4.0)	(2.2-4.2)
Gender				
Male	142	84	23	35
Rate*	3.2	2.9	3.0	4.7
95% C.I.	(2.7-3.9)	(2.3-3.8)	(1.9-4.9)	(3.2-6.9)
Female	83	53	20	10
Rate*	1.8	1.7	2.6	1.4
95% C.I.	(1.5-2.3)	(1.3-2.3)	(1.6-4.1)	(0.7-2.6)
Other/Unknown	0	0	0	0
Race/Ethnicity				
White	201	119	38	44
Rate*	2.7	2.5	3.0	3.3
95% C.I.	(2.3-3.1)	(2.0-3.0)	(2.1-4.1)	(2.4-4.5)
Black	13	11	2	0
Rate*	3.1	2.7		
95% C.I.	(1.6-5.9)	(1.3-5.7)		
Native American	1	0	1	0
Rate*				
95% C.I.				
Asian	3	2	1	0
Rate*				
95% C.I.				
Hispanic	7	5	1	1
Rate*				
95% C.I.				
Other/Unknown	0	0	0	0

\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 227. Lip, Oral Cavity and Pharynx Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region o	f Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	225	137	43	45
Rate*	2.3	2.1	2.6	3.2
95% C.I.	(2.0-2.6)	(1.7-2.4)	(1.8-3.3)	(2.3-4.2)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	1	1	0	0
Rate*				
95% C.I.				
25-34	1	1	0	0
Rate*				
95% C.I.				
35-44	6	4	1	1
Rate*				
95% C.I.				
45-54	26	13	7	6
Rate*	2.0	1.5		
95% C.I.	(1.2-2.8)	(0.7-2.4)		
55-64	60	39	10	11
Rate*	6.5	6.3	6.7	7.6
95% C.I.	(4.9-8.2)	(4.3-8.2)	(2.5-10.8)	(3.1-12.1)
65-74	66	39	11	16
Rate*	10.3	9.0	10.7	14.9
95% C.I.	(7.8-12.8)	(6.2-11.8)	(4.4-17.1)	(7.6-22.2)
75-84	53	36	9	8
Rate*	15.1	15.4		
95% C.I.	(11.0-19.1)	(10.4-20.4)		
85+	12	4	5	3
Rate*	15.7			
95% C.I.	(6.8-24.6)			
Unknown	0	0	0	0

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 228. Lip, Oral Cavity and Pharynx Cancer Mortality by County of Residence, Nevada Residents, 1997-2001

	1997-2001 Mortality						
County of Residence	C	Ra	te*	Age-Adjusted Rate**			
	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	11	4.4	(1.8-7.0)	3.9	(1.9-7.2)		
Churchill	1						
Clark	137	2.1	(1.7-2.4)	2.3	(1.9-2.7)		
Douglas	6						
Elko	3						
Esmeralda	0						
Eureka	0						
Humboldt	0						
Lander	0						
Lincoln	1						
Lyon	6						
Mineral	1						
Nye	9						
Pershing	1						
Storey	3						
Washoe	43	2.6	(1.8-3.3)	2.9	(2.1-4.0)		
White Pine	3						
Unknown	0						
Total	225	2.3	(2.0-2.6)	2.5	(2.2-2.9)		

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 229. Lip, Oral Cavity and Pharynx Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

			Gender	
Race/Ethnicity		Male	Female	Total
White	Mortality	130	71	201
	Rate*	3.5	1.9	2.7
	95% C.I.	(2.9-4.2)	(1.5-2.4)	(2.3-3.1)
Black	Mortality	6	7	13
	Rate*			3.1
	95% C.I.			(1.6-5.9)
Native	Mortality	0	1	1
American	Rate*			
	95% C.I.			
Asian	Mortality		1	3
	Rate*			
	95% C.I.			
Hispanic	Mortality	4	3	7
	Rate*			
	95% C.I.			
Other/Unkr	nown	0	0	0
Total	Mortality	142	83	225
	Rate*	3.2	1.8	2.5
	95% C.I.	(2.7-3.9)	(1.5-2.3)	(2.2-2.9)

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 230. Lip, Oral Cavity and Pharynx Cancer Mortality by Age Group and Gender, Nevada Residents, 1997-2001

Age		Gender	
Group	Male	Female	Total
<1	0	0	0
Rate*			
95% C.I.			
1-4	0	0	0
Rate*			
95% C.I.			
5-14	0	0	0
Rate*			
95% C.I.			
15-24	0	1	1
Rate*			
95% C.I.			
25-34	0	1	1
Rate*			
95% C.I.			
35-44 Bata*	2	4	6
Rate* 95% C.I.			
45-54	17	9	26
Rate*	2.6	9 	2.0
95% C.I.	(1.4-3.9)		(1.2-2.8)
55-64	45	15	60
Rate*	9.9	3.3	6.5
95% C.I.	(7.0-12.8)	(1.6-4.9)	(4.9-8.2)
65-74	48	18	66
Rate*	15.1	5.5	10.3
95% C.I.	(10.9-19.4)	(3.0-8.1)	(7.8-12.8)
75-84	26	27	53
Rate*	16.4	14.0	15.1
95% C.I.	(10.1-22.7)	(8.7-19.3)	(11.0-19.1)
85+	4	8	12
Rate*			15.7
95% C.I.			(6.8-24.6)
Unknown	0	0	0
Total	142	83	225
Rate*	2.9	1.7	2.3
95% C.I.	(2.4-3.3)	(1.4-2.1)	(2.0-2.6)

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.


Table 231. Median Age at Death from Lip, Oral Cavity and Pharynx Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

		Gender									
Race/Ethnicity	Ma	ile	Fem	ale	Total						
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age					
White	130	66.0	71	72.0	201	67.0					
Black	6	58.5	7	68.0	13	64.0					
Native American	0		1		1						
Asian	2		1		3						
Hispanic	4		3		7	72.0					
Other/Unknown	0		0		0						
Total	142	65.5	83	72.0	225	67.0					

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

# **SURVIVAL RATE**

Figure 151. Survival Rates for Lip, Oral Cavity and Pharynx Cancer by Race/Ethnicity, Nevada Residents, 1997-2001



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 152. Survival Rates for Lip, Oral Cavity and Pharynx Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1997-2001




Table 232. Cause-Specific Survival Rates for Lip, Oral Cavity and Pharynx Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

Race/	Number		Median				
Ethnicity and Gender	Ethnicity of Cases		Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	781	78.6%	65.6%	55.5%	48.8%	48.8%	3.82
Male	545	78.5%	67.0%	56.4%	47.6%	47.6%	3.73
Female	236	78.7%	62.2%	53.5%	53.5%	53.5%	>5 years
Race/Ethnicity							
White	691	78.6%	65.1%	53.7%	47.3%	47.3%	3.58
Male	481	78.6%	67.2%	55.3%	47.1%	47.1%	3.65
Female	210	78.3%	60.3%	49.9%	49.9%	49.9%	2.99
Black	33						
Male	21						
Female	12						
Native American	4						
Male	3						
Female	1						
Asian	11						
Male	10						
Female	1						
Hispanic	30						
Male	19						
<u>Female</u>	11						

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 233. Cause-Specific Survival Rates for Lip, Oral Cavity and Pharynx Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1997-2001


Surviv	/al Rate of Stage		Gender	
	at Diagnosis	Total	Male	Female
Total	Cases	781	545	236
	One Year	78.6%	78.5%	78.7%
	5 Years	48.8%	47.6%	53.5%
	Median Survival	3.82	3.73	>5 years
Stage at D	iagnosis			
In situ	Cases	0	0	0
	One Year			
	5 Years			
	Median Survival			
Localized	Cases	251	164	87
	One Year	86.9%	85.3%	89.8%
	5 Years	64.7%	61.6%	71.3%
	Median Survival	>5 years	>5 years	>5 years
Regional	Cases	300	219	81
	One Year	81.6%	80.2%	85.5%
	5 Years	49.2%	48.2%	54.6%
	Median Survival	3.87	3.77	>5 years
Distant	Cases	72	56	16
	One Year	63.8%	65.2%	
	5 Years			
	Median Survival	2.06	2.23	
Unstaged	Cases	158	106	52
	One Year	66.4%	72.0%	55.6%
	5 Years	34.5%	38.0%	
	Median Survival	1.91	2.37	1.23

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

# PANCREATIC CANCER

# PANCREATIC CANCER GENERAL PROFILE<sup>4</sup>

Figure 153. Anatomy of the Endocrine System<sup>5</sup>



**General Anatomy:** The pancreas is a gland located deep in the abdomen between the stomach and the spine (backbone). The pancreas is about 6 inches long and is shaped like a flat pear. The pancreas makes insulin and other hormones that travel throughout the body to help the body use or store the energy that comes from food.

**Risk Factors:** Age, smoking, diabetes, male gender, Black race/ethnicity, family history of pancreatic cancer, and chronic pancreatitis.

**Signs and Symptoms:** Pancreatic cancer is sometimes called a "silent disease" because early pancreatic cancer often does not cause symptoms. But, as the cancer grows, symptoms may include: Pain in the upper abdomen or upper back, yellow skin and eyes, and dark urine from jaundice, weakness, loss of appetite, nausea and vomiting, and weight loss.

**Diagnosing the Cancer:** Physical exam, blood, stool and urine tests (Bilirubin levels), computed tomography (CAT) scan, ultrasonography (transabdominal, endoscopic), endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography (PTC), and fine-needle aspiration.

**Treatment:** Surgery (Whipple procedure, distal pancreatectomy, total pancreatectomy, bypass), radiation therapy, and chemotherapy.

### **HIGHLIGHTS**

- ➤ The ratio of the age-adjusted incidence rate, 10.8, to the age-adjusted mortality rate, 9.8 (per 100,000 2000 US Standard population), for Pancreatic Cancer was 1.12 during the 1996 to 2001 period, which means that for every 1.10 Pancreatic Cancer cases there was one death due to this type of cancer in Nevada. Both females and males were similar with ratios of 1.05 and 1.20 during this period.
- The median age at diagnosis of Pancreatic Cancer for Nevada residents was 69 years of age, while the median age for males and females was 67 and 70 years during the 1997 to 2001 period. The median age at time of death due to cancer of the pancreas was 70 years for Nevada overall, 69 years for males and 72 years of age for females.

#### **INCIDENCE**

- ➤ There were 951 cases of Pancreatic Cancer reported in Nevada from 1997 to 2001. Nevada's age-adjusted incidence rate for Pancreatic Cancer (10.8) was slightly lower than the national rate of 11.0 (per 100,000 2001 US Standard population) from 1997 to 2001.
- ➤ While regional comparisons showed only slight variations between the age-adjusted incidence rates of Pancreatic Cancer for Clark County (11.0), Washoe County (10.5) and All Other Counties (10.4) from 1997 to 2001, statistical analysis shows no statistically significant difference between the three regions. This was the same for males and females in Nevada who had rates of 12.2 and 9.8 (per 100,000 2000 US Standard population), respectively.
- ➤ Blacks, as a racial/ethnic group, had the highest statistically significant age-adjusted incidence rate for Pancreatic Cancer, 14.7 (11.0-19.6), of any racial/ethnic group from 1996 to 2001. Whites, Hispanics and Asians followed with rates of 11.1 (10.4-11.9), 9.9 (6.8-14.2) and 4.8 (2.8-10.2) (per 100,000 2000 US Standard population), respectively, during this time.

#### INPATIENT HOSPITAL DISCHARGES

- ➤ Billed charges from Pancreatic Cancer inpatient hospital discharges accounted for greater than 29.8 million dollars from 1997 to 2001. Nevadans in the 65-74 and 75-84 age groups accounted for 56.8% of the total inpatient discharges and 54.4% of the total billed charges during this period. The overall daily billed amount for Pancreatic Cancer inpatient hospital discharges was approximately \$4,197 in Nevada during this period.
- There were 741 inpatient hospital discharges for Pancreatic Cancer to residents in Nevada from 1997 to 2001. Washoe County had the highest age-adjusted inpatient discharge rate, 8.9 (7.4-10.6), for Pancreatic Cancer and showed statistical significance over the All Other Counties region's rate of 6.3 (5.0-7.8), which was the lowest age-adjusted inpatient discharge rate of any region in Nevada during the 1997 to 2001 period.

The median total billed charges in Nevada for inpatient discharges due to cancer of the pancreas were \$24824 from 1997 to 2001. Washoe and Clark County had the highest median total billed charges, \$43,301 and \$42,844, which were more than double the All Other Counties' median billed amount of \$21,438.

#### **MORTALITY**


- ➤ There were 845 resident Pancreatic Cancer deaths from 1997 to 2001. Regional comparisons were fairly similar between All Other Counties, Clark County and Washoe County with rates of 10.2, 9.9 and 8.9 (per 100,000 2000 US Standard population), respectively.
- ➤ Blacks, as a racial/ethnic group, had the highest age-adjusted Pancreatic Cancer mortality rate, (12.3); followed by Whites (10.0), Hispanics (9.0), and Asians (4.8) (per 100,000 2000 US Standard population). However, statistical analysis does not show any statistical significance between any of the racial/ethnic groups.

#### **SURVIVAL RATE**

- ➤ While the one-year survival rate for Nevada females with Pancreatic Cancer (38.3%) was slightly higher than the rate for males (37.4%) during the 1997 to 2001 period, the five-year survival rate decreased to 15.9% for females and 13.4% for males from 1997 to 2001.
- The one-year survival rate for those diagnosed with Pancreatic Cancer at the localized stage was 36.1%, while those diagnosed at the regional, distant and unstaged stages had rates of 43.8%, 36.8% and 30.3%, respectively, during the 1996 to 2001 period.
- From 1997 to 2001, the median survival time for Pancreatic Cancer diagnosed at the localized stage was 0.81 years, while those diagnosed at the regional, distant and unstaged levels had median survival times of 0.98, 0.82 and 0.67 years, respectively.

# **INCIDENCE**

Figure 154. Pancreatic Cancer Age-Adjusted (2001) Incidence Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 155. Pancreatic Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 156. Pancreatic Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 234. Pancreatic Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)				
Total										
Cases	951	644	154	150	3	18,790				
Rate*	10.8	11.0	10.5	10.4		11.0				
95% C.I.	(10.1-11.6)	(10.1-11.9)	(8.9-12.3)	(8.8-12.3)		(10.8-11.2)				
Gender										
Male	502	348	75	78	1	9,214				
Rate*	12.2	12.6	11.1	11.6		12.6				
95% C.I.	(11.1-13.4)	(11.2-14.2)	(8.6-14.3)	(9.0-14.8)		(12.3-12.8)				
Female	449	296	79	72	2	9,576				
Rate*	9.8	9.6	10.0	9.6		9.7				
95% C.I.	(8.9-10.7)	(8.6-10.8)	(7.9-12.6)	(7.5-12.1)		(9.5-9.9)				
Other/Unknown	0	0	0	0	0	0				
Race/Ethnicity										
White	817	541	134	140	2	14,999				
Rate*	11.1	11.4	10.4	10.5		10.8				
95% C.I.	(10.4-11.9)	(10.5-12.5)	(8.7-12.4)	(8.8-12.5)		(10.6-11.0)				
Black	61	49	11	1	0	2,116				
Rate*	14.7	12.8	47.3			15.4				
95% C.I.	(11.0-19.6)	(9.3-17.7)	(23.0-88.9)			(14.7-16.1)				
Native American	5	2	2	1	0	121				
Rate*						8.3				
95% C.I.						(6.8-6.8)				
Asian	18	13	2	2	1	1,524				
Rate*	4.8	4.4				9.3				
95% C.I.	(2.8-10.2)	(2.2-11.1)				(8.9-9.8)				
Hispanic	47	36	5	6	0	1,470				
Rate*	9.9	9.4				9.7				
95% C.I.	(6.8-14.2)	(6.1-14.5)				(9.2-10.2)				
Other/Unknown	3	3	0	0	0	30				

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 235. Pancreatic Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

			County/Region	n of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)
Total						
Cases	951	644	154	150	3	18,790
Rate*	9.8	9.7	9.2	10.7		10.1
95% C.I.	(9.1-10.4)	(8.9-10.4)	(7.7-10.6)	(9.0-12.5)		(10.0-10.3)
Age Group						
<1	0	0	0	0	0	
Rate*						
95% C.I.						
1-4	0	0	0	0	0	
Rate*						
95% C.I.						
5-14	1	0	1	0	0	6
Rate*						
95% C.I.						
15-24	3	3	0	0	0	22
Rate*						0.1
95% C.I.						(0.0-0.1)
25-34	4	2	1	1	0	73
Rate*						0.2
95% C.I.						(0.2-0.3)
35-44	23	16	5	2	0	513
Rate*	1.5	1.5				1.6
95% C.I.	(0.9-2.1)	(0.8-2.3)				(1.5-1.8)
45-54	102	68	19	15	0	1,826
Rate*	7.9	8.0	8.0	7.5		8.0
95% C.I.	(6.4-9.5)	(6.1-9.9)	(4.4-11.6)	(3.7-11.3)		(7.6-8.3)
55-64	210	148	33	29	0	3,199
Rate*	22.9	23.8	22.0	20.1		22.8
95% C.I.	(19.8-26.0)	(20.0-27.6)	(14.5-29.5)	(12.8-27.4)		(22.1-23.6)
65-74	304	208	42	53	1	5,314
Rate*	47.3	48.1	41.0	49.4		46.1
95% C.I.	(42.0-52.7)	(41.6-54.6)	(28.6-53.4)	(36.1-62.7)		(44.8-47.3)
75-84	246	165	41	38	2	5,567
Rate*	70.0	70.6	70.9	63.4		76.6
95% C.I.	(61.3-78.8)	(59.9-81.4)	(49.2-92.6)	(43.3-83.6)		(74.6-78.6)
85+	58	34	12	12	0	2,270
Rate*	76.1	72.8	77.4	85.5		91.5
95% C.I.	(56.5-95.7)	(48.3-97.3)	(33.6-121.2)	(37.1-133.9)		(87.8-95.3)
Unknown		0	0	0	0	0

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 236. Pancreatic Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1997-2001

County of	1997-2001 Incidence								
Residence	Cases	Ra	te*	Age-Adjus	ted Rate**				
at Diagnosis		Rate	95% C.I.	Rate	95% C.I.				
Carson City	42	16.9	(11.8-22.0)	14.4	(10.3-19.6)				
Churchill	12	9.9	(4.3-15.6)	11.4	(5.8-20.4)				
Clark	644	9.7	(8.9-10.4)	11.0	(10.1-11.9)				
Douglas	21	10.2	(5.9-14.6)	9.3	(5.6-15.1)				
Elko	7								
Esmeralda	1								
Eureka	0								
Humboldt	5								
Lander	3								
Lincoln	1								
Lyon	21	12.3	(7.1-17.6)	11.0	(6.7-17.4)				
Mineral	4								
Nye	27	17.2	(10.7-23.7)	12.2	(7.9-19.1)				
Pershing	0								
Storey	3								
Washoe	154	9.2	(7.7-10.6)	10.5	(8.9-12.3)				
White Pine	3								
Unknown	3								
Total	<u>951</u>	9.8	(9.1-10.4)	10.8	(10.1-11.6)				

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 237. Pancreatic Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

			Gender						
Race/Ethnicity		Male	Female	Other/ Unknown	Total				
White	Incidence	431	386	0	817				
	Rate*	12.4	10.0		11.1				
	95% C.I.	(11.2-13.7)	(9.0-11.1)		(10.4-11.9)				
Black	Incidence	31	30	0	61				
	Rate*	13.8	14.5		14.7				
	95% C.I.	(9.3-22.5)	(9.6-21.3)		(11.0-19.6)				
Native	Incidence	2	3	0	5				
American	Rate*								
	95% C.I.								
Asian	Incidence	8	10	0	18				
	Rate*		4.6		4.8				
	95% C.I.		(2.0-13.6)		(2.8-10.2)				
Hispanic	Incidence	29	18	0	47				
·	Rate*	15.0	6.9		9.9				
	95% C.I.	(8.5-25.4)	(3.8-11.9)		(6.8-14.2)				
Other/Unknown		1	2	0	3				
Total	Incidence	502	449	0	951				
	Rate*	12.2	9.8		10.8				
	95% C.I.	(11.1-13.4)	(8.9-10.7)		(10.1-11.6)				

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population and are aga-adjusted to the 2001 US Standard population.

Table 238. Pancreatic Cancer Cases by Age Group and Gender, Nevada Residents, 1997-2001

Age		Gen	der	
Group	Male	Female	Other/ Unknown	Total
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	1	0	1
Rate* 95% C.I.				
15-24	2	1	0	3
Rate*				3
95% C.I.				
25-34		3	0	4
Rate*	<u></u>			
95% C.I.				
35-44	14	9	0	23
Rate*	1.7			1.5
95% C.I.	(0.8-2.6)			(0.9-2.1)
45-54	66	36	0	102
Rate*	10.2	5.7		7.9
95% C.I.	(7.7-12.6)	(3.8-7.5)		(6.4-9.5)
55-64	113	97	0	210
Rate*	24.8	21.0		22.9
95% C.I.	(20.3-29.4)	(16.8-25.2)		(19.8-26.0)
65-74	177	127	0	304
Rate*	55.8	39.0		47.3
95% C.I.	(47.6-64.1)	(32.3-45.8)		(42.0-52.7)
75-84 Rate*	101 63.7	145 75.2	0	246 70.0
95% C.I.	(51.3-76.1)	(63.0-87.5)		(61.3-78.8)
85+	28	30	0	58
Rate*	113.1	58.3		76.1
95% C.I.	(71.2-155.1)	(37.4-79.1)		(56.5-95.7)
Unknown	0	0	0	0
Total	502	449	0	951
Rate*	10.1	9.4		9.8
95% C.I.	(9.3-11.0)	(8.5-10.2)		(9.1-10.4)

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 239. Pancreatic Cancer Cases by Age Group and Stage, Nevada Residents, 1997-2001

•		Stage							
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total		
<1	Number	0	0	0	0	0	0		
	Percent								
1-4	Number	0	0	0	0	0	0		
	Percent								
5-14	Number	0	0	1	0	0	1		
	Percent			100.0%			100.0%		
15-24	Number	0	1	1	1	0	3		
	Percent		33.3%	33.3%	33.3%		100.0%		
25-34	Number	0	0	2	0	2	4		
	Percent			50.0%		50.0%	100.0%		
35-44	Number	0	1	7	9	6	23		
	Percent		4.3%	30.4%	39.1%	26.1%	100.0%		
45-54	Number	0	6	33	35	28	102		
	Percent		5.9%	32.4%	34.3%	27.5%	100.0%		
55-64	Number	0	10	61	74	65	210		
	Percent		4.8%	29.0%	35.2%	31.0%	100.0%		
65-74	Number	0	25	86	88	105	304		
	Percent		8.2%	28.3%	28.9%	34.5%	100.0%		
75-84	Number	0	18	39	73	116	246		
	Percent		7.3%	15.9%	29.7%	47.2%	100.0%		
85+	Number	0	8	10	10	30	58		
	Percent		13.8%	17.2%	17.2%	51.7%	100.0%		
Unknown	Number	0	0	0	0	0	0		
	Percent								
Total	Number Percent	0	69 7.3%	240 25.2%	290 30.5%	352 37.0%	951 100.0%		

Table 240. Pancreatic Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1997-2001

			Race/Ethnicity								
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total			
In situ	Number	0	0	0	0	0	0	0			
	Percent										
Localized	Number	64	3	0	1	1	0	69			
	Percent	7.8%	4.9%		5.6%	2.1%		7.3%			
Regional	Number	203	16	2	6	13	0	240			
	Percent	24.8%	26.2%	40.0%	33.3%	27.7%		25.2%			
Distant	Number	247	20	0	4	18	1	290			
	Percent	30.2%	32.8%		22.2%	38.3%	33.3%	30.5%			
Unstaged	Number	303	22	3	7	15	2	352			
	Percent	37.1%	36.1%	60.0%	38.9%	31.9%	66.7%	37.0%			
Total	Number	817	61	5	18	47	3	951			
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%			


Table 241. Median Age at Diagnosis of Pancreatic Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

	Gender								
Race/Ethnicity	Ма	le	Fem	ale	Total				
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age			
White	431	68.0	386	70.5	817	69.0			
Black	31	67.0	30	69.5	61	67.0			
Native American	2		3		5	67.0			
Asian	8	65.0	10	73.0	18	69.0			
Hispanic	29	66.0	18	70.0	47	66.0			
Other/Unknown	1		2		3				
Total	502	67.0	449	70.0	951	69.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

# **INPATIENT HOSPITAL DISCHARGES**

Figure 157. Pancreatic Cancer Age-Adjusted (2001) Inpatient Discharge Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 158. Pancreatic Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 159. Median Charges for Pancreatic Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Figure 160. Average Length of Stay for Pancreatic Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001




Table 242. Pancreatic Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

Category	County/Region of Residence					
	Nevada Total	Clark	Washoe	All Other Counties	Unknown	
Total						
Discharges	741	518	132	91	0	
Rate*	8.4	8.7	8.9	6.3		
95% C.I.	(7.8-9.0)	(8.0-9.5)	(7.4-10.6)	(5.0-7.8)		
Gender						
Male	390	279	57	54	0	
Rate*	9.2	9.8	8.0	7.9		
95% C.I.	(8.2-10.3)	(8.6-11.3)	(6.0-10.7)	(5.8-10.8)		
Female	351	239	75	37	0	
Rate*	7.6	7.8	9.5	4.9		
95% C.I.	(6.8-8.5)	(6.8-8.8)	(7.5-12.0)	(3.4-6.8)		
Other/Unknown	0	0	0	0	0	
Inpatient Discharge Ch	narges (\$)					
Total Charges	\$29,859,856	\$22,193,207	\$5,715,771	\$1,950,878		
Average Charges	\$40,297	\$42,844	\$43,301	\$21,438		
Median Charges	\$24,824	\$27,021	\$25,904	\$14,266		
Discharge Length of S	tay (LOS) (Days)					
Total LOS	7,101	5,038	1,494	569		
Average LOS	9.6	9.7	11.3	6.3		
Median LOS	7.0	7.0	9.5	5.0		

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 243. Pancreatic Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

Category	County/Region of Residence					
	Nevada Total	Clark	Washoe	All Other Counties	Unknown	
Total						
Discharges	741	518	132	91	0	
Rate*	7.6	7.8	7.9	6.5		
95% C.I.	(7.1-8.2)	(7.1-8.4)	(6.5-9.2)	(5.2-7.8)		
Age Group						
<1	0	0	0	0	0	
Rate*						
95% C.I.						
1-4	0	0	0	0	0	
Rate*						
95% C.I.						
5-14	0	0	0	0	0	
Rate*						
95% C.I.						
15-24	4	4	0	0	0	
Rate*						
95% C.I.						
25-34	5	3	2	0	0	
Rate*						
95% C.I.						
35-44	17	11	5	1	0	
Rate*	1.1	1.1				
95% C.I.	(0.6-1.6)	(0.4-1.7)				
45-54	85	64	13	8	0	
Rate*	6.6	7.6	5.5			
95% C.I.	(5.2-8.0)	(5.7-9.4)	(2.5-8.5)			
55-64	166	112	30	24	0	
Rate*	18.1	18.0	20.0	16.0		
95% C.I.	(15.4-20.9)	(14.7-21.4)	(12.8-27.1)	(9.6-22.4)		
65-74	254	181	42	31	0	
Rate*	39.5	41.8	41.0	30.2		
95% C.I.	(34.7-44.4)	(35.8-47.9)	(28.6-53.4)	(19.6-40.9)		
75-84	167	118	30	19	0	
Rate*	47.5	50.5	51.9	32.9		
95% C.I.	(40.3-54.8)	(41.4-59.6)	(33.3-70.4)	(18.1-47.6)		
85+	43	25	10	8	0	
Rate*	56.4	53.5	64.5			
95% C.I.	(39.5-73.3)	(32.6-74.5)	(24.5-104.4)			
Unknown	0	0	0	0	0	

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 244. Pancreatic Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1997-2001

Age		Gender					
Group	Male	Female	Total				
<1	0	0					
Rate*							
95% C.I.							
1-4	0	0	0				
Rate*							
95% C.I.							
5-14	0	0	0				
Rate*							
95% C.I.							
15-24	3	1	4				
Rate*							
95% C.I.							
25-34 Rate*	3	2	5				
95% C.I.							
35-44	9	8	17				
Rate*	9	0	1.1				
95% C.I.			(0.6-1.6)				
45-54	57	28	85				
Rate*	8.8	4.4	6.6				
95% C.I.	(6.5-11.0)	(2.8-6.1)	(5.2-8.0)				
55-64	92	74	166				
Rate*	20.2	16.0	18.1				
95% C.I.	(16.1-24.4)	(12.4-19.7)	(15.4-20.9)				
65-74	145	109	254				
Rate*	45.7	33.5	39.5				
95% C.I.	(38.3-53.2)	(27.2-39.8)	(34.7-44.4)				
75-84	62	105	167				
Rate*	39.1	54.5	47.5				
95% C.I.	(29.4-48.8)	(44.1-64.9)	(40.3-54.8)				
85+	19	24	43				
Rate*	76.8	46.6	56.4				
95% C.I.	(42.3-111.3)	(28.0-65.3)	(39.5-73.3)				
<u>Unknown</u> Total	390	351	741				
Rate*	7.9	7.3	741 7.6				
95% C.I.	7.9 (7.1-8.7)	(6.6-8.1)	(7.1-8.2)				
33 /0 O.I.	(1.1-0.1)	(0.0-0.1)	(1.1-0.2)				

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 245. Pancreatic Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1997-2001

County of		1997-2001 Inpatient Hospital Discharges						
County of Residence	Nemales	Rate*			Age-Adjusted Rate**			
	Number	Rate	95% C.I.	Rate	95% C.I.			
Carson City	11	4.4	(1.8-7.0)	3.6	(1.8-6.7)			
Churchill	7							
Clark	518	7.8	(7.1-8.4)	8.7	(8.0-9.5)			
Douglas	14	6.8	(3.3-10.4)	6.1	(3.2-11.3)			
Elko	9							
Esmeralda	1							
Eureka	0							
Humboldt	8							
Lander	0							
Lincoln	3							
Lyon	16	9.4	(4.8-14.0)	8.7	(4.9-14.7)			
Mineral	3							
Nye	17	10.8	(5.7-16.0)	7.3	(4.2-13.1)			
Pershing	0							
Storey	1							
Washoe	132	7.9	(6.5-9.2)	8.9	(7.4-10.6)			
White Pine	1							
Unknown	0							
Total	741	7.6	(7.1-8.2)	8.4	(7.8-9.0)			


Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 246. Pancreatic Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1997-2001

Age	Discharges	Charges (\$)			Length of Stay (Days)		
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	0						
1-4	0						
5-14	0						
15-24	4						
25-34	5	212,989	42,598	17,232	53	10.6	7.0
35-44	17	1,370,490	80,617	43,760	237	13.9	8.0
45-54	85	3,337,046	39,259	26,167	789	9.3	7.0
55-64	166	7,258,277	43,725	27,733	1,707	10.3	7.0
65-74	254	10,385,416	40,887	23,996	2,394	9.4	7.0
75-84	167	5,877,206	35,193	23,432	1,526	9.1	7.0
85+	43	1,111,018	25,838	16,374	316	7.3	6.0
Unknown	0						
Total	741	515,178	708	37,747	92	708.0	9.4

#### **MORTALITY**

Figure 161. Pancreatic Cancer Age-Adjusted (2001) Mortality Rates, Nevada Residents, 1997-2001



Note: Rates are per 100,000 population and age-adjusted to 2001 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 162. Pancreatic Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1997-2001




Figure 163. Pancreatic Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1997-2001




Table 247. Pancreatic Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1997-2001

	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties		
Total						
Mortality	845	572	127	146		
Rate*	9.8	9.9	8.9	10.2		
95% C.I.	(9.1-10.5)	(9.1-10.8)	(7.4-10.7)	(8.6-12.1)		
Gender						
Male	419	283	58	78		
Rate*	10.5	10.6	8.8	11.7		
95% C.I.	(9.4-11.7)	(9.3-12.2)	(6.6-11.7)	(9.1-15.0)		
Female	426	289	69	68		
Rate*	9.3	9.5	8.9	9.1		
95% C.I.	(8.5-10.3)	(8.4-10.7)	(6.9-11.3)	(7.0-11.6)		
Other/Unknown	0	0	0	0		
Race/Ethnicity						
White	726	474	116	136		
Rate*	10.0	10.1	9.2	10.3		
95% C.I.	(9.3-10.8)	(9.2-11.1)	(7.6-11.1)	(8.6-12.2)		
Black	50	47	2	1		
Rate*	12.3	12.6				
95% C.I.	(8.9-17.0)	(9.0-17.6)				
Native American	7	2	2	3		
Rate*						
95% C.I.						
Asian	17	15	0	2		
Rate*	4.8	5.3				
95% C.I.	(2.7-10.2)	(2.9-12.3)				
Hispanic	42	31	7	4		
Rate*	9.0	8.4				
95% C.I.	(6.0-13.2)	(5.2-13.3)				
Other/Unknown	nonulation and are age adi	3	0	0		

\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 248. Pancreatic Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Mortality	845	572	127	146				
Rate*	8.7	8.6	7.6	10.4				
95% C.I.	(8.1-9.3)	(7.9-9.3)	(6.3-8.9)	(8.8-12.1)				
Age Group								
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	0	0	0				
Rate*								
95% C.I.								
15-24	1	1	0	0				
Rate*								
95% C.I.								
25-34	4	2	1	1				
Rate*								
95% C.I.								
35-44	11	8	3	0				
Rate*	0.7							
95% C.I.	(0.3-1.1)							
45-54	77	57	10	10				
Rate*	6.0	6.7	4.2	5.0				
95% C.I.	(4.7-7.3)	(5.0-8.5)	(1.6-6.9)	(1.9-8.1)				
55-64	169	121	22	26				
Rate*	18.4	19.5	14.7	18.0				
95% C.I.	(15.7-21.2)	(16.0-22.9)	(8.5-20.8)	(11.1-24.9)				
65-74	281	189	38	54				
Rate*	43.8	43.7	37.1	50.4				
95% C.I.	(38.6-48.9)	(37.5-49.9)	(25.3-48.9)	(36.9-63.8)				
75-84	237	155	39	43				
Rate*	67.5	66.4	67.4	71.8				
95% C.I.	(58.9-76.1)	(55.9-76.8)	(46.3-88.6)	(50.3-93.2)				
85+	65	39	14	12				
Rate*	85.3	83.5	90.3	85.5				
95% C.I. Unknown	(64.5-106.0) 0	(57.3-109.7) 0	(43.0-137.6) 0	(37.1-133.9) 0				

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 249. Pancreatic Cancer Mortality by County of Residence, Nevada Residents, 1997-2001

	1997-2001 Mortality					
County of Residence	C	Rate*			ted Rate**	
	Cases	Rate	95% C.I.	Rate	95% C.I.	
Carson City	35	14.1	(9.4-18.7)	11.8	(8.2-16.6)	
Churchill	10	8.3	(3.2-13.4)	8.8	(4.2-16.8)	
Clark	572	8.6	(7.9-9.3)	9.9	(9.1-10.8)	
Douglas	22	10.7	(6.2-15.2)	9.3	(5.7-14.9)	
Elko	9					
Esmeralda	0					
Eureka	0					
Humboldt	5					
Lander	2					
Lincoln	3					
Lyon	20	11.8	(6.6-16.9)	10.8	(6.5-17.4)	
Mineral	3					
Nye	27	17.2	(10.7-23.7)	11.9	(7.7-18.7)	
Pershing	2					
Storey	3					
Washoe	127	7.6	(6.3-8.9)	8.9	(7.4-10.7)	
White Pine	5					
Unknown	0					
Total	845	8.7	(8.1-9.3)	9.8	(9.1-10.5)	

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population. \*\*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 250. Pancreatic Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

		Gender				
Race/Ethnicity		Male	Female	Total		
White	Mortality	363	363	726		
	Rate*	10.7	9.5	10.0		
	95% C.I.	(9.5-12.0)	(8.5-10.5)	(9.3-10.8)		
Black	Mortality	24	26	50		
	Rate*	11.0	12.6	12.3		
	95% C.I.	(6.9-19.3)	(8.1-19.2)	(8.9-17.0)		
Native	Mortality	5	2	7		
American	Rate*					
	95% C.I.					
Asian	Mortality	4	13	17		
	Rate*		6.8	4.8		
	95% C.I.		(3.4-16.2)	(2.7-10.2)		
Hispanic	Mortality	22	20	42		
	Rate*	12.6	7.3	9.0		
	95% C.I.	(6.5-22.9)	(4.2-12.3)	(6.0-13.2)		
Other/Unkr	nown	1	2	3		
Total	Mortality	419	426	845		
	Rate*	10.5	9.3	9.8		
	95% C.I.	(9.4-11.7)	(8.5-10.3)	(9.1-10.5)		

Note: The "---" is used for rates calculated on numbers less than ten. \*Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Table 251. Pancreatic Cancer Mortality by Age Group and Gender, Nevada Residents, 1997-2001

Age		Gender					
Group	Male	Female	Total				
<1			0				
Rate*							
95% C.I.							
1-4	0	0	0				
Rate*							
95% C.I.							
5-14	0	0	0				
Rate*							
95% C.I.							
15-24	1	0	1				
Rate*							
95% C.I.							
25-34	1	3	4				
Rate*							
95% C.I.							
35-44 Rate*	3	8	11 0.7				
95% C.I.			(0.3-1.1)				
45-54	49	28	77				
Rate*	7.5	4.4	6.0				
95% C.I.	(5.4-9.6)	(2.8-6.1)	(4.7-7.3)				
55-64	87	82	169				
Rate*	19.1	17.8	18.4				
95% C.I.	(15.1-23.1)	(13.9-21.6)	(15.7-21.2)				
65-74	156	125	281				
Rate*	49.2	38.4	43.8				
95% C.I.	(41.5-56.9)	(31.7-45.2)	(38.6-48.9)				
75-84	93	144	237				
Rate*	58.7	74.7	67.5				
95% C.I.	(46.7-70.6)	(62.5-86.9)	(58.9-76.1)				
85+	29	36	65				
Rate*	117.2	69.9	85.3				
95% C.I.	(74.5-159.8)	(47.1-92.8)	(64.5-106.0)				
Unknown	0	0	0				
Total	419	426	845				
Rate*	8.5 (7.7.0.3)	8.9 (8.1-9.7)	8.7				
95% C.I.	(7.7-9.3)	(8.1-9.7)	(8.1-9.3)				

<sup>\*</sup> Rates are per 100,000 age-specific population.


Table 252. Median Age at Death from Pancreatic Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

	Gender							
Race/Ethnicity	Ма	ile	Fem	nale	Total			
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age		
White	363	70.0	363	72.0	726	71.0		
Black	24	67.0	26	69.5	50	68.0		
Native American	5	68.0	2		7	68.0		
Asian	4		13	68.0	17	68.0		
Hispanic	22	65.5	20	70.5	42	68.0		
Other/Unknown	1		2		3			
Total	419	69.0	426	72.0	845	70.0		

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

### **SURVIVAL RATE**

Figure 164. Survival Rates for Pancreatic Cancer by Race/Ethnicity, Nevada Residents, 1997-2001



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 165. Survival Rates for Pancreatic Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1997-2001




Table 253. Cause-Specific Survival Rates for Pancreatic Cancer by Race/Ethnicity and Gender, Nevada Residents, 1997-2001

Race/		Cause Specific Survival Rate			Median		
Ethnicity and Gender		One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	632	37.8%	21.9%	14.6%	14.6%	14.6%	0.80
Male	359	37.4%	21.6%	13.4%	13.4%	13.4%	0.80
Female	273	38.3%	22.3%	15.9%	15.9%	15.9%	0.81
Race/Ethnicity							
White	545	37.0%	21.3%	13.4%	13.4%	13.4%	0.79
Male	305	36.9%	21.2%	12.3%	12.3%	12.3%	0.79
Female	240	37.1%	21.3%	14.6%	14.6%	14.6%	0.80
Black	39						
Male	23						
Female	16						
Native American	3						
Male	1						
Female	2						
Asian	11						
Male	6						
Female	5						
Hispanic	31						
Male	23	<del></del>					
Female	8						

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 254. Cause-Specific Survival Rates for Pancreatic Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1997-2001

Survival Rate of Stage at Diagnosis		Gender				
		Total	Male	Female		
Total	Cases	632	359	273		
	One Year	37.8%	37.4%	38.3%		
	5 Years	14.6%	13.4%	15.9%		
	Median Survival	0.80	0.80	0.81		
Stage at Di	iagnosis					
In situ	Cases	0	0	0		
	One Year					
	5 Years					
	Median Survival					
Localized	Cases	44	27	17		
	One Year					
	5 Years					
	Median Survival					
Regional	Cases	181	107	74		
	One Year	43.8%	40.1%	49.2%		
	5 Years	15.9%	14.7%	17.2%		
	Median Survival	0.89	0.83	0.98		
Distant	Cases	193	109	84		
	One Year	36.8%	35.2%	38.9%		
	5 Years	16.7%		15.6%		
	Median Survival	0.79	0.77	0.82		
Unstaged	Cases	214	116	98		
	One Year	30.3%	34.8%	25.6%		
	5 Years					
	Median Survival	0.72	0.77	0.67		

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

# ALL OTHER CANCERS

## **ALL OTHER CANCERS**


Table 255. Cancer Incidence, Inpatient Hospital Discharges and Mortality by Type of Cancer, Nevada Residents, 1997-2001

Type of Cancer		Incidence	Hospital Admissions	Mortality
Total		38,261	32,109	16,806
	Rate*	449.2	372.2	207.6
	95% C.I.	(444.6-453.9)	(368.1-376.4)	(204.4-210.9)
Skin		875	71	249
	Rate*	9.8	0.8	2.9
	95% C.I.	(9.2-10.5)	(0.6-1.1)	(2.5-3.3)
Corpus Uteri & Ut	erus NOS	850	853	131
•	Rate*	18.8	18.8	3.1
	95% C.I.	(17.6-20.1)	(17.6-20.2)	(2.6-3.6)
Ovary		741	635	361
•	Rate*	16.6	14.1	8.3
	95% C.I.	(15.4-17.8)	(13.0-15.2)	(7.5-9.3)
Thyroid Gland		563	750	29
	Rate*	6.0	8.0	0.4
	95% C.I.	(5.6-6.6)	(7.4-8.6)	(0.2-0.5)
Brain and Other C	Central Nervous			
System		560	728	320
	Rate*	6.4	8.1	3.7
	95% C.I.	(5.9-7.0)	(7.5-8.7)	(3.3-4.2)
Stomach		544	571	326
	Rate*	6.8	6.9	4.2
	95% C.I.	(6.3-7.5)	(6.3-7.5)	(3.7-4.7)
Liver and Intrahep		501	338	388
	Rate*	5.9	3.9	4.7
0	95% C.I.	(5.4-6.5)	(3.5-4.3)	(4.3-5.3)
Cervix Uteri	D. ( +	497	611	133
	Rate*	10.9	13.3	3.0
F .	95% C.I.	(9.9-11.9)	(12.3-14.4)	(2.5-3.6)
Esophagus	D-4-*	444	293	368
	Rate*	5.2	3.4	4.3
1	95% C.I.	(4.7-5.7)	(3.0-3.8)	(3.8-4.7)
Larynx	Data*	371	226	136
	Rate*	4.3	2.5	1.6
Multiple Muslemen	95% C.I.	(3.8-4.7)	(2.2-2.9)	(1.4-1.9)
Multiple Myeloma	Doto*	337	320	229
	Rate*	4.0	3.7	2.8
Hodgkin's Lympho	95% C.I.	(3.6-4.5)	(3.3-4.1)	(2.4-3.2)
Tiougkii S Lympho	Rate*	2.0	1.2	39 0.4
All Other Sites	95% C.I.	(1.7-2.3)	(1.0-1.5)	(0.3-0.6)
All Other Sites	Rate*	3,145	7,626	2,015
	95% C.I.	37.8 (36.4-39.1)	88.4 (86.4-90.5)	25.5 (24.3-26.7)
	JJ /U J.I.	(30.4-33.1)	(00.4-90.3)	(24.5-20.1)

 $<sup>\</sup>ast$  Rates are per 100,000 population and age-adjusted to the 2001 US Standard population. Gender-specific cancers are per 100,000 gender-specific population and age-adjusted to the 2001 US Standard population.

## SKIN CANCER GENERAL PROFILE<sup>4</sup>

Figure 166. Anatomy of the Skin<sup>4</sup>



General Anatomy: The skin is the body's largest organ. It protects against heat, sunlight, injury, and infection. Skin aids in the regulation of body temperature, stores water and fat, and produces vitamin D. The skin has two main layers: the outer epidermis and the inner dermis. The epidermis is mostly made up of flat, scale-like cells called squamous cells. Round cells called basal cells lie under the squamous cells in the epidermis. The lower part of the epidermis also contains melanocytes. The dermis contains blood vessels, lymph vessels, hair follicles, and glands. Some of these glands produce sweat, which helps regulate body temperature. Other glands produce sebum, an oily substance that helps keep the skin from drying out. Sweat and sebum reach the skin's surface through tiny openings called pores. Melanoma is one of the most common cancers and occurs when melanocytes (pigment cells) become malignant.

**Risk Factors:** Dysplastic nevi moles, many (more than 50) ordinary moles, fair skin, personal history of melanoma or skin cancer, family history of melanoma, weakened immune system, severe, blistering sunburns, and ultraviolet (UV) radiation.

**Signs and Symptoms:** Asymetrical, border, color, and diameter changes in a mole, and dysplastic nevi moles are common signs and symptoms.

**Diagnosing the Cancer:** Excisional biopsy.

**Treatment:** Treatment options include: surgery (sentinel lymph node biopsy, lymph node dissection), chemotherapy (orally or injection or isolated limb perfusion), biological therapy, or radiation therapy.

Table 256. Skin Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)			
Total									
Cases	1,083	700	210	172	1	30,483			
Rate*	11.1	10.5	12.5	12.3		16.5			
95% C.I.	(10.5-11.8)	(9.7-11.3)	(10.8-14.2)	(10.5-14.1)		(16.3-16.6)			
Age Group									
<1	0	0	0	0	0				
Rate*									
95% C.I.									
1-4	0	0	0	0	0	5			
Rate*									
95% C.I.									
5-14	1	0	0	1	0	56			
Rate*						0.2			
95% C.I.						(0.2-0.3)			
15-24	27	14	7	6	0	655			
Rate*	2.0	1.5				2.5			
95% C.I.	(1.3-2.8)	(0.7-2.3)				(2.3-2.7)			
25-34	75	52	12	10	1	2,388			
Rate*	5.1	4.9	4.7	6.4		8.2			
95% C.I.	(3.9-6.2)	(3.6-6.2)	(2.0-7.4)	(2.4-10.3)		(7.8-8.5)			
35-44	156	85	41	30	0	4,676			
Rate*	10.0	8.1	14.5	13.3		15.0			
95% C.I.	(8.5-11.6)	(6.4-9.8)	(10.0-18.9)	(8.5-18.0)		(14.5-15.4)			
45-54	209	125	49	35	0	5,958			
Rate*	16.3	14.8	20.7	17.4		26.0			
95% C.I.	(14.1-18.5)	(12.2-17.4)	(14.9-26.5)	(11.7-23.2)		(25.4-26.7)			
55-64	210	144	39	27	0	5,295			
Rate*	22.9	23.2	26.0	18.7		37.8			
95% C.I.	(19.8-26.0)	(19.4-27.0)	(17.8-34.1)	(11.6-25.7)		(36.8-38.8)			
65-74	222	156	34	32	0	5,597			
Rate*	34.6	36.1	33.2	29.8		48.5			
95% C.I.	(30.0-39.1)	(30.4-41.7)	(22.0-44.3)	(19.5-40.2)		(47.2-49.8)			
75-84	159	109	26	24	0	4,388			
Rate*	45.3	46.7	45.0	40.1		60.4			
95% C.I.	(38.2-52.3)	(37.9-55.4)	(27.7-62.2)	(24.0-56.1)		(58.6-62.2)			
85+	23	14	2	7	0	1,461			
Rate*	30.2	30.0				58.9			
95% C.I.	(17.8-42.5)	(14.3-45.7)				(55.9-61.9)			
Unknown	` , , , , , , , , , , , , , , , , , , ,	1	0	0	0	0			

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 257. Skin Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

		Coun	ty/Region of Resid	lence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	83	60	9	14	0
Rate*	0.9	1.0		0.9	
95% C.I.	(0.7-1.1)	(0.8-1.3)		(0.5-1.6)	
Gender					
Male	54	36	7	11	0
Rate*	1.3	1.4		1.4	
95% C.I.	(0.9-1.8)	(0.9-2.1)		(0.7-2.8)	
Female	29	24	2	3	0
Rate*	0.6	8.0			
95% C.I.	(0.4-0.9)	(0.5-1.1)			
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$1,199,486	\$921,475	\$132,535	\$145,476	
Average Charges	\$14,452	\$15,358	\$14,726	\$10,391	
Median Charges	\$11,291	\$11,139	\$15,423	\$9,768	
Discharge Length of S	tay (LOS) (Days)				
Total LOS	283	226	26	31	
Average LOS	3.4	3.8	2.9	2.2	
Median LOS	2.0	2.0	3.0	1.0	

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.


Table 258. Skin Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region	of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	264	172	39	53
Rate*	2.7	2.6	2.3	3.8
95% C.I.	(2.4-3.0)	(2.2-3.0)	(1.6-3.1)	(2.8-4.8)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	3	2	1	0
Rate*				
95% C.I.				
25-34	6	5	1	0
Rate*				
95% C.I.				
35-44	28	17	7	4
Rate*	1.8	1.6		
95% C.I.	(1.1-2.5)	(0.9-2.4)		
45-54	41	25	7	9
Rate*	3.2	3.0		
95% C.I.	(2.2-4.2)	(1.8-4.1)		
55-64	57	40	4	13
Rate*	6.2	6.4		9.0
95% C.I.	(4.6-7.8)	(4.4-8.4)		(4.1-13.9)
65-74	67	43	10	14
Rate*	10.4	9.9	9.8	13.1
95% C.I.	(7.9-12.9)	(7.0-12.9)	(3.7-15.8)	(6.2-19.9)
75-84 Rate*	51 14.5	37 15.8		7
95% C.I.	(10.5-18.5)	(10.7-20.9)	<del></del>	
95% C.I.	(10.5-18.5)	(10.7-20.9)	2	6
Rate*	14.4			0
95% C.I.	(5.9-23.0)			
Unknown	(5.9-25.0)	0	0	0
CHRIOWII		0		

<sup>\*</sup> Rates are per 100,000 age-specific population.

# UTERINE CANCER GENERAL PROFILE<sup>4</sup>

Figure 167. Anatomical Drawing of Female Reproductive System<sup>4</sup>



**General Anatomy:** The uterus is part of a woman's reproductive system. It is the hollow, pear-shaped organ where a baby grows. The uterus is in the pelvis between the bladder and the rectum. The narrow, lower portion of the uterus is the cervix. The broad, middle part of the uterus is the body, or corpus. The dome-shaped top of the uterus is the fundus. The fallopian tubes extend from either side of the top of the uterus to the ovaries.

The wall of the uterus has two layers of tissue. The inner layer, or lining, is the endometrium. The outer layer is muscle tissue called the myometrium. In women of childbearing age, the lining of the uterus grows and thickens each month to prepare for pregnancy. If a woman does not become pregnant, the thick, bloody lining flows out of the body through the vagina. This flow is called menstruation.

**Risk Factors:** Age (Women over 50), Endometrial hyperplasia, hormone replacement therapy (HRT), obesity and related conditions, women taking the drug Tamoxifen, race (White females), and inherited form of Colorectal Cancer.

**Signs and Symptoms:** Unusual vaginal bleeding or discharge, difficult or painful urination, pain during intercourse, and pain in the pelvic area.

**Diagnosing the Cancer:** Pelvic exam, Pap test, transvaginal ultrasound, and biopsy.

**Treatment:** Treatment options include: surgery (hysterectomy), radiation therapy and hormonal therapy.

Table 259. Uterine Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)				
Total										
Cases	852	589	144	119	0	23,249				
Rate*	8.7	8.8	8.6	8.5		12.6				
95% C.I.	(8.2-9.3)	(8.1-9.6)	(7.2-10.0)	(7.0-10.0)		(12.4-12.7)				
Age Group										
<1	0	0	0	0	0					
Rate*										
95% C.I.										
1-4	0	0	0	0	0					
Rate*										
95% C.I.										
5-14	0	0	0	0	0					
Rate*										
95% C.I.										
15-24	1	1	0	0	0	23				
Rate*						0.1				
95% C.I.						(0.1-0.1)				
25-34	20	16	2	2	0	321				
Rate*	1.4	1.5				1.1				
95% C.I.	(0.8-2.0)	(0.8-2.2)				(1.0-1.2)				
35-44	51	40	4	7	0	1,474				
Rate*	3.3	3.8				4.7				
95% C.I.	(2.4-4.2)	(2.6-5.0)				(4.5-5.0)				
45-54	156	112	25	19	0	4,263				
Rate*	12.2	13.2	10.6	9.5		18.6				
95% C.I.	(10.2-14.1)	(10.8-15.7)	(6.4-14.7)	(5.2-13.7)		(18.1-19.2)				
55-64	213	153	36	24	0	5,907				
Rate*	23.2	24.6	24.0	16.6		42.2				
95% C.I.	(20.1-26.4)	(20.7-28.5)	(16.1-31.8)	(10.0-23.3)		(41.1-43.3)				
65-74	242	164	45	33	0	5,769				
Rate*	37.7	37.9	43.9	30.8		50.0				
95% C.I.	(32.9-42.4)	(32.1-43.7)	(31.1-56.7)	(20.3-41.3)		(48.7-51.3)				
75-84	139	89	24	26	0	4,254				
Rate*	39.6	38.1	41.5	43.4		58.5				
95% C.I.	(33.0-46.1)	(30.2-46.0)	(24.9-58.1)	(26.7-60.1)		(56.8-60.3)				
85+	30	14	8	8	0	1,234				
Rate*	39.4	30.0				49.8				
95% C.I.	(25.3-53.4)	(14.3-45.7)				(47.0-52.5)				
Unknown		0	0	0	0	, o				

<sup>\*</sup> Rates are per 100,000 age-specific female population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 260. Uterine Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	
Total						
Discharges	828	582	128	118	0	
Rate*	8.9	9.3	8.2	8.2		
95% C.I.	(8.3-9.6)	(8.5-10.1)	(6.8-9.8)	(6.7-9.8)		
Gender						
Male	0	0	0	0	0	
Rate*						
95% C.I.						
Female	828	582	128	118	0	
Rate*	17.3	18.0	15.8	15.9		
95% C.I.	(16.1-18.5)	(16.6-19.6)	(13.2-18.8)	(13.1-19.0)		
Other/Unknown	0	0	0	0	0	
Inpatient Discharge Ch	narges (\$)					
Total Charges	\$20,089,485	\$13,984,251	\$3,344,901	\$2,760,333		
Average Charges	\$24,263	\$24,028	\$26,132	\$23,393		
Median Charges	\$17,917	\$17,197	\$25,108	\$15,358		
Discharge Length of S	tay (LOS) (Days)					
Total LOS	3,778	2,727	556	495		
Average LOS	4.6	4.7	4.3	4.2		
Median LOS	3.0	3.0	3.0	3.0		

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.


Table 261. Uterine Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Mortality	134	93	26	15				
Rate*	1.4	1.4	1.5	1.1				
95% C.I.	(1.1-1.6)	(1.1-1.7)	(1.0-2.1)	(0.5-1.6)				
Age Group								
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	0	0	0				
Rate*								
95% C.I.								
15-24	0	0	0	0				
Rate*								
95% C.I.								
25-34	1	1	0	0				
Rate*								
95% C.I.								
35-44	6	6	0	0				
Rate*								
95% C.I.								
45-54	19	16	3	0				
Rate*	1.5	1.9						
95% C.I.	(0.8-2.1)	(1.0-2.8)						
55-64	20	14	6	0				
Rate*	2.2	2.3						
95% C.I.	(1.2-3.1)	(1.1-3.4)						
65-74	34	20	5	9				
Rate*	5.3	4.6						
95% C.I.	(3.5-7.1)	(2.6-6.7)						
75-84	37	28	5	4				
Rate*	10.5	12.0						
95% C.I.	(7.1-13.9)	(7.5-16.4)						
85+	17	8	7	2				
Rate*	22.3							
95% C.I.	(11.7-32.9)							
Unknown	0	0	0	0				

<sup>\*</sup> Rates are per 100,000 age-specific female population.

## OVARIAN CANCER GENERAL PROFILE<sup>4</sup>

Figure 168. Anatomical Drawing of Female Reproductive System<sup>4</sup>



**General Anatomy:** The ovaries are a pair of organs in the female reproductive system. They are located in the pelvis, one on each side of the uterus. Each ovary is about the size and shape of an almond. The ovaries have two functions: they produce eggs and female hormones (chemicals that control the way certain cells or organs function).

Every month, during the menstrual cycle, an egg is released from one ovary in a process called ovulation. The egg travels from the ovary through the fallopian tube to the uterus. The ovaries are also the main source of the female hormones estrogen and progesterone, which influence the development of a woman's breasts, body shape, and body hair. They also regulate the menstrual cycle and pregnancy.

**Risk Factors:** Family history, age (women over 50, especially over 60), women who never had children, personal history of Breast or Colorectal Cancer, use of fertility drugs, use of talc, and hormone replacement therapy (HRT).

**Signs and Symptoms:** General abdominal discomfort and/or pain (gas, indigestion, pressure, swelling, bloating, cramps), Nausea, diarrhea, constipation, or frequent urination, Loss of appetite, feeling of fullness even after a light meal, weight gain or loss with no known reason, and abnormal bleeding from the vagina.

**Diagnosing the Cancer:** Pelvic exam, ultrasound, CA-125 assay blood test, lower gastrointestinal (GI) series, or barium enema (colon and rectum X-rays), CT (or CAT) scan, and biopsy.

**Treatment:** Surgery (hysterectomy with bilateral Salpingo-oophorectomy), chemotherapy, radiation therapy, and clinical trials.

Table 262. Ovarian Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)				
Total										
Cases	737	494	145	98	0	13,348				
Rate*	7.6	7.4	8.6	7.0		7.2				
95% C.I.	(7.0-8.1)	(6.8-8.1)	(7.2-10.0)	(5.6-8.4)		(7.1-7.3)				
Age Group										
<1	0	0	0	0	0					
Rate*										
95% C.I.										
1-4	0	0	0	0	0					
Rate*										
95% C.I.										
5-14	1	1	0	0	0	55				
Rate*						0.2				
95% C.I.						(0.2-0.3)				
15-24	7	6	0	1	0	194				
Rate*						0.8				
95% C.I.						(0.6-0.9)				
25-34	34	22	4	8	0	354				
Rate*	2.3	2.1				1.2				
95% C.I.	(1.5-3.1)	(1.2-2.9)				(1.1-1.3)				
35-44	74	49	17	8	0	1,100				
Rate*	4.8	4.7	6.0			3.5				
95% C.I.	(3.7-5.8)	(3.4-6.0)	(3.1-8.9)			(3.3-3.7)				
45-54	122	81	28	13	0	2,578				
Rate*	9.5	9.6	11.8	6.5		11.3				
95% C.I.	(7.8-11.2)	(7.5-11.7)	(7.5-16.2)	(3.0-10.0)		(10.8-11.7)				
55-64	168	111	30	27	0	2,761				
Rate*	18.3	17.9	20.0	18.7		19.7				
95% C.I.	(15.6-21.1)	(14.5-21.2)	(12.8-27.1)	(11.6-25.7)		(19.0-20.5)				
65-74	190	127	36	27	0	2,884				
Rate*	29.6	29.4	35.1	25.2		25.0				
95% C.I.	(25.4-33.8)	(24.3-34.5)	(23.6-46.6)	(15.7-34.7)		(24.1-25.9)				
75-84	112	75	26	11	0	2,540				
Rate*	31.9	32.1	45.0	18.4		34.9				
95% C.I.	(26.0-37.8)	(24.8-39.4)	(27.7-62.2)	(7.5-29.2)		(33.6-36.3)				
85+	29	22	4	3	0	878				
Rate*	38.0	47.1				35.4				
95% C.I.	(24.2-51.9)	(27.4-66.8)				(33.1-37.7)				
Unknown	0	0	0	0	0	0				

<sup>\*</sup> Rates are per 100,000 age-specific female population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 263. Ovarian Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	
Total						
Discharges	669	450	143	76	0	
Rate*	7.2	7.3	9.1	5.2		
95% C.I.	(6.7-7.8)	(6.6-8.0)	(7.7-10.8)	(4.1-6.5)		
Gender						
Male	0	0	0	0	0	
Rate*						
95% C.I.						
Female	669	450	143	76	0	
Rate*	14.0	14.1	17.6	10.2		
95% C.I.	(13.0-15.2)	(12.8-15.5)	(14.8-20.8)	(8.1-12.9)		
Other/Unknown	0	0	0	0	0	
Inpatient Discharge Cl	narges (\$)					
Total Charges	\$27,619,931	\$17,456,637	\$7,362,703	\$2,800,591		
Average Charges	\$41,285	\$38,793	\$51,487	\$36,850		
Median Charges	\$28,944	\$27,669	\$32,629	\$26,731		
Discharge Length of S	tay (LOS) (Days)					
Total LOS	5,360	3,515	1,337	508		
Average LOS	8.0	7.8	9.3	6.7		
Median LOS	6.0	6.0	7.0	6.0		

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.


Table 264. Ovarian Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Mortality	376	262	72	42				
Rate*	3.9	3.9	4.3	3.0				
95% C.I.	(3.5-4.3)	(3.5-4.4)	(3.3-5.3)	(2.1-3.9)				
Age Group								
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	0	0	0				
Rate*								
95% C.I.								
15-24	0	0	0	0				
Rate*								
95% C.I.								
25-34	3	2	1	0				
Rate*								
95% C.I.								
35-44	15	13	1	1				
Rate*	1.0	1.2						
95% C.I.	(0.5-1.5)	(0.6-1.9)						
45-54	62	48	10	4				
Rate*	4.8	5.7	4.2					
95% C.I.	(3.6-6.0)	(4.1-7.3)	(1.6-6.9)					
55-64	65	40	13	12				
Rate*	7.1	6.4	8.7	8.3				
95% C.I.	(5.4-8.8)	(4.4-8.4)	(4.0-13.4)	(3.6-13.0)				
65-74	114	77	28	9				
Rate*	17.8	17.8	27.3					
95% C.I.	(14.5-21.0)	(13.8-21.8)	(17.2-37.4)					
75-84	89	64	15	10				
Rate*	25.3	27.4	25.9	16.7				
95% C.I.	(20.1-30.6)	(20.7-34.1)	(12.8-39.1)	(6.3-27.0)				
85+	28	18	4	6				
Rate*	36.7	38.5						
95% C.I.	(23.1-50.3)	(20.7-56.4)						
Unknown		0	0	0				

<sup>\*</sup> Rates are per 100,000 age-specific female population.

# THYROID GLAND CANCER GENERAL PROFILE<sup>4</sup>

Figure 169. Anatomical Drawing of the Thyroid Gland<sup>4</sup>



General Anatomy: The thyroid is a gland in the neck. It has two kinds of cells that make hormones. Follicular cells make thyroid hormone, which affects heart rate, body temperature, and energy level. C cells make calcitonin, a hormone that helps control the level of calcium in the blood. The thyroid is shaped like a butterfly and lies at the front of the neck, beneath the voice box (larynx). It has two parts, or lobes. A thin section called the isthmus separates the two lobes of the thyroid. A healthy thyroid is a little larger than a quarter. It usually cannot be felt through the skin. A swollen lobe might look or feel like a lump in the front of the neck. A swollen thyroid is called a goiter. Most goiters are caused by not enough iodine in the diet.

**Risk Factors:** Exposure to radiation, family history, female gender, age (over 40), race (Whites are more likely to be diagnosed with Thyroid Cancer than Blacks, as a racial/ethnic group), and iodine deficiency.

**Signs and Symptoms:** A lump, or nodule, in the front of the neck near the Adam's apple, hoarseness or difficulty speaking in a normal voice, swollen lymph nodes, especially in the neck, difficulty swallowing or breathing, or pain in the throat or neck.

**Diagnosing the Cancer:** Physical exam, blood tests, ultrasonography, radionuclide scanning, and fine-needle aspiration.

**Treatment:** surgery (total thyroidectomy, lobectomy), radioactive iodine, hormone treatment, external radiation, and chemotherapy.

Table 265. Thyroid Gland Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)
Total						
Cases	696	478	141	76	1	13,502
Rate*	7.1	7.2	8.4	5.4		7.3
95% C.I.	(6.6-7.7)	(6.5-7.8)	(7.0-9.8)	(4.2-6.7)		(7.2-7.4)
Age Group						
<1	0	0	0	0	0	
Rate*						
95% C.I.						
1-4	0	0	0	0	0	
Rate*						
95% C.I.						
5-14	2	2	0	0	0	84
Rate*						0.3
95% C.I.						(0.2-0.4)
15-24	42	28	11	3	0	785
Rate*	3.1	3.0	4.8			3.0
95% C.I.	(2.2-4.1)	(1.9-4.1)	(2.0-7.6)			(2.8-3.3)
25-34	125	95	20	10	0	2,234
Rate*	8.5	8.9	7.8	6.4		7.6
95% C.I.	(7.0-10.0)	(7.1-10.7)	(4.4-11.3)	(2.4-10.3)		(7.3-7.9)
35-44	165	102	44	18	1	3,150
Rate*	10.6	9.7	15.5	8.0		10.1
95% C.I.	(9.0-12.2)	(7.9-11.6)	(10.9-20.1)	(4.3-11.6)		(9.7-10.4)
45-54	166	106	36	24	0	2,944
Rate*	12.9	12.5	15.2	12.0		12.9
95% C.I.	(11.0-14.9)	(10.1-14.9)	(10.3-20.2)	(7.2-16.7)		(12.4-13.3)
55-64	105	78	17	10	0	1,931
Rate*	11.5	12.5	11.3	6.9		13.8
95% C.I.	(9.3-13.7)	(9.8-15.3)	(5.9-16.7)	(2.6-11.2)		(13.2-14.4)
65-74	56	41	8	7	0	1,340
Rate*	8.7	9.5				11.6
95% C.I.	(6.4-11.0)	(6.6-12.4)				(11.0-12.2)
75-84	31	24	4	3	0	834
Rate*	8.8	10.3				11.5
95% C.I.	(5.7-11.9)	(6.2-14.4)				(10.7-12.3)
85+	4	2	1	1	0	200
Rate*						8.1
95% C.I.						(6.9-9.2)
Unknown	0	0	0	0	0	0

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 266. Thyroid Gland Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	985	757	151	77	0
Rate*	10.1	11.4	8.8	5.3	
95% C.I.	(9.4-10.7)	(10.6-12.2)	(7.5-10.4)	(4.2-6.7)	
Gender					
Male	216	166	25	25	0
Rate*	4.5	5.2	2.9	3.4	
95% C.I.	(3.9-5.2)	(4.4-6.1)	(1.8-4.6)	(2.2-5.3)	
Female	769	591	126	52	0
Rate*	15.9	18.0	14.9	7.4	
95% C.I.	(14.8-17.1)	(16.5-19.5)	(12.4-17.7)	(5.5-9.7)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Cl	harges (\$)				
Total Charges	\$10,928,533	\$8,057,777	\$2,002,913	\$867,843	
Average Charges	\$11,095	\$10,644	\$13,264	\$11,271	
Median Charges	\$10,071	\$9,592	\$12,298	\$10,741	
Discharge Length of S	Stay (LOS) (Days)				
Total LOS	2,051	1,565	333	153	
Average LOS	2.1	2.1	2.2	2.0	
Median LOS	2.0	2.0	2.0	2.0	

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 267. Thyroid Gland Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001


		County/Region o	f Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	29	18	6	5
Rate*	0.3	0.3	0.4	0.4
95% C.I.	(0.2-0.4)	(0.1-0.4)	(0.1-0.6)	(0.0-0.7)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	0	0	0	0
Rate*				
95% C.I.				
25-34	0	0	0	0
Rate*				
95% C.I.				
35-44	0	0	0	0
Rate*				
95% C.I.				
45-54	2	1	0	1
Rate*				
95% C.I.				
55-64	9	6	2	1
Rate*				
95% C.I.				
65-74	5	3	1	1
Rate*				
95% C.I.				
75-84	10	7	1	2
Rate*	2.8			
95% C.I.	(1.1-4.6)			
85+	3	1	2	0
Rate*				
95% C.I.				
Unknown	0	0	0	0

\* Rates are per 100,000 age-specific population.

## BRAIN AND OTHER CENTRAL NERVOUS SYSTEM CANCER

## GENERAL PROFILE<sup>4</sup>

Figure 170. Anatomical Drawing of the Brain and Nearby Structures<sup>4</sup>



General Anatomy: The brain is a soft, spongy mass of tissue. The bones of the skull and three thin membranes called meninges protect it, and watery fluid called cerebrospinal fluid cushions the brain. This fluid flows through spaces between the meninges and through spaces within the brain called ventricles. A network of nerves carries messages back and forth between the brain and the rest of the body. Some nerves go directly from the brain to the eyes, ears, and other parts of the head. Many nerves run through the spinal cord to connect the brain with the other parts of the body. Within the brain and spinal cord, glial cells surround nerve cells and hold them in place.

**Risk Factors:** Male gender, White race, age (over 70 years of age), family history, and exposure to radiation or certain chemicals: formaldehyde, vinyl chloride, and acrylonitrile.

**Signs and Symptoms:** Headaches (usually worse in the morning), nausea or vomiting, changes in speech, vision, or hearing, problems balancing or walking, changes in mood, personality, or ability to concentrate, problems with memory, muscle jerking or twitching (seizures or convulsions), and numbness or tingling in the arms or legs.

**Diagnosing the Cancer:** Physical exam, neurologic exam, computed tomography (CAT) scan, magnetic resonance imaging (MRI), angiogram, skull x-ray, spinal tap, myelogram, and biopsy.

**Treatment:** surgery (craniotomy), radiation therapy (fractionation, hyperfractionation, stereotactic, 3-dimensional conformal, and proton beam), and chemotherapy.

Table 268. Brain and Other Central Nervous System Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

Category	County/Region of Residence						
	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)	
Total							
Cases	580	392	90	96	2	11,565	
Rate*	6.0	5.9	5.4	6.9		6.2	
95% C.I.	(5.5-6.4)	(5.3-6.5)	(4.3-6.5)	(5.5-8.2)		(6.1-6.4)	
Age Group							
<1	6	2	2	2	0	93	
Rate*						3.4	
95% C.I.						(2.7-4.0)	
1-4	14	12	1	1	0	431	
Rate*	2.5	3.0				3.9	
95% C.I.	(1.2-3.8)	(1.3-4.7)				(3.5-4.2)	
5-14	33	19	7	6	1	800	
Rate*	2.4	2.0				3.0	
95% C.I.	(1.6-3.2)	(1.1-2.9)				(2.8-3.2)	
15-24	20	10	4	6	0	500	
Rate*	1.5	1.1				1.9	
95% C.I.	(0.8-2.1)	(0.4-1.7)				(1.8-2.1)	
25-34	43	30	7	6	0	865	
Rate*	2.9	2.8				3.0	
95% C.I.	(2.0-3.8)	(1.8-3.8)				(2.8-3.2)	
35-44	56	41	8	7	0	1,329	
Rate*	3.6	3.9				4.3	
95% C.I.	(2.7-4.5)	(2.7-5.1)				(4.0-4.5)	
45-54	88	56	17	15	0	1,664	
Rate*	6.9	6.6	7.2	7.5		7.3	
95% C.I.	(5.4-8.3)	(4.9-8.3)	(3.8-10.6)	(3.7-11.3)		(6.9-7.6)	
55-64	109	68	20	21	0	1,769	
Rate*	11.9	10.9	13.3	14.5		12.6	
95% C.I.	(9.7-14.1)	(8.3-13.5)	(7.5-19.2)	(8.3-20.7)		(12.0-13.2)	
65-74	117	85	10	22	0	2,023	
Rate*	18.2	19.7	9.8	20.5		17.5	
95% C.I.	(14.9-21.5)	(15.5-23.8)	(3.7-15.8)	(11.9-29.1)		(16.8-18.3)	
75-84	79	57	· 11	10	1	1,672	
Rate*	22.5	24.4	19.0	16.7		23.0	
95% C.I.	(17.5-27.4)	(18.1-30.7)	(7.8-30.3)	(6.3-27.0)		(21.9-24.1)	
85+	15	12	3	0	0	419	
Rate*	19.7	25.7				16.9	
95% C.I.	(9.7-29.6)	(11.2-40.2)				(15.3-18.5)	
Unknown	0	0	0	0	0	0	

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 269. Brain and Other Central Nervous System Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown		
Total							
Discharges	762	539	110	112	1		
Rate*	8.1	8.4	6.8	7.6			
95% C.I.	(7.5-8.7)	(7.7-9.2)	(5.6-8.3)	(6.3-9.3)			
Gender							
Male	449	324	58	66	1		
Rate*	9.6	10.3	7.2	8.9			
95% C.I.	(8.7-10.6)	(9.2-11.7)	(5.4-9.6)	(6.9-11.6)			
Female	313	215	52	46	0		
Rate*	6.6	6.7	6.4	6.4			
95% C.I.	(5.9-7.4)	(5.8-7.7)	(4.7-8.4)	(4.7-8.6)			
Other/Unknown	0	0	0	0	0		
Inpatient Discharge Charges (\$)							
Total Charges	\$28,160,525	\$20,921,574	\$3,712,360	\$3,520,539	\$6,052		
Average Charges	\$36,956	\$38,816	\$33,749	\$31,433	\$6,052		
Median Charges	\$30,345	\$31,278	\$30,857	\$26,211	\$6,052		
Discharge Length of S	tay (LOS) (Days)						
Total LOS	5,863	4,247	850	765	1		
Average LOS	7.7	7.9	7.7	6.8	1.0		
Median LOS	5.0	5.0	5.0	5.0	1.0		

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.


Table 270. Brain and Other Central Nervous System Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties		
Total						
Mortality	338	223	54	61		
Rate*	3.5	3.3	3.2	4.4		
95% C.I.	(3.1-3.8)	(2.9-3.8)	(2.4-4.1)	(3.3-5.5)		
Age Group						
<1	0	0	0	0		
Rate*						
95% C.I.						
1-4	5	5	0	0		
Rate*						
95% C.I.						
5-14	7	3	3	1		
Rate*						
95% C.I.						
15-24	3	1	1	1		
Rate*						
95% C.I.						
25-34	15	12	3	0		
Rate*	1.0	1.1				
95% C.I.	(0.5-1.5)	(0.5-1.8)				
35-44	29	19	4	6		
Rate*	1.9	1.8				
95% C.I.	(1.2-2.5)	(1.0-2.6)				
45-54	43	31	9	3		
Rate*	3.3	3.7				
95% C.I.	(2.3-4.4)	(2.4-5.0)				
55-64	74	52	10	12		
Rate*	8.1	8.4	6.7	8.3		
95% C.I.	(6.2-9.9)	(6.1-10.6)	(2.5-10.8)	(3.6-13.0)		
65-74	82	55	7	20		
Rate*	12.8	12.7		18.7		
95% C.I.	(10.0-15.5)	(9.4-16.1)		(10.5-26.8)		
75-84	67	39	12	16		
Rate*	19.1	16.7	20.8	26.7		
95% C.I.	(14.5-23.6)	(11.5-21.9)	(9.0-32.5)	(13.6-39.8)		
85+	13	6	5	2		
Rate*	17.1					
95% C.I.	(7.8-26.3)					
* Pates are per 100 000 s	0	0	0	0		

<sup>\*</sup> Rates are per 100,000 age-specific population.

# STOMACH CANCER GENERAL PROFILE<sup>4</sup>

Figure 171. Anatomical Drawing of the Esophagus and Stomach<sup>5</sup>



General Anatomy: The stomach is part of the digestive system. It is located in the upper abdomen, beneath the ribs. The upper part of the stomach connects to the esophagus, and the lower part leads into the small intestine. When food enters the stomach from the esophagus, muscles in the stomach wall create a rippling motion that mixes and mashes the food. At the same time, juices made by glands in the lining of the stomach help digest the food. After about 3 hours, the food becomes a liquid and moves into the small intestine, where digestion continues.

**Risk Factors:** While the cause of Stomach Cancer is still unknown, it is known that some people are more susceptible than others. Stomach Cancer is more common in people over 55 years of age, males, Blacks as a racial/ethnic group, and people who have had stomach surgery or have pernicious anemia, achlorhydria, or gastric atrophy (which generally result in lower than normal amounts of digestive juices). Stomach Cancer is also more prevalent in Japan, Korea, Eastern Europe, and Latin America than it is in the United States.

**Signs and Symptoms:** Indigestion or a burning sensation (heartburn), discomfort or pain in the abdomen, nausea and vomiting, diarrhea or constipation, bloating of the stomach after meals, loss of appetite, weakness and fatigue, and bleeding (vomiting blood or having blood in the stool).

**Diagnosing the Cancer:** Fecal occult blood test, upper gastrointestinal (GI) x-ray series, and endoscopy are some of the common ways of diagnosing Stomach Cancer.

**Treatment:** Surgery (gastrectomy), chemotherapy, radiation therapy, and biological therapy.

Table 271. Stomach Cancer Mortality by Age Group and County/Region of Residence at Diagnosis, Nevada Residents, 1997-2001

Category	County/Region of Residence						
	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)	
Total							
Cases	565	400	98	67	0	15,274	
Rate*	5.8	6.0	5.8	4.8		8.2	
95% C.I.	(5.3-6.3)	(5.4-6.6)	(4.7-7.0)	(3.6-5.9)		(8.1-8.4)	
Age Group							
<1	0	0	0	0	0		
Rate*							
95% C.I.							
1-4	0	0	0	0	0		
Rate*							
95% C.I.							
5-14	0	0	0	0	0		
Rate*							
95% C.I.							
15-24	2	1	1	0	0	24	
Rate*						0.1	
95% C.I.						(0.1-0.1)	
25-34	7	5	1	1	0	230	
Rate*						0.8	
95% C.I.						(0.7-0.9)	
35-44	19	15	2	2	0	704	
Rate*	1.2	1.4				2.3	
95% C.I.	(0.7-1.8)	(0.7-2.2)				(2.1-2.4)	
45-54	57	44	7	6	0	1,558	
Rate*	4.4	5.2				6.8	
95% C.I.	(3.3-5.6)	(3.7-6.7)				(6.5-7.1)	
55-64	108	72	20	16	0	2,410	
Rate*	11.8	11.6	13.3	11.1		17.2	
95% C.I.	(9.6-14.0)	(8.9-14.3)	(7.5-19.2)	(5.6-16.5)		(16.5-17.9)	
65-74	156	107	33	16	0	4,085	
Rate*	24.3	24.7	32.2	14.9		35.4	
95% C.I.	(20.5-28.1)	(20.1-29.4)	(21.2-43.2)	(7.6-22.2)		(34.3-36.5)	
75-84	162	117	25	20	0	4,307	
Rate*	46.1	50.1	43.2	33.4		59.3	
95% C.I.	(39.0-53.2)	(41.0-59.2)	(26.3-60.2)	(18.8-48.0)		(57.5-61.0)	
85+	53	39	8	6	0	1,951	
Rate*	69.5	83.5				78.7	
95% C.I.	(50.8-88.2)	(57.3-109.7)				(75.2-82.2)	
Unknown	1	0	1	0	0	0	

<sup>\*</sup> Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 272. Stomach Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown		
Total							
Discharges	583	419	105	59	0		
Rate*	6.6	7.2	7.1	4.1			
95% C.I.	(6.1-7.2)	(6.5-7.9)	(5.8-8.7)	(3.1-5.4)			
Gender							
Male	398	288	67	43	0		
Rate*	9.6	10.6	9.8	6.0			
95% C.I.	(8.6-10.7)	(9.3-12.1)	(7.5-12.8)	(4.3-8.4)			
Female	185	131	38	16	0		
Rate*	4.1	4.3	4.9	2.2			
95% C.I.	(3.5-4.7)	(3.6-5.1)	(3.4-6.7)	(1.3-3.7)			
Other/Unknown	0	0	0	0	0		
Inpatient Discharge Cl	narges (\$)						
Total Charges	\$31,688,867	\$23,813,962	\$5,177,811	\$2,697,094			
Average Charges	\$54,355	\$56,835	\$49,312	\$45,713			
Median Charges	\$35,342	\$37,334	\$32,835	\$28,281			
Discharge Length of S	tay (LOS) (Days)						
Total LOS	6,455	4,788	1,091	576			
Average LOS	11.1	11.4	10.4	9.8			

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.


Table 273. Stomach Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

Total				
Mortality	325	232	56	37
Rate*	3.3	3.5	3.3	2.6
95% C.I.	(3.0-3.7)	(3.0-3.9)	(2.5-4.2)	(1.8-3.5)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	1	1	0	0
Rate*				
95% C.I.				
25-34	2	2	0	0
Rate*				
95% C.I.				
35-44	13	10	3	0
Rate*	0.8	1.0		
95% C.I.	(0.4-1.3)	(0.4-1.5)		
45-54	34	28	3	3
Rate*	2.6	3.3		
95% C.I.	(1.8-3.5)	(2.1-4.5)		
55-64	53	39	8	6
Rate*	5.8	6.3		
95% C.I.	(4.2-7.3)	(4.3-8.2)		
65-74	81	56	16	9
Rate*	12.6	12.9	15.6	
95% C.I.	(9.9-15.4)	(9.6-16.3)	(8.0-23.3)	
75-84	104	72	19	13
Rate*	29.6	30.8	32.9	21.7
95% C.I.	(23.9-35.3)	(23.7-37.9)	(18.1-47.6)	(9.9-33.5)
85+	37	24	7	6
Rate*	48.5	51.4		
95% C.I.	(32.9-64.2)	(30.8-72.0)		
Unknown	0	0	0	0

<sup>\*</sup> Rates are per 100,000 age-specific population.

# LIVER AND INTRAHEPATIC BILE DUCTS CANCER <u>GENERAL PROFILE<sup>4</sup></u>

Figure 172. Anatomical Drawing of the Digestive System<sup>5</sup>



**General Anatomy:** The liver is the largest organ in the body and is located behind the ribs on the right side of the abdomen. It has two parts, a right lobe and a smaller left lobe. The liver performs many health maintenance functions, including removing harmful material from the blood, creating enzymes and bile that aid in digestion, and converting food into substances needed for life and growth. The liver gets its supply of blood from two vessels, the hepatic portal vein and the hepatic artery.

**Risk Factors:** Chronic liver infection (hepatitis), cirrhosis, Aflatoxin (type of mold), male gender, family history, and age (over 60 years of age).

**Signs and Symptoms:** Pain in the upper abdomen on the right side; the pain may extend to the back and shoulder; swollen abdomen (bloating); weight loss, loss of appetite, or feelings of fullness; weakness or fatigue; nausea and vomiting; yellow skin, eyes, and dark urine from jaundice; and fever.

**Diagnosing the Cancer:** Physical exam, blood tests, computed tomography (CAT) scan, ultrasound test, magnetic resonance imaging (MRI), angiogram, and biopsy.

**Treatment:** Surgery (hepatectomy, transplantation), radio frequency ablation, percutaneous ethanol injection, cryosurgery, hepatic arterial infusion, chemoembolization, chemotherapy, and radiation therapy.

Table 274. Liver and Intrahepatic Bile Ducts Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)		
Total								
Cases	515	380	71	64	0	10,395		
Rate*	5.3	5.7	4.2	4.6		5.6		
95% C.I.	(4.8-5.7)	(5.1-6.3)	(3.2-5.2)	(3.5-5.7)		(5.5-5.7)		
Age Group								
<1	3	3	0	0	0	29		
Rate*						1.0		
95% C.I.						(0.7-1.4)		
1-4	4	1	2	1	0	56		
Rate*						0.5		
95% C.I.						(0.4-0.6)		
5-14	1	1	0	0	0	27		
Rate*						0.1		
95% C.I.						(0.1-0.1)		
15-24	3	3	0	0	0	51		
Rate*						0.2		
95% C.I.						(0.1-0.3)		
25-34	1	1	0	0	0	104		
Rate*						0.4		
95% C.I.						(0.3-0.4)		
35-44	21	14	2	5	0	452		
Rate*	1.3	1.3				1.4		
95% C.I.	(0.8-1.9)	(0.6-2.0)				(1.3-1.6)		
45-54	84	69	9	6	0	1,779		
Rate*	6.5	8.2				7.8		
95% C.I.	(5.1-7.9)	(6.2-10.1)				(7.4-8.1)		
55-64	113	82	16	15	0	2,117		
Rate*	12.3	13.2	10.7	10.4		15.1		
95% C.I.	(10.1-14.6)	(10.3-16.0)	(5.4-15.9)	(5.1-15.6)		(14.5-15.8)		
65-74	154	114	24	16	0	2,785		
Rate*	24.0	26.4	23.4	14.9		24.1		
95% C.I.	(20.2-27.8)	(21.5-31.2)	(14.0-32.8)	(7.6-22.2)		(23.2-25.0)		
75-84	110	80	13	17	0	2,280		
Rate*	31.3	34.3	22.5	28.4		31.4		
95% C.I.	(25.5-37.2)	(26.7-41.8)	(10.3-34.7)	(14.9-41.9)		(30.1-32.7)		
85+	21	12	5	4	0	715		
Rate*	27.5	25.7				28.8		
95% C.I.	(15.8-39.3)	(11.2-40.2)				(26.7-30.9)		
Unknown	0	0	0	0	0	0		

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 275. Liver and Intrahepatic Bile Ducts Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown		
Total							
Discharges	347	272	50	25	0		
Rate*	3.7	4.4	3.3	1.6			
95% C.I.	(3.3-4.2)	(3.8-4.9)	(2.4-4.4)	(1.1-2.5)			
Gender							
Male	232	187	28	17	0		
Rate*	5.1	6.1	4.2	2.2			
95% C.I.	(4.5-5.9)	(5.3-7.2)	(2.7-6.4)	(1.3-3.8)			
Female	115	85	22	8	0		
Rate*	2.4	2.7	2.7				
95% C.I.	(2.0-2.9)	(2.1-3.3)	(1.7-4.1)				
Other/Unknown	0	0	0	0	0		
Inpatient Discharge Cl	harges (\$)						
Total Charges	\$8,918,400	\$7,544,131	\$847,384	\$526,885			
Average Charges	\$25,701	\$27,736	\$16,948	\$21,075			
Median Charges	\$17,789	\$19,215	\$15,613	\$9,966			
Discharge Length of S	Stay (LOS) (Days)						
Total LOS	2,297	1,859	310	128			
Average LOS	6.6	6.8	6.2	5.1			
Median LOS	5.0	5.0	6.0	4.0			

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.


Table 276. Liver and Intrahepatic Bile Ducts Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties					
Total									
Mortality	415	299	59	57					
Rate*	4.3	4.5	3.5	4.1					
95% C.I.	(3.9-4.7)	(4.0-5.0)	(2.6-4.4)	(3.0-5.1)					
Age Group									
<1	0	0	0	0					
Rate*									
95% C.I.									
1-4	1	0	0	1					
Rate*									
95% C.I.									
5-14	2	1	0	1					
Rate*									
95% C.I.									
15-24	3	2	0	1					
Rate*									
95% C.I.									
25-34	1	0	0	1					
Rate*									
95% C.I.									
35-44	11	9	0	2					
Rate*	0.7								
95% C.I.	(0.3-1.1)								
45-54	62	52	8	2					
Rate*	4.8	6.1							
95% C.I.	(3.6-6.0)	(4.5-7.8)							
55-64	77	52	12	13					
Rate*	8.4	8.4	8.0	9.0					
95% C.I.	(6.5-10.3)	(6.1-10.6)	(3.5-12.5)	(4.1-13.9)					
65-74	132	94	24	14					
Rate*	20.6	21.7	23.4	13.1					
95% C.I.	(17.0-24.1)	(17.3-26.1)	(14.0-32.8)	(6.2-19.9)					
75-84	95	66	11	18					
Rate*	27.0	28.3	19.0	30.0					
95% C.I.	(21.6-32.5)	(21.4-35.1)	(7.8-30.3)	(16.2-43.9)					
85+	31	23	4	4					
Rate*	40.7	49.3							
95% C.I.	(26.3-55.0)	(29.1-69.4)							
Unknown	0	0	0	0					

<sup>\*</sup> Rates are per 100,000 age-specific population.

# CERVICAL CANCER GENERAL PROFILE<sup>4</sup>

Figure 173. Anatomical Drawing of the Female Reproductive System<sup>4</sup>



General Anatomy: The cervix is the lower, narrow part of the uterus (womb). The uterus, a hollow, pear-shaped organ, is located in a woman's lower abdomen, between the bladder and the rectum. The cervix forms a canal that opens into the vagina, which leads to the outside of the body. Cells on the surface of the cervix sometimes appear abnormal but not cancerous. Scientists believe that some abnormal changes in cells on the cervix are the first step in a series of slow changes that can lead to cancer years later. If these changes form abnormal cells that spread deeper into the cervix or to other tissues or organs, the disease is then called cervical cancer, or invasive cervical cancer.

**Risk Factors:** Researchers believe that, in many cases, cervical cancer develops when two or more risk factors act together. These include: women who began having sexual intercourse before age 18, women who have had many sexual partners, women whose partners began having sexual intercourse at a young age, have had many sexual partners, or were previously married to women who had cervical cancer, some sexually transmitted human papillomaviruses (HPVs), smoking, women whose mothers were given the drug diethylstilbestrol (DES) during pregnancy to prevent miscarriage, weakened immune systems, and the use of oral contraceptives (the pill).

**Signs and Symptoms:** Precancerous changes of the cervix usually do not cause pain. In fact, they generally do not cause any symptoms until abnormal cervical cells become cancerous and invade nearby tissue, unless a woman has a pelvic exam and a Pap test. Symptoms include: abnormal bleeding (longer and heavier than usual), bleeding after menopause, and increased vaginal discharge.

**Diagnosing the Cancer:** Pap smear tests (early detection), colposcopy, endocervical curettage, conization, dilation and curettage.

**Treatment:** Surgery (hysterectomy), cryosurgery, cauterization, laser surgery, conization, radiation therapy, and chemotherapy.

Table 277. Cervical Cancer Screening by County/Region of Residence, Education, Age Group, and Income, Nevada Residents, 1997-2001

				Answers			
Responses	Yes			No			
	Number	Percent*	95% C.I.	Number	Percent*	95% C.I.	Total
Total							
Responses	5,339	95.3%	(94.7%-95.9%)	244	4.7%	(4.1%-5.3%)	5,583
County/Region of Resid	dence						
Clark County	1,711	95.2%	(94.2%-96.2%)	82	4.8%	(3.8%-5.8%)	1,793
Washoe County	1,769	95.7%	(94.8%-96.6%)	79	4.3%	(3.4%-5.2%)	1,848
All Other Counties	1,859	95.7%	(94.8%-96.6%)	83	4.3%	(3.4%-5.2%)	1,942
Education							
Less than High School	457	88.6%	(85.8%-91.4%)	42	11.4%	(8.6%-14.2%)	499
High School	1,715	95.0%	(94.0%-96.0%)	95	5.0%	(4.0%-6.0%)	1,810
Some Post High School	1,885	96.2%	(95.4%-97.0%)	76	3.8%	(3.0%-4.6%)	1,961
College Graduate	1,270	97.3%	(96.4%-98.2%)	31	2.7%	(1.8%-3.6%)	1,301
Age Group							
18-24 years old	425	84.1%	(80.9%-87.3%)	83	15.9%	(12.7%-19.1%)	508
25-34 years old	1,008	96.1%	(94.9%-97.3%)	30	3.9%	(2.7%-5.1%)	1,038
35-44 years old	1,284	98.3%	(97.6%-99.0%)	22	1.7%	(1.0%-2.4%)	1,306
45-54 years old	1,033	98.6%	(97.9%-99.3%)	17	1.4%	(0.7%-2.1%)	1,050
55-64 years old	678	98.4%	(97.5%-99.3%)	14	1.6%	(0.7%-2.5%)	692
65+ years old	887	92.0%	(90.3%-93.7%)	76	8.0%	(6.3%-9.7%)	963
Income							
Less than \$15,000	605	92.9%	(90.9%-94.9%)	44	7.1%	(5.1%-9.1%)	649
\$15,000 - \$24,999	493	94.8%	(92.9%-96.7%)	33	5.2%	(3.3%-7.1%)	526
\$25,000 - \$34,999	820	95.2%	(93.8%-96.6%)	43	4.8%	(3.4%-6.2%)	863
\$35,000 - \$49,999	1,042	97.1%	(96.1%-98.1%)	21	2.9%	(1.9%-3.9%)	1,063
\$50,000 or More	1,546	98.0%	(97.3%-98.7%)	23	2.0%	(1.3%-2.7%)	1,569

<sup>\*</sup>Denominator is persons age 18-64 and excludes missing, don't know, and refused responses. Note: This table includes those respondents who answered "Yes" or "No" to the following question:

<sup>1)</sup> A Pap smear is a test for cancer of the cervix. Have you ever had a Pap smear?

Table 278. Cervical Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)			
Total									
Cases	497	367	81	49	0	8,983			
Rate*	5.1	5.5	4.8	3.5		4.9			
95% C.I.	(4.7-5.6)	(4.9-6.1)	(3.8-5.9)	(2.5-4.5)		(4.8-5.0)			
Age Group									
<1	0	0	0	0	0				
Rate*									
95% C.I.									
1-4	0	0	0	0	0				
Rate*									
95% C.I.									
5-14	0	0	0	0	0				
Rate*									
95% C.I.									
15-24	6	5	0	1	0	122			
Rate*						0.5			
95% C.I.						(0.4-0.6)			
25-34	57	42	10	5	0	1,334			
Rate*	3.9	4.0	3.9			4.6			
95% C.I.	(2.9-4.9)	(2.8-5.1)	(1.5-6.4)			(4.3-4.8)			
35-44	120	87	25	8	0	2,421			
Rate*	7.7	8.3	8.8			7.7			
95% C.I.	(6.3-9.1)	(6.6-10.1)	(5.4-12.3)			(7.4-8.1)			
45-54	118	87	16	15	0	2,000			
Rate*	9.2	10.3	6.8	7.5		8.7			
95% C.I.	(7.5-10.8)	(8.1-12.4)	(3.5-10.1)	(3.7-11.3)		(8.4-9.1)			
55-64	90	67	14	9	0	1,251			
Rate*	9.8	10.8	9.3			8.9			
95% C.I.	(7.8-11.9)	(8.2-13.4)	(4.4-14.2)			(8.4-9.4)			
65-74	67	50	10	7	0	977			
Rate*	10.4	11.6	9.8			8.5			
95% C.I.	(7.9-12.9)	(8.4-14.8)	(3.7-15.8)			(7.9-9.0)			
75-84	26	19	3	4	0	626			
Rate*	7.4	8.1				8.6			
95% C.I.	(4.6-10.2)	(4.5-11.8)				(7.9-9.3)			
85+	13	10	3	0	0	251			
Rate*	17.1	21.4				10.1			
95% C.I.	(7.8-26.3)	(8.1-34.7)				(8.9-11.4)			
Unknown	0 100 000 age specific femal	0	0	0	0	0			

<sup>\*</sup> Rates are per 100,000 age-specific female population.

Table 279. Cervical Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	646	482	88	75	1			
Rate*	6.7	7.4	5.2	5.1				
95% C.I.	(6.1-7.2)	(6.7-8.1)	(4.2-6.4)	(4.0-6.5)				
Gender								
Male	0	0	0	0	0			
Rate*								
95% C.I.								
Female	646	482	88	75	1			
Rate*	13.4	14.8	10.4	10.4				
95% C.I.	(12.4-14.5)	(13.5-16.3)	(8.4-12.9)	(8.1-13.0)				
Other/Unknown	0	0	0	0	0			
Inpatient Discharge Cl	narges (\$)							
Total Charges	\$14,651,235	\$10,696,558	\$2,200,110	\$1,734,990	\$19,577			
Average Charges	\$22,680	\$22,192	\$25,001	\$23,133	\$19,577			
Median Charges	\$17,697	\$17,627	\$21,637	\$15,836	\$19,577			
Discharge Length of S	Discharge Length of Stay (LOS) (Days)							
Total LOS	3,125	2,409	373	339				
Average LOS	4.8	5.0	4.2	4.5				
Median LOS	3.0	4.0	3.0	3.0				

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.


Table 280. Cervical Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region o	f Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	140	108	18	14
Rate*	1.4	1.6	1.1	1.0
95% C.I.	(1.2-1.7)	(1.3-1.9)	(0.6-1.6)	(0.5-1.5)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	0	0	0	0
Rate*				
95% C.I.				
25-34	6	5	1	0
Rate*				
95% C.I.				
35-44	24	20	2	2
Rate*	1.5	1.9		
95% C.I.	(0.9-2.2)	(1.1-2.7)		
45-54	39	31	4	4
Rate*	3.0	3.7		
95% C.I.	(2.1-4.0)	(2.4-5.0)		
55-64	26	21	2	3
Rate*	2.8	3.4		
95% C.I.	(1.7-3.9)	(1.9-4.8)		
65-74	24	17	4	3
Rate*	3.7	3.9		
95% C.I.	(2.2-5.2)	(2.1-5.8)		
75-84	13	9	2	2
Rate*	3.7			
95% C.I.	(1.7-5.7)			
85+	8	5	3	0
Rate*				
95% C.I.				
Unknown	ge-specific female population	0	0	0

<sup>\*</sup> Rates are per 100,000 age-specific female population.

# ESOPHAGEAL CANCER GENERAL PROFILE<sup>4</sup>

Figure 174. Anatomical Drawing of the Esophagus and Stomach<sup>5</sup>



**General Anatomy:** The esophagus is a hollow tube that carries food and liquids from the throat to the stomach. When a person swallows, the muscular walls of the esophagus contract to push food down into the stomach. Glands in the lining of the esophagus produce mucus, which keeps the passageway moist and makes swallowing easier. The esophagus is located just behind the trachea (windpipe). In an adult, the esophagus is about 10 inches long.

**Risk Factors:** Age (over 60 years of age), male gender, tobacco use, chronic and/or heavy alcohol use, Barrett's Esophagus (Long-term irritation from gastric reflux), and medical history. Other problems that may increase the risk of developing Esophagual Cancer include the intake of substances that may irritate or damage the lining of the esophagus, such as swallowing lye or other caustic substances.

**Signs and Symptoms:** Difficult or painful swallowing, severe weight loss, pain in the throat or back, pain behind the breastbone or between the shoulder blades, hoarseness or chronic cough, vomiting, and coughing up blood.

**Diagnosing the Cancer:** Barium swallow x-rays (also called an esophagram), biopsy procedures (esophagoscopy/endoscopy), computed tomography (CAT) scan, bone scan, and bronchoscopy are common ways of diagnosing this type of cancer.

**Treatment:** Surgery (esophagectomy), radiation therapy, chemotherapy, laser therapy, and photodynamic therapy (PDT).

Table 281. Esophageal Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

			County/Region	on of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)
Total						
Cases	481	331	73	77	0	7,772
Rate*	4.9	5.0	4.3	5.5		4.2
95% C.I.	(4.5-5.4)	(4.4-5.5)	(3.4-5.3)	(4.3-6.7)		(4.1-4.3)
Age Group						
<1	0	0	0	0	0	
Rate*						
95% C.I.						
1-4	0	0	0	0	0	
Rate*						
95% C.I.						
5-14	0	0	0	0	0	
Rate*						
95% C.I.						
15-24	1	1	0	0	0	8
Rate*						
95% C.I.						
25-34	0	0	0	0	0	32
Rate*						0.1
95% C.I.						(0.1-0.1)
35-44	17	13	1	3	0	208
Rate*	1.1	1.2				0.7
95% C.I.	(0.6-1.6)	(0.6-1.9)				(0.6-0.8)
45-54	49	36	3	10	0	941
Rate*	3.8	4.3		5.0		4.1
95% C.I.	(2.7-4.9)	(2.9-5.6)		(1.9-8.1)		(3.8-4.4)
55-64	140	92	31	17	0	1,694
Rate*	15.3	14.8	20.7	11.8		12.1
95% C.I.	(12.7-17.8)	(11.8-17.8)	(13.4-27.9)	(6.2-17.4)		(11.5-12.7)
65-74	153	98	25	30	0	2,415
Rate*	23.8	22.7	24.4	28.0		20.9
95% C.I.	(20.0-27.6)	(18.2-27.1)	(14.8-33.9)	(18.0-38.0)		(20.1-21.8)
75-84	102	80	9	13	0	1,879
Rate*	29.0	34.3		21.7		25.9
95% C.I.	(23.4-34.7)	(26.7-41.8)		(9.9-33.5)		(24.7-27.0)
85+	19	11	4	4	0	593
Rate*	24.9	23.6				23.9
95% C.I.	(13.7-36.1)	(9.6-37.5)				(22.0-25.8)
Unknown	0	0	0	0	0	0

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 282. Esophageal Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown		
Total							
Discharges	297	220	36	41	0		
Rate*	3.2	3.6	2.4	2.7			
95% C.I.	(2.9-3.6)	(3.1-4.1)	(1.7-3.4)	(1.9-3.7)			
Gender							
Male	224	165	28	31	0		
Rate*	5.1	5.6	4.0	4.1			
95% C.I.	(4.4-5.9)	(4.7-6.6)	(2.6-6.2)	(2.7-6.1)			
Female	73	55	8	10	0		
Rate*	1.6	1.7		1.3			
95% C.I.	(1.2-2.0)	(1.3-2.3)		(0.6-2.5)			
Other/Unknown	0	0	0	0	0		
Inpatient Discharge Ch	narges (\$)						
Total Charges	\$13,057,012	\$10,067,242	\$1,370,392	\$1,619,378			
Average Charges	\$43,963	\$45,760	\$38,066	\$39,497			
Median Charges	\$24,273	\$25,575	\$28,728	\$18,475			
Discharge Length of S	tay (LOS) (Days)						
Total LOS	2,974	2,303	305	366			
Average LOS	10.0	10.5	8.5	8.9			
Median LOS	7.0	7.0	7.0	6.0			

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.


Table 283. Esophageal Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Mortality	384	268	68	48				
Rate*	3.9	4.0	4.1	3.4				
95% C.I.	(3.5-4.3)	(3.5-4.5)	(3.1-5.0)	(2.5-4.4)				
Age Group								
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	0	0	0				
Rate*								
95% C.I.								
15-24	0	0	0	0				
Rate*								
95% C.I.								
25-34	0	0	0	0				
Rate*								
95% C.I.								
35-44	10	9	1	0				
Rate*	0.6							
95% C.I.	(0.2-1.0)							
45-54	30	25	2	3				
Rate*	2.3	3.0						
95% C.I.	(1.5-3.2)	(1.8-4.1)						
55-64	123	79	26	18				
Rate*	13.4	12.7	17.3	12.5				
95% C.I.	(11.1-15.8)	(9.9-15.5)	(10.7-24.0)	(6.7-18.2)				
65-74 Rate*	118	76	24	18				
	18.4	17.6	23.4	16.8				
95% C.I.	(15.1-21.7)	(13.6-21.5)	(14.0-32.8)	(9.0-24.5)				
75-84 Rate*	88 25.1	70 30.0	11 19.0	7				
95% C.I.	(19.8-30.3)	(23.0-37.0)	(7.8-30.3)					
95% C.I.	(19.8-30.3)	(23.0-37.0)	(7.8-30.3)	2				
Rate*	19.7		4					
95% C.I.	(9.7-29.6)							
Unknown	(9.7-29.0)	0	0	0				
OHAHOWH		0						

<sup>\*</sup> Rates are per 100,000 age-specific population.

# LARYNX CANCER GENERAL PROFILE<sup>4</sup>

Figure 175. Anatomy of the Oral Cavity<sup>5</sup>



**General Anatomy:** The larynx, also called the voice box, is a 2-inch-long, tube-shaped organ made of cartilage in the neck. The larynx is used for breathing, talking, and swallowing. The larynx is situated at the top of the windpipe (trachea). The large cartilage that forms the front of the larynx is sometimes called the Adam's apple. The vocal cords, which are two bands of muscle, form a "V" inside the larynx.

**Risk Factors:** Cancer of the Larynx occurs most often in people over the age of 55, men, Blacks, smokers, and those who work with asbestos.

**Signs and Symptoms:** The symptoms of Cancer of the Larynx depend mainly on the size and location of the tumor. Most Cancers of the Larynx begin on the vocal cords. These tumors are seldom painful, but they almost always cause hoarseness or other changes in the voice. Tumors in the area above the vocal cords may cause a lump on the neck, a sore throat, or an earache. Tumors that begin in the area below the vocal cords are rare. They can make it hard to breathe, and breathing may be noisy.

A cough that doesn't go away or the feeling of a lump in the throat may also be warning signs of Cancer of the Larynx. As the tumor grows, it may cause pain, weight loss, bad breath, and frequent choking on food. In some cases, a tumor in the larynx can make it hard to swallow.

**Diagnosing the Cancer:** Direct and indirect laryngoscopy, computed tomography (CAT) scan, and magnetic resonance imaging (MRI) are some common ways of diagnosing cancer of the larynx.

**Treatment:** Radiation therapy, surgery (partial or total laryngectomy), and chemotherapy are the most common treatment options for those diagnosed with Larynx Cancer.

Table 284. Larynx Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

			County/Region	of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)
Total						
Cases	348	224	69	55	0	6,510
Rate*	3.6	3.4	4.1	3.9		3.5
95% C.I.	(3.2-3.9)	(2.9-3.8)	(3.1-5.1)	(2.9-5.0)		(3.4-3.6)
Age Group						
<1	0	0	0	0	0	
Rate*						
95% C.I.						
1-4	0	0	0	0	0	
Rate*						
95% C.I.						
5-14	0	0	0	0	0	
Rate*						
95% C.I.						
15-24	0	0	0	0	0	5
Rate*						
95% C.I.						
25-34	3	2	1	0	0	22
Rate*						0.1
95% C.I.						(0.0-0.1)
35-44	9	3	4	2	0	257
Rate*						0.8
95% C.I.						(0.7-0.9)
45-54	55	34	13	8	0	975
Rate*	4.3	4.0	5.5			4.3
95% C.I.	(3.2-5.4)	(2.7-5.4)	(2.5-8.5)			(4.0-4.5)
55-64	106	77	17	12	0	1,764
Rate*	11.6	12.4	11.3	8.3		12.6
95% C.I.	(9.4-13.8)	(9.6-15.2)	(5.9-16.7)	(3.6-13.0)		(12.0-13.2)
65-74	98	59	15	24	0	2,054
Rate*	15.3	13.6	14.6	22.4		17.8
95% C.I.	(12.2-18.3)	(10.2-17.1)	(7.2-22.0)	(13.4-31.3)		(17.0-18.6)
75-84	67	44	17	6	0	1,185
Rate*	19.1	18.8	29.4			16.3
95% C.I.	(14.5-23.6)	(13.3-24.4)	(15.4-43.4)			(15.4-17.2)
85+	10	5	2	3	0	247
Rate*	13.1					10.0
95% C.I.	(5.0-21.2)					(8.7-11.2)
Unknown	0	0	0	0	0	0

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 285. Larynx Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	203	132	40	31	0			
Rate*	2.2	2.2	2.5	2.0				
95% C.I.	(1.9-2.5)	(1.8-2.6)	(1.8-3.5)	(1.4-2.9)				
Gender								
Male	160	105	27	28	0			
Rate*	3.6	3.7	3.2	3.6				
95% C.I.	(3.0-4.3)	(3.0-4.7)	(2.1-5.1)	(2.4-5.5)				
Female	43	27	13	3	0			
Rate*	0.9	0.8	1.7					
95% C.I.	(0.7-1.2)	(0.5-1.2)	(0.9-2.9)					
Other/Unknown	0	0	0	0	0			
Inpatient Discharge Ch	narges (\$)							
Total Charges	\$8,375,014	\$5,935,608	\$1,505,441	\$933,965				
Average Charges	\$41,256	\$44,967	\$37,636	\$30,128				
Median Charges	\$30,842	\$33,384	\$32,094	\$25,649				
Discharge Length of S	Discharge Length of Stay (LOS) (Days)							
Total LOS	2,005	1,325	414	266				
Average LOS	9.9	10.0	10.4	8.6				
Median LOS	8.0	7.0	9.5	7.0				

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.


Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 286. Larynx Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Mortality	124	88	16	20				
Rate*	1.3	1.3	1.0	1.4				
95% C.I.	(1.0-1.5)	(1.0-1.6)	(0.5-1.4)	(0.8-2.1)				
Age Group								
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	0	0	0				
Rate*								
95% C.I.								
15-24	0	0	0	0				
Rate*								
95% C.I.								
25-34	0	0	0	0				
Rate*								
95% C.I.								
35-44	1	1	0	0				
Rate*								
95% C.I.								
45-54	10	7	1	2				
Rate*	0.8							
95% C.I.	(0.3-1.3)							
55-64	33	27	2	4				
Rate*	3.6	4.3						
95% C.I.	(2.4-4.8)	(2.7-6.0)						
65-74	42	28	5	9				
Rate*	6.5	6.5						
95% C.I.	(4.6-8.5)	(4.1-8.9)						
75-84	30	22	5	3				
Rate*	8.5	9.4						
95% C.I.	(5.5-11.6)	(5.5-13.4)						
85+	8	3	3	2				
Rate*								
95% C.I. * Rates are per 100,000 a	ge-specific population.							

# MULTIPLE MYELOMA GENERAL PROFILE<sup>4</sup>

Figure 176. Picture of Myeloma Cells<sup>4</sup>



General Anatomy: Multiple Myeloma affects specific white blood cells, known as plasma cells, that are part of the body's immune system. Plasma cells begin their development in the bone marrow and help the immune system fight infection and disease by producing antibodies. When cancer involves plasma cells, the body keeps producing more and more of these cells. The unneeded plasma cells -- all abnormal and all exactly alike -- are called myeloma cells. Myeloma cells tend to collect in the bone marrow and in the hard, outer part of bones. Sometimes they collect in only one bone and form a single mass, or tumor, called a plasmacytoma. In most cases, however, the myeloma cells collect in many bones, often forming many tumors and causing other problems. When this happens, the disease is called multiple myeloma.

**Risk Factors:** While the cause is unknown, the majority of multiple myeloma patients are between 50 and 70 years of age. This disease disproportionately affects Blacks, as a racial/ethnic group, and men. Those with a family history of multiple myeloma, and those exposed to certain chemicals and radiation, seem to have a slightly higher risk of developing this type of cancer. In most cases, people who develop multiple myeloma have no clear risk factors. This disease may be the result of several factors (known and/or unknown) acting together.

**Signs and Symptoms:** Symptoms of multiple myeloma depend on the stage of the disease. In the earliest stage of the disease, there may be no symptoms. When symptoms do occur, patients commonly have bone pain in the back or ribs, broken bones, weakness, fatigue, weight loss, or repeated infections. With advanced disease, symptoms may include nausea, vomiting, constipation, urination problems, and weakness or numbness in the legs.

**Diagnosing the Cancer:** X-rays, blood and urine tests (high levels of antibody proteins), bone marrow aspiration and/or bone marrow biopsy.

**Treatment:** Chemotherapy, radiation therapy, and secondary surgical procedures, bone marrow transplantation, peripheral stem cell support, and treatment with colony-stimulating factors.

Table 287. Multiple Myeloma Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)	
Total							
Cases	372	222	96	54	0	9,539	
Rate*	3.8	3.3	5.7	3.9		5.2	
95% C.I.	(3.4-4.2)	(2.9-3.8)	(4.6-6.9)	(2.8-4.9)		(5.0-5.3)	
Age Group							
<1	0	0	0	0	0		
Rate*							
95% C.I.							
1-4	0	0	0	0	0		
Rate*							
95% C.I.							
5-14	0	0	0	0	0		
Rate*							
95% C.I.							
15-24	0	0	0	0	0	5	
Rate*							
95% C.I.							
25-34	0	0	0	0	0	59	
Rate*						0.2	
95% C.I.						(0.2-0.3)	
35-44	14	10	1	3	0	318	
Rate*	0.9	1.0				1.0	
95% C.I.	(0.4-1.4)	(0.4-1.5)				(0.9-1.1)	
45-54	49	33	11	5	0	1,074	
Rate*	3.8	3.9	4.7			4.7	
95% C.I.	(2.7-4.9)	(2.6-5.2)	(1.9-7.4)			(4.4-5.0)	
55-64	87	51	18	18	0	1,779	
Rate*	9.5	8.2	12.0	12.5		12.7	
95% C.I.	(7.5-11.5)	(6.0-10.5)	(6.5-17.5)	(6.7-18.2)		(12.1-13.3)	
65-74	115	66	34	15	0	2,727	
Rate*	17.9	15.3	33.2	14.0		23.6	
95% C.I.	(14.6-21.2)	(11.6-18.9)	(22.0-44.3)	(6.9-21.1)		(22.7-24.5)	
75-84	82	46	24	12	0	2,706	
Rate*	23.3	19.7	41.5	20.0		37.2	
95% C.I.	(18.3-28.4)	(14.0-25.4)	(24.9-58.1)	(8.7-31.4)		(35.8-38.6)	
85+	22	15	6	1	0	871	
Rate*	28.9	32.1				35.1	
95% C.I.	(16.8-40.9)	(15.9-48.4)				(32.8-37.5)	
Unknown		<u>1</u>	2	0	0	0	

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 288. Multiple Myeloma Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	321	202	83	36	0			
Rate*	3.5	3.3	5.4	2.3				
95% C.I.	(3.1-3.9)	(2.9-3.8)	(4.3-6.8)	(1.6-3.3)				
Gender								
Male	193	117	53	23	0			
Rate*	4.4	4.1	7.6	2.9				
95% C.I.	(3.8-5.2)	(3.3-5.0)	(5.6-10.3)	(1.8-4.7)				
Female	128	85	30	13	0			
Rate*	2.7	2.7	3.8	1.7				
95% C.I.	(2.2-3.2)	(2.1-3.4)	(2.5-5.4)	(0.9-3.0)				
Other/Unknown	0	0	0	0	0			
Inpatient Discharge Cl	harges (\$)							
Total Charges	\$11,628,151	\$7,905,231	\$2,849,854	\$873,066				
Average Charges	\$36,225	\$39,135	\$34,336	\$24,252				
Median Charges	\$22,694	\$24,325	\$20,778	\$18,079				
Discharge Length of Stay (LOS) (Days)								
Total LOS	2,926	1,842	826	258				
Average LOS	9.1	9.1	10.0	7.2				
Median LOS	8.0	8.0	7.0	7.0				

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.


Table 289. Multiple Myeloma Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Mortality	261	167	62	32				
Rate*	2.7	2.5	3.7	2.3				
95% C.I.	(2.4-3.0)	(2.1-2.9)	(2.8-4.6)	(1.5-3.1)				
Age Group								
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	0	0	0				
Rate*								
95% C.I.								
15-24	0	0	0	0				
Rate*								
95% C.I.								
25-34	0	0	0	0				
Rate*								
95% C.I.								
35-44	3	3	0	0				
Rate*								
95% C.I.								
45-54	22	19	2	1				
Rate*	1.7	2.2						
95% C.I.	(1.0-2.4)	(1.2-3.3)						
55-64	57	33	13	11				
Rate*	6.2	5.3	8.7	7.6				
95% C.I.	(4.6-7.8)	(3.5-7.1)	(4.0-13.4)	(3.1-12.1)				
65-74	85	47	26	12				
Rate*	13.2	10.9	25.4	11.2				
95% C.I.	(10.4-16.0)	(7.8-14.0)	(15.6-35.1)	(4.9-17.5)				
75-84	76	53	16	7				
Rate*	21.6	22.7	27.7					
95% C.I.	(16.8-26.5)	(16.6-28.8)	(14.1-41.2)					
85+	18	12	5	1				
Rate*	23.6	25.7						
95% C.I.	(12.7-34.5)	(11.2-40.2)						
Unknown	ge-specific population	0	0	0				

<sup>\*</sup> Rates are per 100,000 age-specific population.

# HODGKIN'S LYMPHOMA GENERAL PROFILE<sup>4</sup>

Figure 177. Anatomy of the Lymphatic System<sup>4</sup>



General Anatomy: Lymphoma is a general term for cancers that develop in the lymphatic system. The lymphatic system is part of the body's immune system that helps the body fight disease and infection and includes a network of thin tubes (lymphatic vessels) that branch, like blood vessels, into tissues throughout the body. These vessels carry lymph, a colorless, watery fluid that contains infection-fighting cells called lymphocytes. Along this network of vessels are small organs called lymph nodes that are found in the underarms, groin, neck, chest, and abdomen. Other parts of the lymphatic system are the spleen, thymus, tonsils, and bone marrow. Lymphatic tissue is also found in other parts of the body, including the stomach, intestines, and skin.

Hodgkin's disease, an uncommon lymphoma, accounts for less than 1 percent of all cases of cancer in the United States. This type of cancer tends to spread in a fairly orderly way from one group of lymph nodes to the next group. For example, Hodgkin's disease that arises in the lymph nodes in the neck spreads first to the nodes above the collarbones, and then to the lymph nodes under the arms and within the chest. Eventually, it can spread to almost any other part of the body.

**Risk Factors:** Common risk factors that are believed to be associated with the development of Hodgkin's Lymphoma are: age (between 15 and 34 and over 55 years of age), male gender, family history, and certain viruses (such as Epstein-Barr virus).

**Signs and Symptoms:** A painless swelling in the lymph nodes in the neck, underarm, or groin, unexplained recurrent fevers, night sweats, unexplained weight loss, and itchy skin are some common symptoms that can be associated with Hodgkin's Lymphoma.

**Diagnosing the Cancer:** X-rays, computed tomography (CAT) scan, and magnetic resonance imaging (MRI), and biopsy (Reed-Sternberg cells in lymph node tissue).

**Treatment:** Radiation therapy and chemotherapy are the most common treatments, but others include bone marrow transplantation, peripheral stem cell transplantation, and biological therapies being studied in clinical trials.

Table 290. Hodgkin's Lymphoma Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)
Total						
Cases	214	143	42	29	0	5,101
Rate*	2.2	2.1	2.5	2.1		2.8
95% C.I.	(1.9-2.5)	(1.8-2.5)	(1.7-3.3)	(1.3-2.8)		(2.7-2.8)
Age Group						
<1	0	0	0	0	0	
Rate*						
95% C.I.						
1-4	0	0	0	0	0	12
Rate*						0.1
95% C.I.						(0.0-0.2)
5-14	7	4	2	1	0	229
Rate*						0.9
95% C.I.						(0.7-1.0)
15-24	33	22	6	5	0	944
Rate*	2.5	2.4				3.7
95% C.I.	(1.6-3.3)	(1.4-3.4)				(3.4-3.9)
25-34	49	34	12	3	0	1,188
Rate*	3.3	3.2	4.7			4.1
95% C.I.	(2.4-4.3)	(2.1-4.3)	(2.0-7.4)			(3.8-4.3)
35-44	37	26	6	5	0	957
Rate*	2.4	2.5				3.1
95% C.I.	(1.6-3.1)	(1.5-3.4)				(2.9-3.3)
45-54	36	23	9	4	0	594
Rate*	2.8	2.7				2.6
95% C.I.	(1.9-3.7)	(1.6-3.8)				(2.4-2.8)
55-64	21	14	3	4	0	411
Rate*	2.3	2.3				2.9
95% C.I.	(1.3-3.3)	(1.1-3.4)				(2.7-3.2)
65-74	21	12	4	5	0	392
Rate*	3.3	2.8				3.4
95% C.I.	(1.9-4.7)	(1.2-4.3)				(3.1-3.7)
75-84	7	7	0	0	0	289
Rate*						4.0
95% C.I.						(3.5-4.4)
85+	3	1	0	2	0	84
Rate*						3.4
95% C.I.						(2.7-4.1)
Unknown	0	0	0	0	0	0

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 291. Hodgkin's Lymphoma Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	116	87	19	10	0
Rate*	1.2	1.3	1.2	0.7	
95% C.I.	(1.0-1.4)	(1.0-1.6)	(0.7-1.9)	(0.3-1.4)	
Gender					
Male	63	51	10	2	0
Rate*	1.3	1.5	1.2		
95% C.I.	(1.0-1.7)	(1.1-2.1)	(0.6-2.6)		
Female	53	36	9	8	0
Rate*	1.1	1.1			
95% C.I.	(0.8-1.5)	(0.8-1.5)			
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$4,349,602	\$3,262,003	\$796,484	\$291,115	
Average Charges	\$37,497	\$37,494	\$41,920	\$29,112	
Median Charges	\$19,402	\$20,576	\$19,513	\$15,939	
Discharge Length of S	tay (LOS) (Days)				
Total LOS	927	720	149	58	
Average LOS	8.0	8.3	7.8	5.8	
Median LOS	5.0	5.0	5.0	4.5	

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 292. Hodgkin's Lymphoma Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region o	of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	38	23	8	7
Rate*	0.4	0.3	0.5	0.5
95% C.I.	(0.3-0.5)	(0.2-0.5)	(0.1-0.8)	(0.1-0.9)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	2	1	0	1
Rate*				
95% C.I.				
25-34	4	4	0	0
Rate*				
95% C.I.				
35-44	3	2	1	0
Rate*				
95% C.I.				
45-54	8	2	5	1
Rate*				
95% C.I.				
55-64	3	2	0	1
Rate*				
95% C.I.				
65-74	14	9	2	3
Rate*	2.2			
95% C.I.	(1.0-3.3)			
75-84	3	3	0	0
Rate*				
95% C.I.				
85+	1	0	0	1
Rate*				
95% C.I.				
* Pates are per 100 000 a	0	0	0	

\* Rates are per 100,000 age-specific population.

## **ALL OTHER SITES**

Table 293. Cancer Cases for All Other Sites by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1997-2001) and SEER-11 (1997-2001)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1997-2001)			
Total									
Cases	2,749	1,863	483	402	1	57,238			
Rate*	28.2	28.0	28.8	28.8		30.9			
95% C.I.	(27.2-29.3)	(26.7-29.2)	(26.2-31.3)	(26.0-31.6)		(30.7-31.2)			
Age Group									
<1	13	9	1	3	0	317			
Rate*	8.9					11.4			
95% C.I.	(4.1-13.8)					(10.2-12.7)			
1-4	15	12	0	3	0	461			
Rate*	2.6	3.0				4.1			
95% C.I.	(1.3-4.0)	(1.3-4.7)				(3.8-4.5)			
5-14	35	23	6	6	0	674			
Rate*	2.5	2.4				2.5			
95% C.I.	(1.7-3.4)	(1.4-3.4)				(2.3-2.7)			
15-24	77	48	15	13	1	1,861			
Rate*	5.7	5.2	6.5	7.0		7.2			
95% C.I.	(4.4-7.0)	(3.7-6.6)	(3.2-9.8)	(3.2-10.8)		(6.9-7.5)			
25-34	151	111	26	14	0	3,737			
Rate*	10.2	10.4	10.2	8.9		12.8			
95% C.I.	(8.6-11.9)	(8.5-12.4)	(6.3-14.1)	(4.2-13.6)		(12.4-13.2)			
35-44	207	144	45	18	0	5,333			
Rate*	13.3	13.8	15.9	8.0		17.1			
95% C.I.	(11.5-15.1)	(11.5-16.0)	(11.2-20.5)	(4.3-11.6)		(16.6-17.5)			
45-54	343	236	65	42	0	6,562			
Rate*	26.7	27.9	27.5	20.9		28.7			
95% C.I.	(23.9-29.5)	(24.3-31.4)	(20.8-34.2)	(14.6-27.2)		(28.0-29.4)			
55-64	472	325	77	70	0	7,941			
Rate*	51.5	52.3	51.3	48.4		56.7			
95% C.I.	(46.9-56.2)	(46.6-58.0)	(39.8-62.7)	(37.1-59.8)		(55.5-58.0)			
65-74	668	456	108	104	0	11,710			
Rate*	104.0	105.4	105.3	97.0		101.5			
95% C.I.	(96.1-111.9)	(95.8-115.1)	(85.5-125.2)	(78.4-115.7)		(99.7-103.3)			
75-84	599	383	109	107	0	12,714			
Rate*	170.5	164.0	188.5	178.6		174.9			
95% C.I.	(156.9-184.2)	(147.6-180.4)	(153.1-223.9)	(144.8-212.5)		(171.9-178.0)			
85+	168	115	31	22	0	5,928			
Rate*	220.4	246.3	199.9	156.8		239.0			
95% C.I.	(187.0-253.7)	(201.3-291.3)	(129.5-270.2)	(91.3-222.3)	<del></del>	(232.9-245.1)			
Unknown	1	1	0	0	0	0			

<sup>\*</sup> Rates are per 100,000 age-specific population.

Table 294. Inpatient Discharges for All Other Sites by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1997-2001

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	7,828	5,552	1,323	949	4
Rate*	86.1	90.7	87.6	64.8	
95% C.I.	(84.2-88.1)	(88.3-93.2)	(82.9-92.5)	(60.7-69.1)	
Gender					
Male	3,543	2,496	578	466	3
Rate*	82.8	86.5	83.0	66.9	
95% C.I.	(79.9-85.7)	(82.9-90.3)	(76.0-90.6)	(60.7-73.7)	
Female	4,285	3,056	745	483	1
Rate*	90.8	96.4	93.3	64.0	
95% C.I.	(88.1-93.6)	(93.0-99.9)	(86.7-100.3)	(58.4-70.0)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$227,286,686	\$170,120,375	\$34,782,493	\$22,175,687	\$208,131
Average Charges	\$29,035	\$30,641	\$26,291	\$23,367	\$52,033
Median Charges	\$19,384	\$20,334	\$17,939	\$15,887	\$48,534
Discharge Length of S	tay (LOS) (Days)				
Total LOS	57,308	41,112	9,854	6,289	53
Average LOS	7.3	7.4	7.4	6.6	13.3
Median LOS	5.0	5.0	6.0	5.0	11.5

<sup>\*</sup> Rates are per 100,000 population and are age-adjusted to the 2001 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 295. All Other Sites Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1997-2001

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Mortality	2,030	1,282	382	366				
Rate*	20.8	19.2	22.8	26.2				
95% C.I.	(19.9-21.8)	(18.2-20.3)	(20.5-25.0)	(23.5-28.9)				
Age Group								
<1	2	2	0	0				
Rate*								
95% C.I.								
1-4	3	2	0	1				
Rate*								
95% C.I.								
5-14	11	7	3	1				
Rate*	0.8							
95% C.I.	(0.3-1.3)							
15-24	6	3	1	2				
Rate*								
95% C.I.								
25-34	27	22	3	2				
Rate*	1.8	2.1						
95% C.I.	(1.1-2.5)	(1.2-2.9)						
35-44	65	44	8	13				
Rate*	4.2	4.2		5.7				
95% C.I.	(3.2-5.2)	(3.0-5.4)		(2.6-8.9)				
45-54	168	118	22	28				
Rate*	13.1	13.9	9.3	13.9				
95% C.I.	(11.1-15.1)	(11.4-16.5)	(5.4-13.2)	(8.8-19.1)				
55-64	371	248	58	65				
Rate*	40.5	39.9	38.6	45.0				
95% C.I.	(36.4-44.6)	(34.9-44.9)	(28.7-48.6)	(34.0-55.9)				
65-74	615	385	123	107				
Rate*	95.8	89.0	120.0	99.8				
95% C.I.	(88.2-103.3)	(80.1-97.9)	(98.8-141.2)	(80.9-118.7)				
75-84	547	324	120	103				
Rate*	155.7	138.7	207.5	171.9				
95% C.I.	(142.7-168.8)	(123.6-153.8)	(170.4-244.6)	(138.7-205.2)				
85+	215	127	44	44				
Rate*	282.0	272.0	283.7	313.6				
95% C.I.	(244.3-319.7)	(224.7-319.3)	(199.9-367.5)	(220.9-406.2)				
Unknown	0	0	0	0				

<sup>\*</sup> Rates are per 100,000 age-specific population.

### APPENDIX A – CODES USED FOR GROUPING

One of the challenges of this report was to combine information on cancer from several different sources and develop a comprehensive report that details the burden and risk of cancer in the State of Nevada. To add to the complexity of it all, each data source did not use identical coding to identify each type of cancer.

The Nevada Central Cancer Registry uses the International Classification of Diseases – Oncology (ICD-O) coding system that is then broken down into the Topography, or Primary Site, as well as the Morphology of the specific cancer. The Topography section of the ICD-O coding structure is fairly comparable to the ICD-10 mortality classification system, with very little variation between the two systems. However, there are some variations, so this report uses the ICD-O coding structure as the primary source for identifying the type of cancer for this report.

The ICD-10 structure was implemented in 1999 for the coding of the underlying cause of death. However, for the 1997 to 1998 data that are used for this report, the mortality database used the ICD-9 mortality coding structure, which is a different structured system, but is fairly comparable to the ICD-10 revision. However, for this report, due to the variations between the ICD-0 and ICD-10 coding structures and the fact that the ICD-0 system is the primary one used, there have not been any adjustments made to account for potential coding differences that may have occurred due to the change from the ICD-9 to the ICD-10 system in 1999 for all mortality data used in this report.

The ICD-9 coding structure is also used by the inpatient hospital discharge (UB92) database that was used to provide the inpatient discharge statistics for this report. However, all of the 1997 to 2001 hospital discharge data listed in this report is based upon the ICD-9 coding system.

The following pages detail the codes used for each type of coding structure present in the data used for this report. The codes used to identify the leading types of cancer for this report are highlighted. Those not falling under any of the highlighted leading groups were categorized into the All Other Sites grouping.

## Table 296. ICD-O Codes Used

	ICD-O Codes				
Type of Cancer	Topography	Morphology	Excluding (M = Morphology)		
Total	Sum	Sum			
Lip, Oral Cavity and Pharynx	Sum of subgroups				
Lip	C00		M-9590:9989		
Base of Tongue	C01		M-9590:9989		
Other & Unspecified Parts of Tongue	C02		M-9590:9989		
Parotid Gland	C07		M-9590:9989		
Other & Unspecified Major Salivary glands	C08		M-9590:9989		
Floor of Mouth	C04		M-9590:9989		
Gum	C03		M-9590:9989		
Palate	C05		M-9590:9989		
Other & Unspecified Parts of Mouth	C06		M-9590:9989		
Nasopharynx	C11		M-9590:9989		
Tonsil	C09		M-9590:9989		
Oropharynx	C10		M-9590:9989		
Pyriform Sinus	C12		M-9590:9989		
Hypopharynx	C13		M-9590:9989		
Other & Unspecified Oral (Buccal) Cavity & Pharynx	C14		M-9590:9989		
Digestive System	Sum of Subgroups				
Esophagus	C15		M-9590:9989		
Stomach	C16		M-9590:9989		
Small Intestine	C17				
Colorectal		ectosigmoid Junction, Anus,	Anal Canal and Anorectum		
Colon (excluding Rectum)	Sum of Subgroups		14.0500.0000		
Cecum	C18.0		M-9590:9989		
Appendix	C18.1		M-9590:9989		
Ascending Colon	C18.2		M-9590:9989		
Hepatic Flexure	C18.3		M-9590:9989		
Transverse Colon	C18.4 C18.5		M-9590:9989		
Splenic Flexure	C18.6		M-9590:9989 M-9590:9989		
Descending Colon Sigmoid Colon	C18.7		M-9590:9989		
	C18.8-C18.9, C26.0		M-9590:9989		
Large Intestine, NOS Rectum	C20		M-9590:9989		
Rectosigmoid Junction	C19		M-9590:9989		
Anus, Anal Canal and Anorectum	C21		M-9590:9989		
Liver	C22.0		M-9590:9989		
Intrahepatic Bile Ducts	C22.1		M-9590:9989		
Gallbladder	C23		M-9590:9989		
Other & Unspecified Biliary Tract	C24		M-9590:9989		
Pancreas	C25		M-9590:9989		
Retroperitoneum	C48.0		M-9590:9989		
Peritoneum, Omentum and Mesentery	C48.1-C48.2		M-9590:9989		
Other Digestive Organs	C26.8-C26.9, C48.8		M-9590:9989		
Respiratory System	Sum of Subgroups				
Nasal Cavity and Middle Ear	C30		M-9590:9989		
Accessory Sinuses	C31		M-9590:9989		
Larynx	C32		M-9590:9989		
Lung and Bronchus	C34		M-9590:9989		
Pleura	C38.4		M-9590:9989		
Trachea	C33		M-9590:9989		
Mediastinum and Other Respiratory Organs	C38.1, C38.3, C38.8, C39		M-9590:9989		
Bones, Joints and Articular Cartilage	Sum of Subgroups				
Bones, Joints & Articular Cartilage of Limbs	C40		M-9590:9989		
Bones, Joints & Articular Cartilage of Other & Unspec Sites	C41		M-9590:9989		
Soft Tissue (Including Heart)	Sum of Subgroups				
Heart	C38.0		M-9590:9989		
Peripheral Nerves & Autonomic Nervous System	C47		M-9590:9989		
Connective, Subcutaneous & Other Soft Tissues	C49		M-9590:9989		

## Table 296. ICD-O Codes Used (Continued)

	ICD-O Codes				
Type of Cancer	Topography	Morphology	Excluding (M = Morphology)		
Skin (Excluding Basal And Squamous)	Sum of Subgroups	0700 0700			
Melanomas Of The Skin Other Non-Epithelial Skin	C44 C44		M-8000:8004, 8010:8045, 8050:8082, 8090:8110, 8720:8790,		
Breast	C50		M-9590:9989		
Female Genital System Cervix Uteri	Sum of Subgroups C53		M-9590:9989		
Corpus Uteri & Uterus, NOS	Sum of Corpus Uteri and		M 0500.0000		
Corpus Uteri Uterus, NOS	C54 C55		M-9590:9989 M-9590:9989		
Ovary	C56		M-9590:9989		
Vagina	C52		M-9590:9989		
Vulva	C51		M-9590:9989		
Placenta	C58		M-9590:9989		
Other Female Genital Organs	C57		M-9590:9989		
Male Genital System	Sum of Subgroups		11.0500.0000		
Prostate Testis	C61 C62		M-9590:9989 M-9590:9989		
Penis	C62		M-9590:9989		
Other Male Genital Organs	C63		M-9590:9989		
Urinary System	Sum of Subgroups		5555.5555		
Urinary Bladder	C67		M-9590:9989		
Kidney and Renal Pelvis	Sum of Kidney and Rena				
Kidney	C64		M-9590:9989		
Renal Pelvis	C65		M-9590:9989		
Ureter	C66 C68		M-9590:9989		
Other Urinary Organs  Eye and Orbit	C69		M-9590:9989		
Brain and Other Central Nervous System	Sum of Subgroups				
Brain	C71		M-9530:9539, 9590:9989		
Meninges	C70		M-9590:9989		
Spinal Cord, Cranial Nerves, & Other Parts of CNS	C72	C71 & M-9530:9539	M-9590:9989		
Endocrine System	Sum of Subgroups				
Thyroid Gland	C73				
Adrenal Gland Other Endocrine (Including Thymus)	C74 C37, C75		M-9590:9989		
Hodgkin's Lymphoma	631, 613	M-9650:9667	W-9390.3909		
Non-Hodgkin's Lymphoma  Multiple Myeloma		M-9590:9595, 9670:9717, 9823:9827 M-9731:9732	C42.0, C42.1, C42.4		
Leukemia	Sum of subgroups				
Lymphocytic	Sum of subgroups				
Acute Lymphocytic	C40.0 C40.4 C40.4	M-9821:9828			
Chronic Lymphocytic Other Lymphocytic	C42.0, C42.1, C42.4	M-9823 M-9820, 9822, 9824:9826			
Granulocytic (Myeloid)	Sum of subgroups	101-3020, 3022, 3024.3020			
Acute Myeloid	com a construction	M-9840, 9861, 9866,			
·		9867, 9871:9874			
Chronic Myeloid		M-9863:9868			
Other Myeloid		M-9860, 9862, 9864			
Monocytic	Sum of subgroups	11.0004			
Acute Monocytic		M-9891 M-9893			
Chronic Monocytic Other Monocytic		M-9890, 9892, 9894			
Other	Sum of subgroups	W-9090, 9092, 9094			
Other Acute	Cam or cabgroups	M-9801, 9841, 9931, 9932			
Other Chronic		M-9803, 9842			
Aleukemic, Subleukemic and NOS					
		M-9800, 9802, 9804,			
		9830, 9850, 9870, 9880,			
	0400 0404 045	9900, 9910, 9930, 9940,			
Other, III-Defined and Unspecified Sites	C42.0, C42.1, C42.4 All Others				
Salot, in Dollinea and Oriopeomea Ottes	All Others	<u> </u>			

## Table 297. ICD-9 and ICD-10 Codes Used

Type of Cancer	ICD-9	ICD-10
Total	Sum	Sum
Lip, Oral Cavity and Pharynx	Sum of subgroups	Sum of subgroups
Lip	140	C00
Base of Tongue	141.0	C01
Other & Unspecified Parts of Tongue	141.1-141.9	C02
Parotid Gland	142.0	C07
Other & Unspecified Major Salivary glands	142.1-142.9	C08
Floor of Mouth	144	C04
Gum	143	C03
Palate	145.2-145.5	C05
Other & Unspecified Parts of Mouth	145.0, 145.1, 145.6-145.9	C06
Nasopharynx	147	C11
Tonsil Oropharynx	146.0-146.2 146.3-146.9	C09 C10
Pyriform Sinus	146.3-146.9	C10
Hypopharynx	148.0, 148.2-148.9	C12 C13
Other & Unspecified Oral (Buccal) Cavity & Pharynx	140.0, 140.2-140.9	C14
Digestive System	Sum of Subgroups	Sum of Subgroups
Esophagus	150	C15
Stomach	151	C16
Small Intestine	152	C17
Colorectal	Sum of Colon, Rectum, Rectosigmoid Ju	nction, Anus, Anal Canal and Anorectum
Colon (excluding Rectum)	Sum of Subgroups	Sum of Subgroups
Cecum	153.4	C18.0
Appendix	153.5	C18.1
Ascending Colon	153.6	C18.2
Hepatic Flexure	153.0	C18.3
Transverse Colon	153.1	C18.4
Splenic Flexure	153.7	C18.5
Descending Colon	153.2	C18.6
Sigmoid Colon	153.3	C18.7
Large Intestine, NOS	153.8-153.9, 159.0	C18.8-C18.9, C26.0
Rectum	154.1	C20
Rectosigmoid Junction	154.0	C19
Anus, Anal Canal and Anorectum	154.2-154.8	C21
Liver	155.0, 155.2	C22.0, C22.2-C22.4, C22.7, C22.9
Intrahepatic Bile Ducts	155.1	C22.1
Gallbladder	156.0	C23
Other & Unspecified Biliary Tract	156.1-156.9 157	C24 C25
Pancreas Retroperitoneum	158.0	C48.0
Peritoneum, Omentum and Mesentery	158.8-158.9	C45.1, C48.1, C48.2
Other Digestive Organs	159.8, 159.9	C26.8-C26.9, C48.8
Respiratory System	Sum of Subgroups	Sum of Subgroups
Nasal Cavity and Middle Ear	160.0, 160.1	C30
Accessory Sinuses	160.2-160.9	C31
Larynx	161	C32
Lung and Bronchus	162.2-162.9	C34
Pleura	163	C38.4, C45.0
Trachea	162.0	C33
Mediastinum and Other Respiratory Organs	164.2-164.9, 165	C38.1, C38.3, C38.8, C39
Bones, Joints and Articular Cartilage	Sum of Subgroups	Sum of Subgroups
Bones, Joints & Articular Cartilage of Limbs	170.4, 170.5, 170.7, 170.8	C40
Bones, Joints & Articular Cartilage of Other & Unspec Sites	170.0-170.3, 170.6, 170.9	C41
Soft Tissue (Including Heart)	Sum of Subgroups	Sum of Subgroups
Heart	164.1	C38.0
Peripheral Nerves & Autonomic Nervous System	_ <del></del>	C47
Connective, Subcutaneous & Other Soft Tissues	171	C49

## Table 297. ICD-9 and ICD-10 Codes Used (Continued)

	ICD-O Codes				
Type of Cancer	Topography	Morphology			
Skin (Excluding Basal And Squamous)	Sum of Subgroups	Sum of Subgroups			
Melanomas Of The Skin	172	C43			
Other Non-Epithelial Skin	173, 176	C44, C46			
Breast	174-175	C50			
Female Genital System	Sum of Subgroups	Sum of Subgroups			
Cervix Uteri	180	C53			
Corpus Uteri & Uterus, NOS	Sum of Corpus Uteri and Uterus, NOS	Sum of Corpus Uteri and Uterus, NOS			
Corpus Uteri	182	C54			
Uterus, NOS	179	C55			
Ovary	183.0	C56			
Vagina	184.0	C52			
Vulva	184.1-184.4	C51			
Placenta	181	C58			
Other Female Genital Organs	183.2-183.9, 184.8, 184.9	C57			
Male Genital System	Sum of Subgroups	Sum of Subgroups			
Prostate	185	C61			
Testis	186	C62			
Penis	187.1-187.4	C60			
Other Male Genital Organs	187.5-187.9 Sum of Subgroups	C63			
Urinary System Urinary Bladder	Sum of Subgroups 188	Sum of Subgroups C67			
Kidney and Renal Pelvis	Sum of Kidney and Renal Pelvis	Sum of Kidney and Renal Pelvis			
Kidney	189.0	C64			
Renal Pelvis	189.1	C65			
Ureter	189.2	C66			
Other Urinary Organs	189.3-189.9	C68			
Eye and Orbit	190	C69			
Brain and Other Central Nervous System	Sum of Subgroups	Sum of Subgroups			
Brain	191	C71			
Meninges	192.1, 192.3	C70			
Spinal Cord, Cranial Nerves, & Other Parts of CNS	192.0, 192.2, 192.8, 192.9	C72			
Endocrine System	Sum of Subgroups	Sum of Subgroups			
Thyroid Gland	193	C73			
Adrenal Gland	194.0	C74			
Other Endocrine (Including Thymus)	164.0, 194.1-194.9	C37, C75			
Hodgkin's Lymphoma	201	C81			
Non-Hodgkin's Lymphoma	200, 202.8, 202.9, 202.0-202.2	C82-C85.9, C96.3			
Multiple Myeloma	203.0, 238.6	C90.0, C90.2			
Leukemia	Sum of subgroups	Sum of subgroups			
Lymphocytic	Sum of subgroups	Sum of subgroups			
Acute Lymphocytic	204.0	C91.0			
Chronic Lymphocytic	204.1	C91.1			
Other Lymphocytic	204.2-204.9	C91.2, C91.3, C91.7, C91.9			
Granulocytic (Myeloid) Acute Myeloid	Sum of subgroups	Sum of subgroups			
Chronic Myeloid	205.0 205.1	C92.4, C92.5, C92.0 C92.1			
Other Myeloid	205.2-205.9	C92.2, C92.3, C92.7, C92.9			
Monocytic	Sum of subgroups	Sum of subgroups			
Acute Monocytic	206.0	C93.0			
Chronic Monocytic	206.0	C93.0 C93.1			
Other Monocytic	206.2-206.9	C93.2, C93.7, C93.9			
Other	Sum of subgroups	300.2, 000.7, 000.0			
Other Acute	207.0, 208.0	C94.0, C95.0			
Other Chronic	207.1, 208.1	C94.1, C95.1			
Aleukemic, Subleukemic and NOS	202.4, 203.1, 207.2, 207.8, 208.2-208.9	C90.1, C94.7, C91.4, C91.5, C94.2,			
,,	- , , , ,	C94.5, C95.2, C95.7, C95.9			
Other, III-Defined and Unspecified Sites	All Others	All Others			

### APPENDIX B – FORMULAS

#### **AGE-ADJUSTED RATE:**

$$\frac{E_t}{S_t} \times 100,000$$

$$E_t$$
 = Total Expected Number of Events =  $\sum_{i=1}^{k} E_i$ 

$$S_t$$
 = Total Standard Population =  $\sum_{i=1}^k S_i$ 

$$CR$$
 = Crude Rate =  $\frac{N_t}{P_t} \times 100,000$ 

$$P_t$$
 = Total State Population =  $\sum_{i=1}^{k} P_i$ 

$$N_t$$
 = Total Number of Events =  $\sum_{i=1}^{K} N_i$ 

$$E_i$$
 = Age-Specific Expected Number of Events =  $\frac{N_i}{P_i} \times S_i$ 

$$S_i$$
 = Standard Age-Specific Population

$$k$$
 = Number of Age Groups

# AGE-ADJUSTED RATE CONFIDENCE INTERVALS:

$$w_i = \frac{stdmil_i}{\left(pop_i \times \sum_{j=x}^{y} stdmil_j\right)}$$

$$w_m = \max(w_i)$$

$$v = \sum_{i=x}^{y} (w_i^2 \times count_i)$$

$$CI_{low} = \left(\frac{v}{2 \times rate}\right) \times \left(ChiInv\left(\frac{p}{2}, \frac{\left(2 \times rate^2\right)}{v}\right)\right) \times 100,000$$

$$CI_{upper} = \left(\frac{v + w_m^2}{2(rate + w_m)}\right) \times \left(ChiInv\left(1 - \frac{p}{2}, \frac{2(rate + w_m)^2}{\left(v + w_m^2\right)}\right)\right) \times 100,000$$

# AGE-ADJUSTED RATE STANDARD ERROR:

$$SE_{AArate} = \left[ \sum_{i=x}^{y} \left( \frac{stdmil_{i}}{\sum_{j=x}^{y} stdmil_{j}} \right)^{2} \times \left( \frac{count_{i}}{population_{i}^{2}} \right) \right]^{\frac{1}{2}} \times 100,000$$

#### **CAUSE SPECIFIC SURVIVAL RATE:**

$$L_{x} = L_{x-1} - D_{x-1} - U_{x-1} - W_{x-1}$$

$$L_{x}^{*} = L_{x} - \frac{1}{2} (U_{x} + W_{x})$$

$$P_{x} = 1 - \frac{D_{x}}{L_{x}^{*}}$$

$$CP_{x} = P_{1}, P_{2}, \dots, P_{x}$$

 $L_1$  = Total number of cases included in table

 $L_x$  = Number of cases alive at beginning of interval x

 $L_x^*$  = Adjusted number of cases alive at during interval x

 $D_x$  = Number of cases dying from Cancer during interval x

 $U_x$  = Number of cases untraced (lost to follow up) during interval x, where the definition for "lost to follow up" is: alive with follow up date prior to some prescribed date

 $W_x$  = Number of cases withdrawn alive during interval x, where the definition of "withdrawn alive" is: alive with follow up date later than some specified date (This is the same as in previous definition.)

 $P_x$  = Cause specific survival rate for interval x

 $CP_{x}$  = Cumulative cause specific survival rate

#### **CRUDE RATE:**

$$CR = \frac{Number of Events}{Population} \times 100,000$$

# CRUDE RATE CONFIDENCE INTERVALS:

$$CI_{lower} = \left(\frac{100,000}{Population}\right) \times \left(Events - \left(1.96 \times \sqrt{Events}\right)\right)$$

$$CI_{upper} = \left(\frac{100,000}{Population}\right) \times \left(Events + \left(1.96 \times \sqrt{Events}\right)\right)$$

#### **MEDIAN SURVIVAL RATE:**

$$MedianSurvival = \left(Interval - 1\right) + \left(\frac{\left(CP_{x-1} - .5\right)}{\left(CP_{x-1} - CP_{x}\right)}\right)$$

**ELSE IF:**  $CP_x$  for first interval is less than .5, then median survival:

$$MedianSurvival = \frac{.5}{(1 - CP_x)}$$

**ELSE IF:**  $CP_x$  for interval is equal to .5, then median survival:

MedianSurvival = Interval

 $CP_x$  = Cumulative cause specific survival rate for interval x

# PERCENTAGE (BRFSS) CONFIDENCE INTERVALS:

$$CI_{lower} = Weighted \% - 1.96 \times \sqrt{\frac{Weighted \% \times (1 - Weighted \%)}{Total \text{Re sponses}}}$$

$$CI_{upper} = Weighted\% + 1.96 \times \sqrt{\frac{Weighted\% \times (1 - Weighted\%)}{Total \text{Re sponses}}}$$

### **REFERENCES**

- Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973-1999), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002, based on the November 2001 submission.
- 2). "ICD-9 to ICD-10" text document, ICD Conversion Programs, Surveillance, Epidemiology and End Results (SEER), National Cancer Institute, October 2002. <a href="http://seer.cancer.gov/tools/">http://seer.cancer.gov/tools/</a>, 2002.
- 3). National Cancer Institute, Surveillance, Epidemiology and End Results (SEER), February 2003. <a href="http://seer.cancer.gov/">http://seer.cancer.gov/</a>, 2003.
- 4). National Cancer Institute, "What you need to know about..." publications. <a href="http://cancer.gov/cancer\_information/list.aspx?viewid=920AFA90-5547-4739-8D2D-89968F77A87D">http://cancer.gov/cancer\_information/list.aspx?viewid=920AFA90-5547-4739-8D2D-89968F77A87D</a>, 2003.
- 5). Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds). SEER Summary Staging Manual 2001: Codes and Coding Instructions, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001. <a href="http://seer.cancer.gov/tools/ssm/">http://seer.cancer.gov/tools/ssm/</a>. 2003.

### FEEDBACK AND SUGGESTIONS

In a continuing effort to provide an annual Cancer Report that is useful to the communities of Nevada, feedback and suggestions on the information contained in this report is welcome. An electronic form is also available for completion at: <a href="http://health2k.state.nv.us/nihds/cancer/1997-2001Report/feedback">http://health2k.state.nv.us/nihds/cancer/1997-2001Report/feedback</a>.

Please return the completed survey by mail, fax or email to:

Center for Health Data and Research Bureau of Health Planning and Statistics 505 E. King Street, Rm 102 Carson City, NV 89701 Fax: (775) 684-4156

wyang@nvhd.state.nv.us

1.	How did you first find the	e report?					
	Hard Copy	Electronic	Сору	S	tate Web	site	
2.	Please rate the overall val	lue of the re	port:				
	Extremely Valuable 5	4		3		2	No value 1
3.	Please rate the general in	formation in	cluded	in this repo	rt:		
	Type of Information	Extremely Helpful 5	4	Somewhat Helpful 3	2	Not Helpful 1	Not Applicable 0
	General Sections Overview						
	Cancer Incidence						
	Inpatient Discharge						
	Mortality						
	Survival Rate						

(PLEASE CONTINUE SURVEY ON NEXT PAGE)

### 4. Please rate the information on specific types of cancer included in this report:

Extremely Helpful		Somewhat Helpful		Not Helpful	Not Applicable
5	4	3	2	1	0
	Em	nail Notificati	ion		
Tiliation:	itle:			_ Phone:	
	Helpful 5	Helpful 5 4	Helpful 4 3  Helpful 5 4 3  Helpful 6 4 3  Helpful 7 4 3	Helpful 4 3 2  Helpful 5 4 3 2  Helpful 6 4 3 2	Helpful 5 4 3 2 1  Helpful 5 4 3 2 1  Helpful 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1